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SUMMARY	
	
	
	Dietary	polyphenols	have	been	widely	 studied	 for	 their	health	effects	on	different	
components	of	metabolic	syndrome	(MetS).	In	the	present	Thesis	it	was	aimed	to	evaluate	
the	 beneficial	 effect	 of	 grape-seed	 polyphenols	 on	 endothelial	 dysfunction	 and	
hypertension	(HTN)	associated	with	MetS	using	cafeteria	diet-fed	rats	as	a	model	of	MetS.	
Results	showed	that	an	acute	dose	of	375	mg/kg	of	a	low-molecular	grape	seed	extract	(LM-
GSPE)	 6h	 after-administration	was	 the	most	 effective	 in	 lowering	 BP	 in	 this	 diet-induced	
HTN	model.	This	improvement	was	seen	to	be	mediated	by	Sirtuin-1	(sirt-1)	and	blockage	of	
the	 Renin-Angiotensin-Aldosterone	 System	 (RAAS)	 at	 reducing	 Ang	 I	 and	 in	 turns	 Ang	 II	
plasma	levels,	and	as	a	consequence,	improving	the	endothelial	function.	Otherwise,	some	
of	the	principal	polyphenol	forms	in	LM-GSPE,	such	as	(-)-epicatechin	and	(+)-catechin,	also	
showed	to	act	as	modulators	of	endothelial	dysfunction.	Furthermore,	it	was	demonstrated	
that	 at	 a	 low	 dose	 of	 7mg/Kg	 of	 gallic	 acid,	 the	main	 phenolic	 acid	 present	 in	 LM-GSPE,	
acutely	reduced	BP	 in	spontaneously	hypertensive	rats,	 improving	endothelial	dysfunction	
by	blockage	of	the	RAAS	as	LM-GSPE.	However,	gallic	acid	in	contrast	to	LM-GSPE	increased	
plasma	bradykinin	levels	and	not	involved	Sirt-1	in	its	antihypertensive	effect.	Finally	it	was	
demonstrated	 that	 a	 chronic	 administration	 of	 grape-seed	 polyphenols	 attenuated	 the	
development	 of	 HTN	 and	 other	 cardiometabolic	 risk	 factors	 associated	 with	 MetS.	
Therefore,	grape-seed	polyphenols,	 including	gallic	acid,	are	proposed	as	good	candidates	
to	be	used	as	as	BP	lowering	agents	in	HTN	associated	with	MetS.		
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RESUM	
		
Els	 polifenols	 presents	 a	 la	 dieta	 s’han	 estudiat	 extensament	 pels	 seus	 efectes	
positius	sobre	diferents	components	de	la	síndrome	metabòlica	(MetS).	En	aquesta	Tesi,	es	
va	 proposar	 avaluar	 els	 efectes	 beneficiosos	 dels	 polifenols	 de	 pinyol	 de	 raïm	 sobre	 la	
disfunció	endotelial	 i	 la	hipertensió	(HTN)	associada	a	la	MetS,	utilitzant	el	model	de	dieta	
de	 cafeteria	 com	 a	 model	 de	MetS.	 Els	 resultats	 mostraren	 que	 una	 dosi	 aguda	 de	 375	
mg/Kg	 d’un	 extracte	 de	 polifenols	 de	 baix	 pes	molecular	 de	 pinyol	 de	 raïm	 (LM-GSPE)	 6	
hores	 postadministració	 va	 ser	 la	més	 efectiva	 per	 a	 baixar	 la	 pressió	 arterial	 en	 aquest	
model	de	HTN	induït	per	dieta.	En	aquesta	millora	es	va	veure	la	implicació	de	la	Sirtuina-1	
(Sirt-1)	així	com	bloqueig	del	Sistema	Renina-Angiotensina-Aldosterona	(SRAA),	que	com	a	
conseqüència	va	millorar	la	funció	endotelial.	Per	una	altra	banda,	es	va	veure	com	alguns	
dels	polifenols	més	abundants	del	LM-GSPE,	com	l’(-)-epicatequina,	la	(+)-catequina	o	l’àcid	
gàl·lic,	actuaren	com	a	moduladors	de	la	funció	endotelial.	A	més	a	més,	es	demostrà	que	a	
una	dosi	baixa	de	7	mg/Kg,	l’àcid	gàl·lic,	l’àcid	fenòlic	més	abundant	de	l’extracte,	baixava	la	
pressió	arterial	de	manera	aguda	en	rates	espontàniament	hipertenses,	millorant	a	més	la	
funció	endotelial	a	través	del	bloqueig	el	SRAA,	com	succeí	amb	LM-GSPE.	No	obstant	això,	i	
al	 contrari	 que	 LM-GSPE,	 es	 trobaren	 nivells	 elevats	 de	 bradiquinina	 i	 es	 descartà	 la	
implicació	 de	 les	 sirtuïnes	 en	 aquest	 efecte	 antihipertensiu.	 Finalment,	 es	 demostrà	 que	
l'administració	 crònica	de	polifenols	 de	pinyol	 de	 raïm	atenuaren	el	 desenvolupament	de	
HTN	 així	 com	 d’altres	 factors	 de	 risc	 associats	 amb	 la	 MetS.	 Per	 tant,	 es	 proposen	 els	
polifenols	de	pinyol	de	raïm,	inclòs	l’àcid	gàl·lic,	com	a	bons	candidats	per	a	ser	utilitzats	en	
el	tractament	de	la	HTN	associada	a	la	MetS.	
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RESUMEN	
	
	Los	 polifenoles	 presentes	 en	 la	 dieta	 se	 han	 estudiado	 extensivamente	 por	 sus	
efectos	positivos	 sobre	diferentes	 componentes	del	 síndrome	metabólico	 (MetS).	 En	esta	
Tesis,	 se	 propuso	 evaluar	 el	 efecto	 positivo	 de	 los	 polifenoles	 de	 pepita	 de	 uva	 sobre	 la	
disfunción	 endotelial	 y	 la	 hipertensión	 (HTN)	 asociada	 al	 MetS,	 utilizando	 el	 modelo	 de	
dieta	de	cafetería	como	modelo	de	HTN	asociada	al	MetS.	Los	resultados	mostraron	que	la	
una	 dosis	 aguda	 de	 375	mg/Kg	 de	 un	 extracto	 de	 polifenoles	 de	 bajo	 peso	molecular	 de	
pepita	 de	 uva	 (LM-GSPE)	 6	 horas	 post-administración	 fue	 la	más	 efectiva	 para	 reducir	 la	
presión	arterial	en	este	modelo	de	HTN	inducido	por	dieta.	La	 implicación	de	 la	Sirtuina-1	
(Sirt-1)	 y	 el	 bloqueo	 del	 Sistema	 Renina-Angiotensina-Aldosterona	 (SRAA),	 y	 por	
consiguiente,	 la	 mejora	 de	 la	 función	 endotelial,	 fueron	 demostrados.	 Por	 otro	 lado,	 se	
observó	 como	 algunos	 de	 los	 polifenoles	 más	 abundantes	 del	 LM-GSPE,	 como	 la	 (-)-
epicatequina,	 la	(+)-catequina	o	el	ácido	gálico,	actuaron	como	moduladores	de	la	función	
endotelial.	Además	 se	demostró	que	el	 ácido	gálico,	 el	 ácido	 fenólico	más	abundante	del	
extracto,	a	una	dosis	baja	de	7	mg/Kg	bajaba	la	presión	arterial	de	manera	aguda	en	ratas	
espontáneamente	 hipertensas,	 mejorando	 además	 la	 función	 endotelial	 mediante	 el	
bloqueo	del	SRAA,	como	sucedía	con	LM-GSPE.	No	obstante,	y	al	contrario	que	el	extracto,	
el	 ácido	 gálico	 aumentó	 la	 concentración	 de	 bradiquinina	 en	 plasma	 y	 además	 no	 se	 vio	
implicación	 de	 Sirt-1	 en	 el	 efecto	 antihipertensivo.	 Finalmente	 se	 demostró	 que	 la	
administración	 crónica	 de	 polifenoles	 de	 pepita	 de	 uva	 atenúa	 la	 elevación	 de	 la	 presión	
arterial	 y	 el	 empeoramiento	 de	 otros	 factores	 de	 riesgo	 asociados	 al	MetS.	 Por	 tanto,	 se	
proponen	 los	polifenoles	de	pepita	de	uva,	 incluido	el	ácido	gálico,	como	buenos	agentes	
para	el	control	de	la	presión	arterial	asociada	al	MetS.		
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INTRODUCTION	
Hypertension	 (HTN)	 is	 a	 major	 risk	 factor	 for	 the	 development	 of	 cardiovascular	
diseases	 (CVD)	 (Papadogiannis	 &	 Protogerou	 2010).	 In	 fact,	 its	 treatment	 has	 been	
associated	with	an	approximately	40%	reduction	in	the	risk	of	stroke	and	an	approximately	
15%	reduction	in	the	risk	of	myocardial	infarction	(Collins	et	al.	1990).	Although	by	definition	
essential	 HTN	 has	 no	 identifiable	 cause,	 epidemiological	 studies	 implicate	 several	 dietary	
and	 other	 lifestyle-related	 factors	 as	 contributors	 to	 its	 development	 (Satterfield	 et	 al.	
2012).	Indeed,	HTN	frequently	occurs	concurrently	with	many	other	CVD	risk	factors	related	
to	 the	 lifestyle,	 such	as	obesity,	dyslipidemia	or	 impaired	glucose	 tolerance	 (Reaven	1988;	
Lakka	et	al.	 2002;	 Isezuo	et	al.	 2003),	which	all	 contribute	 to	metabolic	 syndrome	 (MetS).	
Lifestyle	 modifications	 can	 substantially	 reduce	 blood	 pressure	 (BP)	 and	 cause	 additional	
health	benefits	or	eliminate	other	complications	associated	with	MetS.	Indeed,	many	foods	
and	dietary	components	reduce	BP.	Available	evidence	suggests	that	a	vegetable-	and	fruit-
rich	 diet,	 abundant	 in	 flavonoids	 and	 phenolic	 compounds,	 helps	 to	 control	 BP.	 In	 fact,	
increased	 fruit	 and	 vegetable	 intake	 has	 been	 included	 in	 the	 guidelines	 for	 the	
management	of	arterial	HTN	(Mancia,	Fagard,	Narkiewicz,	Redon,	et	al.	2013).		
BLOOD	PRESSURE	AND	HYPERTENSION	
BP	is	defined	as	the	force	exerted	by	circulating	blood	pumped	by	the	heart	against	
the	 arterial	 walls.	 There	 are	 two	 measurable	 values	 of	 BP.	 The	 maximum	 BP,	 known	 as	
systolic	blood	pressure	 (SBP),	 is	 the	pressure	 that	 is	 recorded	 in	 systole	or	 contraction	of	
the	 ventricles.	While,	 the	minimum	BP	 or	 diastolic	 blood	 pressure	 (DBP),	 is	 the	 pressure	
that	 is	 reached	 when	 left	 ventricle	 is	 relaxing	 and	 refilling,	 i.e.	 when	 the	 heart	 rests	
between	beats	(Figure	1).	Changes	in	SBP	are	compromised	by	the	compliance	of	the	aorta;	
while	DBP	changes	are	 relative	 to	 the	ventricular	 stroke	volume.	Generally,	SBP	 increases	
progressively	 with	 age	 due	 to	 stiffness	 of	 large	 arteries,	 long-term	 build-up	 of	
atherosclerotic	 plaque	 and,	 increased	 incidence	 of	 CVD	 (American	 Heart	 Association	 &	
American	Stroke	Association	n.d.).	In	fact,	there	is	a	strong	positive	correlation	between	BP	
values	 and	 risk	of	CVD,	 renal	disease	and	mortality	 even	 in	 the	normotensive	 range.	 This	
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correlation	is	more	robust	with	SBP	than	with	DBP	(Carretero	&	Oparil	2000).	
	
Figure	1.	Schematic	representation	of	the	heart	in	systole	(right)	and	diastole	(left).	Extracted	from	(Samuel	2009)	
BP	 naturally	 changes	 subjected	 to	 circadian	 rhythms,	 it	 is	 lower	 during	 sleep	 and	
rises	on	awakening.	During	 the	day,	BP	peaks	 in	 the	afternoon	and	drops	 in	 the	evening.	
Moreover,	BP	can	also	rise	in	response	of	excitement,	stress	or	physical	activity	(Hermida	&	
Smolensky	 2004).	 HTN	 is	 known	 as	 the	 chronic	 elevation	 of	 SBP	 or	 DBP.	 The	 European	
Society	of	Hypertension	(ESH)	and	the	European	Society	of	Cardiology	(ESC)	defines	HTN	as	
values	greater	than	140	mmHg	in	SBP	and/or	greater	than	90	mmHg	in	DBP,	based	on	the	
evidence	from	controlled	trials	where	treatment-induced	BP	reduction	was	beneficial.	The	
classification	of	HTN	(Table	1)	 from	ESH/ESC	 is	used	 in	all	age	ranges	but	 for	children	and	
teenagers	 for	 whom	 data	 from	 interventional	 trials	 is	 not	 available	 (Mancia,	 Fagard,	
Narkiewicz,	Redón,	et	al.	2013).		
Table	 1.	 Classification	 of	 hypertension	 based	 in	 the	 European	 Society	 of	 Hypertension	 (ESH)	 and	 the	 European	
Society	of	Cardiology	(ESC)	(Mancia,	Fagard,	Narkiewicz,	Redón,	et	al.	2013).	
	
	 	
Category	 Systolic	 	 Diastolic	
Optimal	 <120	 and	 <80	
Normal	 120-129	 and/or	 80-84	
High	normal	 130-139	 and/or	 85-89	
Grade	1	hypertension	 140-159	 and/or	 90-99	
Grade	2	hypertension	 160-179	 and/or	 100-109	
Grade	3	hypertension	 ≥180	 and/or	 ≥110	
Isolated	systolic	hypertension	 ≥140	 and	 >90	
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HTN	has	been	 identified	as	one	of	 the	 leading	 risk	 factors	 for	mortality,	 and	 it	has	
also	 been	 ranked	 the	 third	 cause	 of	 disability-adjusted-life-years	 reduction	 (Ezzati	 et	 al.	
2002).	Globally,	26.4%	of	the	world’s	adult	population	in	2000	was	diagnosed	with	HTN	and	
an	 increase	 of	 about	 10%	 is	 predicted	 by	 2025	 (Kearney	 et	 al.	 2005).	 However,	 the	
distribution	between	countries	varies.	Between	2000	and	2025	a	rise	of	80%	is	predicted	for	
economically	 developing	 countries,	 compared	 with	 a	 24%	 increase	 for	 economically	
developed	 countries	 (Kearney	 et	 al.	 2005).	 Moreover,	 low	 socioeconomical	 status	 and	
interestingly	 low	 level	 of	 education	 are	 associated	 with	 higher	 BP	 (Leng	 et	 al.	 2015).	
Remarkably,	the	age-	and	sex-adjusted	prevalence	of	HTN	in	North	American	is	lower	than	
in	Europe	(28%	vs.	44%)	at	the	140/90	mm	Hg	threshold	(Wolf-Maier	et	al.	2003).	When	it	
comes	to	Spain,	the	prevalence	of	HTN	in	adults	 is	around	40%	(Banegas	et	al.	1998),	and	
this	percentage	increases	to	65%	in	over	60	year-olds	(Banegas	et	al.	2015).	Furthermore,	it	
is	calculated	that	approximately	the	half	of	hypertensive	population	in	Spain	are	untreated,	
and	 a	 quarter	 of	 older	 patients,	 even	 under	 pharmacological	 treatment,	 still	 have	
uncontrolled	BP	(Banegas	et	al.	2015).	The	main	reason	of	this	high	percentage	of	untreated	
population	is	the	lack	of	symptoms	of	this	disease;	in	fact,	it	is	referred	to	as	a	silent	killer.	
Unfortunately,	 the	 consequences	 of,	 untreated	 elevated	 BP	 are	 drastic	 including	 heart	
disease	and	stroke,	kidney	and	brain	damage,	blindness	or	dementia;	hence	the	importance	
of	the	regular	check	ups	(WHO	2013).	
In	 the	 90-95%	 of	 patients	 the	 origin	 of	 HTN	 is	 unknown,	 this	 condition	 is	
denominated	 primary	 or	 essential	 HTN.	 The	 remaining	 percentage	 of	 patients	 have	
secondary	HTN	as	a	consequence	of	other	pathologies	(Carretero	&	Oparil	2000).	As	it	will	
be	 explained	 in	 the	 next	 pages,	 primary	 HTN	 is	 a	 result	 of	 multiple	 genetic	 and	
environmental	 factors,	 including	 blood	 plasma	 volume,	 activity	 of	 the	 renin-angiotensin-
aldosterone	 system	 (RAAS),	 abnormalities	 in	 catecholamine	 pathways,	 ion	 channel	
regulation	 or	 inflammation	 (Luft	 2014).	 Secondary	 HTN	 has	 specific	 causes	 that	 can	 be	
reversible,	 such	 as	 excessive	 alcohol	 intake,	 the	 use	 of	 contraceptives	 or	 the	 hormone	
therapy,	among	others.	Other	causes	of	secondary	HTN	are	obstructive	sleep	apnoea,	renal	
parenchymal	 disease,	 renal	 artery	 stenosis,	 aldosteronism,	 hyperthyroidism,	 Cushing	
syndrome	 (or	 hypercortisolism),	 pheochromocytoma,	 or	 coarctation	 of	 the	 aorta	 (Bakris	
2014).	There	is	also	a	heredity	factor,	even	though	the	mechanism	is	not	clear.	Importantly,	
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lifestyle	 factors	 like	physical	 inactivity,	salt-rich	and	fat-rich	diet	or	 low	dietary	potassium,	
strongly	contribute	to	the	pathogenesis	of	this	disease	(Bakris	2014;	WHO	2013).			
Anatomy	of	the	vascular	system	
There	are	different	 types	of	vessels	 in	 the	body:	arteries,	veins	and	capillaries.	The	
larger	conducting	arteries,	or	elastic	arteries,	conduct	the	blood	from	the	heart	to	muscular	
or	distribution	arteries.	Then	blood	flows	to	the	arterioles,	where	vascular	resistance,	and	
consequently	BP,	is	controlled.	Finally	blood	enters	capillaries	where	water,	oxygen,	carbon	
dioxide	and	nutrients	exchange	takes	place	and	then,	the	blood	flows	to	veins.	(Tortora	&	
Derrickson	2005)	
Blood	vessels	are	formed	of	three	layers	or	tunics	that	surround	the	lumen	or	light	of	
the	vessels	(Figure	2).	The	inner	tunic,	in	contact	with	the	blood,	contains	the	flat	fitted	cells	
that	compose	the	endothelium	monolayer,	which	is	continuous	with	the	endocardial	 layer	
of	 the	 heart.	 The	 endothelium	 is	 associated	 with	 connective	 tissue,	 the	 basement	
membrane,	which	 is	 especially	 important	 for	 the	exchange	of	molecules	 in	 the	 capillaries	
that	lack	the	other	layers.	(Tortora	&	Derrickson	2005)	
Beneath	the	basement	membrane	and	separating	the	tunica	intima	from	the	media,	
the	 internal	 elastic	 lamella	 is	 found.	 The	 middle	 tunic	 is	 composed	 of	 a	 layer	 of	
circumferential	vascular	smooth	muscle	cells	(VSMC)	and	collagen	fibres	between	sheets	of	
elastin	 forming	 lamellar	 units.	 Generally,	 the	 tunica	media	 is	 the	 thickest	 layer	 in	 vessels	
and,	small	changes	of	diameter	of	this	tunic	are	critical	for	BP	control.	The	activity	of	VSMC	
is	controlled	by	sympathetic	vasomotor	nerve	fibres	of	the	autonomic	nervous	system	and	
by	molecules,	such	as,	noradrenaline,	endothelin-1	(ET-1)	or	angiotensin	(Ang)	II.	The	tunica	
media	of	elastic	arteries,	like	the	aorta	or	the	brachiocephalic	trunk,	is	in	proportion	to	the	
light	of	the	vessel,	relatively	thin.	This	allows	the	tunica	intima	to	move	independently	from	
the	other	layers,	as	the	elastic	fibres	that	compose	the	tunica	media	of	this	vessels	expand	
with	 the	 increase	 of	 SBP	 and	 come	 back	 to	 their	 initial	 length	when	 the	 ventricles	 relax,	
pushing	 the	 blood	 forward	 and	 acting	 as	 pressure	 reservoir.	 On	 the	 contrary,	 the	 tunica	
media	of	 the	smaller	arteries,	or	 conductor	arteries,	 is	generally	 thick	because	 it	 contains	
more	 muscular	 cells	 than	 elastic	 arteries,	 so	 the	 regulation	 of	 vasodilation	 and	
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vasoconstriction	is	more	important	in	these	vessels.	(Tortora	&	Derrickson	2005)	
Supporting	 the	 tunica	 media	 and	 delimiting	 it	 from	 tunica	 adventitia,	 there	 is	 a	
second	 elastic	 layer,	 the	 external	 elastic	 lamella.	 The	 external	 tunica	 is	 formed	mainly	 of	
collagen	 and	 elastic	 fibres	 and,	 sometimes	 is	 hard	 to	 distinguish	 from	 the	 other	 lamellar	
units.	 In	this	external	 layer,	 lymphatic	vessels	can	be	found	and,	 in	 larger	vessels	the	vasa	
vasorum,	 that	allows	the	direct	delivery	of	nutrients	to	the	 interior	 layers	of	the	wall.	The	
external	tunica	is	the	biggest	layer	in	the	veins,	which	are	designed	to	distend	and	adapt	to	
the	changes	in	volume	and	BP	and	prevent	backflow.	(Tortora	&	Derrickson	2005)	
	
Figure	2.	Schematic	representation	of	the	blood	vessel	anatomy.	Copyright	©	The	McGraw-Hill	companies,	Inc.	
REGULATION	OF	BLOOD	PRESSURE	
BP	 is	controlled	by	complex	mechanisms	that	 involve	multiple	organs	and	systems,	
including	 the	 autonomic	 nervous	 system,	 vasopressor	 and	 vasodepressor	 hormones,	 the	
structure	 of	 the	 vascular	 system	 (as	mentioned	 in	 the	 previous	 section),	 total	 body	 fluid	
volume	and	 renal	 function.	Thus,	 the	 study	of	 the	BP	 regulation	 is	 complex.	 In	 this	 thesis	
some	of	the	principal	mechanisms	are	studied	and	reviewed.		
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Endothelial	function	
The	endothelium	is	the	largest	organ	in	the	body.	It	lines	the	lumen	of	all	the	blood	
vessels	of	the	human	body	and	it	has	been	estimated	to	be	100,000	Km	long	(Rajendran	et	
al.	2013)	and	to	cover	an	area	of	919,657	cm2	(Wolinsky	1980).	Since	it	was	discovered	at	
the	 beginning	 of	 the	 80’s	 that	 the	 action	 of	 acetylcholine	 requires	 the	 presence	 of	
endothelial	 cells	 (EC)	 to	 produce	 relaxation	 of	 arterial	 smooth	 muscle	 (Furchgott	 &	
Zawadzki	1980),	the	perceived	importance	of	the	endothelium	has	grown	exponentially.	As	
seen	 in	 the	 last	 section,	 the	 endothelial	 layer,	 is	 strategically	 located	 between	 the	 blood	
stream	and	the	vessel	wall	and	is	the	key	regulator	of	vascular	homeostasis.	Moreover,	it	is	
able	to	respond	to	physical	and	chemical	signals	regulating	vascular	tone,	cellular	adhesion,	
thromboresistance,	 VSMC	 proliferation	 and	 vessel	 wall	 inflammation	 (Deanfield	 et	 al.	
2007).	 In	 addition,	 it	 ensures	 the	 correct	 delivery	 of	 nutrients	 and	 oxygen	 to	 tissues.	
Alterations	of	endothelium	can	contribute	directly	 to	 the	progression	of	multiple	diseases	
including	 atherosclerosis,	 HTN,	 diabetes,	 or	 even	 cancer	 (Rajendran	 et	 al.	 2013).	 But	
probably	the	most	important	capacity	of	endothelium	is	its	ability	to	regulate	vascular	tone	
by	 releasing	 vasoconstrictor	 and	 vasodilator	 factors	 and	 to	 react	 to	 circulating	 vasoactive	
molecules	(Förstermann	&	Sessa	2012).		
Endothelial	dysfunction,	which	results	in	reduced	endothelium-dependent	dilatation,	
is	 defined	 as	 the	 disequilibrium	 between	 the	 vasodilator	 and	 vasoconstrictors	 factors	
released	 by	 the	 EC	 and	 the	 induction	 of	 a	 proinflammatory	 and	 prothrombotic	 state	
(Endemann	 &	 Schiffrin	 2004).	 When	 the	 endothelium	 is	 injured,	 it	 activates	 as	 a	 host	
defence	 response.	 This	 active	 state	 of	 the	 endothelium	 results	 in	 the	 expression	 of	
chemokines,	cytokines	and	adhesion	molecules	that	 interact	with	 leucocytes	and	platelets	
(Deanfield	 et	 al.	 2007),	 such	 as,	 intercellular	 adhesion	 molecule-1	 (ICAM-1),	 vascular	
adhesion	molecule-1	 (VCAM-	1),	E-selectin,	and	nuclear	 factor	kappa-light-chain-enhancer	
of	activated	B	cells	(NFkB)	(Endemann	&	Schiffrin	2004).	Chronic	exposure	to	cardiovascular	
(CV)	 risk	 factors	 can	 lead	 to	a	 loss	 in	 integrity	of	 EC	 that	 can	progress	 to	 senescence	and	
detachment	 from	 the	 vascular	 wall	 (Deanfield	 et	 al.	 2007).	 As	 changes	 in	 endothelial	
function	precede	the	development	of	CVD,	endothelial	dysfunction	reflects	the	on-going	CV	
risk	 and,	moreover,	 changes	 in	 the	 endothelial	 function	 can	 be	 useful	 also	 to	 assess	 the	
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success	of	therapy	(Matsuzawa	et	al.	2014).		
The	endothelium	locally	produces	vasodilator	substances	 like	nitric	oxide	(NO),	one	
of	 the	 best-characterised	 vasodilator	 endothelial	 factors	 (Loscalzo	 &	 Welch	 1995),	 and	
other	 vasodilator	 agents	 such	 as	 prostacyclin	 or	 prostaglandin	 I2	 (PGI2),	 endothelium-
derived	hyperpolarizing	factor	and	C-type	natriuretic	peptide	(Endemann	&	Schiffrin	2004).	
Also	endothelium	regulates	vasomotion	by	secreting	vasoconstrictor	factors	including	ET-1,	
one	 of	 the	 strongest	 known	 vasoconstrictors	 (Yanagisawa	 et	 al.	 1988;	 Böhm	 &	 Pernow	
2007)	and	thromboxane	A2	(TXA2)	(Smith	et	al.	1980).	Endothelium	also	produces	reactive	
oxygen	 species	 (ROS)	 (Yoshihiro	 Taniyama	&	Griendling	 2003)	 and	 converts	 Angiotensin	 I	
(Ang	I)	to	Ang	II	at	the	endothelial	surface	(Brasier	2002).	Figure	3	summarises	some	of	the	
endothelial	mechanisms	to	regulate	BP.	
Endothelial-derived	vasodilator	factors	
As	mentioned	before,	the	most	 important	endothelial	vasodilator	factor	 is	NO.	This	
molecule	 in	physiological	state,	maintains	the	vascular	wall	 in	a	quiescent	state,	 inhibiting	
platelet	aggregation	and	adhesion,	 leucocyte	adhesion,	vascular	 inflammation	and	growth	
factor	 stimulated	 proliferation	 and	 migration	 of	 VSMC	 (Deanfield	 et	 al.	 2007).	 NO	 also	
stimulates	 angiogenesis	 and	 extracellular	 matrix	 turnover	 (Förstermann	 &	 Sessa	 2012;	
Deanfield	et	al.	2007).	This	signalling	molecule	is	synthetized	by	nitric	oxide	synthase	(NOS)	
enzyme.	There	are	three	isoforms	of	the	enzyme:	the	neuronal	NOS,	 inducible	NOS	or	the	
endothelial	NOS	(eNOS).	This	last	one	is	mostly	expressed	in	the	endothelium;	however,	 it	
can	also	be	found	in	cardiac	myocytes,	platelets,	certain	neurons	of	the	brain,	 in	syncytio-
trophoblasts	of	 the	human	placenta	and	 in	kidney	 tubular	epithelial	 cells	 (Förstermann	&	
Sessa	2012).	In	EC,	eNOS	is	located	in	the	plasmatic	membrane	in	a	complex	with	caveolin-
1,	its	inhibitor.	When	shear	stress,	bradykinin	(BK),	adenosine,	Ca2+,	serotonin	or	endothelial	
growth	factor	activates	endothelium,	eNOS	dissociates	from	its	complexes.	Protein	kinase	b	
(Akt)	and	protein	kinase	A,	phosphorylate	and	activate	eNOS	 (Lee	et	al.	2014).	Moreover,	
the	binding	of	eNOS	with	Heat-shock	protein	90	 (HSP-90)	 facilitates	 the	disruption	of	 the	
eNOS-caveolin-1	 complex	 and	 facilitates	 the	 phosphorylation	 of	 eNOS	 (Nedvetsky	 et	 al.	
2002).	 Active	 eNOS	 catalyses	 the	 transformation	 of	 L-arginine	 to	 L-citrulline	 and	 NO;	
whereupon,	 NO	 diffuses	 to	 the	 surrounding	 VSMC	 and	 activates	 soluble	 guanylyl	 cyclase	
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producing	cyclic	guanosine	monophosphate	(cGMP).	This	molecule	activates	protein	kinase	
G,	the	primary	downstream	target,	which	activates	the	myosin	light-chain	phosphatase,	and	
this	last	dephosphorylates	smooth	muscle	myosin.	All	this	leads	to	relaxation	of	the	muscle	
layer	 and	 vasodilatation	 (Kang	 2014;	 Förstermann	 &	 Sessa	 2012).	 L-arginase	 can	 also	
catalyse	 the	 transformation	of	 L-arginine	 to	ornithine	 and	urea,	 and	 compete	directly	 for	
the	substrate	of	eNOS	(Durante	et	al.	2007).		
	
Figure	 3.	 Endothelial-derived	 vasoactive	molecules.	 ACE:	 angiotensin	 converting	 enzyme;	Ang:	 angiotensin;	 AT1:	
Angiotensin	 type	 1	 receptor;	 cAMP:	 cyclic	 adenosine	monophosphate;	 cGMP:	 cyclic	 guanosine	monophosphate;	
COX:	 cyclooxygenase;	ECE:	endothelin	 converting	enzyme;	EDHF:	endothelial-derived	hyperpolarizing	 factors;	ET:	
endothelin;	ETA:	endothelin	receptor	A;	ETB:	endothelin	receptor	B;	eNOS:	endothelial	nitric	oxide	synthase;	L-Arg:	
L-arginine;	NADPH	ox:	nicotinamide	adenine	dinucleotide	phosphate-oxidase;	NO:	nitric	oxide;	PGI2:	prostaglandin.	
I2	 or	 prostacyclin;	 PGI2S:	 Prostaglandin	 I2	 synthase;	 ROS:	 reactive	 oxygen	 species;	 Sirt-1:	 Sirtuin	 1;	 TXA2:	
thromboxane	A2.	
On	the	other	hand,	eNOS	transcription	can	be	modulated	by	numerous	physiological	
and	 pathophysiological	 stimuli	 like	 shear	 stress,	 transforming	 growth	 factor-beta1,	
lysophosphatidylcholine	 (LPC),	 cell	 growth,	 oxidized	 linoleic	 acid	 or	 hydrogen	 peroxide	
(H2O2)	 (Searles	 2006).	 Moreover,	 eNOS	 can	 be	 upregulated	 by	 the	 transcriptor	 factor	
Krüpple	 like	 factor	 2	 (KLF2),	 a	 key	 endothelial	 transcription	 factor	with	 a	 broad	 range	 of	
cardioprotective	actions	(Dekker	et	al.	2006;	SenBanerjee	et	al.	2004;	Parmar	et	al.	2006),	
including	 inhibition	 of	 endothelial	 genes	 like	 ET-1	 (Atkins	 &	 Jain	 2007).	 On	 the	 contrary,	
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stimuli	 like	 tumour	 necrosis	 factor-alpha	 (TNFα),	 hypoxia,	 lipopolysaccharide,	 thrombin,	
and	oxidized	low-density	lipoprotein	(LDL)	can	decrease	eNOS	mRNA	levels	(Searles	2006).	
In	 endothelial	 dysfunction,	 the	 ROS	 signalling	 gets	 activated.	 Superoxide	 (O2
-)	 that	
reacts	 with	 NO	 to	 form	 peroxynitrite	 (ONOO-),	 reduces	 NO	 availability	 and	 decreases	 its	
protective	 action	 in	 endothelium.	 In	 this	 pathological	 condition,	 eNOS	 uncoupling	 can	 be	
also	 induced.	 eNOS	 which	 normally	 helps	 maintain	 the	 endothelial	 function,	 can	 also	
produce	of	O2
-	 in	absence	of	its	cofactor	tetrahydrobiopterin	(BH4)	or,	produce	H2O2	when	
L-arginine	 is	 deficient	 (Förstermann	 &	 Münzel	 2006;	 Landmesser	 et	 al.	 2003).	 This	
controversial	 action	 of	 eNOS	 puts	 this	 enzyme	 in	 the	 centre	 of	 endothelial	 homeostasis	
(Deanfield	et	al.	2007).		
In	addition	to	NO,	EC	secrete	PGI2	(or	prostacyclin),	which	was	the	first	endothelium-
derived	relaxing	substance	described	(Vane	et	al.	1987).	The	stimuli	needed	for	the	release	
of	 PGI2	 are	 similar	 to	 those	necessary	 for	NO	 release.	Arachidonic	 acid	 is	 transformed	by	
cyclooxygenase	 (COX)	 to	 prostaglandin	 H2	 (PGH2)	 and,	 by	 the	 action	 of	 prostacyclin	
synthase,	PGH2	is	transformed	to	PGI2	(Kang	2014).	Due	to	its	lipid	structure,	PGI2	can	easily	
diffuse	 to	 the	 VSMC	 layer	 where	 it	 binds	 to	 its	 receptor,	 activates	 adenylyl	 cyclase	 and	
protein	 kinase	 A	 signal	 transduction	 pathway	 that	 would	 lead	 to	 vasorelaxation	 (Kang	
2014).	 In	 EC	 the	 release	 of	 NO	 is	 facilitated	 by	 PGI2,	 and	 vice	 versa;	 NO	 potentiates	 the	
action	of	PIG2	in	VSMC	(Flammer	&	Lüscher	2010b).	PGI2	 is	released	in	a	transient	manner	
and	 is	 not	 responsible	 of	 the	 basal	 vascular	 tone	 in	 large	 arteries;	 although,	 its	 role	 in	
vasculature	 is	 important	 when	 NO	 bioavailability	 is	 compromised	 (Flammer	 &	 Lüscher	
2010b).		
In	 the	 absence	 of	 eNOS	 and	 COX	 relaxing	 pathways,	 the	 endothelium	 releases	
endothelial-derived	 hyperpolarizing	 factors	 (EDHF)	 to	 produce	 vasorelaxation.	 EDHF	
stimulate	 the	 opening	 of	 K+	 channels	 of	 VSMC,	 increasing	 the	 efflux	 of	 this	 ion	 and	
producing	hyperpolarization.	Consequently,	 the	Ca2+	channels	are	 inhibited	to	reduce	Ca2+	
influx,	 which	 causes	 vasorelaxation	 (Flammer	 &	 Lüscher	 2010a;	 Kang	 2014).	 When	
inhibition	 of	 NO	 (by	 N(ω)-monomethyl-L-arginine	 (L-NAME))	 and	 PGI2	 (by	 aspirin)	 is	
produced,	 regulation	 of	 vasodilatation	 occurs	 through	 EDHF	 mechanisms	 (Taddei	 et	 al.	
1999).	Moreover,	in	early	stages	of	endothelial	dysfunction,	the	action	of	PGI2	and	EDHF	are	
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essential	for	the	maintenance	of	vascular	homeostasis	and,	in	fact,	EDHF	are	described	as	a	
compensatory	 mechanism	 when	 NO	 availability	 decreases	 (Flammer	 &	 Lüscher	 2010b).	
Some	of	the	EDHF	compounds	are	potassium,	cytochrome	P450	metabolites,	lipoxygenase	
products,	 NO	 itself,	 H2O2,	 cyclic	 adenosine	 monophosphate	 (cAMP),	 C-type	 natriuretic	
peptide,	and	electrical	coupling	through	myoendothelial	gap	junctions	(Flammer	&	Lüscher	
2010b).		
Endothelial-derived	vasoconstrictor	factors	
In	 addition,	 the	maintenance	of	 vascular	homeostasis	 also	depends	of	presence	of	
vasoconstrictor	 factors	 that	 help	 keeping	 the	 correct	 endothelial	 function.	 In	 this	 regard,	
the	 most	 important	 endothelial-derived	 vasoconstrictor	 factor	 is	 ET-1.	 This	 peptide	 is	
formed	 by	 the	 action	 of	 endothelin	 converting	 enzyme	 (ECE)	 on	 its	 precursors,	 the	 big	
endothelin.	Mature	ET-1	diffuses	to	the	VSMC	layer	and	binds	to	its	receptors,	ETA	and	ETB	
(Flammer	&	Lüscher	2010b).	The	induction	of	ET-1	production	and	release	is	modulated	by	
different	 stimulus;	 such	 us,	 shear	 stress,	 Ang	 II,	 adrenaline,	 thrombin,	 oxidised	 LDL	 and	
inflammatory	cytokines	(Flammer	&	Lüscher	2010a).	
On	 the	 other	 hand,	 PGH2	 can	 also	 be	 targeted	 by	 thromboxane	 synthase	 for	 the	
formation	 of	 TXA2,	with	 contractile	 actions.	 In	 fact,	 there	 is	 a	 balance	 between	 PIG2	 and	
TXA2.	 TXA2	 is	mainly	 produced	by	 the	 immune	 system;	 however,	 EC	 in	 response	of	 shear	
stress	can	also	produce	this	vasoconstrictor	factor	(Gryglewski	et	al.	2001;	Kang	2014).	
Sirtuins	in	endothelial	function	
Silent	 information	 regulator	 factor	 2	 related	 enzyme	1	 (Sirt-1)	 is	 a	 class	 III	 histone	
deacetylase	 involved	 in	 many	 physiological	 processes	 such	 as	 gene	 silencing,	 genomic	
stability,	 cell	 longevity,	 and	metabolic	 regulation.	 Sirt-1	 can	 act	 through	 deacetylation	 of	
histones	 and	 a	 variety	 of	 non-histone	 substrates	 (Ma	&	 Li	 2015).	 Initially	 Sirt-1	 had	 been	
studied	 for	 its	 implication	 in	 the	 aging	 process	 but	 recently	 it	 has	 been	 described	 to	 be	
important	 in	 CVD	 and	 arteriosclerosis	 (Potente	 &	 Dimmeler	 2008).	 Sirt-1	 in	 endothelium	
mainly	 acts	 through	 inhibition	 of	 leukocytes	 adhesion	 and	 regulation	 of	 eNOS	 (Stein	 &	
Matter	2011).	Specifically,	Sirt-1	 increases	availability	of	NO	by	deacetylation	of	eNOS	and	
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enhancing	 NO	 synthesis	 (Mattagajasingh	 et	 al.	 2007).	Moreover,	 overexpression	 of	 Sirt-1	
specifically	 in	 endothelium	 improves	 endothelium-dependent	 vasodilation	 (Zhang	 et	 al.	
2008).	 On	 the	 other	 hand,	 Sirt-1	 decreases	 oxidative	 stress;	 in	 fact,	 knockouts	 for	 Sirt-1	
have	 increased	 inflammatory	 cytokines	 (Yoshizaki	 et	 al.	 2009).	 Furthermore,	 in	 MetS	
induced	by	high-fat	diet	a	 reduction	 in	Sirt-1	expression	 in	aorta	has	been	described	and,	
overexpression	 of	 Sirt-1	 promotes	 endothelium-dependent	 vasodilation	 under	 high	
cholesterol	conditions	(Ota	et	al.	2007).	
Oxidative	stress	and	vascular	homeostasis	
When	 chronic	 production	 of	 ROS	 exceeds	 the	 capacity	 of	 cellular	 enzymatic	 and	
nonenzymatic	antioxidants,	oxidative	stress	is	produced.	ROS	overproduction	contributes	to	
endothelial	dysfunction	and	vascular	disease	(Konior	et	al.	2014).	In	fact,	inflammation	and	
vascular	 oxidative	 stress	 are	 the	 key	 phenotypic	 disorders	 related	 to	 endothelial	
dysfunction	 and,	 the	 improvement	 of	 both	 states	 has	 been	 described	 to	 reverse	 this	
pathological	 condition	 (Widlansky	et	al.	2003).	Normal	 cells	 form	 free	 radicals	 through	 its	
physiological	 metabolism.	 The	 major	 source	 of	 ROS	 in	 the	 cells	 is	 the	 mitochondria	
(Deanfield	 et	 al.	 2007).	 However,	 in	 endothelium,	 nicotinamide	 adenine	 dinucleotide	
phosphate	(NADPH)	oxidases	are	the	major	sources	of	ROS	(Gorlach	et	al.	2000).	Actually,	
coordinated	 sources	 of	 ROS	 from	 mitochondria	 and	 NADPH	 have	 been	 described	 to	 be	
found	in	hypertensive	states	(Dharmashankar	&	Widlansky	2010).	Besides,	in	patients	with	
coronary	 diseases,	 increased	 activity	 of	 NADPH	 oxidase	 in	 arteries	 has	 been	 found	
(Griendling	 et	 al.	 2000;	 Spiekermann	 2003),	 and	 inhibition	 of	 this	 enzyme	 improves	
endothelial	function	in	rat	and	human	vessels	(Hamilton	et	al.	2002).		
NADPH	oxidases	 form	a	complex	with	multiple	subunits	 like	Nox1,	Nox2,	Nox4	and	
Nox5;	 these	 lasts	 are	 all	 expressed	 in	 endothelium,	 VSMC,	 fibroblasts	 and	 perivascular	
adipocytes	 (Konior	 et	 al.	 2014).	 The	 importance	 of	NADPH	oxidase	 in	 the	 endothelium	 is	
due	to	its	capacity	to	react	to	different	agonists	like	Ang	II,	which	increases	NADPH	oxidase-
derived	 ROS	 (Drummond	 et	 al.	 2011).	 Nox1/Nox2	 are	 involved	 in	 the	 development	 of	
endothelial	dysfunction,	HTN	and	inflammation.	While	Nox4	may	have	a	protective	role	in	
vasculature	under	stress	condition;	however	this	is	a	controversial	fact	because	an	increase	
in	this	subunit	may	be	also	detrimental	(Konior	et	al.	2014).	In	fact,	overexpression	of	Nox4	
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has	been	described	 in	 atherosclerotic	 arteries	 (Sorescu	et	 al.	 2002).	Nox5	by	 its	 side,	 has	
been	 reported	 to	 be	 related	 to	 oxidative	 damage	 in	 human	 arthrosclerosis	 (Konior	 et	 al.	
2014).	
In	HTN,	NADPH	oxidases	activity	 leads	 to	oxidation	 in	endothelium	of	 the	 cofactor	
BH4	and,	as	mentioned	above,	at	 low	concentration	of	BH4	and	L-arginine,	eNOS	can	also	
generate	significant	amounts	of	ROS	and	promote	endothelial	dysfunction	 (Drummond	et	
al.	2011).	Moreover,	in	hypertensive	patients,	oxidative	stress	decreases	NO	availability	by	
direct	 scavengement;	 and	 moreover,	 oxidative	 stress	 correlates	 with	 endothelial	
dysfunction	and	endothelium-dependent	vasodilation	(Chen	et	al.	2001;	Taddei	et	al.	1998).	
Additionally,	ROS	are	 involved	 in	the	endothelial	damage	 leading	to	apoptosis	and	anoikis	
(Li	et	al.	1999;	Dimmeler	&	Zeiher	2000)	as	well	as	in	the	expression	of	adhesion	molecules	
and	angiogenesis	(Y	Taniyama	&	Griendling	2003).		
Renin-Angiotensin-Aldosterone	System		
RAAS	 is	 probably	 the	 most	 important	 BP	 regulator	 system.	 Under	 physiological	
conditions,	 the	 decrease	 of	 blood	 volume	 induces	 the	 production	 of	 renin	 in	 the	 kidney.	
Renin	 cleavages	 angiotensinogen	 produced	 in	 liver,	 to	 form	 an	 inactive	 peptide,	 Ang	 I	
(Figure	4).	This	last	is	then	hydrolysed	by	the	angiotensin-converting	enzyme	(ACE)	to	form	
Ang	 II,	 the	 vasoactive	 peptide	 of	 the	 system	 (Stolarz-Skrzypek	 et	 al.	 2013).	 ACE	 can	 also	
hydrolyse	BK,	a	strong	vasodilator	needed	for	 the	generation	of	NO	 in	endothelium.	Even	
that	 the	 most	 evident	 action	 of	 ACE	 is	 the	 formation	 of	 Ang	 II,	 studies	 in	 animals	 have	
showed	that	 inhibition	of	BK	degradation	contributes	more	to	the	BP	lowering	effect	than	
the	inhibition	of	Ang	II	formation	(Aptecar	et	al.	2000;	Barbe	et	al.	1996;	Su	et	al.	1999).	
ACE	 is	 mainly	 produced	 in	 the	 endothelium	 of	 lungs	 (Xiao	 et	 al.	 2004)	 but	 local	
production	 of	 ACE	 by	 EC	 in	 other	 tissues	 has	 been	 described	 in	 the	 literature	 (Riet	 et	 al.	
2015).	However,	 the	 local	production	of	ACE	 in	endothelium	has	been	reported	not	 to	be	
essential	for	the	maintenance	of	BP;	in	fact,	depletion	of	endothelial	ACE	in	mice	does	not	
affect	BP	because	the	production	of	ACE	in	liver	and	kidney	counteracts	this	lack	(Cole	et	al.	
2002).	 In	 endothelium,	 ACE	 is	 located	 in	 the	 cell	 surface	 and	 converts	 circulating	 Ang	 I	
rapidly	to	Ang	II,	that	binds	to	its	receptors	AT1	(AT1a	and	AT1b	in	rats)	and	AT2	that	induce	
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its	internalization.	Indeed,	the	concentration	of	tissue	levels	of	Ang	II	are	closely	related	to	
AT	 receptor	 density	 (van	 Kats	 et	 al.	 1997).	 Ang	 II	 bound	 to	 AT1	 receptor	 produces	
vasoconstriction	of	 the	vessels,	endothelial	dysfunction,	 thirst	and	release	of	aldosterone,	
which	elevates	water	and	salt	reabsorption	in	the	kidneys	(Endemann	&	Schiffrin	2004).	In	
fact,	the	blockage	of	RAAS	in	humans	with	ACE	inhibitors	or	Ang	II	blockers	no	only	reduces	
BP	 but	 also	 restores	 endothelial	 function	 (Endemann	 &	 Schiffrin	 2004).	 Moreover,	 the	
binding	 of	 Ang	 II	 to	 AT1	 receptor	 stimulates	 NADPH	 oxidases	 in	 EC	 and	 VSMC	 and,	 it	
produces	 oxidative	 stress	 and	 inflammation	 (Endemann	 &	 Schiffrin	 2004);	 whereas	 the	
binding	 of	 Ang	 II	 to	 AT2	 receptors	 is	 believed	 to	 counteract	 all	 these	 deleterious	 effects	
(Padia	&	Carey	2013).	However,	there	are	controversial	results	in	this	last	funding,	because	
it	has	been	described	in	spontaneously	hypertensive	rats	(SHR)	that	AT2	receptors	may	act	
as	AT1	receptors	(You	et	al.	2005;	Moltzer	et	al.	2010).	Therefore,	the	beneficial	effects	of	
the	 upregulation	 of	 AT2	 receptors	 in	 pathological	 conditions	 are	 questioned	 (Riet	 et	 al.	
2015).	
	
Figure	 4.	 Schematic	 representation	 of	 the	 classical	 Renin-Angiotensin-Aldosterone	 system.	 ACE:	 angiotensin	
converting	enzyme;	Ang:	angiotensin;	AT1	R:	Angiotensin	II	type	1	receptor;	AT2	R:	angiotensin	II	type	2	receptor;	
Mas	R:	Mas	receptor.	
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As	tissue	production	of	each	of	the	components	of	RAAS	was	observed,	lately	it	was	
questioned	the	real	site	of	action	of	the	RAAS	blockers	and	it	has	led	to	the	concept	of	local	
RAAS	 in	various	organs,	 including	 the	vessels	or	adipose	tissue	 (Nguyen	Dinh	Cat	&	Touyz	
2011;	Engeli	et	al.	2003).	However,	 circulating	RAAS	and	 local	 tissue	RAAS	are	 thought	 to	
work	complementary,	not	in	a	opposite	way	(Fyhrquist	&	Saijonmaa	2008).	Systemic	RAAS	
is	 the	 regulator	 of	 systemic	 volume,	 electrolyte	 balance	 and	 BP;	 while	 local	 RAAS	 is	 in	
charge	 of	 tissue	 effects	 like	 proliferation,	 growth	 and	 protein	 synthesis	 (Fyhrquist	 &	
Saijonmaa	2008).	Nevertheless,	Ang	 II	 generation	 completely	depends	on	 renal	 renin	and	
largely	 on	 hepatic	 angiotensinogen.	 However,	 both	 can	 diffuse	 to	 the	 interstitium	 of	 the	
cells	and	generate	locally	Ang	II	(Riet	et	al.	2015).		
On	 the	 other	 hand,	 and	 as	mention	 before,	 the	 binding	 of	 Ang	 II	 to	 AT1	 receptor	
induced	 the	 production	 of	 aldosterone	 in	 the	 suprarenal	 glands.	 This	 steroid	 hormone	 is	
involved	in	volume	and	BP	regulation	through	sodium	and	water	retention	regulation	(Briet	
&	 Schiffrin	 2013).	 Beyond	 BP,	 aldosterone	 also	 induces	 renal	 inflammation,	 fibrosis	 and	
remodelling	(Riet	et	al.	2015).	In	fact,	it	has	been	described	as	CV	and	HTN	risk	factor	(Vasan	
et	 al.	 2004).	 In	 EC,	 high	 aldosterone	 levels	 increase	 the	 expression	 of	 sodium	 channels	
leading	 to	 stiffening	of	 the	 cells	 and	 to	 an	 increase	of	 sodium	 influx,	which	will	 lead	 to	 a	
decrease	 of	 NO	 release	 by	 eNOS	 (Oberleithner	 et	 al.	 2007).	 Consequently,	 endothelial	
dysfunction	will	be	induced	(Riet	et	al.	2015).		
In	 pathological	 situations	 as	 HTN,	 an	 overactivation	 of	 RAAS	 occurs,	 that	 not	 only	
produces	an	 increase	of	BP	but	also	produces	damages	 in	other	tissues	(Jayasooriya	et	al.	
2008;	de	Kloet	et	al.	2009;	Weisinger	et	al.	2008;	Santos,	Ferreira	&	Simões	E	Silva	2008).	
Initially	hyperactivation	of	RAAS	can	produce	asymptomatic	damages	like	microalbuminuria	
or	 left	 ventricle	hypertrophy,	and	derive	 to	 renal,	 cerebrovascular,	 cardiac	and	peripheral	
vascular	disease	(Dzau	et	al.	2006).	Moreover,	RAAS	hyperactivity	is	associated	with	obesity	
(Kotsis	et	al.	2010);	in	fact,	fat	restriction	reduces	the	levels	of	RAAS	components,	indicating	
that	 the	 degree	 of	 adiposity	 might	 have	 direct	 influence	 in	 this	 BP-regulating	 system	 (L	
Mathai	et	al.	2011).	Moreover,	Ang	II	has	proinflammatory,	pro-oxidative	and	salt	retaining	
effects	and,	Ang	 II	 is	 capable	of	 inhibiting	 the	action	of	 insulin	 in	 the	VSMC	 layer	 through	
AT1	 receptor,	 interfering	 with	 the	 phosphatidylinositol	 4	 kinase	 (PI3K)	 and	 Akt	 signalling	
pathways	 (Weir	 1999;	 Leung	 &	 Leung	 2008).	 This	 interference	 in	 signalling	 pathways	
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directly	decreases	NO	production	and	reduces	glucose	transport	in	skeletal	muscle	(Sowers	
2004).	 On	 the	 other	 hand,	 Ang	 II	 action	 can	 also	 interfere	 in	 the	 progression	 of	 hepatic	
steatosis	and	fibrosis	(Jonsson	et	al.	2001).	
In	vascular	function,	cross	talks	between	RAAS	and	other	 important	pathways	have	
been	described.	As	 it	will	be	explained	below,	one	of	 these	 interactions	occurs	with	RAAS	
and	Kallikrein-Kinin	system	(KKS).	Another	one	is	the	link	between	Ang	II	and	Sirt-1	though	a	
mitogen	activated	pathway	kinases	(MAPK).	The	MAPK	signalling	pathway	controls	cellular	
response	 to	 the	oxidative	 stress	 and	 regulates	 the	 expression	of	 several	 proteins	 such	 as	
Sirt-1	(Passariello	et	al.	2011).	According	to	the	results	of	Marampon	et	al.	(Marampon	et	al.	
2013),		the	binding	of	Ang	II	to	AT1	activates	RAS/p38	(MAPKs)	pathway	and	consequently	
p38,	 forming	 a	 protein	 complex	 that	 sequestrates	 Sirt-1	 into	 the	 cytoplasm	 avoiding	 to	
travel	 to	 the	nucleus	 to	 exert	 its	 function.	Moreover,	 the	 activation	of	 p38	 represses	 the	
Sirt-1	protein	expression.	In	addition,	another	described	connection	between	RAAS	and	Sirt-
1	is	mediated	by	the	inhibition	of	AT1	receptor	expression	by	Sirt-1	(Miyazaki	et	al.	2008)	
In	addition	to	the	classical	RAAS,	this	system	presents	a	cardioprotective	branch.	In	
fact,	Ang	 II	 can	also	been	hydrolysed	by	angiotensin	 converting	enzyme	2	 (ACE2)	 to	 form	
Ang-(1-7)	(Sampaio	et	al.	2007),	which	present	a	weak	direct	vasodilator	effect	(Riet	et	al.	
2015).	Ang-(1-7)	binds	to	Mas	receptor	and	exerts	opposite	effects	to	Ang	II	bound	to	AT1	
receptor	 (Santos	 et	 al.	 2003)	 producing	 an	 increment	 of	 NO	 release,	 thus	 improving	
endothelial	function	(Sampaio	et	al.	2007).	Moreover,	Ang	–(1-7)	promotes	the	production	
of	 the	 vasodilator	 BK	 (Paula	 et	 al.	 1995;	 Tom	 et	 al.	 2003)	 and	 it	 has	 been	 attributed	
beneficial	 effects	 as	 protection	 against	 heart	 failure,	 natriuretic,	 antithrombotic,	
antihypertrophic,	antifibrotic,	and	antiarrhythmic	effects,	attenuation	of	plaque	formation	
and	 amelioration	 of	MetS-related	 vascular	 dysfunction	 (Santos,	 Ferreira	&	 Simões	 e	 Silva	
2008).		
Kallikrein-Kinin	system	
KKS	 is	 another	 pathway	 involved	 in	 BP	 regulation,	 and	 inflammation,	 CV	
homeostasis,	 analgesic	 responses,	 pain-transmitting	mechanisms,	 cytokines	 release,	 PGI2,	
NO	or	cell	proliferation	(Bhoola	et	al.	1992;	Pesquero	&	Bader	1998).	The	BK	is	the	effector	
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molecule	of	the	system,	which	is	liberated	to	circulation	to	exert	its	functions.	It	is	formed	
by	 the	 action	 of	 kallikrein	 on	 high	 molecular	 weight	 kininogen	 (Mombouli	 &	 Vanhoutte	
1995).	 The	 biological	 effects	 of	 BK	 are	 mediated	 by	 the	 stimulation	 of	 their	 specific	
receptors:	BK	receptor	1	(B1R)	and	2	(B2R)	(Su	2006).	The	binding	to	B2R	results	in	release	
of	 NO	 and	 PGI2,	 thus	 producing	 vasodilation;	 while	 the	 activation	 of	 B1R	 may	 play	 a	
deleterious	 action	 producing	 injury	 and	 inflammatory	 condition	 (Mombouli	 &	 Vanhoutte	
1995).	 However,	 BK	 has	 more	 affinity	 to	 B2R	 than	 for	 B1R	 (Albert-Weißenberger	 et	 al.	
2013).	BK	can	rapidly	be	metabolized	to	its	inactive	peptides	by	several	kininases	including	
aminopeptidases,	 casboxypeptidase	N	and	M	or	ACE	 (Su	2006).	 In	 fact,	ACE	 is	one	of	 the	
links	between	RAAS	and	KKS.	In	addition,	the	enzyme	kallikrein,	involved	in	the	generation	
of	 BK	 can	 also	 induce	 the	 generation	 of	 Ang	 II,	 since	 it	 catalyses	 the	 transformation	 of	
prorenin	to	renin,	which	constitutes	another	 level	of	cross-talks	between	the	RAS	and	the	
KKS	 (Figure	 5)	 (Su	 2014).	 Also,	 prolylcarboxypeptidase	 (PRCP),	 the	 enzyme	 that	 produces	
kallikrein,	 can	 also	 inactivate	 Ang	 II.	 Moreover,	 Ang-(1-7)	 exerts	 kinin-like	 effects	 and	
potentiates	the	effects	of	BK	and,	Ang	II	can	enhance	the	B1R	and	B2R	expression	(Su	2014).	
Consequently	 targeting	 both	 RAAS	 and	 KKS	 should	 be	 taken	 into	 account	 in	 the	
development	of	new	drugs	for	BP	control.		
	
Figure	 5.	 Schematic	 representation	 of	 cross-talk	 sites	 between	 Kallikrein-Kinin	 system	 and	 Renin-Angiotensin-
Aldosterone	system.	Ang:	angiotensin;	AT1	R:	Angiotensin	II	type	1	receptor;	AT2R:	angiotensin	II	type	2	receptor;	
ACE:	angiotensin	converting	enzyme;	PRCP:	prolylcarboxypeptidase;	MAS	R:	Mas	receptor;	B1R:	Bradykinin	type	1	
receptor;	B2R:	Bradykinin	type	2	receptor.	
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HYPERTENSION	AND	METABOLIC	SYNDROME	
There	 are	 evidences	 that	 obesity,	 high	 alcohol	 and	 salt	 intake,	 sedentary	 lifestyle,	
stress	and,	dyslipidemia	 increase	BP	(Carretero	&	Oparil	2000).	The	relation	between	HTN	
and	 obesity	 has	 extensively	 demonstrated	 since	 the	 1960’s	 with	 the	 Framingham	 Heart	
Study	 (Kannel	 et	 al.	 1967).	 Obesity,	 and	 especially	 abdominal	 obesity,	 is	 the	 main	
hypertensinogenic	 factor.	 Indeed,	 it	 is	 estimated	 that	 the	75%	of	 the	 incidence	of	HTN	 is	
directly	 related	 to	 obesity	 (Go	 et	 al.	 2013).	 Moreover,	 the	 risk	 of	 development	 of	 HTN	
increases	20-30%	with	every	5%	 increment	of	body	weight	 (Drøyvold	et	al.	2005).	On	 the	
other	hand,	patients	with	HTN	also	tend	to	gain	more	weight	than	normotensive	patients,	
indicating	that	HTN	contributes	also	to	 increase	the	risk	of	obesity	(Kannel	et	al.	1967).	 In	
fact,	only	a	 small	 fraction	of	hypertensive	patients	present	only	HTN,	 the	majority	exhibit	
additional	 CV	 risk	 factors,	 that	 may	 potentiate	 each	 other	 (Mancia,	 Fagard,	 Narkiewicz,	
Redón,	et	al.	2013).	
According	 to	 the	 International	 Diabetes	 Federation	 (IDF)	 definition,	 patients	 with	
central	obesity	and	two	or	more	components	described	in	Table	2	are	diagnosed	with	MetS	
This	 syndrome	 is	 defined	 as	 a	 cluster	 of	 the	 most	 dangerous	 heart	 attack	 risk	 factors:	
diabetes	and	raised	fasting	plasma	glucose,	abdominal	obesity,	high	cholesterol	and	high	BP	
(Alberti	et	al.	2006).	HTN	 is	one	of	 the	most	 important	 components	of	MetS,	 in	 fact,	one	
third	 of	 hypertensive	 patients	 are	 also	 diagnosed	 with	 MetS	 (Schillaci	 et	 al.	 2004).	 The	
combination	of	obesity	with	HTN	and	hyperglucemia	confers	 the	highest	 risk	 for	CVD	and	
mortality	(Franco	et	al.	2009).	
Table	2.	The	International	Diabetes	Federation	definition	of	metabolic	syndrome	(Alberti	et	al.	2006).	
Raised	triglycerides	 >=	150	mg/dL	
Reduced	high-density	lipoprotein	
(HDL)	cholesterol	
<	40	mg/dL	(males)	
<	50	mg/dL	(females)	
Raised	blood	pressure	
Systolic	BP	>=130	mmHg	
Diastolic	BP	>=	85	mmHg	
Raised	fasting	plasma	glucose	 >=	100	mg/dL	
	
It	 is	 estimated	 by	 the	 IDF	 that	 a	 quarter	 of	 the	world	 population	 have	MetS	 and,	
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patients	with	MetS	are	twice	likely	to	die	and	three	times	to	have	a	heart	attack	or	stroke	
(Alberti	 et	 al.	 2006).	Moreover,	MetS	 is	 associated	with	 an	 increment	 of	 healthcare	 cost	
that	is	estimated	to	increases	about	24%	for	each	additional	MetS	component	present	(Go	
et	al.	2013).	
One	 of	 features	 of	MetS	 is	 the	 obesity	 that	 is	 characterized	 by	 hyperplasia	 of	 the	
adipose	tissue.	The	adipose	tissue	is	a	major	endocrine	organ	that	secretes	a	large	number	
of	 cytokines	 known	 as	 adipocytokines,	 among	 them	 interleukin-6	 (IL-6),	 TNFα,	
angiotensinogen,	 aldosterone	 stimulating	 factor,	dipeptidyl	peptidase	4,	 leptin,	 resistin	or	
adiponectin	(Cordero	et	al.	2006).	Some	of	the	cytokines	secreted	by	the	expanded	adipose	
tissue	are	directly	associated	with	 the	endothelial	 function	and	HTN.	 In	 fact,	 low	 levels	of	
adiponectin	are	directly	related	to	increase	BP	and	to	exert	other	actions	on	the	rest	of	the	
components	 of	 MetS,	 like	 increasing	 overweight,	 triglyceridemia	 and	 decreasing	 HDL	
cholesterol	or	to	induce	insulin	resistance	(Iwashima	et	al.	2004).	Actually,	Ang	II	high	levels,	
characteristic	of	HTN	and	MetS,	are	described	to	downregulate	adiponectin	 levels	 (Ran	et	
al.	2006).	Patients	with	obesity	and	HTN	have	also	elevated	 levels	of	 leptin,	 the	hormone	
secreted	by	adipocytes	to	regulate	energy	balance	(Eikelis	et	al.	2003).	On	the	other	hand,	
TNFα	in	EC	decreases	eNOS	expression	and	increases	ET-1,	NADPH	oxidase	in	VSMC	(Zhang	
et	al.	2009)	and	angiotensinogen	expression	(Brasier	et	al.	1996).	Furthermore,	IL-6	also	is	
able	 to	 increase	 plasma	 angiotensinogen	 and	 Ang	 II,	 leading	 to	 development	 of	 HTN	
(Takano	et	al.	1993).		
Mechanistically,	 the	 enlargement	 of	 the	 adipose	 tissue	 produces	 an	 excess	 of	
circulating	 free	 fatty	 acid	 (FFA)	 that	 in	 the	 liver,	 induce	 glucogenolysis,	 and	 synthesis	 of	
triglycerides	 and	 secretion	 of	 very	 low-density	 lipoprotein	 (VLDL).	 The	 abnormalities	
between	lipids	and	lipoproteins	produce	a	decrease	of	HDL	cholesterol	and	an	increase	of	
cholesterol	 associated	 with	 LDL	 (Eckel	 et	 al.	 2005;	 Redon	 et	 al.	 2008).	 Furthermore,	 the	
circulating	FFA’s	also	reduce	the	sensibility	of	 the	muscle	to	 insulin	and	 insulin	resistance,	
inhibiting	 the	 insulin-dependent	 internalization	 of	 glucose	 and,	 inducing	 an	 excessive	
accumulation	 of	 triglycerides.	 FFA	 by	 itself	 also	 contribute	 to	 the	 pathogenesis	 of	 the	
vascular	dysfunction	(Campia	et	al.	2012).	Moreover,	high	concentration	of	circulating	FFA	
and	glucose	 in	the	pancreas	 increase	the	secretion	of	 insulin,	producing	hyperinsulinemia.	
This	last	condition	produces	a	reabsorption	of	sodium	in	the	kidneys	and	an	overactivity	of	
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the	sympathetic	nervous	system,	which	indeed	increases	BP	(Eckel	et	al.	2005).	
Likewise,	insulin	resistance	produces	a	proinflammatory	state.	As	mentioned	before	
adipocytes	and	also	macrophages	secrete	IL-6	and	TNFα,	which	will	 lead	to	lipolysis	of	the	
triglycerides	 in	 the	 adipose	 tissue	 and	 liberation	 of	 more	 FFA’s.	 Moreover,	 the	
proinflammatory	cytokines	will	increase	insulin	resistance,	production	of	glucose,	VLDL	and,	
together	with	FFA	will	activate	the	production	of	fibrinogen	in	the	liver	and	inhibitor	of	the	
activator	 of	 plasminogen	 I	 in	 liver	 and	 adipose	 tissue,	 leading	 to	 a	 prothrombotic	 state	
(Eckel	 et	 al.	 2005).	Additionally,	 insulin	 resistance	 contributes	 to	 vascular	 stiffness	 and	 to	
endothelial	 and	VSMC	dysfunction.	 Specifically	 it	 contributes	 to	 reduce	availability	of	NO,	
impair	vascular	relaxation	and	increase	ET-1	pathway	(Irving	et	al.	2001).		
	
Figure	 6.	Schematic	 representation	of	 the	mechanisms	of	HTN	associated	with	MetS.	Adapted	 from	(Yanai	et	al.	
2008).	 Ang:	 angiotensin;	 ET:	 endothelin;	 FFA:	 free	 fatty	 acids;	 IL-6:	 interleukin	 6;	 NO:	 nitric	 oxide;	 TNFα:	 tumor	
necrosis	factor	α.	
Additionally,	 MetS	 also	 produces	 dysfunction	 of	 RAAS	 by	 inducing	 changes	 in	 the	
renal	system,	glomerular	filtration	and	producing	natriuresis,	which	indeed	will	activate	the	
RAAS	 and	 increase	 BP	 and	 CV	 risk	 (DeMarco	 et	 al.	 2014).	 Furthermore,	 the	 described	
overactivation	 of	 RAAS,	 characteristic	 of	 HTN	 and	 MetS,	 produces	 an	 increase	 in	 ACE	
activity	and	expression,	a	decrease	in	renin	gene	expression	and	an	increase	of	AT1	(Engeli	
et	 al.	 2003).	 In	 the	 vasculature	 and,	 specifically	 in	 the	 perivascular	 adipose	 tissue,	 local	
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secretion	of	angiotensinogen	and	Ang	II	are	also	achieved	when	MetS	is	present	(Engeli	et	
al.	2003).	And	in	atherosclerotic	arteries,	increased	expression	of	NADPH	oxidase	subunit	2	
and	4	(Nox2	and	Nox4,	respectively)	has	been	also	observed	(Förstermann	&	Münzel	2006).	
Patients	with	MetS	also	have	incremented	levels	of	ET-1	(Tesauro	&	Cardillo	2011).	All	these	
changes	induce	vasoconstriction	and	endothelial	dysfunction	and,	are	examples	of	the	close	
relationship	between	MetS	and	HTN	(summarized	in	Figure	6).	
Animal	models	
The	 two	 animal	 models	 used	 in	 this	 thesis	 are	 the	 SHR	 and	 the	 Wistar	 rats	 fed	
cafeteria	diet.	Moreover	in	this	thesis	as	the	control	animals	it	has	been	used:	normotensive	
Wistar	Kyoto	rats	 (WKY)	as	control	 for	SHR	and	the	standard-fed	Wistar	rats	as	control	of	
the	cafeteria	rats.	
SHR	are	the	most	used	model	of	HTN.	This	model	was	developed	at	Kyoto	University	
by	inbreeding	Wistar	rats	that	showed	elevated	values	of	BP	(Okamoto	&	Aoki	1963).	This	
model	 of	 essential	 o	 primary	 HTN	 is	 very	 similar	 to	 the	 HTN	 present	 in	 humans,	 in	 both	
cases	 conditioned	 genetically	 (Okamoto	&	 Aoki	 1963;	 Trippodo	&	 Frohlich	 1981;	 Zicha	&	
Kuneš	1999).	On	the	onset	of	the	disease	the	SHR	present	an	increase	of	cardiac	output,	not	
accompanied	 by	 an	 increase	 of	 total	 peripheral	 resistance,	 but	when	HTN	 is	 established,	
cardiac	output	turn	back	to	normal	values	and	the	peripheral	resistance	increases	(Smith	&	
Hutchins	 1979)	 as	 it	 happens	 in	 humans	 (Palatini	 &	 Julius	 1997).	 Moreover,	 and	 as	 it	
happens	with	humans,	HTN	 in	SHR	gets	worse	when	abusing	of	 a	high-salt	diet,	 stress	or	
other	 environmental	 factors.	 In	 contrast	 with	 humans,	 the	 SHR	 do	 not	 tend	 to	 increase	
body	 weight,	 are	 less	 sensible	 to	 diuretics	 (as	 antihypertensive	 treatment)	 and	 seem	
protected	against	atherosclerosis	(Trippodo	&	Frohlich	1981)	(Trippodo	&	Frohlich	1981).			
Cafeteria	 diet-fed	 rats	 are	 considered	 as	 an	 exceptional	 tool	 to	 study	 obesity	 and	
MetS	that	are	pandemic	in	western	civilisation	today	(Sampey	et	al.	2011;	Higa	et	al.	2014).	
Diet	 is	 a	major	 factor	 in	 the	development	of	 these	pathologies	 (Barnard	et	al.	 1998),	 and	
one	of	the	advantages	of	this	model	is	that	it	shares	with	humans	the	pathogenesis	of	the	
disease	 (Panchal	&	Brown	2010;	 Sampey	 et	 al.	 2011),	 since	 the	majority	 of	 patients	with	
MetS	develop	this	disease	due	to	an	unhealthy	lifestyle	and	not	because	a	predisposition	to	
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genetic	 factors	 (Mancia,	 Fagard,	 Narkiewicz,	 Redón,	 et	 al.	 2013).	 Cafeteria	 diet-fed	 rats	
develop	hyperphagia,	adiposity	and	obesity	(Prats	et	al.	1989;	Muntzel	et	al.	2012;	Castro	et	
al.	 2015),	 dyslipidaemia,	 hyperinsulinemia	 and	hyperglycemia	or	prediabetes	 (Castell-Auví	
et	al.	2011;	Pinto	Júnior	&	Seraphim	2012),	hyperleptinemia	(Macedo	et	al.	2012),	hepatic	
steatosis	 (MacQueen	 et	 al.	 2007;	 Kucera	 &	 Cervinkova	 2014)	 and,	 chronic	 inflammation	
(Sampey	et	al.	2011;	Zeeni	et	al.	2015).	Regarding	the	CV	system,	these	animals	can	develop	
cardiac	 hypertrophy,	 ventricular	 dilatation,	 cardiac	 inflammation	 a	 fibrosis,	 endothelial	
dysfunction	and	impairment	of	renal	system	(Coatmellec-Taglioni	et	al.	2000).	Additionally,	
punctuated	elevated	BP	in	cafeteria	diet-fed	rats	respect	to	standard	diet-fed	rats	has	been	
reported	(Coatmellec-Taglioni	et	al.	2003;	du	Toit	et	al.	2005;	Howitt	et	al.	2011;	Pasarín	et	
al.	2012).	However,	the	use	of	cafeteria	diet-fed	rats	as	an	experimental	model	of	HTN	has	
not	been	explored,	although	this	model	could	be	very	useful	because	as	mentioned	before,	
in	 humans	 HTN	 often	 is	 associated	 with	 obesity	 and	 MetS.	 Indeed,	 two	 third	 of	
hypertensive	patients	also	exhibit	dyslipidemia	(Ferdinand	&	Kleinpeter	2006),	and	most	of	
them	present	changes	in	carbohydrate	metabolism	and	MetS	(Cordero	et	al.	2006;	Redon	et	
al.	2008).	
This	dietary	approach	consists	 in	 feeding	normal	Wistar	 rats	 to	standard	chow	and	
water,	while	 concurrently	offering	highly	palatable,	 energy	dense,	 unhealthy	human	 food	
ad	 libitum.	 Specifically,	 cafeteria	 diet	 is	 a	 high-sugar	 and	 high-fat	 diet	 given	 as	 human	
palatable	 food	 and	 not	 in	 a	 blend	 or	 pellet.	 The	 animals	 are	 given	 standard	 chow	
concurrently	with	cafeteria	food	like	muffins,	cookies,	chees,	paté,	bacon,	milk	with	sugar,	
etc.	 The	diet	can	vary	from	one	research	centre	to	another	and	one	of	the	limitations	of	the	
model	is	that	every	rat	has	freedom	to	choose	which	kind	of	food	it	prefers	and	can	be	not	
very	 homogenous	 (Rogers	 &	 Blundell	 1984),	 but	 this	 animal	 behaviour	 is	 closer	 to	 what	
happens	in	humans.		
TREATMENT	 OF	 HYPERTENSION	 ASSOCIATED	WITH	 METABOLIC	
SYNDROME		
A	change	in	lifestyle	is	the	first	strategy	suggested	in	the	current	guidelines	to	treat	
hypertensive	and	patients	with	MetS	(Mancia,	Fagard,	Narkiewicz,	Redón,	et	al.	2013;	Perk	
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et	al.	2012).	These	lifestyle	changes	that	have	demonstrated	to	reduce	significantly	BP	and	
CV	risk	factors	are:	salt	restriction,	moderation	of	alcohol	consumption,	high	consumption	
of	 vegetables	 and	 fruits	 and	 low-fat,	weight	 reduction	 and	maintenance,	 regular	 physical	
exercise	and	cessation	of	smoking	(Mancia,	Fagard,	Narkiewicz,	Redon,	et	al.	2013).	Lifestyle	
changes	 also	 have	 a	 positive	 effect	 on	 other	 CV	 risk	 factors	 such	 as	 obesity	 and	 type	 2	
diabetes	(Kotsis	et	al.	2010).	In	fact,	randomized	controlled	trials	have	found	that	lowering	
as	little	as	10	mmHg	to	hypertensive	patients	reduces	lifetime	risk	for	CVD	and	stroke	death	
by	25-40%	 (Law	et	al.	2009).	Depending	on	 the	grade	of	HTN,	pharmacological	 treatment	
would	be	needed.	But,	the	threshold	for	the	beginning	of	the	treatment	decreases	as	more	
CV	risk	factors	are	added	(Mancia,	Fagard,	Narkiewicz,	Redon,	et	al.	2013).	Normal	values	to	
start	with	medication	in	humans	are	140/90	mmHg	of	SBP	and	DBP;	while	when	obesity	or	
diabetes	 is	 present,	 the	 threshold	 decreases	 to	 130/85	mmHg	 of	 SBP	 and	 DBP	 (Mancia,	
Fagard,	Narkiewicz,	Redon,	et	al.	2013).	The	overall	goal	 in	the	treatment	of	HTN	 in	MetS	
will	 be	 to	 reduce	 the	 CV	 and	 renal	 risk	 associated	with	 each	 component	 of	MetS	 and	 to	
reduce	the	risk	of	developing	type	2	diabetes.		
Regarding	 HTN,	 the	 current	 pharmacological	 treatments	 can	 be	 classified	 in	 five	
main	groups:	diuretics,	beta-blockers,	ACE	 inhibitors	 (iACE),	angiotensin	 receptor	blockers	
and	calcium	antagonists.	The	diuretics	drugs	are	the	oldest	group	of	drugs	for	the	treatment	
of	HTN,	but	still	being	one	of	the	most	used	drugs	in	clinic	for	its	inexpensive	value	and	its	
efficacy	(National	Clinical	Guideline	center	2011).	Diuretics	decrease	the	blood	volume,	by	
stimulating	the	secretion	of	water	and	sodium,	which	indeed	decreases	the	pressure	in	the	
arterial	walls	 (Cohuet	&	Struijker-Boudier	2006).	On	the	other	hand,	β-blockers	bind	to	β-
adrenergic	 receptors	 blocking	 the	 action	 of	 its	 agonists	 like	 adrenalin	 and	 noradrenalin,	
always	at	non-detrimental	concentrations.	ACE	inhibitors	of	iACE	are	a	group	of	drugs	that	
inhibit	the	conversion	of	Ang	I	to	Ang	II.	Due	to	the	fact	that	ACE	is	also	capable	to	degrade	
the	vasorelaxing	factor	BK	(Figure	5),	these	drugs	inhibit	also	that	transformation.	Because	
Ang	II	is	also	associated	with	the	vascular	remodelling	and	oxidative	stress,	as	explained	in	
the	previous	sections,	its	inhibition	will	improve	the	detrimental	conditions	associated	with	
HTN	 (Cohuet	&	 Struijker-Boudier	 2006).	 Angiotensin	 receptor	 blockers	 are	 antagonists	 of	
AT1	 receptor	 and	 prevent	 Ang	 II	 signalling	 and,	 consequently	 its	 vasoconstrictive	 action	
(Figure	4).	However,	the	beneficial	branch	of	RAAS	regarding	AT2	receptor	is	unaffected	by	
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the	use	of	these	drugs.	The	group	of	calcium	blockers	are	drugs	that	inhibit	ionic	flow	of	this	
ion,	inhibiting	its	entrance	into	the	cytoplasm.	This	action	relaxes	the	muscle	layer,	reducing	
the	peripheral	resistance	and	the	cardiac	overload	(Cohuet	&	Struijker-Boudier	2006).	
Although	all	categories	of	antihypertensive	drugs	could	be	administrated	to	patients	
with	MetS,	 there	 are	 some	 limitations.	 It	 has	 been	 described	 that	 the	 use	 of	 diuretics	 at	
high	doses	 increases	hyperglucemia,	hyperlipidemia	and	hyperuricemia	and,	consequently	
its	 administration	 to	 patients	 with	 these	 problems	 would	 magnify	 them	 and	 would	 be	
counterproductive	 (Mancia	 et	 al.	 2006).	 On	 the	 other	 hand,	 the	 administration	 of	 β-
blockers	may	cause	 lipid	and	glucose	disorders	and	 increase	 the	risk	of	developing	 type	2	
diabetes	 (Lindholm	 et	 al.	 2003;	 Pepine	&	 Cooper-DeHoff	 2004;	 Pischon	&	 Sharma	 2001).	
Even	 though	 some	 new	 generation	 of	 β-blockers	 seem	 to	 have	 less	 negative	 effects.	
However,	ACE	 inhibitors	and	Ang	 II	blockers	are	 the	 first	 choice	 for	hypertensive	patients	
with	 MetS,	 because	 both	 have	 been	 described	 to	 inhibit	 the	 development	 of	 diabetes	
(Mancia	et	al.	2006).	Calcium	antagonists	can	be	used	alternatively	or	in	combination	with	
iACE	or	Ang	blockers	if	BP	became	resistant	to	monotherary	(Kotsis	et	al.	2010).	
POLYPHENOLS	AS	REGULATORS	OF	METABOLIC	SYNDROME	AND	
HYPERTENSION	
As	mentioned	before,	a	change	in	diet	is	considered	the	first	goal	in	the	treatment	of	
CVD.	 In	 this	 regard,	 Mediterranean	 diet	 has	 been	 described	 to	 improve	 global	 CV	 risk	
(Estruch	et	al.	2006;	Estruch	et	al.	2013)	and	also	 to	 improve	BP	and	endothelial	 function	
(Esposito	et	al.	2004;	Toledo	et	al.	2013;	Doménech	et	al.	2014).	These	beneficial	effects	on	
health	has	been	attributed	to	the	high	consumption	of	fruits	and	vegetables	(Bazzano	et	al.	
2002;	He	et	al.	2007).	Specifically	 to	polyphenols,	as	part	of	 food	composition,	have	been	
attributed	 multiple	 of	 these	 health	 benefits	 (Tresserra-Rimbau	 et	 al.	 2014).	 Polyphenols	
may	protect	CV	system	by	preventing	oxidation	of	LDL-cholesterol,	platelet	aggregation	and	
adhesion,	VSMC	migration	and	proliferation	and	by	a	direct	action	on	endothelial	function	
(Schini-Kerth	et	al.	2011).		
Polyphenols	 can	 be	 found	 as	 glycosides	 (i.e.	 attached	 to	 sugar	 moieties)	 or	 as	
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aglycones	(i.e.	not	attached	to	sugar	moieties)	and	its	bioavailability	is	fairly	low	and	highly	
dependent	of	 its	chemical	structure	and	the	degree	of	polymerisation	(Tomas-Barberán	et	
al.	 2007).	 Briefly,	 once	 ingested,	 glycosylated	 polyphenols	 are	 hydrolysed	 in	 the	 brush	
border	 of	 the	 enterocytes	 by	 α-glucosidases,	 while	 free	 forms	 are	 absorbed	 by	 passive	
diffusion.	 Glycosylated	 polyphenols	 can	 also	 be	 directly	 taken	 up	 by	 enterocytes	 via	 a	
sodium-dependent	glucose	transporter,	after	which	they	are	hydrolysed	by	α-glucosidases	
inside	 the	 cells	 (Gee	 et	 al.	 2000).	 After	 absorption,	 aglycones	 are	 metabolized	 and	
conjugated	by	phase	 II	enzymes	 i.e.,	 sulfotransferases,	 catechol-O-methyltransferases	and	
uridine-5’-diphosphate	 glucuronosyl	 transferases	 (Del	 Rio	 et	 al.	 2013).	 The	 modifications	
made	by	this	enzymes	extend	the	half-life	of	polyphenols,	typically	23-28	hours,	which	will	
increase	its	time	in	circulation	and	decrease	its	toxicity	(Thilakarathna	&	Rupasinghe	2013).	
Several	studies	have	demonstrated	that	1-2	hours	after	grape-seed	polyphenols	 ingestion,	
free	 forms	and	 their	metabolites	 target	most	 tissues,	 such	as	 the	 liver,	adipose	 tissues	or	
the	brain	 (Arola-Arnal	et	al.	2013;	Serra	et	al.	2013).	 In	addition,	the	polyphenols	that	are	
not	absorbed	in	enterocytes	can	be	metabolised	by	the	microbiota	in	the	colon,	producing	
low	 molecular	 weight	 compounds	 by	 skeleton	 cleavage	 that	 can	 then	 be	 absorbed	 and	
distributed	 throughout	 the	organism	(Serra	et	al.	2013;	Monagas	et	al.	2010).	Due	 to	 this	
complex	metabolism,	 it	 is	 important	 to	 take	 into	account	 that	 the	 circulating	metabolites	
may	substantially	differ	from	the	forms	present	in	food	sources.	
Polyphenols	can	be	classified	by	its	structure	in	flavonoids	and	non-flavonoids	forms.		
Non-flavonoids		
The	non-flavonoids	are	divided	into	two	subfamilies,	the	phenolic	and	non-phenolic	
acids.	Gallic	acid	(GA)	and	resveratrol	are	examples	of	this	family	of	polyphenols	(Figure	7).	
Resveratrol	can	be	found	in	red	wine,	grapes,	raspberries,	blueberries	or	Mexican	bamboo	
(Kopp	1998;	 Jasiński	 et	 al.	 2013;	Del	 Rio	 et	 al.	 2013)	 and,	 it	 has	been	described	 to	be	 an	
important	regulator	of	the	CV	system	(Tomé-Carneiro	et	al.	2013;	Li	et	al.	2012;	Mokni	et	al.	
2007;	Y.	Li	et	al.	2006)	and	to	have	a	direct	effect	on	BP	(Zou	et	al.	2003;	Liu	et	al.	2005;	Liu	
et	 al.	 2015).	Health	benefits	 associated	with	 resveratrol	 are	 also	 related	with	 age-related	
diseases,	including	neurodegeneration	and	carcinogenesis	(Carter	et	al.	2014;	Jasiński	et	al.	
2013);	 in	 fact,	 is	 the	 most	 potent	 natural	 activator	 of	 Sirt-1	 (Howitz	 et	 al.	 2003).	
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Furthermore,	 long-term	 treatment	with	 resveratrol	 has	 been	 described	 to	mitigate	MetS	
(Rivera	et	al.	2009).		
Gallic	acid	
GA,	also	known	as	3,4,5-trihydroxybenzoic	acid	can	be	found	as	its	free	form	in	some	
fruits	(Soong	&	Barlow	2006;	Bajpai	et	al.	2005),	vegetables	or	wine	(Pal	et	al.	2003),	or	as	a	
conjugate	 of	 the	 flavonoid	 subgroup	 flavanols	 (Press	 et	 al.	 2010).	 Specially	 asparagus,	
broccoli,	eggplants,	strawberry,	bananas	or	tea	a	natural	sources	of	GA	(Chu	et	al.	2002).	GA	
absorption	in	humans	occurs	rapidly	and	in	2	hours	reached	the	maximum	concentration	in	
plasma	(Shahrzad	et	al.	2001).		
The	health	benefits	described	 for	GA	are	multiple.	GA	has	been	described	 to	exert	
anticarcinogenic	 action	 in	 vivo	 (Mirvish	 et	 al.	 1975)	 and,	 in	 vitro	 through	 its	 antioxidant	
capacity,	GA	is	able	to	induce	selective	apoptosis	in	cancer	cells	(Inoue	et	al.	1994;	Ohno	et	
al.	 1999;	 Kawada	 et	 al.	 2001).	 Moreover,	 in	 experimental	 animal	 models	 it	 has	 been	
described	 to	 exert	 beneficial	 effects	 on	 the	 patho-biochemistry	 of	 diabetes	 and	
dyslipidaemia	 (Latha	 &	 Daisy	 2011)	 and	 in	 oxidative	 stress-induced	 myocardial	 infarcted	
hearts	 (Priscilla	 &	 Prince	 2009).	 In	 addition,	 in	 vitro	 and	 in	 vivo	 anti-inflammatory	 and	
antioxidant	 effects	 have	 been	 described	 for	GA	 (Kroes	 et	 al.	 1992).	 Furthermore,	 chronic	
supplementation	 of	 GA	 (from	 25	 to	 100	 mg/kg)	 showed	 to	 improve	 dyslipidaemia,	
hepatosteatosis	and	oxidative	stress	in	rats	with	diet-induced	obesity	(Hsu	&	Yen	2007),	to	
revert	non-alcoholic	fatty	acid	disease	induced	by	a	high-fat	diet	in	mice	by	an	improvement	
of	 lipid	 metabolism,	 glucose	 metabolism	 (glycolysis	 and	 gluconeogenesis),	 amino	 acids	
metabolism,	 choline	 metabolism	 and	 gut-microbiota-associated	 metabolism	 (Chao	 et	 al.	
2014)	 and,	 to	 exhibit	 cardioprotective	 effects	 in	 in	 streptozotocin-induced	 diabetic	 rats	
(Patel	&	Goyal	 2011).	 Improvement	 of	 platelet-leucocytes	 activation	 and	 aggregation	 has	
also	 been	 demonstrated	 in	 vitro	 after	 GA	 treatment	 (Chang	 et	 al.	 2012).	 Recently,	 the	
vasorelaxant	and	antihypertensive	effect	of	an	extract	 from	the	green	algae	Spirogyra	sp.	
rich	 in	 GA	 has	 been	 investigated	 (Kang	 et	 al.	 2015).	 Taken	 all	 together,	 it	 points	 this	
molecule	out	as	a	new	promising	treatment	of	a	bunch	of	pathologies,	including	the	MetS.		
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Figure	7.	Structure	of	the	main	non-flavonoid	subfamily	
Flavonoids	
Flavonoids	 are	 the	most	 abundant	 polyphenol	 in	 human	 diet	 and	 can	 be	 found	 in	
multiple	 plants,	 fruits	 and	 vegetables.	 The	 intake	 of	 flavonoids	 has	 been	 associated	with	
prevention	of	 chronic	diseases	 like	 cancer,	 chronic	 inflammation,	allergy,	osteoporosis,	or	
CVD	(Nijveldt	et	al.	2001;	Kumar	&	Pandey	2013).	Furthermore,	a	prospective	cohort	study	
in	men	 and	 women	 showed	 a	 positive	 correlation	 between	 flavonoid	 intake	 and	 CV	 risk	
mortality	(McCullough	et	al.	2012).		
The	 chemical	 structure	of	 flavonoids	 is	 based	on	 a	 nucleus	 of	 three	phenolic	 rings	
referred	to	as	A,	B,	and	C	rings	(Figure	8).	Specifically,	the	flavonoid	basic	structure	is	a	2-
phenyl	benzopyrone	in	which	the	three-carbon	bridge	between	the	phenyl	groups	is	usually	
a	 cyclised	 oxygen.	 Flavonoids	 can	 be	 differentiated	 into	 6	 subfamilies	 according	 to	 their	
degree	 of	 unsaturation	 and	 the	 oxidation	 level	 of	 the	 oxygenated	 heterocycle	 (Figure	 8).	
Flavanols	(essentially,	flavan-3-ols)	and	anthocyanidins	have	a	heterocyclic	pyran	as	their	C	
ring	 and	 are	 the	 most	 relevant	 for	 the	 human	 diet.	 In	 contrast,	 flavonols,	 flavones,	
flavanones,	and	isoflavones	have	a	pyrone	as	their	C	ring	(Aherne	&	O’Brien	2002).		
In	 addition,	 the	 basic	 flavonoid	 skeleton	 can	 undergo	 numerous	 substitutions,	
including	 glycosylation,	 hydrogenation,	 hydroxylation,	 malonylation,	 methylation,	 and	
sulphation.	 Hydroxyl	 groups	 are	 usually	 present	 at	 the	 4-,	 5-	 and	 7-positions.	 Sulphate	
groups	 and	glycosides	 increase	 the	water	 solubility	of	 flavonoids.	 In	 contrast,	methyl	 and	
isopentyl	 groups	 make	 flavonoids	 lipophilic.	 Finally,	 different	 studies	 have	 revealed	 the	
important	 role	 that	 the	structure	of	 flavonoid	molecules	plays	 in	 their	biological	 function;	
the	position	and	number	of	substitutions	in	the	flavonoid	basic	structure	significantly	affect	
the	antiproliferative,	cytotoxic,	antioxidant,	anti-inflammatory	and	anti-enzymatic	activities	
 
 
 
 
 
For example, resveratrol, also known as 3,5,4'-trihydroxy-trans-stilbene (Figure 3) is a 
stilbenoid produced by injured plants or after exposure to pathogens 55. This stilbene is 
a polyphenol characteristic of red wine 59, although it can be found in several fruits like 
grapes, raspberries, mulberries, or blueberries 56 and in unusually high concentrations 
in the Japanese knotweed or Mexican bamboo 6. The health benefits reported for 
resveratrol ranges from cardiopreventive 60,61 to anticarcinogenic 56,62. Some authors 
have also reported that resveratrol could have a tentative potential benefit in type-II 
diabetes 63. 
Gallic acid, also known as 3,4,5-trihydroxybenzoic acid (Figure 3), is a C6-C1 phenolic 
acid that can be present in plants as its free form in some fruits 64,65, vegetables and 
white wine 66, or as a conjugate of flavanols such as epigallocatechin (EGC), 
epicallocatechin galate (EGCG), or PC dimer B2 gallate 41. The health benefits 
attributed to Gallic acid have been reported for in vitro 67,68,57 and in vivo 69–71 studies, 
specially as a ticarcinogen 72, cardioprotectant 58, lipid home stasis modulator, and 
insulin secretor 73. 
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Figure 3. General structures of the main non-flavonoid 
compounds. 
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of	such	compounds	(Amić	et	al.	2007;	Guerrero	et	al.	2011).	
	
Figure	8.	Basic	structures	and	examples	of	the	main	subclasses	of	dietary	flavonoids.	
In	 addition,	 the	 basic	 flavonoid	 skeleton	 can	 undergo	 numerous	 substitutions,	
including	 glycosylation,	 hydrogenation,	 hydroxylation,	 malonylation,	 methylation,	 and	
sulphation.	 Hydroxyl	 groups	 are	 usually	 present	 at	 the	 4-,	 5-	 and	 7-positions.	 Sulphate	
groups	 and	glycosides	 increase	 the	water	 solubility	of	 flavonoids.	 In	 contrast,	methyl	 and	
isopentyl	 groups	 make	 flavonoids	 lipophilic.	 Finally,	 different	 studies	 have	 revealed	 the	
important	 role	 that	 the	structure	of	 flavonoid	molecules	plays	 in	 their	biological	 function;	
the	position	and	number	of	substitutions	in	the	flavonoid	basic	structure	significantly	affect	
the	antiproliferative,	cytotoxic,	antioxidant,	anti-inflammatory	and	anti-enzymatic	activities	
of	such	compounds	(Amić	et	al.	2007;	Guerrero	et	al.	2011).	
Flavonols	
Flavonols	are	the	most	abundant	flavonoids	 in	human	diet	(Kumar	&	Pandey	2013)	
and	 can	 be	 found	 in	 food	 like	 onions,	 broccoli	 and	 tea	 (Figure	 8).	 The	 most	 common	
flavonols	 are,	 kaempferol,	 myrestin	 and,	 quercertin;	 being	 this	 last	 one	 the	most	 widely	
distributed	 in	 diet.	 Quercertin	 has	 been	 described	 to	 exert	 antihypertensive	 effects	 in	
animal	models	(Perez-Vizcaino	et	al.	2009;	Loke	et	al.	2008)	and	in	humans	(Edwards	et	al.	
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2007;	 Egert	et	 al.	 2009;	 Zahedi	et	 al.	 2013)	 and,	 to	ameliorate	MetS	and	 inflammation	 in	
rats	 (Rivera	 et	 al.	 2008).	 It	 is	 suggested	 that	 it	 may	 contribute	 to	 the	 improvement	 of	
endothelial	 function	 through	 the	 found	 increase	 in	 eNOS;	 however,	 the	 mechanism	 is	
unknown	(Rivera	et	al.	2008).		
Flavanones	
Flavanones	 are	 abundant	 in	 oranges	 and	 citrus	 fruits	 and,	 the	 most	 common	
molecules	in	this	class	are	naringin	and	hesperidin	(Figure	8).	The	antioxidant	properties	of	
naringin	 confer	 to	 this	molecule	 a	wide	beneficial	 effects	 (Thangavel	 et	 al.	 2012).	Among	
them,	 the	 effect	 on	 HTN	 associated	 with	 MetS	 (Alam	 et	 al.	 2013)	 and	 in	 essential	 HTN	
animal	 models	 (Ikemura	 et	 al.	 2012).	 This	 effects	 can	 be	 explained	 by	 its	 capacity	 to	
increase	NO	production	and	consequently	 to	 improve	endothelial	 function	(Ikemura	et	al.	
2012).	Hesperidin	also	has	been	described	to	ameliorate	HTN	in	rats	(Yamamoto	et	al.	2008;	
Ikemura	et	al.	2012).		
Flavones	
Flavones	 are	 a	 subclass	 of	 flavonoids	 that	 can	 be	 found	 in	 fruits	 like	 peppers,	
aromatic	herbs	like	thyme	or	garlic	(Figure	8).	The	most	abundant	flavones	are	luteolin	and	
apigenin	 (Kumar	&	Pandey	2013).	The	antihypertensive	effect	of	 luteolin	has	been	widely	
studied	 (Ichimura	et	al.	2006;	Qian	et	al.	2010;	Lv	et	al.	2013);	 in	 fact,	Chinese	traditional	
medicine	 treats	 HTN	 with	 luteolin-abundant	 plants.	 Luteolin	 effects	 on	 BP	 have	 been	
described	 to	 act	 via	 enhancement	 of	 NO	 production	 and	 inhibition	 of	 migration	 and	
proliferation	of	VSMC	through	a	reduction	of	oxidative	stress	in	rat	aorta	(Lv	et	al.	2013;	Si	
et	al.	2014;	Qian	et	al.	2010).		
Isoflavones	
Isoflavones	are	especially	abundant	in	soybeans	and	soy	derivate	being	genistein	the	
principal	 isoflavone.	 The	 antihypertensive	 effect	 of	 soy	 isoflavones	 has	 been	described	 in	
hypertensive	animal	models	 (Douglas	et	 al.	 2006;	Martin	et	 al.	 2001)	 and	also	 in	humans	
(He	et	al.	2005).	However,	 the	effect	 in	humans	seems	to	be	a	bit	controversial	 (Liu	et	al.	
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2012),	because	 some	clinical	 trials	had	achieved	not	effect	 in	BP,	but	 that	 it	was	 justified	
because	most	of	the	patients	were	normotensives	or	because	of	the	short-term	treatment	
(Martin	et	al.	2008;	Sacks	2006).	Ex	vivo	experiments	have	showed	that	isoflavones	reduce	
contraction	 in	 an	 endothelium-dependent	 (Mishra	 et	 al.	 2000)	 and	 -independent	manner	
(H.-F.	Li	et	al.	2006).	Moreover,	 in	experimental	animals	 it	has	been	described	to	enhance	
NO	production	(Kuriyama	et	al.	2014)	and	to	affect	RAAS	(Xu	et	al.	2004;	Xu	et	al.	2006).		
Anthocyanidines	
Anthocyanidines	are	 the	molecules	 that	confer	 the	 red,	purple	and	blue	colours	 to	
fruits	 like	blue	berries	and	 leaves	of	plants	 (Figure	8).	To	the	date,	 there	 is	 lack	of	studies	
demonstrating	 the	effect	 of	 pure	 anthocyanidins,	 because	when	given	 in	 the	 food	matrix	
there	 can	 be	 other	 bioactive	 molecules.	 In	 fact,	 there	 is	 only	 one	 study	 that	 associated	
anthocyanidins	consumption	in	the	whole	food	with	decrease	of	peripheral	and	central	BP	
(Jennings	et	al.	2014).	Moreover,	 there	 is	another	study	 that	used	pure	anthocyanidins	 in	
pre-hypertensive	patients;	however,	 it	 lacked	 to	demonstrate	any	 significant	effect	on	BP	
(Hassellund	et	al.	2013).			
Flavanols	
Flavan-3-ols	or	Flavanols,	range	from	monomers	i.e.,	(+)-catechin	and	its	isomer	(-)-
epicatechin,	 to	 more	 complex	 structures	 that	 include	 oligomeric	 and	 polymeric	
procyanidins	(Figure	9),	which	are	also	known	as	condensed	tannins.	Moreover,	as	mention	
above,	monomeric	 forms	can	undergo	esterification	with	GA	at	position	3	 in	the	C	ring	to	
form	catechin	or	epicatechin	gallate	and	it	can	also	be	hydroxylated	at	the	5’position	in	the	
B	 ring	 to	 form	 gallocatechins	 or	 epigallocatechins	 (Braicu	 et	 al.	 2011).	 The	 term	
proanthocyanidins	 is	 used	 to	 design	 polymeric	 flavanols	 that	 can	 be	 esterified	 with	 GA.	
Flavanols	 can	 be	 found	 in	 food	 like	 cocoa,	 dark	 chocolate,	 tea,	 grapes	 or	 wine,	 among	
others	 and	 (Figure	8),	 it	 has	been	estimated	 that	 the	 consumption	of	 flavanols	 in	 human	
diet	is	about	100	mg	per	day	(Mink	et	al.	2007;	Chun	et	al.	2007).		
Flavanols	have	been	described	to	have	direct	effect	on	endothelial	function,	insulin	
sensitivity,	BP	and	platelet	aggregation	(C	Heiss	et	al.	2010).	Specifically,	flavanols-rich	food	
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have	 been	 described	 to	 restore	 endothelial	 dysfunction	 in	 patients	 with	 coronary	 artery	
disease	 (Stein	 et	 al.	 1999;	 Duffy	 et	 al.	 2001;	 Christian	 Heiss	 et	 al.	 2010);	 and	 to	 induce	
endothelial-dependent	 vasodilation	 both	 in	 healthy	 (Fisher	 et	 al.	 2003;	 Bondonno	 et	 al.	
2012;	Grassi	et	al.	2015)	and	unhealthy	humans	(Grassi	et	al.	2005;	Wang-Polagruto	et	al.	
2006).	
	
Figure	9.	Reseprentative	flavanol	monomers	and	polymeric	forms	(procyanidins)	and	their	gallate	forms.		
	Cocoa	 flavanols	 have	 been	 widely	 studied	 for	 its	 antihypertensive	 effects.	
Although	 the	 polyphenol	 content	 of	 cocoa-derived	 products	 depends	 on	 the	 botanical	
variety	as	well	as	on	genetic,	agronomical,	and	other	factors	(Tomas-Barberán	et	al.	2007)	
cocoa	 flavanols	 consist	 of	 a	 complex	 mixture	 of	 the	 monomeric	 (−)-epicatechin	 and	 (+)-
catechin	and	the	oligomers	of	these	monomeric	units	(Ellinger	et	al.	2012).	Epidemiological	
studies	have	associated	that	the	ingestion	of	cocoa	is	inversely	correlated	to	HTN	(Buijsse	et	
al.	2006)	and,	intervention	studies	in	humans	has	demonstrated	a	decrease	in	SBP	and	DBP	
(Taubert	et	al.	2003;	Grassi	et	al.	2005;	Taubert	et	al.	2007).	 In	animal	models	 it	has	also	
been	studied	in	acute	(Cienfuegos-Jovellanos	et	al.	2009;	Quiñones,	Miguel,	et	al.	2011)	and	
long-term	 studies	 (Quiñones	 et	 al.	 2010).	 The	mechanisms	 described	 for	 cocoa	 flavanols	
antihypertensive	action	is	the	implication	of	NO	pathway	(Fisher	et	al.	2003;	Schroeter	et	al.	
2006;	 Quiñones,	 Muguerza,	 et	 al.	 2011),	 ACE	 inhibition	 (Actis-Goretta	 et	 al.	 2003;	 Actis-
epicatechin	gallate	(+)-catechin	(-)-epicatechin	
Procyanidin	dimer	B2	 Procyanidin	dimer	B2	gallate	 Procyanidin	trimer	C1	
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Goretta	et	al.	2006;	Persson	et	al.	2011)	and	reduction	of	oxidative	stress	(Ramiro-Puig	et	al.	
2007;	Quiñones,	Sánchez,	et	al.	2011).		
	Different	 studies	 have	 identified	 flavanols	 as	 catechin,	 epicatechin	 or	
epigallocatechin	gallate	as	responsible	of	these	positive	effects	of	cocoa	flavanols	on	BP	and	
endothelial	 function	 in	 humans	 (Schroeter	 et	 al.	 2006;	Widlansky	 et	 al.	 2007;	 Loke	 et	 al.	
2008;	Matsuyama	et	al.	2008)	and	in	animal	models		(Igarashi	et	al.	2007;	Gómez-Guzmán	
et	 al.	 2012;	 Gómez-Guzmán	 et	 al.	 2011;	 Galleano	 et	 al.	 2013;	 Quiñones	 et	 al.	 2015).	
Nevertheless,	 although	 (–)-epicatechin	 is	 the	 monomeric	 flavanol	 that	 possesses	 better	
known	anti-hypertensive	properties	(Gómez-Guzmán	et	al.	2012;	Ellinger	et	al.	2012)	the	BP	
lowering	 effect	 of	 its	 isomer	 catechin,	 has	 only	 recently	 been	 reported	 (Quiñones	 et	 al.	
2015).	 The	 beneficial	 vascular	 effects	 of	 flavanols	 has	 been	 associated	 with	 the	
enhancement	of	NO	availability,	that	can	be	produced	by	a	increment	of	eNOS	activity	or	by	
an	inhibition	of	negative	pathways	as	NADPH	oxidase,	ACE	and	ET-1	(Schewe	et	al.	2008;	C	
Heiss	et	al.	2010).	In	fact,	cocoa	flavanols	and	epicatechin	are	able	to	inhibit	the	expression	
of	arginase	 in	EC	and	erythrocytes,	 thus	 increasing	eNOS	substrate	availability	 (Schnorr	et	
al.	2008).	On	the	other	hand	tea	flavanols	have	been	described	to	inhibit	ACE	activity	and	to	
increase	NO	production	in	EC	(Persson	et	al.	2006).	Besides,	it	also	has	been	described	that	
epicatechin	decreases	ET-1	and	increases	NO	acutely	in	healthy	humans	(Loke	et	al.	2008).	
And	that	epicatechin	is	able	to	increase	NO	in	EC	by	inhibition	of	NADPH	oxidase	(Steffen	et	
al.	2007;	Steffen	et	al.	2008).	Thus	 the	cardioprotective	effect	of	 this	class	of	polyphenols	
has	been	widely	demonstrated.		
Low	molecular	weight	grape-seed	polyphenol	extract	
As	it	was	commented	above,	important	sources	of	flavanols	are	cocoa	and	grapes.	
The	main	difference	between	cocoa	and	grape	flavanols	are	the	presence	of	gallate	forms	in	
this	last	one	(Quiñones,	Miguel,	et	al.	2011;	Quiñones	et	al.	2013).	But	as	it	was	mentioned	
for	 cocoa	 flavanols,	 grape	 flavonoids	 also	 exhibit	 several	 pharmacological	 properties,	
including	 vasodilator	 (Diebolt	 et	 al.	 2001;	 Zenebe	 et	 al.	 2003;	 Moura	 et	 al.	 2002;	
Andriambeloson	et	al.	1997),	antihypertensive	(Diebolt	et	al.	2001)	and	antioxidant	(Zenebe	
et	 al.	 2003)	 effects.	 Moreover,	 a	 meta-analysis	 study	 reported	 that	 participants	
supplemented	with	grape-seed	flavonoids	had	significantly	reduce	BP	compared	with	that	
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of	the	control	subjects	(Feringa	et	al.	2011).	As	it	occurs	for	cocoa,	the	phenolic	composition	
between	 grape	 products	 may	 vary	 subjected	 to	 agricultural,	 environmental	 and	
technological	 factors	 (Downey	 et	 al.	 2006).	 Moreover,	 the	 distribution	 of	 phenolic	
compounds	 in	 the	 juice,	pulp,	 skins	and	seeds	 is	different,	comprising	about	5%,	1%,	30%	
and	64%,	respectively	(Singleton	1981;	Singleton	&	Esau	1969)	and,	flavanols	are	principally	
present	 in	 seeds,	 while	 other	 flavonoid	 like	 anthocyanidins	 or	 non-flavonoid	 compounds	
like	resveratrol	are	mainly	located	in	the	skin	of	the	grapes	(Yang	et	al.	2009).	Grape	seed	is	
a	by-product	of	the	grape/wine	industry,	and	it	has	been	extensively	investigated	due	to	its	
flavanol	abundance	(Nakamura	et	al.	2003).	A	low	molecular-weight	grape-seed	polyphenol	
extract	(LM-GSPE)	exerts	a	broad	range	of	functional	activities	all	related	with	the	MetS,	as	
will	be	more	developed	in	the	next	section.	Reverse-phase	LC–MS	analysis	of	the	individual	
phenolic	compounds	in	this	grape	extract	revealed	that	the	most	abundant	phenols	include	
GA,	monomeric	flavanols	(-)-epicatechin	and	(+)-catechin,	and	dimer	flavanols,	both	in	their	
free	 forms	 and	 linked	 to	 gallate	 (Quiñones	 et	 al.	 2013).	 LM-GSPE	 has	 been	 described	 to	
improve	oxidative	 stress	 (Llópiz	et	 al.	 2004;	Puiggròs	et	 al.	 2005;	 Fernández-Iglesias	et	 al.	
2013;	Fernández-Iglesias	et	al.	2014)	and	lipid	metabolism	(Del	Bas	et	al.	2005;	Del	Bas	et	al.	
2008;	 Quesada	 et	 al.	 2009;	 Baiges	 et	 al.	 2010)	 through	 modulation	 of	 miRNA	 (Baselga-
Escudero	et	al.	2012;	Baselga-Escudero	et	al.	2013).	Moreover,	it	has	been	also	described	to	
improve	adipogenesis	and	obesity	(Pinent	et	al.	2005;	Caimari	et	al.	2013)	and	to	improve	
insulin	 resistance	 and	 diabetes,	 acting	 as	 an	 insulinomimetic	 agent	 (Pinent	 et	 al.	 2004;	
Montagut	 et	 al.	 2010;	 Castell	 et	 al.	 2009;	 Castell-Auví	 et	 al.	 2012;	 Cedó	 et	 al.	 2013).	
Furthermore,	 the	 improvement	 of	 the	 obesity-induce	 inflammation	 has	 also	 been	
attributed	to	LM-GSPE	(Terra	et	al.	2007;	Terra	et	al.	2009;	Martinez-Micaelo	et	al.	2012).		
Regarding	BP,	previous	results	of	the	group	described	that	LM-GSPE	can	decrease	BP	
and,	this	decrease	was	statistically	similar	to	the	decrease	reached	when	the	animals	were	
treated	with	a	known	antihypertensive	drug	(Quiñones	et	al.	2013).	This	experiments	where	
carried	 out	with	 SHR	 and	 some	 of	 the	mechanisms	 of	 the	 antihypertensive	 effect	where	
assessed.	It	was	demonstrated	the	total	implication	of	NO,	because	its	inhibition	completely	
reverted	 the	 decrease	 of	 BP	 (Quiñones	 et	 al.	 2014).	 Furthermore,	 this	 in	 vivo	 result	 was	
confirmed	with	an	ex	vivo	experiment	in	tissue	baths	where	relaxation	of	SHR	arteries	when	
treated	 with	 LM-GSPE	 was	 found	 and,	 this	 effect	 disappeared	 with	 inhibition	 of	 the	 NO	
pathway	(Quiñones	et	al.	2014).	On	the	other	hand,	a	partial	implication	in	the	decrease	of	
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BP	 by	 PGI2	 where	 also	 demonstrated;	 in	 fact,	 elevated	 values	 of	 PGI2	 metabolite	 where	
found	 in	 plasma	 after	 the	 treatment	 (Quiñones	 et	 al.	 2014).	 Moreover,	 a	 previous	
experiment	 showed	 a	 simultaneous	 effect	 of	 LM-GSPE	 in	 BP	 and	 lipid	 metabolism	 in	
cafeteria	diet-fed	rats	(Guerrero	Orjuela	2013).		
Taken	 together	 all	 these	 promising	 results,	 LM-GSPE	 is	 proposed	 as	 a	 good	
candidate	to	be	used	as	BP	lowering	agent	in	HTN	associated	with	MetS.		
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ABSTRACT
Grapes and wine are well-known significant sources of flavonoids, which
exhibit several pharmacological properties. This fact has led them to be
considered as functional food candidates. Nevertheless, the phenolic
distribution in juice, pulp, skins and seeds is different. Grape seeds, a by-
product of the grape/wine industry, are one of the richest sources of flavanols
and proanthocyanidins (PAs), a class of flavonoids for which beneficial
effects have been extensively investigated. In fact, grape seed polyphenols
have been reported by many studies to be bioactive, exhibiting various
beneficial properties for some metabolic syndrome (MetS)-related and
cardiovascular disease (CVD) parameters, i.e., they act as antioxidants,
modulate adipogenesis, present anti-inflammatory properties, act as insulin-
mimetic agents, improve lipid metabolism and exhibit antihypertensive
effects. Therefore, grape seed polyphenols may be used as functional food
ingredients for simultaneously controlling different MetS components and
risk factors associated with CVD.
Key words: By-product, Cardiovascular disease, Flavonoids, Grape seed
procyanidin, Metabolic syndrome
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1. INTRODUCTION
Based on World Health Organization (WHO) data, cardiovascular disease
(CVD) is the primary cause of mortality worldwide, representing 30% of all
global deaths. It is estimated that the number of people who die from CVD
will reach 23.3 million by 2030[1]. In contrast, metabolic syndrome (MetS)
is a multifactorial disorder associated with risk factors such as hypertension
(HTN), dyslipidaemia, obesity and hyperglycaemia, which directly increase
the risk for CVD and type 2 diabetes[2,3]. This syndrome affects
approximately 34% of U.S. adults[4] and is not regarded as a single disease
but rather can be defined as an association of health problems caused by
genetic and environmental factors[5,6] that induce physiopathological
changes at the corporal level.
The effects of diet on multiple CVD risk factors, including obesity,
elevated blood lipids or high blood pressure (BP), are clear. In fact, the
first recommendation for the treatment of MetS is to change nutritional
habits. There is evidence that a diet rich in vegetables and fruits decreases
the risk for CVD[6,7] and this have been attributed to phenolic compounds.
Among others, flavonoids are the principal polyphenols present in the
human diet, and their intake has been inversely correlated with CVD and
stroke[8].
2. GRAPE POLYPHENOLS
Grapes and wine are significant sources of flavonoids. Grape compounds
for their potential beneficial health effects has been focused with great
interest. In fact, grape flavonoids exhibit several pharmacological
properties, including vasodilator[9-12], antihypertensive[9] and antioxidant[10]
effects. Nevertheless, grape products often widely vary in their phenolic
compound type and content and their characterisation is essential for
understanding the potential health-promoting effects associated with its
consumption. In fact, both agricultural and technological factors affect the
phenolic content of grapes, grape extracts and wine[13]. In addition, the
phenolic distribution in juice, pulp, skins and seed grapes is different,
comprising approximately 5%, 1%, 30% and 64%, respectively[14,15].
Moreover, polyphenols such as anthocyanidins and resveratrol are mainly
localised in skins, while flavanols are principally present in seeds[16].
Grape seed is a by-product of the grape/wine industry, and it has been
extensively investigated[17] due to flavanol abundance[18]. It has been
demonstrated that grape seed polyphenol (GSP) extract, which is rich in
monomeric flavanols and proanthocyanidins, exerts a broad range of
functional activities[19-22]. Flavan-3-ols or flavanols are the most structurally
complex subclass of flavonoids. They range from monomers i.e., (+)-catechin
and its isomer (-)-epicatechin to more complex structures that include
BOOK	CHAPTER	
58	
 3Beneficial Effects of Grape Seed Polyphenols...
oligomeric and polymeric proanthocyanidins which are also known as
condensed tannins. Monomeric forms can undergo esterification at position
3 in the C ring to form catechin or epicatechin gallate. Moreover, monomers
can also be hydroxylated at the 5’position in the B ring to form gallocatechins
or epigallocatechins[23]. The basic flavanol skeleton structure shown in Fig.
1. With regards to GSP extract, quantification of its total phenolic content
demonstrated that phenolic compounds constitute 52% of GSP extract,
which supports the substantial potential of this extract. In fact, the total
polyphenol content of this extract is 2.3 times higher than that reported
for grape seeds[24]. Reverse-phase LC–MS analysis of the individual phenolic
compounds in this grape extract revealed that the most abundant phenols
include the monomeric flavanols catechin and epicatechin, which exist in
free form as dimers and linked to gallate[25]. Other examples of flavanol-
rich sources include cocoa and tea.
Fig. 1: Chemical skeletal structure of flavanols
Concerning bioavailability, its understanding is essential to link
polyphenols with their healthy beneficial properties. However, the absorption
of polyphenols is highly dependent on chemical structure and degree of
polymerisation with monomeric forms having higher bioavailability[26].
Briefly, once ingested, glycosylated polyphenols are hydrolysed in the brush
border of the enterocytes by E-glucosidases, while free forms are absorbed
by passive diffusion. Glycosylated polyphenols can also be directly taken up
by enterocytes via a sodium-dependent glucose transporter, SGLT1, after
which they are hydrolysed by E-glucosidase inside the cells[27]. In the case of
grape seed, polyphenols are mostly unglycosylated flavanols; therefore, they
can be directly absorbed into cells by passive diffusion.
After absorption, aglycones are conjugated by phase II enzymes i.e.,
sulfotransferases, catechol-O-methyltransferases and uridine-5’-diphosphate
glucuronosyl transferases[28]. Several studies have demonstrated that 1-2
hours after GSPs ingestion, free forms and their metabolites target most
tissues, such as the liver, adipose tissues or the brain[29,30]. Interestingly, an
imprinting effect was observed when pregnant rats were fed GSPs with
phenolic metabolites being detected in the mother’s placenta, amniotic liquid
and foetuses[29].
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In addition, polyphenols that are not absorbed in enterocytes can be
metabolised by the microbiota in the colon, producing low molecular weight
compounds by skeleton cleavage that are absorbed and distributed
throughout the organism[30,31]. Due to this intense metabolism, metabolites
that circulate in the body after the ingestion of polyphenols substantially
differ from the forms present in food sources.
3. HEALTHY PROPERTIES OF GRAPE SEED POLYPHENOLS
3.1. Antioxidant Activity
Highly reactive oxygen species (ROS), such as single oxygen molecules,
superoxide anion radicals, hydroperoxyl radicals, nitrogen oxide radicals,
and alkyl peroxyl free radicals are regularly produced in humans[32]. These
molecules cause damage to lipids proteins, and DNA, contributing to
pathogenesis and ageing. Humans possess endogenous antioxidant defences
that scavenge radicals and repair oxidative damage. However, diets rich in
exogenous antioxidants such as polyphenols are thought to further
contribute to this defence. Polyphenols scavenge ROS through electron-
donating properties, generating relatively stable phenoxyl radicals[32]. For
most flavanols with an o-dihydroxyphenyl group in the B-ring and a fully
saturated C-ring, the radical site is in the B-ring, and substitutions in the
A-ring have only limited influence on the reduction potential of the
semiquinone radicals formed (Fig. 1). These semi-quinone radicals are quite
stable, and flavanols may therefore protect the body against oxidation and
limit the risk of developing CVD[33].
Several in vitro studies have been conducted for inhibiting the oxidation
of low-density lipoproteins (LDLs) or membrane systems with purified
flavanols[34]. These studies have concluded that oligomer chain length
influences antioxidant activity such that increasing protection against
oxidation correlates with increasing flavanol chain length. Mckay et al.
(2007) have also observed that only fractions containing polymeric forms
are able to increase the lag time in the Cu2+-induced oxidation of LDLs[35],
and Lotito et al. (2000) found increased LDL protection as the
proanthocyanidin chain lengths increase[36]. Llopiz et al. (2004) reported
that GSPs increased the enzymatic activity of the antioxidant system in
rat hepatocytes (Fao cells)[37]. Furthermore, it has been reported that GSPs
affect the activity and mRNA expression of antioxidant enzymes
(glutathione peroxidase, glutathione reductase, and glutathione S-
transferase) in human hepatocarcinoma HepG2 cells[38]. GSPs also affect
antioxidant enzymes in cells subjected to H2O2-induced oxidative stress
[39],
confirming that GSPs not only act as an antioxidant but also affects
antioxidant enzyme gene expression. Recently, FernDndez-Iglesias et al.
(2014) demonstrated that the administration of GSPs to genetically obese
rats (Zucker rats) reduced oxidised glutathione hepatic accumulation,
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decreasing the activation of antioxidant enzymes and increasing the total
antioxidant capacity of hepatocytes[40].
3.2. Anti-inflammatory Effects
There is a large body of scientific evidence describing the broad effects of
flavanols on inflammation[41,42]. The molecular mechanisms targeted by
flavanols include, but are not limited to, modulation of various mediators
of inflammation (eicosanoids, cytokines, and nitric oxide (NO) production)
and the nuclear factor kappa B (NF-NB) and mitogen-activated protein
kinases (MAPK) pathways (reviewed in[22]).
Modulation of the arachidonic acid pathway has been considered one of
the most important anti-inflammatory mechanisms of dietary flavonoids,
including flavanols. This modulation involves inhibition of eicosanoid-
generating enzymes such as cyclooxygenases (COX) and lipoxygenases
(LOXs). COX2 is considered a pivotal enzyme in inflammation and its
modulation plays a key role in the regulation of the inflammatory response.
GSPs have been found to inhibit COX2 in several ways, including through
COX2 gene transcription
[43], protein expression[44] and enzyme activity[45].
Moreover, flavanols have been identified as modulators of LOX activity[46].
However, the interactions between these compounds and LOXs have not
been fully elucidated.
Cytokines are intercellular mediators that modulate a broad range of
cellular and physiological responses, including activation of several pro-
inflammatory pathways and transcription factors[47]. An imbalance in pro-
inflammatory/anti-inflammatory cytokine secretion is considered a
hallmark of activation/repression of inflammatory responses. Furthermore,
cytokines are often used as biomarkers of inflammation and their
transcription and secretion have been directly associated with several
human diseases[48]. Several in vitro and in vivo studies have shown that
GSPs can downregulate the transcription and secretion of proinflammatory
cytokines, including the interleukins (ILs) IL-1E, IL-2, IL-6, and IL-8,
tumour necrosis factor-D (TNF-D) and interferon-J (INF-J) and can
upregulate the secretion of anti-inflammatory cytokines, such as IL-10,
IL-4, and transforming growth factor-E (TGF-E) in peripheral blood
mononuclear cells, macrophages, and lymphoid cell lines[49-52].
Otherwise, NO is synthesised from L-arginine by nitric oxide synthases
(NOS) and is considered to be a pivotal signalling molecule in endothelial
macrophages[53]. At physiological concentrations, NO exerts several anti-
inflammatory, antioxidant, and vasodilatory activities; however, when
produced in excessive amounts under oxidative and inflammatory
conditions, NO can be a precursor of potent pro-oxidant and nitrating
compounds[54]. GSPs have also been found to be a strong in vitro inhibitor
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of NO synthesis, downregulating NOS mRNA and protein expression and
therefore reducing NO production and secretion in murine macrophages[55].
With regards to intracellular signalling pathways, NF-NB plays a critical
role in the transcriptional regulation of a wide range of genes that are
involved in the regulation of inflammation[56]. GSPs has been described to
be a strong and selective inhibitor of NF-NB activation in in vitro and animal
models[45,52,57]. One of the finding support the hypothesis that flavanols
(extracts, dimers, or trimers) downregulate inhibitor of nuclear factor kappa-
B kinase (INNB) activity, thus decreasing the phosphorylation of pINB-D
and its subsequent ubiquitination and proteasomal degradation[52,58].
Finally, MAPKs are Ser/Thr kinases that are involved in the regulation
of several cellular processes[47] including the extracellular signal related
kinase (ERK), p38 MAPK and Jun N-terminal kinase (JNK) pathways,
which regulate NF-NB and activator protein-1 (AP-1) DNA binding. MAPK
signalling pathway activation can be regulated by protein phosphorylation
and extracts rich in GSP and pure flavanol compounds including dimers
and trimers markedly suppress the phosphorylation of ERK, JNK and p38
in immune cells[47,52]. Inhibition of MAPK activation elicits a decrease in
AP-1 activity thus, suppressing the production of several proinflammatory
cytokines[34].
3.3. Adipogenesis Modulation
Adipose tissue is a key target in obesity, which plays an important role in
the regulation and pathological dysregulation of metabolic homeostasis.
This tissue is both a fat storage organ and endocrine tissue that secretes
adipocytokines. Thus, basic research into the effects of GSPs on adipocytes
is important for understanding more about their potential beneficial roles
in these pathologies. Although this field is currently quite unexplored, some
studies have shown that flavanols modulate adipocyte processes such as
lipolysis, lipid and glycogen synthesis and differentiation (reviewed in[21]).
In this sense, chronic GSP treatment increase the lipolytic rate and
downregulates some mature adipocyte markers, such as glycerol-3-
phosphate dehydrogenase (G3PDH), peroxisome proliferator-activated
receptor-g (PPARg) and hormone-sensitive lipase (HSL) mRNA, in 3T3-L1
adipocytes[59,60]. Moreover, flavanols limit adipocyte formation by altering
the gene expression profile during in vitro adipocyte differentiation[61].
Therefore, flavanols can modulate several metabolic processes, such as
mobilisation of lipid stores or inhibition of adipocyte differentiation[21]. In
addition, GSPs mimic the anabolic effects of insulin because it activates
lipid and glycogen synthesis in 3T3-L1 adipocytes (62). However, GSPs
stimulate glycogen synthesis less than that for insulin and induces a higher
incorporation of glucose into lipids mainly because more glucose is directed
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toward glycerol synthesis. These results therefore suggest that flavanols
may use a different mechanism of action than that of insulin, although
they share some intracellular mediators, such as PI3K and p38 MAPK,
and metabolic process such as Glut-4 translocation[63].
3.4. Insulin Resistance
Abnormalities affecting insulin secretion and/or insulin action, lead to a
progressive deterioration in glucose tolerance and causes hyperglycaemia,
which in turn leads to diabetes mellitus. Several in vivo and in vitro studies
have investigated flavanol effects on glucose homeostasis, although a clear
consensus has not been reached. Some evidence suggests that flavanols
might act as hypoglycaemic agents, but hyperglycaemia can result from
various causes. On the one hand, hyperglycaemia might be a consequence
of type-1 diabetes (T1D) in which there is a loss of b cells due to an immune
assault (64). On the other hand, high glucose levels can occur due to an
ineffectiveness of insulin i.e., insulin resistance, a condition in which insulin
levels initially increase to compensate for a lack of effects before reaching
a state in which the pancreas is no longer functional, which is type-2 diabetes
(T2D) (65). It can be speculated that the effects of flavanols might depend
on the specific condition of glucose homeostasis disruption in which they
are analysed. Consequently, it is important to take into account all of these
situations before making general statements about these compounds.
Hyperglycaemia in T1D is the result of the body’s inability to synthesise
and/or secrete functional insulin. Several groups have assayed the ability
of GSPs to ameliorate this physiological state using animal models with a
disrupted pancreas mainly through the action of streptozotocin (STZ)
(reviewed in (66)). In this sense, Pinent et al. (2004) described an acute
improvement in serum glucose in male STZ-diabetic Wistar rats in a fed
state after the administration of an extract rich in GSPs at 250 mg/kg body
weight (63). Similarly, a parallel study with fasted animals showed that
reduction in glucose absorption was not the main mechanism used by GSPs
to decrease glycaemia. The effects of the same dose of extracts rich in GSPs
in oral glucose tolerance tests did not delay the appearance of glucose in
the blood in GSPs-treated animals compared with controls, suggesting that
GSPs do not primarily act by disrupting glucose absorption. Instead, the
study suggested that the antihyperglycaemic effects of GSPs are in part
due to the fact that it has central insulin-mimetic effects on the liver and
other peripheral metabolic tissues such as muscles and white adipose tissue
(67). However, Li et al. (2008) tested the same dose of GSP extract for 24
weeks (68). This study found neither a change in glycaemia nor HbA1c but
a clear improvement in body weight gain and several other aspects linked
to diabetes, such as an improved diabetic nephropathy and inflammatory
status.
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Collectively, these studies suggest that GSPs have short-lived insulin-
mimetic effects on internal targets in organisms and it is useful for
improving the general situation of an entire organism, most likely due to
oligomeric forms and forced acute doses. What remains unclear is the ability
of GSPs to ameliorate the actual cause of T1D, i.e., to restore pancreas
functionality. However, little information concerning the effects of GSPs
on pancreatic insulin synthesis, secretion and degradation is available.
Similarly, the ability of GSPs to mimic insulin effects on insulin sensitive
targets when insulin is scarce or absent has also been proven in vivo and
in vitro. However, such effects are not clear when there is a normal amount
of insulin in the body.
Theoretically, if glucose absorption inhibition is the main mechanism,
similar effects would be expected in non-diabetic animals. However, most
of the experiments published do not confirm that hypothesis (reviewed
in[66]). Of all of the results obtained from flavanol treatments in healthy
animals, only Al-Awwadi et al. (2004) has described a GSP effect on plasma
glucose[69]. For this male Wistar rats was used as a healthy model for TD1
animals and they described similar but milder effects in normal rats,
which they explain as being due to a reduction in food intake and/or
absorption. These controversial data lead to the conclusion that when
there is a lack of insulin, flavanols may act as insulin-mimetic agents
affecting some insulin targets. However, under normal insulinaemia, the
results presented thus far suggest no clear GSPs effect on whole glucose
homeostasis, which is likely because insulin is more effective in terms of
physiological effects.
Animal models for disrupted glucose homeostasis can be achieved by
different approaches, such as special diets. Several studies have analysed
the effects of flavanols administered to fructose-induced, insulin-resistant
animals[69-71]. Although these studies differ in terms of doses, treatment
times, and flavanol extracts, all have found an improvement in
hyperglycaemia as a result of flavanol treatment. In contrast, other studies
have found that flavanols have little effect on hyperglycaemia. In this sense,
Terra et al. (2009) assayed the preventive role of a final dose of
approximately 20 mg/kg body weight of GSP extract given concurrently
with two similar medium-fat diets (31.8 and 45% fat) to lean male Zucker
rats and female Wistar rats, respectively, for a period of 19 weeks[72].
Surprisingly, while Zucker rats showed a slight improvement in glycaemia,
the Wistar rat glycaemia tended to increase, and insulinaemia decreased
as a result of GSP treatment. Because the GSP extract used was the same
in both studies, this difference in response could partially be explained by
sex differences. Finally, glycaemia was also not affected in a parallel group
of female Wistar rats treated with a higher dose of GSP extract (35.8 mg/
kg body weight) included in a 60% fat diet, although increased insulinaemia
due to GSP treatment was documented[73].
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Glucose homeostasis disruption can also be studied using genetically
altered animal models. A dose of GSP extract similar to that previously
shown to be effective for cafeteria-diet fed male Zucker fa/fa rats did not
improve the glycaemia. Notably, in studies of db/db mice, GSP extract
improved glucose homeostasis at low doses i.e., approximately 10 mg/kg
body weight daily[74] and 40 or 70 mg/kg body weight in feed pellets[75]. The
same genetic alterations in obese Zucker fa/fa rats are found in db/db mice,
but the genetic background of each species gives rise to metabolic differences
in their disrupted metabolic profiles. According to Shafrir et al. (1999) (76),
fa/fa rats have b-cells that maintain a robust, life-long insulin secreting
capacity. In contrast, db/db mice are characterised by b-cells that only allow
transient insulin hypersecretion with short-term obesity. Some preliminary
results indicate that b-cells are a target of flavanols[77,78]. Hence, differences
in b-cells may be one explanation for different responses to GSPs in fa/fa
rats and db/db mice although more work needs to be done.
3.5. Lipid Homeostasis
Several randomised controlled trials have been conducted to evaluate the
effects of GSPs on human plasma lipids, but their results are inconsistent.
Meta-analysis of nine trials evaluating the effects of GSPs showed no
statistically significant effects on the total cholesterol (TC), triglycerides
(TGs), LDL-cholesterol (LDL-C), or HDL-cholesterol (HDL-C) levels[79].
However, other studies have shown that GSPs significantly decrease TC
and LDL-C[80]10 (80). Several causes can account for these discrepancies,
such as low sample size, different commercial GSP extracts, GSP dose and
weeks of treatment as well as the clinical condition of the populations
studied. Therefore, more studies are needed to clarify the true GSP effects
on plasma lipids.
However, many studies have demonstrated that GSPs have
hypolipidaemic effects in animal models[19]. GSPs reduce plasma TGs,
apolipoprotein B (apoB) and LDL-C levels, and it increases the percentage
of HDL-C in healthy rats given an acute oral dose, thus improving their
atherosclerotic risk index[81]. The hypolipidaemic effects of GSPs is even
more obvious using a lipid tolerance test model, showing an increase in
tolerance to ingested lipids because the area under the curve for TC and
TG is significantly reduced[82]. Additionally, chronic treatment with GSPs
correct dyslipidemia associated with high-fat, diet-fed rats[83-85] and
hamsters[86] mainly for TG levels. Chronic treatment also reduces the hepatic
steatosis induced by a high-fat diet[84,85].
Using a lipid tolerance test model, it has been shown that chylomicrons
(CM) and very low-density lipoproteins (VLDL) contribute to the
hypotriglyceridaemic actions of GSPs as both are significantly reduced after
an acute dose[82]. The level of CM and VLDL depend on their secretion by
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the intestine and liver, respectively and on their catabolism by lipoprotein
lipase (LPL) in extra-hepatic tissues. While GSPs have no effect on LPL
activity and expression in white adipose tissue and muscle[82], they represse
the secretion of VLDL[82] and CM[87]. Together, these results strongly suggest
that GSPs induce hypotriglyceridaemia by repressing lipoprotein secretion
and not increasing lipoprotein catabolism.
Lipid availability, apoB and microsomal triglyceride transfer protein
(MTP) are known to be central for the efficient assembly and secretion of
CM and impaired lipid availability in enterocytes appears to be the primary
cause of the reduction in intestinal CM secretion by GSP. In this sense, it
has been demonstrated that GSPs increase the faecal excretion of cholesterol
in rats[88] indicating reduced cholesterol absorption. In addition, GSPs inhibit
the activity of pancreatic lipase in vitro[89] thus suggesting limited dietary
TG absorption. Moreover, GSPs repress the expression of long-chain acyl-
CoA synthetase (ACSL) 5 and 3, which supply fatty acids for TG synthesis
in enterocytes.
Although GSPs exert some hypolipidaemic effects by inhibiting the
absorption of dietary lipids and diminishing CM secretion by enterocytes,
repression of VLDL secretion by the liver also plays an important role in
reducing plasma lipids. For example, in the intestine, impaired lipid
availability in hepatocytes appears to be the main contributor to reducing
hepatic VLDL secretion. It has been demonstrated that de novo TG and
cholesterol synthesis, as well as their secretion is inhibited by GSP in HepG2
(90), whereas fatty acid oxidation is activated in livers of rats treated with
an acute dose of GSP extract (82). This modulation of lipid metabolic
pathways is a consequence of modulation of the expression of numerous
key genes related to fatty acid, TG and cholesterol metabolism in liver
even if the precise gene modulated depends on the species and physiological
conditions. For instance, acute administration of GSP represses the
expression of 3-hydroxy-3-methyl-glutaryl-CoA (HMG-CoA) reductase[91]
(the rate-limiting enzyme in the cholesterol biosynthetic pathway),
phosphatidic acid phosphatise[83,91] (the enzyme that generates diglycerides
from phosphatidic acid for TG synthesis) and diacylglycerol acyl
transferase[82,83] (the enzyme that catalyses the last reaction of TG
synthesis), whereas it increases the expression of carnitine palmitoyl
transferase (CPT) 1a (the rate-limiting enzyme on fatty acid
oxidation)[82,91,92]. A proteomic study also confirmed that chronic GSP
consumption represses fatty acid and triglyceride synthesis in rats fed a
high fat diet[93]. Thus, it can be suggested that reduction in VLDL secretion
by the liver is mainly due to a reduction in the bioavailability of lipids,
especially TGs.
Furthermore, GSPs improve lipid homeostasis by increasing the
reverse transport of cholesterol. The ATP-binding cassette transporter
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ABCA1, which is a crucial factor for nascent HDL secretion by the liver
and cholesterol efflux from extra-hepatic tissues to HDL, is overexpressed
by GSPs in livers of healthy and hyperlipidaemic rats and peripheral
blood mononuclear cells. Therefore, it increases cholesterol efflux to the
liver. The last step in reverse cholesterol transport is bile acid synthesis,
which is controlled by the activity of CYP7A1. Interestingly, acute GSP
treatment induces the overexpression of CYP7A1 (81). Together, these
results strongly suggest that GSP favours cholesterol elimination from
the body via bile.
The molecular mechanisms by which GSPs modulate lipid metabolism
have been studied in liver. Using FXR-null and SHP-null mice, it has been
demonstrated that GSPs decrease plasma TG concentrations by activating
the nuclear receptor farnesoid X receptor (FXR), upregulating the nuclear
receptor small heterodimer partner (SHP) and subsequently repressing
the transcription factor SREBP1 in liver[91,92]. The importance of the
activation of FXR by GSPs lies in the functionality of this nuclear receptor.
FXR activity plays a key role in controlling not only triglyceridaemia but
also cholesterol, bile acid and glucose homeostasis.
Recently mi(cro)RNAs have emerged as a new molecular mechanism by
which GSPs could modulate lipid metabolism[20,94]. Acute and chronic GSP
treatment represses miR-33a and miR-122, two miRNAs that are key
controllers of lipid metabolism, in livers of healthy and dyslipidaemic
rats[84,95]. The mechanisms by which miRNA levels are modulated are poorly
understood. However, there has been recent evidence that polyphenols can
bind directly and distinctively to miR-33 and miR-122[96]. The binding of
polyphenols to miRNAs is specific, and the molecular structure of polyphenol
determines the nature of the binding[96]; thus, the polyphenol signature of
GSP can condition miR-33a and miR-122 modulation.
3.6. Antihypertensive Effects
Flavanol-rich foods, such as cocoa have demonstrated antihypertensive
properties in vitro and in vivo[97-99]. In addition, epidemiological studies have
related the ingestion of cocoa with a low prevalence of atherosclerotic disease
and no increase in BP with age[100]. Nevertheless, the ingestion of green or
black tea, which are also rich in flavanols, appears to have no effect on
BP[98], which could be due to the different flavanol composition in cocoa and
tea. Although, the main monomeric polyphenols in black and green tea are
epicatechin gallates and gallic acid[35] the main polymers are condensed
catechins[101], suggesting that flavanols differ in their behaviour with respect
to their antihypertensive properties.
The most abundant flavanols present in GSPs are monomers i.e.,
catechin and epicatechin which are mostly free with a minor proportion
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conjugated to a gallate moiety and similar to cocoa, low molecular weight
oligomers, which mainly include dimmers[25]. A meta-analysis study on the
effects of GSPs on cardiovascular risk factors reported that participants
supplemented with GSPs have significantly reduce systolic blood pressure
(SBP) compared with control subjects[79] although this reduction is more
modest than that observed with cocoa[98]. However, a reduction of 4 to 5
mmHg in SBP decreases substantially decreased the cardiovascular risk[102]
and an increase of only 2 mmHg in SBP was associated with a 7% increase
in mortality from ischemic heart disease and a 10% increase in risk of
mortality from stroke[103].
In accord with these data, studies performed by our group using
spontaneously hypertensive rats (SHRs)[25] and hypertensive cafeteria fed
rats (CHRs)[85] showed that a GSP extract acts as an antihypertensive
agent in a dose-dependent manner. Cafeteria diet-fed rats have been
described as a robust model for human MetS, promoting voluntary
hyperphagia that results in rapid weight gain[104]. Moreover, the decreases
in SBP achieved in animal models for the most effective dose (375 mg/Kg)
were similar to values achieved using Captopril, which is a specific
competitive angiotensin converting enzyme (ACE) inhibitor that is known
to be an effective antihypertensive treatment in clinical practice.
Paradoxically, the highest dose of the GSP extract (500 mg/Kg)
demonstrated a lower antihypertensive effect than medium doses, in both
SHRs and CHRs. This apparently surprising finding has also been
described in SHRs for other flavanol-rich compounds such as cocoa[105].
These results could be explained by the pro-oxidant properties and
excessive production of ROS caused by high flavanol doses. In addition,
GSPs administered in CHRs were able to simultaneously reduce more
than one risk factor for CVD or abnormalities related to MetS by exhibiting
beneficial effects on BP and lipid homeostasis[85].
The antihypertensive properties of flavanols are associated with different
biological activities, such as NO-mediated vasodilation[106], ACE
inhibition[107,108] and a reduction in oxidative stress[109,110]. In a recent study,
our group reported that although the ACE inhibitory activity of flavanols
has been demonstrated in vitro[107,108] and in vivo[111], no changes in plasmatic
ACE activity after the administration of GSPs to CHRs were found[85].
However, a decrease in the hepatic lipid peroxidation products of CHRs
administered GSPs was reported, which indicated a decrease in oxidative
stress[85]. In addition, other studies performed with SHRs showed that the
antihypertensive effects of cocoa flavanols are associated with an
improvement in oxidative stress markers and antioxidant defences[112].
Nevertheless, although the flavanol chemical structure allows them to act
as a classic antioxidant, the actual concentration that reaches vessels is so
low that the action of these compounds by a direct antioxidant mechanism
is not likely[113] and it is possible that other mechanisms related to specific
BOOK	CHAPTER	
68	
 13Beneficial Effects of Grape Seed Polyphenols...
interactions with proteins or lipids will be responsible for their in vivo
effects. Nonetheless, the antihypertensive effects of flavanols is mainly
mediated through the NO pathway and for GSPs in particular, it is also
partially mediated by prostacyclin[114]. Results showns that the NG-nitro-
L-arginine methyl ester (L-NAME), a non-selective NO synthesis inhibitor,
completely inhibited the antihypertensive effects of cocoa and grape seed
polyphenols[114,115]. In addition, the administration of indomethacin, an
inhibitor of prostacyclin synthesis, partially inhibited the antihypertensive
effects of GSPs in SHRs[114] and CHRs (data not published). These findings
indicate that the antihypertensive effects of GSPs in SHRs and CHRs are
mediated by changes in the endothelium NO availability and prostacyclin
may also contribute to this effect[114].
The molecular mechanisms involved in the flavonoid-induced availability
of NO have been extensively studied in recent years. The optimum levels
of NO can been reached by an increase in its synthesis or by a decrease in
its degradation. In the vasculature, the main degrading mechanisms include
direct reaction of NO and superoxide anion thus producing peroxynitrite[116].
It has been demonstrated that increases in NO availability are correlated
with increases in endothelial NOS (eNOS) activity[117,118]. However, post-
transcriptional modifications are also implicated in the activation of this
enzyme[119]. Other mechanism to increase NO availability is to preserve
the intracellular pool of arginine, eNOS substrate for NO synthesis which
can be metabolized by arginase enzyme. A decrease in arginase activity
has also been described in vitro for epicatechin and post-administration of
flavanol-rich cocoa in vivo[120]. In addition, direct inhibition of NADH
oxygenase (NOX) could modulate the concentration of NO because this
enzyme is a principal superoxide productive enzyme in the endothelium[121].
Other mechanisms that may be involved in the vasodilator effect of
flavonoids include the inhibition of phosphodiesterases (PDEs) 2 and 4,
which catalyse the degradation of AMPc and GMPc, and PDE-5, which
degrades GMPc[122,123].
 4. CONCLUSIONS
GSPs are potential ingredients for use in functional food as a nutritional
supplement or in pharmaceutical formulations for simultaneously
controlling different risk factors associated with CVD and involved in MetS
(Fig. 2). Improvements in many “overarching processes” such as
inflammation and metabolic and oxidative stress, which initiate many
diseases including CVD and MetS[124], may be some of the mechanisms
involved in the beneficial effects of GSPs (Fig. 2). Nevertheless, additional
research is needed to determine the actual clinical value of GSPs, and future
studies are recommended to better clarify the mechanisms involved in the
health-promoting properties of these compounds.
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HYPOTHESIS	AND	OBJECTIVES	
Dietary	 polyphenols	 have	 been	 shown	 to	 improve	 human	 health	 exihibiting	
cardioprotective	and	antioxidant	properties	among	others.	Results	obtained	by	members	of	
the	Nutrigenomic	Research	Group	of	 the	Universitat	Rovira	 i	Virgili,	 in	which	the	research	
work	 for	 this	 Thesis	 was	 carried	 out,	 confirmed	 the	 antihypertensive	 effect	 of	 flavanols	
from	cocoa	and	grape	seed	in	genetically	associated	HTN	using	the	SHR	model.	Moreover,	
the	 antihypertensive	 properties	 of	 cocoa	 and	 grape-seed	 polyphenols	 in	 SHR	 have	 been	
demonstrated	 to	 be	mostly	mediated	 by	 changes	 in	 endothelium-derived	NO	 availability.	
PGI2	was	also	seen	to	contribute	to	the	antihypertensive	effect	of	grape-seed	polyphenols,	
but	 not	 cocoa	 polyphenols.	 Moreover,	 the	 Nutrigenomic	 Research	 Group	 has	 wide	
experience	 and	 shown	 multiple	 health	 benefits	 of	 grape-seed	 polyphenols	 on	 different	
components	of	MetS	in	cafeteria	diet-fed	rats.	In	particular,	a	simultaneous	beneficial	effect	
on	BP	and	 lipid	homeostasis	was	demonstrated	 for	 these	compounds.	 In	 this	 context,	we	
hypothesized	that	the	administration	of	polyphenols	from	grape	seed	can	be	used	in	the	
improvement	of	endothelial	dysfunction	and	hypertension	associated	with	MetS.		
Thus,	the	main	objective	of	this	Thesis	was	to	determinate	the	most	effective	dose	of	a	
grape-seed	 extract	 for	 its	 administration	 in	 HTN	 associated	 with	 MetS,	 to	 identify	 the	
bioactive	 compounds	 responsible	 of	 these	 vasoprotective	 properties	 and	 to	 establish	 the	
mechanism	operating	in	this	beneficial	effect.	
In	order	to	assess	the	established	assumption,	specific	objectives	were	proposed:	
1:	 	 To	 validate	 cafeteria	 diet-fed	 rats	 as	 a	 model	 of	 diet-induced	 HTN	 associated	 with	
MetS	 and	 to	 evaluate	 the	 antihypertensive	 effectiveness	 of	 grape-seed	 polyphenols	
(Chapter	1)	
SHR	are	one	of	the	most	used	experimental	models	of	HTN	due	to	the	similarity	of	its	
pathophysiology	with	essential	HTN	in	humans.	Although	by	definition	essential	HTN	has	no	
identifiable	 cause,	 epidemiological	 studies	 implicate	 several	 dietary	 and	 other	 lifestyle-
related	factors	to	contribute	to	its	development.	In	fact,	HTN	frequently	occurs	concurrently	
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with	 many	 other	 CV	 risk	 factors	 related	 to	 lifestyle,	 such	 as	 obesity,	 dyslipidemia	 or	
impaired	 glucose	 tolerance	 (hyperglycemia),	 which	 all	 contribute	 to	 MetS.	 Therefore,	 in	
addition	 to	 the	 previously	 described	 use	 of	 cafeteria-diet	 rats	 as	 a	 model	 for	 MetS,	 the	
establishment	of	their	additional	use	as	a	model	for	HTN	was	need.	In	order	to	assess	this	
objective,	four	goals	were	proposed:		
a) To	validate	the	use	of	cafeteria	diet-fed	rats	as	a	model	of	HTN	associated	with	
MetS		[Manuscript	1]	and	[Manuscript	2].		
b) To	 determinate	 the	 acute	 dose	 of	 a	 grape-seed	 polyphenol	 extract	 most	
effective	to	reduce	BP	 in	 the	model	of	diet-induced	HTN	associated	with	MetS	
and	to	establish	the	time-course	of	the	acute	antihypertensive	effect	produced	
by	these	compounds	[Manuscript	2].		
c) To	establish	the	mechanisms	operating	in	the	BP	lowering	effect	of	grape-seed	
polyphenols	 in	 this	 model	 of	 diet-induced	 HTN	 associated	 with	 MetS.	
Specifically,	to	clarify	the	role	of	NO	and	PGI2	[Manuscript	1]	and	[Manuscript	2]	
in	 addition	 to	 evaluate	 the	 role	 of	 Sirt-1	 [Manuscript	 3]	 and	 the	 RAAS	
[Manuscript	 4]	 in	 the	 antihypertensive	 effect	 of	 these	 compounds	 in	 this	 rat	
model.		
2:	 	 To	 investigate	 the	 bioactive	 vasoprotective	 compounds	 present	 in	 the	 LM-GSPE	
(Chapter	2).	
The	most	 abundant	polyphenols	 in	 the	 LM-GSPE	are	monomers	 and	dimers	of	 the	
flavanols	 (-)-epicatechin	 and	 (+)-catechin,	 both	 in	 their	 free	 or	 gallate	 forms,	 and	 the	
phenolic	acid	GA.	The	antihypertensive	effect	of	 (-)-epicatechin	and	 (+)-catechin	has	been	
previously	 described,	 but	 their	 capability	 to	 modulate	 endothelial	 function	 and	 their	
regulatory	 genes	was	 not.	GA	 is	 not	 only	 abundant,	 but	 also	 characteristic	 of	 grape-seed	
extracts	 since	 it	 is	 not	 present	 in	 other	 polyphenol	 extracts	 such	 as	 cocoa;	 and	 the	
antihypertensive	 effect	 of	 GA	 has	 not	 been	 widely	 studied.	 Therefore,	 one	 aim	 of	 the	
present	Thesis	was	to	investigate	the	antihypertensive	effect	of	these	principal	polyphenols	
in	the	grape-seed	extract.	In	order	to	achieve	this	objective,	two	goals	were	proposed:	
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a) To	 investigate	 the	 (-)-epicatechin	 and	 (+)-catechin	 ability	 to	 modulate	 gene	
expression	 of	 the	 major	 endothelial	 function	 regulators	 and	 to	 compare	 this	
capacity	 with	 that	 shown	 by	 other	 flavonoids	 in	 order	 to	 define	 the	 key	
flavonoid	structural	features	that	are	required	in	modulation	of	the	endothelial	
function	[Manuscript	5].	
b) To	 investigate	 the	 antihypertensive	 effectiveness	 of	 GA	 and	 to	 establish	 the	
mechanism	involved	in	its	BP	lowering	effect	[Manuscript	6]	and	[Patent	1]	(see	
in	Annex	I).	
3:		To	evaluate	the	long-term	administration	of	grape-seed	polyphenols	in	HTN	associated	
with	MetS	(Chapter	3).	
HTN	 and	 other	 cardiometabolic	 risk	 factors	 associated	 with	 MetS	 are	 chronic	
pathologies,	 which	 require	 chronic	 treatment.	 Therefore,	 the	 effects	 of	 long-term	
administration	 of	 grape-seed	 polyphenols	 on	 BP	 needed	 to	 be	 evaluated.	 In	 order	 to	
achieve	this	objective	the	following	goal	was	proposed:	
a) To	 evaluate	 the	 effect	 of	 long-term	 intake	 of	 different	 doses	 of	 grape-seed	
polyphenols	 on	 the	 development	 of	 HTN	 and	 other	main	 cardiometabolic	 risk	
factors	associated	with	MetS	in	cafeteria-diet	rats	[Manuscript	7].	
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CHAPTER	 1:	 VALIDATION	 OF	 CAFETERIA	 DIET	 FED	 RATS	 AS	 A	
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Abstract Cardiovascular disease (CVD) and related
pathologies are the leading cause of death worldwide.
Fruits and vegetables are known to improve CVD, an
effect that has been associated with flavonoid intake.
The aim of this study was to simultaneously evaluate the
acute effect of a low molecular grape seed
proanthocyanidin extract (LM-GSPE) on two of the
main risk factors of CVD, high blood pressure (BP)
and dyslipidaemia, using high-fat diet-fed rats. There-
fore, male Wistar rats that were cafeteria diet fed for
10 weeks were administered with 375 mg/kg of body
weight of LM-GSPE, and the BP as well as plasmatic
and hepatic parameters were determined at 6 h post-
administration. The BP and plasmatic and hepatic lipid
were decreased 6 h after the LM-GSPE administration.
Moreover, the liver lipid peroxidation products de-
creased after the LM-GSPE treatment, indicating a re-
duction in oxidative stress. However, hepatic-reduced
glutathione or plasma angiotensin converting enzyme
activity was not altered by the LM-GSPE. In conclusion,
grape proanthocyanidins is able to simultaneously re-
duce more than one risk factor for CVD by decreasing
the BP and improving hypertriglyceridaemia at least in
part due to an improvement in oxidative stress. These
results open up the possibility of using grape
proanthocyanidins in functional foods for CVD
improvement.
Keywords Cardiovascular disease . Flavonoids . Grape
proanthocyanidins . Hypertension . Dyslipidaemia .
Oxidative stress
Introduction
Cardiovascular disease (CVD) is the leading cause of
death worldwide. A total of 17.3 million people died
from CVD in 2008, which represents 30 % of the global
deaths; and in 2030, approximately 23.3 million people
are estimated to die annually from this disease [68]. Two
of the major risk factors for CVD, which often occur
together, are hypertension (HTN) and dyslipidaemia,
which is the elevation of total cholesterol (TC) and/or
triglyceride (TG) levels. In fact, 20 % of adults in the
USA have been d iagnosed wi th HTN and
dyslipidaemia, with the frequency increasing to 50 %
in elderly adults [69]. The molecular mechanisms that
explain the relationship of these two risk factors are
mainly related to the damage of the endothelial wall.
Dyslipidaemia produces endothelial damage [41–43],
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which in addition to diminishing the anti-atherogenic
role of the vascular endothelium [25] and increasing the
oxidative stress [10], has a causal role in the molecular
mechanisms leading to HTN.
Animals fed with a high-fat diet are a good
model for studying different risk factors associated
with CV events, conditions that cannot be regarded
as a single disease and that together comprise what
is known as metabolic syndrome (MS), which is
defined as a group of interconnected factors that
directly increase the risk of CVD [31]. The cafete-
ria diet is a robust experimental model of a western
high sugar and high-fat diet extensively used to
produce obesity and MS in rats because its palat-
ability induces the animals to increase their energy
intake [59, 62]. In fact, the cafeteria diet-fed rats
present increased body weight and more abdominal
fat and develop hyperinsulinaemia, hyperglycaemia
and hepatic steatosis (see review of animal models
of MS in [46]). In addition, dyslipidaemia [51] and
elevated BP have been reported in these animals
[13, 14, 19, 29, 47].
There is evidence that a diet rich in vegetables and
fruits decreases the risk of CVD [27, 33, 35], which has
been attributed to the phenolic compounds present in
plants. Specifically, grapes and wine are known to exert
beneficial health effects. The major bioactive com-
pounds in these products are known to be the flavonoids
[3], which are the most abundant polyphenols in human
diet [60]. Grape seeds, which are by-product of the
grape/wine industry, are one of the richest sources of
flavanols and proanthocyanidins (PAs), a class of flavo-
noids [39], and their beneficial effects have been exten-
sively investigated. Grape seed PAs have been reported
by many studies as being bio-active, exhibiting different
beneficial properties on some MS-related parameters
and CVD, acting as antioxidants [50], limiting adipo-
genesis [49], presenting anti-inflammatory properties
[37] and acting as insulin-mimetic agents [11]. More-
over, a reduction of the de novo synthesis of hepatic
lipids, mainly TG, by grape seed PAs has been
established [17]. Furthermore, the antihypertensive ef-
fect of a low molecular grape seed proanthocyanidin
extract (LM-GSPE) in spontaneously hypertensive rats
(SHR) was recently reported by our group [52].
Therefore, the aim of this study was to assess the
simultaneous effects of LM-GSPE on two of the major
risk factors for CVD, elevated BP and dyslipidaemia, in
cafeteria diet-fed rats.
Material and methods
Low molecular proanthocyanidin-rich grape seed
extract
LM-GSPE was obtained from white grape seeds and
was kindly provided by Les Dérives Résiniques et
Terpéniques (Dax, France). Table 1 shows the flavanol
and phenolic acid contents of the grape seed extract used
in this study (taken from [52]).
Animal experimental procedure
Male Wistar rats Crl:WI (Charles River Laboratories,
Barcelona, Spain) that were 8 weeks old and weighed
150–175 g were singly housed in animal quarters at
22 °C with a light/dark period of 12 h. The rats (n=16)
were fed standard chow Panlab A04 (Panlab, Barcelona,
Spain) and tap water ad libitum. After a quarantine
period (1 week), the animals were fed standard chow
diet or the cafeteria diet consisting of bacon, biscuits
with paté, cheese, muffins, carrots, milk with 20 %
sucrose (w/v) daily and tap water in addition to the
standard chow diet. The cafeteria diet was composed
Table 1 Individual phenolic compounds of LM-GSPE (flavanols
and phenolic acids) determined by reverse-phase HPLC–MS
Compound Amounta (mg/g)
Catechin 90.7±7.6
Epicatechin 55.0±0.8
Procyanidin dimer 144.2±32.2
Procyanidin trimmer 28.4±2.0
Procyanidin tetramer 2.0±0.2
Dimer gallate 39.7±7.1
Epigallocatechin gallate 0.4±0.1
Epicatechin gallate 55.3±1.5
p-Coumaric acid 0.1±0.0
Gallic acid 17.7±2.0
3,4-Dihydroxybenzoic acid 1.0±0.1
Vanillic acid 0.1±0.0
Quercetin 0.3±0.0
Quercetin-3-O-gallate 0.2±0.0
Naringenin-7-glucoside 0.1±0.0
Kaempferol-3-glucoside 0.1±0.0
Values are expressed as mg compound/g extract and are the means
of three samples
*Data adapted from [51]
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of 13.6 % fat, 21 % carbohydrates, 9 % protein, 51.3 %
water and 5.1 % other nutrients [5]. The different diets
were maintained until sacrifice.
Ten weeks after the beginning of the experiment, a
group of cafeteria diet-fed rats (n=8) were treated with
375 mg/kg LM-GSPE 6 h before being sacrificed, and
the remaining animals (n=8) were given water 6 h be-
fore being sacrificed. The sacrifice was conducted by
live decapitation without anaesthesia after overnight
fasting. The LM-GSPE and water were orally adminis-
tered by gastric intubation between 9 and 10 a.m. The
volume orally administered to the rats was consistently
1 mL. The systolic blood pressure (SBP) and diastolic
blood pressure (DBP) were recorded in the rats by the
tail-cuff method [8], before and 6 h post-administration.
Before the measurement, the rats were kept at 38 °C for
10 min to allow the dilatation of blood vessels to in-
crease the level of the heartbeat signal and also to calm
the animal, as recommended by the manufacturer. The
equipment used in this study, the LE 5001 non-invasive
blood pressure meter (Panlab; Harvard apparatus, Bar-
celona, Spain), can detect the SBP and DBP. Both the
SBP and DBP values were determined by calculating
the average of at least seven measurements. The animals
were maintained during the measurements in a heater
(LE 5610, Panlab; Harvard apparatus, Barcelona, Spain)
to maintain the animal in a state of relaxation as well as
to retain an external view and minimise environmental
noises. To minimise stress-induced variations in BP, all
measurements were taken by the same person in the
same peaceful environment. After the quarantine period,
the BP method was performed during a training period
to acclimatise the animals to the procedure. To ensure
the accuracy of the results, the animals were subjected to
the experimental procedure for 2 weeks prior to testing,
enabling them to adapt to the measurement protocol and
reducing the rat stress-induced errors during the test.
The animal protocol followed in this study was ap-
proved by the bioethical committee of Rovira i Virgili
University (European Commission Directive 86/609
and Spanish Royal Decree 223/1988).
Plasma and liver lipid determinations
Blood samples from the sacrificed animals were collect-
ed in tubes containing the anticoagulant lithium heparin.
These samples were centrifuged at 2,000×g for 15 min
at 4 °C to obtain the plasma. In addition, the liver was
removed and a lipid total extraction was performed
using the method described by Caimari et al. [9]. Both
plasma and the tissue were stored at −80 °C until their
use. Plasmatic and hepatic TC and TG concentrations
were determined by a colorimetric enzymatic kit (QCA,
Barcelona, Spain).
Thiobarbituric acid reactive substances analysis
The lipid peroxidation products in the liver were mea-
sured by a thiobarbituric acid assay [58], modified as
previously described [36]. The liver homogenate was
mixed with 20 % trichloroacetic acid in 0.6 M HCl (1:1,
v/v), and the sample tubes were kept on ice for 20 min to
precipitate the plasma components and thus avoid any
interference. The samples were centrifuged at 1,500×g
for 15min before adding thiobarbituric acid (120 mM in
Tris 260 mM, pH 7) to the supernatant in a ratio of 1:5
(v/v). The mixture was subsequently boiled at 97 °C for
30 min. Spectrophotometric measurements at 540 nm
were conducted at 20 °C. The liver thiobarbituric acid
reactive substances (TBARS) were expressed as nmol
TBARS/g tissue protein.
Reduced glutathione assay
The glutathione (GSH) levels in the liver were measured
by the monochlorobimane fluorometric method [34].
For this analysis, 90 μL of homogenised supernatant
from the liver was mixed with monochlorobimane
(100 mM; Sigma, Barcelona, Spain) and 10 μL of the
catalyst (glutathione S-transferase) solution (1 U/mL),
which was obtained from horse liver (Sigma). The levels
of GSH were quantified using a fluorometer, the
FLx800 Fluorescence Microplate Reader (BioTek-
IZASA, Barcelona, Spain) and expressed as μmol/g
tissue protein.
Determination of angiotensin converting enzyme
activity in plasma
The angiotensin converting enzyme (ACE) activity in
plasma was measured using a fluorometric method, as
previously reported [38]. Briefly, plasma aliquots were
incubated in triplicate for 15 min at 37 °C with 40 μL of
assay buffer containing the ACE substrate (5 mM Hip-
His-Leu, 0,1 M sodium tetraborate decahydrate,
300 mM NaCl, pH 8.3; Sigma, Barcelona, Spain). The
reactionwas quenched by the addition of 0.35MNaOH.
The concentration of the product, His-Leu, was
Grape seed proanthocyanidins effects in cafeteria-fed rats 631
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measured fluorimetrically after 30 min of incubation
with 2 % O-phthaldialdehyde in methanol. The fluores-
cence measurements were performed at 37 °C in an
FLx800 Fluorescence Microplate Reader (BioTek-
IZASA) with 350 nm excitation and 520 nm emission
filters and Gen5TM Data Analysis Software. Black 96-
well polystyrene microplates (Thermo Scientific,
MERCK, Barcelona, Spain) were used. A calibration
curve was constructed by adding different concentra-
tions of rabbit lung ACE (Sigma, Barcelona, Spain) to
each plate. The ACE activity was expressed as mU
ACE/mL of plasma.
Statistical analysis
The results were expressed as the mean ± standard error
of the mean (SEM) and were analysed by the unpaired
Student t test for independent samples using IBM SPSS
Statistics software (Version 20.0.0). Differences be-
tween the averages were considered significant when
p<0.05.
Results
Effects of cafeteria diet on BP and plasma lipid levels
The ingestion of a cafeteria diet for 10 weeks resulted in
a significant increase in BP compared with the values
recorded before the diet administration. The measure-
ments showed increases of 24.75±3.06 and 25.39±
3.88 mmHg for the SBP and DBP, respectively,
reaching values of 140.1±2.86 mmHg for the SBP and
119.0±2.08 mmHg for the DBP.
At the end of the cafeteria-feeding period, the
plasma TC and TG levels were 67.5±4.9 and 132.1±
9.3 mg/dL, respectively.
Effect of LM-GSPE on BP and lipid levels in cafeteria
diet-fed rats
Previous studies have demonstrated that the greatest
antihypertensive effect of GSPE in SHR rats was ob-
tained 6 h after the administration of 375 mg/kg LM-
GSPE [52]. Therefore, in this study using cafeteria diet-
fed rats, a dose of 375 mg/kg LM-GSPE was selected to
be administered for 6 h. The administration of LM-
GSPE (375 mg/kg) resulted in a decrease in both the
SBP (Fig. 1a) and DBP (Fig. 1b) within 6 h, being
significant for the SBP. In contrast, the water adminis-
tration did not lead to changes in either the SBP or DBP
(Fig. 1a, b). The LM-GSPE administration produced a
decrement in both the plasmatic and hepatic TC and TG
levels (Fig. 2) compared with the cafeteria diet-fed
animals receiving water.
Effect of LM-GSPE on the lipid peroxidation products
and GSH levels and ACE activity in the cafeteria
diet-fed rats
The TBARS levels, as well as the lipid peroxidation
product levels and GSH levels and the plasma ACE
activity, were measured in cafeteria diet-fed rats that
Fig. 1 Decrease in systolic blood pressure (SBP) (a) and diastolic
blood pressure (DBP) (b) in cafeteria diet-fed rats 6 h after the
administration of 375 mg/kg LM-GSPE (black box) or water
(white box). The results are expressed as the mean ± standard error
(SEM).Double asterisk indicates significant differences at p<0.01
632 Z. Pons et al.
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were untreated and treated with 375 mg/kg LM-GSPE
6 h after the administration. The livers of the LM-GSPE-
treated and untreated animals had very similar GSH
levels (Fig. 3a). The levels of TBARS were decreased
in the livers of the treated cafeteria diet-fed rats (Fig. 3b),
whereas the plasma ACE activity was similar in the
untreated and LM-GSPE-treated rats 6 h after the ad-
ministration of 375 mg/kg LM-GSPE (Fig. 4).
Discussion
Among the modifiable risk factors for CVD, HTN and
dyslipidaemia, together with smoking and diabetes
mellitus, have particular relevance [63]. In addition,
patients with one risk factor tend to present other factors,
and the probability of occurrence increases as the num-
ber of risk factors increases, with the risk being more
pronounced as the MS itself is presented [30]. Thus,
interventions for all risk factors present and assessing
the ‘global CV risk of the patients’ are recommended
[21, 23]. However, currently, there is not a pharmaco-
logical treatment completely successful for the cluster-
ing of CVD risk factors, and the overall approach used is
the treatment of each individual component [57]. The
experimental model of rats fed a cafeteria diet proposed
in this study can be especially useful because, in addi-
tion to being induced by the diet, the increased BP is
associated with other risk factors of CVD, such as
elevated lipid concentrations. Although the measured
SBP after 10 weeks of feeding a cafeteria diet was not
as high as that reached in SHR [52], the obtained values
can be considered to be borderline or a state that could
be designated as pre-hypertension, which thus already
implies a risk factor.
Regarding the grape PAs effect on the lipid levels in
this animal model, the LM-GSPE treatment decreases
the plasmatic and hepatic TC levels in animals fed with
Fig. 2 Plasma cholesterol (mg/dL) (a), plasma triglyceride
(mg/dL) (b), hepatic cholesterol (mg/g tissue) (c) and hepatic
triglyceride (mg/g tissue) (d) levels in cafeteria diet-fed rats 6 h
after the administration of 375 mg/kg LM-GSPE (black box) or
water (white box). The results are expressed as the mean ±
standard error (SEM)
Grape seed proanthocyanidins effects in cafeteria-fed rats 633
RESULTS	
94	
a cafeteria diet after overnight fasting (22 and 21 %
decrement, respectively). Other studies have also found
a decrease in plasmatic TC after the administration of
PAs from grape seeds [15–17, 45, 51]. However, a lack
of an effect by grape seed PAs on plasma lipids has been
previously reported for these animals [7]. These discrep-
ancies could be due to the different doses of extract
used, the time of the administration of the extracts, the
different types of cafeteria diet used, the fasting period
of the animals and even the use of different animal
models [7, 9]. In addition to the findings for TC, a
decrease in the plasmatic and hepatic TG levels after
the administration of LM-GSPE was recorded only 6 h
after the administration of grape PAs (20 and 16 %
decrement, respectively). In agreement, a liver lipid
decrement was previously described in a lipid tolerance
test after an acute treatment with a grape seed extract
only 3 h after the administration [6]. A repression of
genes related to TG synthesis was highlighted as the
cause of this quick modulation of the concentration of
hepatic TG by the grape seed extract [15, 17, 51] (see
the review about the hypolipidaemic effect of PAs and
its biochemical mechanisms in [7]).
The results of this study also showed that the admin-
istration of LM-GSPE exhibited an antihypertensive
effect with respect to the animals administered with
water in this model of pre-hypertension. This antihyper-
tensive effect of PAs has been previously reported in
both short-term [12, 40, 53] and long-term studies con-
ducted with SHR [55, 65], once the hypertension has
been fully established.
One of the mechanisms involved in endothelial dam-
age and the control of BP is oxidative stress. The ele-
vated production of free radicals in the endothelium, as
has been described for high lipid circulation, augments
the contractibility of the vascular smooth muscle and
promotes its proliferation [64], which has been
recognised as the central pathology for HTN and ath-
erosclerosis [61]. Moreover, free radicals in the endo-
thelium can directly scavenge NO and avoid NO-
dependent vasodilatation. In addition, the oxidative
stress also stimulates the production of endothelium-
derived vasoconstrictor factors and pro-inflammatory
agents [10]. Nevertheless, it is controversial whether
the antioxidant properties of polyphenols could explain
their health benefits. In fact, an important feature of
flavonoids is the changes that occur to these molecules
during first-pass metabolism. Moreover, considerable
quantities of the ingested PAs reach the large intestine
Fig. 3 Hepatic TBARS (a) and reduced glutathione (GSH) (b) in
cafeteria diet-fed rats 6 h after the administration of 375 mg/kg
LM-GSPE (black box) or water (white box). The results are
expressed as the mean ± standard error (SEM). Double asterisk
indicates significant differences at p<0.01
Fig. 4 Plasma angiotensin-converting enzyme activity (ACE) in
cafeteria diet-fed rats 6 h after the administration of 375 mg/kg
LM-GSPE (black box) or water (white box). The results are
expressed as the mean ± standard error (SEM)
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where they are degraded by colonic microbiota, yielding
other smaller molecules that are also absorbed into the
body [18]. Consequently, the molecular forms that reach
the peripheral circulation and tissues are different from
those that are present in foods. Therefore, their physio-
logical properties differ from the original compounds
ingested, including their antioxidant activities. Two of
the known biomarkers for the global oxidative stress
status in the body are the liver concentrations of GSH
and TBARS. The latter are the final products of lipidic
peroxidation [32, 66]. In contrast, the GSH concentra-
tion can be directly related to the concentration of free
radicals in the tissue [67]. Although we did not find
changes in this antioxidant system in the liver, we de-
scribe in the present study a decrement in the hepatic
lipid peroxidation products of the rats treated with LM-
GSPE, which indicates an improvement in oxidative
stress. These results are in concordance with other rat
[54] and human [22] studies that revealed a decrease in
oxidative stress biomarkers after the administration of
PAs.
Finally, as the renin–angiotensin–aldosterone system
(RAAS) is a key factor in the maintenance of arterial BP,
and one of its main components is the ACE, we studied
whether the administration of LM-GSPE modified the
activity of this enzyme. ACE catalyses the conversion of
angiotensin I into the potent vasoconstrictor angiotensin
II [62]. In addition, angiotensin II stimulates the cell
intake of lipids and their free radical production by
promoting the action of the enzyme NADPH oxidase
[20]. The ACE inhibitory activity of PAs has been
demonstrated both in vitro [1, 2, 24, 44] and in vivo
[48]. However, in this study, we did not find any change
in the plasmatic ACE activity 6 h after the administra-
tion of LM-GSPE, although these results did not elim-
inate the participation of this enzyme before this mo-
ment or the participation of the RAAS system in the
improvement of the BP.
As is well known, lifestyle habits, such as dietary
habits or physical activity, have been associated with
improvements in CVD, and the regular consumption of
vegetables and fruits has been associated with the re-
duced mortality and risk of CVD [4, 26, 28, 56]. In this
context, the study of the beneficial effects of plant-
derived compounds, such as PAs, on different risk fac-
tors associated with CVD can be very useful because
these compounds can be used as functional ingredients,
especially when the limits set to begin pharmacological
treatment have not been reached yet for the pre-
hypertensive state. Nevertheless, the quantity of LM-
GSPE necessary to decrease arterial BP in humans
should be definitively established when clinical trials
are conducted.
Therefore, the results obtained in this study have
demonstrated a simultaneous beneficial effect of grape
seed PAs on HTN and hepatic TG. In addition, the
beneficial effect of LM-GSPE on hepatic lipids and
HTN is mediated, at least in part, by a reduction in
oxidative stress. In conclusion, we have described some
mechanisms implicated in the cardiovascular protective
effect of LM-GSPE, a grape seed extract that could be
used as a functional food ingredient for simultaneously
controlling different risk factors associated with CVD.
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effect was completely abolished by L-NAME and partially 
inhibited by indomethacin.
Conclusions GSPE acts as an antihypertensive agent in a 
rat model of hypertension associated with MS. The change 
in endothelium-derived NO availability is one of the mech-
anisms involved in the antihypertensive effect of GSPE in 
CHRs. Additionally, endothelial prostacyclin contributes to 
the effect of GSPE on arterial BP.
Keywords Cafeteria diet · Hypertension · 
Antihypertensive agent · Endothelial-relaxing factors
Introduction
Hypertension (HTN) is a major risk factor for the devel-
opment of cardiovascular disease (CVD) [1]. In fact, high 
blood pressure (BP) treatment has been associated with an 
approximately 40 % reduction in the risk of stroke and an 
approximately 15 % reduction in the risk of myocardial 
infarction [2]. Human HTN frequently occurs concurrently 
with many other CVD risk factors related to lifestyle, such 
as obesity, dyslipidaemia or impaired glucose tolerance 
(hyperglycaemia) [3], resulting in metabolic syndrome 
(MS). Wistar rats fed cafeteria (CAF) diet, which consists 
of free access to highly palatable, energy dense, unhealthy 
human food, are considered a robust model of human MS 
[4], which is pandemic in Western civilisation today [5]. 
CAF diet-fed rats present increased body weight (BW) and 
additional abdominal fat and develop hyperinsulinemia, 
hyperglycaemia and hepatic steatosis (see review of animal 
model of MS in [6]). Additionally, elevated measures of BP 
in CAF diet-fed rats have been reported [7, 8]. Neverthe-
less, the use of CAF diet-fed hypertensive rats (CHRs) as 
an experimental model of HTN to assay antihypertensive 
Abstract 
Purpose The aims of this study were to evaluate the anti-
hypertensive effectiveness of different doses of grape seed 
polyphenols in cafeteria diet-fed hypertensive rats (CHRs) 
and to establish the mechanism involved in the blood pres-
sure (BP) lowering effect of these compounds in this exper-
imental model of metabolic syndrome (MS).
Methods Male 8-week-old Wistar rats were fed cafeteria 
or standard (ST) diet for 10 weeks. After this, the antihy-
pertensive effect of a single oral administration of a poly-
phenol grape seed extract (GSPE) was tested at different 
doses (250, 375 and 500 mg/kg) in CHRs. BP was recorded 
before and 2, 4, 6, 8, 24 and 48 h post-administration. The 
hypotensive effect of GSPE was also proved in ST diet-fed 
rats. Additionally, in other experiment, CHRs were orally 
administered 375 mg/kg GSPE. Four hours post-adminis-
tration, the rats were intraperitoneally administrated 30 mg/
kg NG-nitro-L-arginine methyl ester (L-NAME) or 5 mg/kg 
indomethacin [inhibitors of nitric oxide (NO) and prostacy-
clin synthesis, respectively]. BP was recorded initially and 
6 h post-administration.
Results GSPE produced a decrease in SBP and DBP, the 
most effective dose (375 mg/kg) showing an antihyperten-
sive effect in CHRs similar to the drug captopril, and did 
not affect BP of ST diet-fed rats. The antihypertensive 
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compounds has not been widely explored. However, this 
dietary model presents many of the complications asso-
ciated with MS. Moreover, it is important to note that in 
humans, diet is a major factor in the development of these 
pathologies.
Increasing evidence suggests that a vegetable- and fruit-
rich diet, which is abundant in polyphenolic compounds, 
helps to control BP. In fact, increased fruit and vegetable 
intake has been included in the guidelines for the manage-
ment of arterial HTN [9]. Cocoa and grapes are a signifi-
cant source of polyphenols, and particularly of flavanols. 
Our research group has previously demonstrated the anti-
hypertensive effect of cocoa or grape seed flavanols in 
spontaneously hypertensive rats (SHRs) [10–12]. The anti-
hypertensive properties of cocoa and grape seed flavanols 
in SHRs have been demonstrated to be mostly mediated by 
changes in endothelium-derived nitric oxide (NO) availa-
bility [13, 14]. Additionally, prostacyclins could contribute 
also to this effect for grape seed polyphenols [14]. How-
ever, although SHRs are one of the well-established and 
most used experimental model of HTN, these animals do 
not present other CVD risk factors frequently associated 
with human HTN, which result in MS.
Therefore, the purpose of the present study was to 
investigate the antihypertensive effect of different doses 
of grape seed polyphenols in an experimental model of 
HTN associated with MS. In addition, the involvement of 
endothelial-relaxing factors as BP-regulating mechanism 
of grape seed polyphenols in this dietary model has also 
been studied using CHRs treated alternatively with NG-
nitro-L-arginine methyl ester (L-NAME), an inhibitor of 
NO synthesis, or with indomethacin, an inhibitor of pros-
tacyclin synthesis.
Methods
Grape-derived product and reagents
GSPE is a low molecular weight polyphenol-rich extract 
obtained from white grape seeds and was kindly pro-
vided by Les Dérives Résiniques et Terpéniques (Dax, 
France). The total polyphenol content was determined 
according to the Folin–Ciocalteu spectrophotomet-
ric method, and it was expressed by using gallic acid 
as the standard [15]. Individual phenolic compounds 
were characterised by an high-performance liquid chro-
matography (HPLC) Agilent 1200 series coupled to a 
time-of-flight mass spectrometer Agilent TOF 6210 as 
previously described [12]. The antioxidant capacity of 
this extract was determined by the hydrophilic oxygen 
radical absorbance capacity (ORAC) assay according to 
the methodology reported previously [16]. The ORAC 
values were calculated by using the area-under-curve 
(AUC) results for Trolox, expressed as micromoles 
of Trolox equivalents (TE) per gram of GSPE. All the 
analyses were performed in triplicate, and the results are 
reported on dry basis (Table 1).
Captopril, L-NAME and indomethacin were purchased 
from Sigma (Barcelona, Spain).
Experimental procedure in rats
General procedure
Six-week-old male Wistar rats Crl:WI were purchased 
from Charles River Laboratories (Barcelona, Spain) and 
were singly housed in animal quarters in at 22 °C with 
a light/dark period of 12 h. After quarantine and a train-
ing period of 2 weeks, the animals were divided into 
two dietary groups (Fig. 1). The control group was fed 
with the standard (ST) chow Panlab A04 (Panlab, Barce-
lona, Spain) and tap water ad libitum. The second group 
had free access to a fresh CAF diet consisting of bacon 
(10–12 g); frankfurter (8–12 g); biscuit with pâté (12–
15 g); biscuit with cheese (10–12 g); ensaïmada (pas-
try) or muffins (4–5 g); carrots (8–10 g); milk with sugar 
(220 g/L; 50 mL); water (ad libitum); and ST diet. The 
ST chow had a calorie breakdown of 14 % protein, 8 % 
fat and 73 % carbohydrates and 0.3 % of Na, whereas the 
Table 1  Total polyphenol content, individual phenolic compounds 
and antioxidant capacity of the grape seed extract studied
a
 The values are expressed on a dry basis as mean ± SEM (n = 3)
b
 Measured by Folin–Ciocalteu method
c
 HPLC-MS
d
 ORAC assay, expressed as µmol of Trolox equivalents (TE) per 
gram of LM-GSPE
e
 Quantified using the calibration curve of procyanidin B2
f
 Quantified using the calibration curve of epigallocatechin gallate
Compounds Total amount (mg/g)a
Total polyphenol contentb 554.16 ± 13.02
Phenolic compoundc
 Gallic acid 19.0 ± 2.1
 Protocatechuic acid 1.1 ± 0.1
 Procyanidin dimere 154.5 ± 34.6
 Catechin 97.2 ± 8.2
 Epicatechin 59.0 ± 0.8
 Dimer gallatee 42.6 ± 7.6
 Epigallocatechin gallate 0.4 ± 0.1
 Procyanidin trimere 30.5 ± 2.2
 Procyanidin tetramere 2.4 ± 0.2
 Epicatechin gallatee 59.3 ± 1.6
Antioxidant capacityd 18,161.22 ± 698.85
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calorie breakdown of the CAF diet was: 14 % proteins; 
35 % fat; 51 % carbohydrates; and 0.2 % of Na. The 
animals were fed ad libitum, and the food was renewed 
daily. The CAF administration was maintained to the end 
of the experiment.
Values of BP, BW and abdominal circumference (AC) 
were recorded at the beginning, middle (5th week) and 
final (10th week) of feeding period in both groups of rats 
(Fig. 1). Systolic BP (SBP) and diastolic BP (DBP) were 
recorded between 9 and 11 a.m. in the rats by the tail-cuff 
method [17] as previously described [8]. To minimise 
stress-induced variations in BP, all measurements were 
taken by the same person in the same peaceful environ-
ment. After the quarantine period, the BP method was per-
formed as a training period to acclimatise the animals to 
the procedure.
AC was assessed on the largest zone of the rat abdomen, 
vertically immobilized, using a non-extensible measuring 
tape with an accuracy of 0.1 cm, without applying pressure 
to the body surface. Initially and after 5 and 10 weeks of 
feeding period, the animals were housed for 24 h in meta-
bolic cages to estimate the daily food and liquid intake and 
to collect faeces and urine samples.
The animal protocol followed in this study was approved 
by the Bioethical Committee of Universitat Rovira i 
Virgili (European Commission Directive 86/609 and Span-
ish Royal Decree 223/1988).
Biochemical assays
Plasma biochemical assays were measured 10 weeks after 
the beginning of the experiment using tail vein blood draws 
after fasting overnight.
Glucose, total cholesterol and triglyceride plasma con-
centration were assayed using enzymatic colorimetric kits 
(GOD-PAP method for glucose, CHOD-POD method for 
total cholesterol and GPO method for triglycerides; QCA, 
Tarragona, Spain). Insulin plasma concentrations were 
determined using a Rat Insulin ELISA/Ultrasensitive kit 
(Mercodia, Uppsala, Sweden).
Antihypertensive effects of grape seed polyphenols
After 10 weeks of diet feeding, the acute effect of GSPE 
on SBP and DBP was evaluated in CAF and ST diet-fed 
rats (Fig. 1). GSPE was dissolved in water and orally 
administered by gastric intubation, between 9 and 10 
a.m. Water was used as a negative control and captopril 
(50 mg/kg), a known antihypertensive drug, as a positive 
control. Different doses of GSPE (250, 375 and 500 mg/
Fig. 1  Graphical representation of experimental design used in this study
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kg) were administered to CHRs, and 375 mg/kg GSPE 
was also evaluated in ST diet-fed rats. The animals were 
always orally administered a single dose of either 1 mL 
of water or the appropriate solution of GSPE or captopril. 
SBP and DBP were recorded at 0, 2, 4, 6, 8, 24 and 48 h 
post-administration.
Cafeteria diet-fed rats treated with NG-nitro-L-arginine 
methyl ester and indomethacin
Additional trials were conducted administering a sin-
gle dose of 375 mg/kg GSPE or water by gastric intuba-
tion between 9 and 10 a.m. to CHRs. In addition, both 
groups were intraperitoneally treated with 1 mL of saline 
or 30 mg/kg L-NAME or 5 mg/kg indomethacin 4 h after 
the oral treatment (n = 5 per group). SBP and DBP were 
recorded initially and 6 h post-administration (Fig. 1).
Statistical analysis
Data were analysed by one-way ANOVA, two-way 
ANOVA (Tukey’s test) or independent Student’s t test using 
IBM SPSS Statistics 20.0.0 for Mac as required. Kolmogo-
rov–Smirnov and Levene’s tests were used, respectively, 
to check for the normality and equality of variances of the 
data as required.
Results
Effects of cafeteria diet on blood pressure, physiological 
and plasmatic parameters
At the beginning of the experiment, BW, AC and BP did 
not differ (Table 2). However, the animals fed CAF diet for 
10 weeks presented increased BW, AC and BP (SBP and 
DBP) with respect to ST diet-fed rats. Compared to the 
control group, the animals fed a CAF diet had significantly 
increased BW throughout, with differences of 12.0 and 
19.2 % at the 5th and 10th weeks, respectively. Concern-
ing the AC, the differences were of 7.8 % at the 5th week 
and 16.4 % at 10th week of the feeding period. CAF rats 
presented significant increase in SBP in both 5th (142 ± 3 
vs. 122 ± 2 mmHg) and 10th (140 ± 2 vs. 122 ± 3 mmHg) 
weeks of feeding period compared with the ST group.
Pre-treatment fluid intake was not different between 
groups. The fluid intake by the CAF group was higher 
than by the ST group at the 5th week of the feeding period. 
Throughout the 10 weeks of CAF administration, the fluid 
intake by the CAF group was almost three times higher than 
by the ST group. It has to be taken into account that the 
CAF diet includes milk, which increases per se the total liq-
uid intake of the CAF-fed animals. Thus, urine volume was 
four times higher in rat fed CAF diet than in the ST group.
Table 2  Physiological parameters determined along the feeding period of the experiment
The results are expressed as the mean ± SEM for n = 10 animals per group
ST standard diet-fed group of rats, CAF cafeteria diet-fed group of rats, SBP systolic blood pressure, DBP diastolic blood pressure, BW body 
weight, AC abdominal circumference
** Differences between groups in each specific time (Student’s t test. p < 0.01). Differences between groups along the experiment were analysed 
by two-way ANOVA p < 0.01. D shows that the differences in each parameter are a consequence of diet. T shows that differences in each param-
eter are a consequence of time. D*T suggests the interaction of diet and time in each analysed parameter
Initial values 5th week 10th week Two-way 
ANOVA
ST CAF ST CAF ST CAF
SBP (mmHg) 113 ± 2 117 ± 2 122 ± 3 142 ± 3** 122 ± 2 140 ± 2** D
DBP (mmHg) 79 ± 4 83 ± 2 94 ± 3 101 ± 2 85 ± 5 98.4 ± 4 D
BW (g) 226 ± 3 235.5 ± 5 337.6 ± 10.0 384.1 ± 10.5** 390.9 ± 11.6 483.6 ± 14.5** D, T
AC (cm) 13.9 ± 0.3 13.6 ± 0.2 16.0 ± 0.3 17.4 ± 0.3** 17.3 ± 0.3 20.7 ± 0.2** D
Chow intake (g) 16.7 ± 1.4 17.2 ± 0.9 18.6 ± 0.4 3.2 ± 0.7** 19.7 ± 0.8 3.3 ± 0.6** D, T, D*T
Total intake (g) 16.7 ± 1.4 17.2 ± 0.9 18.6 ± 0.4 59.7 ± 3.9** 19.7 ± 0.8 68.9 ± 3.5** D, T
Protein (g) 2.5 ± 0.1 2.5 ± 0.1 2.7 ± 0.1 1.8 ± 0.1** 2.8 ± 0.1 1.5 ± 0.2** D, T, D*T
Carbohydrates (g) 12.6 ± 0.5 12.5 ± 0.6 13.5 ± 0.3 31.2 ± 1.9** 14.3 ± 0.4 35.8 ± 1.8** D, T, D*T
Fat (g) 1.4 ± 0.1 1.4 ± 0.1 1.5 ± 0.0 19.9 ± 1.5** 1.6 ± 0.0 23.1 ± 1.3** D
Kcal intake 129.4 ± 5.6 128.2 ± 6.5 138.3 ± 2.8 367.8 ± 22.7** 146.2 ± 4.3 422.2 ± 21.1** D, T
Water (mL) 21.4 ± 2.6 21.9 ± 1.3 25.7 ± 1.7 12.5 ± 1.3** 23.9 ± 3.0 9.0 ± 1.6** D, T, D*T
Total fluid (mL) 21.4 ± 2.6 21.9 ± 1.3 25.7 ± 1.7 56.9 ± 3.9** 21.6 ± 2.1 63.3 ± 1.7** D
Faeces (g) 3.1 ± 0.2 3.9 ± 0.3 4.5 ± 0.2 1.4 ± 0.3** 4.0 ± 0.8 0.5 ± 0.2** D
Urine (mL) 9.4 ± 1.8 8.3 ± 0.8 13.4 ± 1.6 32.4 ± 3.1** 17.6 ± 3.6 33.1 ± 2.8** D
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Pre-treatment food total intake was not different between 
groups. However, the total food intake by the CAF group 
was significantly higher than that of the ST group at the 5th 
and 10th weeks of feeding period (3.5-fold and fourfold 
higher, respectively). Consequently, the protein, fat, carbo-
hydrate and energy intake were also higher in the CAF than 
in the ST group at the 5th and 10th weeks of diet. On the 
contrary, the amount of deposited faeces at the 5th and 10th 
weeks of feeding period decreased in the CAF groups with 
respect to ST diet-fed rats (Table 2).
The consumption of CAF diet for 10 weeks by rats 
resulted in a significant increase in plasma cholesterol, tri-
glycerides and insulin concentrations under fasting condi-
tions (Table 3).
Short-term effect of grape seed polyphenols on blood 
pressure in cafeteria diet-fed rats
 All doses of GSPE produced an antihypertensive effect 
in rats fed CAF diet (Fig. 2a, b). The maximum effect on 
SBP and DBP was caused by the dose of 375 mg/kg GSPE 
at 6 h post-administration (−21 ± 2 and −22 ± 3 mmHg, 
respectively), statistically similar to those found for cap-
topril (−19 ± 4 and −26 ± 3 mmHg, respectively). Oral 
administration of 500 mg/kg GSPE showed a similar effect 
on SBP and DBP to the results observed with 250 mg/kg. 
Water administration had no effect on SBP and DBP.
Effect of grape seed polyphenols on blood 
pressure in cafeteria diet-fed rats treated 
with NG-nitro-l-arginine methyl ester 
and indomethacin
As expected, the animals that received only water and 
saline did not modify their SBP and DBP (Fig. 3a, b). On 
the contrary, 375 mg/kg GSPE and saline caused a signifi-
cant decrease in SBP and DBP that could be appreciated 
6 h post-administration. Intraperitoneal administration of 
30 mg/kg of L-NAME caused an increase in SBP in the 
water group. The antihypertensive effect of GSPE was 
completely abolished by L-NAME treatment. Nevertheless, 
5 mg/kg indomethacin had no effect in the water-treated 
rats, but the effect of GSPE was slightly modified in the 
indomethacin-treated rats (Fig. 3c, d).
Short-term effect of grape seed polyphenols on blood 
pressure in standard diet-fed rats
The ST diet-fed animals that received water and 375 mg/kg 
GSPE did not modify their SBP and DBP (Fig. 4), ruling 
out a hypotensive effect in normotensive rats.
Discussion
CAF diet-fed rats have been described as a robust model 
of human MS, and this diet promotes voluntary hyper-
phagia that results in rapid weight gain [4]. Our study 
clearly confirms the development of hyperphagia, obesity 
and HTN in animals feeding on CAF diet for 10 weeks, 
mimicking the classical model of human MS (Table 2). 
In fact, HTN is one of the predominant complications 
associated with MS in humans, even more prevalent than 
obesity [18], although all of the factors are interlinked. In 
this study, the values of SBP reached in CHRs were not as 
high as the values reported for other experimental models 
of HTN such as SHRs, approximately 200 mmHg SBP at 
17–20 weeks of age [19]. Nevertheless, the CAF diet-fed 
rats can be considered hypertensive, SBP 140 mm Hg or 
greater [20], at the 5th week of the CAF diet administration 
(Table 2). Moreover, in addition to the progressive increase 
in BW and BP, high plasma insulin levels in CAF diet-fed 
rats were observed (Table 3). Also, a significant elevation 
in HOMA-IR and HOMA-β levels has been reported for 
these animals with respect to ST diet-fed rats (10.7 ± 1.0 
vs. 5.0 ± 0.5 and 1509 ± 389 vs. 609 ± 93, respectively), 
indicating the presence of peripheral insulin resistance and 
an increase in pancreatic insulin secretion [21]. Addition-
ally, the consumption of CAF diet induced dyslipidaemia in 
rats, as evidenced by an increase in plasma total cholesterol 
and triglycerides at the 10th week of CAF diet administra-
tion (Table 3).
To test the antihypertensive effect of grape seed poly-
phenols in HTN associated with MS, in vivo studies were 
carried out in CHRs administered GSPE. The administra-
tion of this extract produced a significant decrease in the 
SBP of CHRs, the most effective dose (375 mg/kg) show-
ing an antihypertensive effect similar to captopril, which 
is a specific competitive angiotensin-converting enzyme 
inhibitor that is known to be a very effective antihyperten-
sive treatment in clinical practice. Interestingly and in con-
trast to SHRs [12], the antihypertensive effects of GSPE 
Table 3  Effect of cafeteria diet versus standard diet on fasting plas-
matic values related to metabolic syndrome at 10 weeks
The results are expressed as the mean ± SEM for 10 animals per 
group
ST standard diet-fed group of rats and CAF cafeteria diet-fed group 
of rats
** Differences between groups (Student’s t test. p < 0.01)
ST CAF
Plasmatic triglycerides (mg/dL) 64.13 ± 6.45 104.37 ± 12.75**
Plasmatic total cholesterol (mg/dL) 48.27 ± 1.53 72.42 ± 1.91**
Plasmatic insulin (µU/dL) 29.02 ± 2.93 59.26 ± 5.83**
Plasmatic glucose (mg/dL) 74.34 ± 4.32 80.82 ± 4.86
RESULTS	
106	
 Eur J Nutr
1 3
were maintained 48 h post-administration in CAF diet-fed 
rats, indicating a more sustained antihypertensive effect in 
this dietary model of HTN. Taking into account that HTN 
is a chronic pathology that requires chronic treatment and 
that the use of strategies with long-lasting antihypertensive 
effects is always desirable, the antihypertensive properties 
of these compounds would be more favourable in hyperten-
sive rats with MS. Paradoxically, the highest dose of GSPE 
(500 mg/kg) demonstrated a lower antihypertensive effect 
than the medium dose (375 mg/kg). This apparently surpris-
ing finding has also been described in SHRs administered 
grape seed polyphenols [12] and other flavanol-rich com-
pounds such as cocoa [10]. These results could be explained 
by the pro-oxidant properties and the excessive production 
of reactive oxygen species caused by high doses of flavanols 
described previously [10, 22]. In fact, endothelial tissue 
regulates vascular tone and exerts finely tuned control over 
cardiovascular homoeostasis, with NO being one of the 
best-characterised vasodilator endothelial factors. However, 
NO is also a precursor of potent pro-oxidant and nitrating 
compounds, such as peroxynitrite and nitrogen dioxide [23].
Many different molecular targets and mechanisms have 
been proposed to explain the cardiovascular effects of 
polyphenols, including participation of the renin angio-
tensin aldosterone system (RAAS). In fact, angiotensin-
converting enzyme (ACE) inhibitory activity of flavanols 
has been demonstrated both in vitro [24–27] and in vivo 
[8, 28]. However, no changes in plasma ACE activity after 
the administration of flavanols from grape seed have been 
found [8, 12]. Nevertheless, these results did not eliminate 
Fig. 2  Changes in systolic 
blood pressure (SBP) (a) and 
diastolic blood pressure (DBP) 
(b) in cafeteria-fed rats after 
the administration of water, 
captopril or different doses 
of GSPE. Data expressed 
as MEAN ± SEM for eight 
animals per group. Letters 
represent significant differences 
(two-way ANOVA; p < 0.05)
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the participation of this enzyme before this moment or the 
participation of other RAAS system components in the 
improvement of the BP.
A dysregulation between the vasodilator and vaso-
constrictor secreted factors in the endothelium has been 
described for MS and also for HTN [29]. NO is an impor-
tant mediator of BP homoeostasis, and the increase in arte-
rial tone that characterises the hypertensive state frequently 
implies an excess of free radicals that destroy this media-
tor. Enhanced endothelial superoxide anion production has 
been described in HTN, and these effects are related to 
impairment of endothelium-dependent relaxation [30]. In 
addition, a decreased NO availability due to the increased 
oxidative stress in a rat model of obesity-induced HTN 
has been reported [31]. In a recent study, we reported a 
decrement in hepatic lipid peroxidation products of rats 
fed CAF diet administered grape seed polyphenols, which 
indicates a decrease in oxidative stress [8]. Hence, in this 
study, we evaluated the involvement of NO as BP-regulat-
ing mechanism of GSPE in CHRs intraperitoneally injected 
L-NAME. L-NAME is an in vivo and in vitro non-specific 
inhibitor of NO synthase [32], and in the present study, a 
clear increase in SBP was observed in the L-NAME-treated 
CHRs. The inhibition of basal NO synthesis by L-NAME in 
these animals could justify these results, but what was more 
important in order to fulfil the aim of the present study was 
the observed impairment of GSPE antihypertensive effect 
in the L-NAME-treated CHRs. These results suggest that 
facilitation of NO release is a mechanism of action in the 
antihypertensive effect of grape seed polyphenols in HTN 
(A) (B)
(C) (D)
Fig. 3  Differences in systolic blood pressure (SBP) (a) and diastolic 
blood pressure (DBP) (b) in cafeteria-fed rats 6 h post-administration 
of water or GSPE and L-NAME or saline. Differences in systolic 
blood pressure (SBP) (c) and diastolic blood pressure (DBP) (d) in 
cafeteria-fed rats 6 h post-administration of water or GSPE and Indo-
methacin or saline. Data expressed as MEAN ± SEM for 5–8 ani-
mals per group. Letters represent significant differences (one-way 
ANOVA; p < 0.05)
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associated with MS. Our results are in accordance with the 
majority of available data, which support the evidence that 
flavanols are able to improve NO availability [13, 14].
Nevertheless, the endothelium secretes other vasodi-
lator agents in addition to NO such as prostaglandin I2 
(PGI2), also known as prostacyclin. PGI2 is synthesised 
by the action of the cyclooxygenase (COX) enzyme and 
prostacyclin synthase [33]. Therefore, we have also evalu-
ated the effect of GSPE in CHRs intraperitoneally injected 
indomethacin, which is an inhibitor of COX enzyme and 
of the endothelial prostanoid biosynthesis. Indomethacin 
treatment partially abolished the GSPE antihypertensive 
effect in CHRs (Fig. 3b), indicating that endothelial pros-
tacyclin could also contribute to the effect of grape seed 
polyphenols on arterial BP in this animal model. In agree-
ment, increases in the release of PGI2 in flavanol-treated 
human aortic endothelial cells [34] and high plasmatic lev-
els of prostacyclin in humans [34] and rats [14, 35] after 
flavanol consumption have been reported.
Finally, this study demonstrates the antihypertensive 
effect of GSPE in hypertensive rats but not in normotensive 
rats, establishing the specific effects of grape seed polyphe-
nols on the hypertensive condition and ruling out a hypo-
tensive effect.
In conclusion, grape seed polyphenols exhibit a clear 
antihypertensive effect in a rat model of HTN associ-
ated with MS. The change in endothelium-derived NO 
availability is one of the mechanisms involved in the 
Fig. 4  Differences in systolic 
blood pressure (SBP) (a) and 
diastolic blood pressure (DBP) 
(b) in standard diet-fed rats 
after the administration of water 
or 375 mg/kg of GSPE. Data 
are expressed as mean ± SEM 
for six animals per group. No 
statistical differences were 
observed between groups (two-
way ANOVA)
(A)
(B)
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antihypertensive effect of GSPE in CHRs. In particular, our 
results indicate that grape seed polyphenols affect endothe-
lial NO synthesis in these animals. Additionally, endothe-
lial prostacyclin contributes to the effect of GSPE on arte-
rial BP. However, more studies are necessary to clarify the 
molecular mechanisms responsible for the antihypertensive 
properties of grape seed polyphenols in this animal model 
of MS and to demonstrate its long-term efficiency.
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Abstract	
Involvement	of	nitric	oxide	(NO)	in	the	antihypertensive	effect	of	grape	seed	
flavanols	 was	 previously	 demonstrated.	 This	 study	 investigates	 the	 endothelial	
vasoprotective	 and	 the	 role	 of	 Sirtuin-1	 (Sirt-1)	 in	 this	 antihypertensive	 effect.	
Cafeteria	diet-fed	hypertensive	rats	(CHR)	were	administered	water	or	375mg/kg	of	
a	 low-molecular	 grape	 seed	 polyphenol	 extract	 (LM-GSPE)	 rich	 in	 flavanols	 and	
sacrificed	6h	post-administration.	Plasma	endothelin-1	(ET-1)	and	aortic	expression	
of	 NO	 pathway	 genes,	 NADPH	 oxidase	 subunit	 4	 (NOX4)	 and	 ET-1	 genes	 were	
measured.	 LM-GPSE	 decreased	 plasma	 ET-1,	 upregulating	 eNOS	 and	 Sirt-1	 and	
downregulating	aortic	gene	expression	of	ET-1	and	NADPH,	the	endothelial	major	
producer	 of	 free	 radicals,	 indicating	 the	 vasoprotective	 effect	 of	 grape	 seed	
flavanols.	 Additionally,	 twenty-four	 spontaneously	 hypertensive	 rats	 (SHR)	 were	
administered	 water	 or	 375mg/kg	 LM-GSPE	 and	 treated	 with	 1mg/kg	 sirtinol	
(inhibitor	 of	 Sirt-1).	 The	 antihypertensive	 effect	 of	 LM-GSPE	 was	 completely	
abolished	by	 sirtinol,	 indicating	 that	 grape	 seed	 flavanols	decrease	BP	 in	 a	 Sirt-1-
dependent	manner.		
Chemical	compounds	studied	in	this	article	
(+)-catechin	(PubChem	CID:	9064);	(-)-Epicatechin	(PubChem	CID:	72276);	(-)-
Epigallocatechin	 gallate	 (PubChem	 CID:	 65064);	 Gallic	 acid	 (PubChem	 CID:	 370);	
Procyanidin	 B2	 (PubChem	 CID:	 122738);	 Protocatechuic	 acid	 (PubChem	 CID:	 72);	
Sirtinol	(PubChem	CID:	5717148).		
Keywords:	 endothelial	 nitric	 oxide	 synthase;	 endothelin-1;	 flavanols;	
hypertension;	NADPH	oxidase;	nitric	oxide.	
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1. Introduction	
Grape	seed	is	a	by-product	of	the	grape/wine	industry	that	has	been	extensively	
investigated	 due	 to	 its	 flavanol	 abundance	 (Cherniack,	 2011;	 Nakamura,	 Tsuji,	 &	
Tonogai,	2003).	Flavan-3-ols	or	flavanols	are	the	most	structurally	complex	subclass	
of	 flavonoids.	 They	 range	 from	 monomers	 (i.e.,	 (+)-catechin	 and	 its	 isomer	 (-)-
epicatechin)	 to	 more	 complex	 structures	 that	 include	 oligomeric	 and	 polymeric	
proanthocyanidins,	which	are	also	known	as	condensed	tannins.		
Increasing	 evidence	 suggests	 that	 a	 vegetable	 and	 fruit-rich	 diet	 that	 is	
abundant	 in	polyphenolic	compounds	helps	to	control	blood	pressure	(BP).	Cocoa	
and	grapes	are	a	significant	source	of	polyphenols	and	especially	flavanols.	Studies	
performed	 by	 our	 group	 showed	 that	 a	 low-molecular-weight	 grape	 seed	
polyphenol	 extract	 (LM-GSPE)	 improved	 endothelial	 function	 (Quiñones	 et	 al.,	
2014)	and	acted	as	an	antihypertensive	agent	 in	 spontaneously	hypertensive	 rats	
(SHR)	 (Quiñones	 et	 al.,	 2013)	 and	 cafeteria-fed	 hypertensive	 rats	 (CHR)	 (Pons,	
Margalef,	 Bravo,	 Arola-Arnal,	 &	 Muguerza,	 2015).	 However,	 the	 molecular	
mechanisms	involved	in	the	benefits	of	grape	seed	flavanols	on	hypertension	(HTN)	
have	not	been	elucidated.		
The	 antihypertensive	 properties	 of	 flavanols	 are	 associated	 with	 different	
biological	activities,	such	as	nitric	oxide	(NO)-mediated	vasodilation	(Mukai	&	Sato,	
2009;	 Yamamoto,	 Suzuki,	 &	 Hase,	 2008),	 reduced	 oxidative	 status	 caused	 by	 the	
antioxidant	capacity	of	these	compounds	(Duarte	et	al.,	2001;	Negishi	et	al.,	2004;	
Peng	 et	 al.,	 2005;	 Pons	 et	 al.,	 2014)	 and	 an	 inhibition	 of	 angiotensin	 converting	
enzyme	(ACE)	(I.	A.	L.	Persson,	Persson,	Hägg,	&	Andersson,	2011;	I.	A.-L.	Persson,	
Josefsson,	Persson,	&	Andersson,	2006),	which	is	a	key	enzyme	in	the	control	of	BP.	
The	 involvement	of	NO	 in	 the	antihypertensive	effect	of	grape	seed	 flavanols	has	
been	recently	described	by	our	group	in	SHR	(Quiñones	et	al.,	2014)	and	CHR	(Pons	
et	 al.,	 2015).	 NO	 is	 synthesized	 by	 the	 Ca-dependent	 endothelial	 isoform	 of	 NO	
synthase	 (eNOS),	which	catalyzes	 the	 reaction	of	L-arginine	 to	L-citruline	and	NO.	
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This	 latter	 molecule	 diffuses	 to	 the	 smooth	 muscular	 layer	 where	 it	 activates	
guanylate	 cyclase	 to	 produce	 cyclic	 guanosine	 monophosphate	 (cGMP),	 which	
relaxes	the	musculature	of	the	vessels	(Förstermann	&	Sessa,	2012).		
Endothelial	 dysfunction	 occurs	 through	 enhanced	 endothelium-dependent	
vasoconstriction	or	loss	of	endothelium-dependent	vasorelaxation	(Ferro	&	Webb,	
1997;	 Ruschitzka,	 Corti,	Noll,	&	 Lüscher,	 1999),	 of	which	 low	 availability	 of	NO	 is	
one	of	the	primary	characteristics	(Hermann,	Flammer,	&	Lscher,	2006).	Endothelial	
function	 is	 known	 to	 be	 affected	 by	 oxidative	 stress	 (Cai	 et	 al.,	 2000).	 Thus,	
pathological	 conditions	 that	 lead	 to	 oxidative	 stress	 may	 result	 in	 endothelial	
dysfunction	(Berliner	&	Heinecke,	1996).	 In	the	vasculature,	nicotinamide	adenine	
dinucleotide	 phosphate	 (NADPH)	 oxidase	 is	 the	 main	 producer	 of	 free	 radicals	
(Gorlach	et	al.,	2000).	Superoxide	anion	(O2-)	can	directly	scavenge	NO,	producing	
peroxynitrite	(ONOO-)	and	inactivating	its	vasodilator	action	(Cai	&	Harrison,	2000;	
Gorlach	et	al.,	2000).	This	process	promotes	the	decrease	in	the	eNOS	cofactor	BH4	
(Förstermann	 &	 Sessa,	 2012),	 thereby	 stimulating	 free	 radical	 production	 by	 the	
uncoupled	 eNOS	 (Thum	 et	 al.,	 2007).	 Moreover,	 a	 diminution	 of	 the	 eNOS	
substrate	 arginine	 by	 the	 enzyme	 L-arginase	 has	 also	 been	 described	 to	 be	 a	
possible	mechanism	 to	 decrease	NO	 (Durante,	 Johnson,	&	 Johnson,	 2007)	 or	 the	
eNOS	cofactors	(Landmesser	et	al.,	2003;	Murata,	Sato,	Hori,	Ozaki,	&	Karaki,	2002)	
or	 to	 result	 in	 a	 posttranscriptional	modification	of	 the	 enzyme	 (Drummond,	Cai,	
Davis,	Ramasamy,	&	Harrison,	2000;	Papapetropoulos,	1999;	Searles,	2006).		
Sirtuin	(Sirt-1)	is	an	important	NAD-dependent	deacetylase	that	targets	multiple	
substrates.	 Sirt-1	 is	 highly	 expressed	 in	 endothelial	 cells	 and	 is	 able	 to	 influence	
endothelial	functions	and	oxidative	stress	(Zarzuelo	et	al.,	2013).	The	activation	of	
Sirt-1	activates	eNOS	by	deacetylation	and	thereby	increases	the	production	of	NO	
and	 promotes	 endothelial-dependent	 vasodilatation	 (Arunachalam,	 Yao,	 Sundar,	
Caito,	 &	 Rahman,	 2010;	 Mattagajasingh	 et	 al.,	 2007;	 Ungvari	 et	 al.,	 2009).	
Moreover,	 Sirt-1	 activation	 has	 been	 reported	 to	 activate	 the	 transcription	 of	
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Krüppel-like	 factor	 2	 (KLF2)	 (Gracia-Sancho,	 Villarreal,	 Zhang,	 &	 García-Cardeña,	
2010),	 which	 is	 a	 key	 endothelial	 transcription	 factor	 with	 a	 broad	 range	 of	
cardioprotective	 actions	 including	 the	 activation	 of	 eNOS	 expression	 (Martínez-
Fernández,	 Pons,	 Margalef,	 Arola-Arnal,	 &	 Muguerza,	 2014;	 SenBanerjee	 et	 al.,	
2004)	 and	 synthesis	 (Dekker	 et	 al.,	 2006;	Parmar	et	 al.,	 2006;	 SenBanerjee	et	 al.,	
2004).	KLF2	can	also	inhibit	the	expression	of	other	important	genes	involved	in	the	
regulation	 of	 vessel	 tone,	 such	 as	 the	 potent	 vasoconstrictor	 endothelin	 1	 (ET-1)	
(Atkins	 &	 Jain,	 2007),	 which	 is	 overexpressed	 in	 the	 vasculature	 in	 different	
hypertensive	models	(Iglarz	&	Schiffrin,	2003).	In	turn,	ET-1	has	also	been	reported	
to	 be	 involved	 in	 the	 antihypertensive	 effect	 of	 flavanols.	 The	 expression	 of	 this	
vasoconstrictor	molecule	 has	 been	 shown	 to	 be	 downregulated	 by	 pure	 flavanol	
compounds	 (Loke	 et	 al.,	 2008;	 Martínez-Fernández	 et	 al.,	 2014),	 a	 flavanol	 rich	
extract	(X.	Liu	et	al.,	2012)	and	food-derived	proanthocyanidins	(Caton	et	al.,	2010).	
Therefore,	 we	 investigated	 whether	 Sirt-1	 was	 involved	 in	 the	 antihypertensive	
effect	 of	 flavanols	 by	 mediating	 flavanol-increased	 NO	 availability	 and	 the	
endothelial	vasoprotective	pattern	of	these	compounds.		
2. Material	and	Methods	
2.1. Reagents	
LM-GSPE	was	obtained	 from	white	grape	seed	and	was	kindly	provided	by	Les	
Dérives	 Résiniques	 et	 Terpéniques	 (Dax,	 France).	 According	 to	 the	manufacturer,	
this	flavanol-rich	extract	contained	essentially	monomeric	(21.3%),	dimeric	(17.4%),	
trimeric	 (16.3%),	 tetrameric	 (13.3%)	 and	 oligomeric	 (5–13	 units)	 (31.7%)	
procyanidins.	 Table	 1	 shows	 the	 total	 polyphenol	 and	 flavan-3-ol	 content	 of	 LM-
GSPE	used	in	this	study	(taken	from	(Pons	et	al.,	2015)).	
2.2. Experimental	procedure	in	cafeteria	diet-fed	rats	
Six-week-old	male	Wistar	 rats	 (Crl:WI)	were	purchased	 from	Charles	River	
Laboratories	(Barcelona,	Spain)	and	singly	housed	in	animal	quarters	at	22ºC	with	a	
light/dark	 period	 of	 12	 h.	 After	 two	 weeks	 of	 quarantine,	 the	 animals	 were	
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provided	free	access	to	a	fresh	cafeteria	diet	consisting	of	bacon	(10-12	g),	biscuit	
with	pâté	(12–15	g),	biscuit	with	cheese	(10–12	g),	muffins	(4-5	g),	carrots	(8-10	g),	
milk	with	sugar	(220	g/L;	50	mL),	water	(ad	libitum)	and	the	standard	chow	Panlab	
A04	(Panlab,	Barcelona,	Spain).	The	standard	chow	had	a	calorie	breakdown	of	14%	
protein,	 8%	 fat	 and	 73%	 carbohydrates	 with	 0.3%	 Na,	 whereas	 the	 calorie	
breakdown	of	the	cafeteria	diet	was	14%	protein,	35%	fat,	and	51%	carbohydrates	
with	0.2%	of	Na.	The	animals	were	fed	ad	libitum,	and	the	food	was	renewed	daily.	
The	cafeteria	administration	was	maintained	to	the	end	of	the	experiment.		
At	the	end	of	the	feeding	period,	the	animals	were	administered	tap	water	
(n=8)	or	a	single	dose	of	375	mg/kg	LM-GSPE	(n=8)	dissolved	in	tap	water	by	gastric	
intubation	between	9	and	10	am.	The	animals	were	sacrificed	by	decapitation	after	
overnight	fasting	6	h	post-administration.	Systolic	(SBP)	and	diastolic	BP	(DBP)	were	
recorded	prior	to	administration	and	just	before	sacrifice.	The	BP	was	recorded	in	
the	rats	initially	and	6	h	post-administration	by	the	tail-cuff	method	(Buñag,	1973)	
with	some	modifications	as	described	by	Pons	et	al.	(Pons	et	al.,	2014).	The	initial	
values	of	blood	pressure	before	grape	 seed	 flavanol	 administration	were	140	±	2	
mmHg	of	SBP	and	98	±	4	mmHg	of	DBP.	
The	 thoracic	 region	 of	 the	 aorta	 was	 removed	 from	 the	 animals,	
immediately	 submerged	 in	 cold	 PBS	 buffer	 treated	 with	 diethylpyrocarbonate	
(DEPC)	 at	 0.1%	 v/v	 and	 maintained	 on	 ice	 during	 the	 cleaning	 process.	 All	
perivascular	adipose	tissue	and	residual	blood	was	removed	from	the	aorta	prior	to	
freezing	in	liquid	nitrogen.	
Plasma	was	obtained	by	centrifugation	(2000g,	15	min,	4ºC)	and	stored	at	-
80ºC	until	analysis.	ET-1	was	measured	 in	 the	plasma	 following	 the	manufactures	
guidelines	using	Endothelin-1	ELISA	Kit	(Enzo	Life	Sciences,	Switzerland).	
2.3. mRNA	extraction	from	the	aorta	
The	 frozen	 thoracic	 aortic	 tissue	 was	 homogenized	 without	 buffer	 in	 the	
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TissueLyser	LT	(Qiagen,	Barcelona,	Spain)	with	7	mm	stainless	steel	beads	(Qiagen	
Barcelona,	Spain);	lysis	buffer	was	added	immediately	thereafter	(RNeasy	Mini	Kit,	
Qiagen	Barcelona,	Spain).	The	extracted	mRNA	was	quantified	using	the	Nanodrop	
1000	Spectrophotometer	(Thermo	Scientific,	Madrid,	Spain),	and	the	RNA	integrity	
was	checked	using	a	1%	agarose	gel	with	formaldehyde.		
2.4. Quantitative	polymerase	chain	reaction.	
Retrotranscription	 of	 the	 extracted	 mRNA	 was	 performed	 using	 the	 High	
Capacity	 cDNA	 Reverse	 Transcription	 Kit	 (Applied	 Biosystems,	 Madrid,	 Spain).	
Quantitative	PCR	amplification	and	detection	were	performed	in	the	CFX96	Touch	
Real	 Time	 PCR	 System	 (Bio-Rad,	 Barcelona,	 Spain)	 using	 96-well	 plates	 and	 SYBR	
PCR	 Premix	 reagent	 Ex	 TaqTM	 (Takara,	 Barcelona,	 Spain)	 according	 to	 the	
commercial	 protocol.	 Glyceraldehyde	 3-phosphate	 dehydrogenase	 (GADPH)	 was	
used	 as	 the	 housekeeping	 gene.	 Table	 2	 shows	 the	 characteristics	 of	 all	 primers,	
which	were	 synthetized	 by	 Biomers	 (Söflinger,	 Germany).	 The	 specificity	 of	 each	
primer	was	verified	by	melting	curve	analysis,	and	the	amplicon	size	was	verified	by	
3%	agarose	gel	electrophoresis.	The	qPCR	efficiency	was	calculated	by	analyzing	a	
2-fold	dilution	series	of	aortic	cDNA.	The	results	were	represented	as	the	logarithm	
of	 the	 cDNA	 concentration	 vs	 the	 obtained	 Ct.	 The	 efficiency	 (E)	 of	 the	 PCR	was	
calculated	by	E=10(1/slope).	Each	sample	was	performed	in	triplicate,	and	the	relative	
expression	was	calculated	by	dividing	the	ECt	of	the	studied	gene	by	the	ECt	of	the	
housekeeping	gene	used	as	the	control	and	then	divided	by	the	value	of	the	control	
situation	(water-treated	rats	gene	expression).	
2.5. Spontaneously	hypertensive	rats	treated	with	sirtinol	
For	the	evaluation	of	the	effect	of	sirtuins	on	the	decrease	in	BP	due	to	LM-
GSPE,	 additional	 trials	 were	 conducted	 with	 SHR,	 which	 is	 the	 most	 established	
experimental	model	for	essential	HTN.	BP	trials	were	conducted	by	administering	a	
single	dose	of	375	mg/kg	LM-GSPE	or	water	to	the	SHR	in	a	total	volume	of	1	mL	by	
gastric	 intubation	 between	 9	 and	 10	 am.	 Additionally,	 both	 groups	 were	
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intraperitoneally	 treated	with	1	mL	of	saline	or	1	mg/kg	sirtinol	4	h	after	 the	oral	
treatment	(n=5	per	group).	BP	was	recorded	before	administration	and	just	before	
sacrifice.	
All	of	the	above-mentioned	experiments	were	performed	as	authorized	by	the	
Animal	Ethics	Committee	of	the	University	Rovira	i	Virgili	(Tarragona,	Spain).	
2.6. Plasma	Endothelin-1	
Plasma	 ET-1	 was	measured	 following	 the	manufacturer	 instructions	 with	 the	
ELISA	kit	(Endothelin-1	ELISA	kit,	Enzo	Life	Sciences,	Barcelona,	Spain)		
2.7. Statistical	analysis	
The	results	are	expressed	as	mean	values	±	standard	error	of	the	mean	(SEM).	
Differences	between	groups	were	analyzed	by	Student’s	t	test	or	one-way	ANOVA	
as	 required	 using	 IBM	 SPSS	 Statistics	 software	 (Version	 21.0.0).	 Differences	
between	the	means	were	considered	significant	when	p<0.05.		
3. Results	and	Discussion	
A	meta-analysis	study	reported	that	participants	supplemented	with	grape	
seed	 flavonoids	 had	 significantly	 reduced	 SBP	 compared	 with	 control	 subjects	
(Feringa,	 Laskey,	 Dickson,	 &	 Coleman,	 2011).	 Studies	 performed	 by	 our	 group	
showed	 that	 LM-GSPE	 acted	 as	 an	 antihypertensive	 agent	 in	 a	 dose-dependent	
manner	in	SHR	(Quiñones	et	al.,	2014)	and	CHR	(Pons	et	al.,	2014,	2015).	The	most	
effective	 dose	 was	 375	 mg/kg,	 and	 the	 antihypertensive	 effect	 was	 most	
pronounced	 after	 6	 h	 (Pons	 et	 al.,	 2014;	 Quiñones	 et	 al.,	 2013).	 According	 to	
previous	 results,	 CHR	administered	375	mg/kg	of	 LM-GSPE	exhibited	 a	 significant	
decrease	 in	 SBP	 (−21	 ±	 2	 mmHg)	 and	 DBP	 (−22	 ±	 3	 mmHg)	 6	 hours	 post-
administration	compared	to	rats	administered	water	(Pons	et	al.,	2015).	
3.1. Grape	seed	flavanol	regulation	of	the	genes	involved	in	the	nitric	oxide	
pathway	
RESULTS	
	 121	
The	 improvement	 of	 HTN	 by	 grape	 seed	 flavanols	 has	 been	 attributed	
mainly	to	an	enhancement	of	NO	in	SHR	(Quiñones	et	al.,	2014)	and	CHR	(Pons	et	
al.,	2015).	The	production	of	NO	induces	the	production	of	cAMP	and	consequently	
increases	dilatation,	 thereby	decreasing	 the	BP.	Specifically,	 the	administration	of	
the	non-selective	NO	synthesis	inhibitor	NG-nitro-L-arginine	methyl	ester	(L-NAME)	
completely	 inhibited	 the	 antihypertensive	 effect	 of	 grape	 seed	 flavanols	 in	 SHR	
(Quiñones	 et	 al.,	 2014)	 and	 CHR	 (Pons	 et	 al.,	 2015),	 indicating	 that	 grape	 seed	
flavanols	 act	 via	 eNOS.	 However,	 the	 detailed	mechanism	 is	 not	 clear.	 Thus,	 we	
aimed	 to	 elucidate	 it	 in	 this	 work.	 In	 this	 in	 vivo	 study,	 our	 results	 clearly	
demonstrated	 that	 aortic	 eNOS	 mRNA	 expression	 was	 increased	 by	 grape	 seed	
flavanols,	 which	 supported	 the	 enhancement	 of	 the	 availability	 of	 NO	 previously	
reported	 in	 CHR	 (Pons	 et	 al.,	 2015).	 Aortic	 eNOS	 gene	 expression	 was	 2.5-fold	
higher	 in	 rats	 administered	 375	mg/kg	 LM-GSPE	 compared	 with	 the	 control	 rats	
(Figure	 1A).	 An	 increase	 in	 eNOS	 expression	 in	 endothelial	 cells	 due	 to	 the	
administration	of	red	wine	polyphenols	(Schini-Kerth,	Auger,	Kim,	Etienne-Selloum,	
&	 Chataigneau,	 2010)	 and	 a	 grape	 seed	 extract	 was	 previously	 shown	 (Cui,	 Liu,	
Feng,	Zhao,	&	Gao,	2012),	but	to	the	best	of	our	knowledge	this	is	the	first	report	
on	 an	 induction	 of	 eNOS	 expression	 in	 vivo	 by	 grape	 seed	 flavanols.	 Other	
endothelial	enzymes	in	addition	to	eNOS	have	also	been	implicated	in	endothelial	
NO	 availability.	 A	 reduction	 in	 the	 eNOS	 substrate	 arginine	 by	 the	 enzyme	 L-
arginase	has	been	 reported	 to	be	a	possible	mechanism	 to	decrease	NO.	 Indeed,	
inhibition	 of	 arginase	 activity	 has	 been	 reported	 to	 improve	 endothelium-
dependent	vasorelaxation	(Durante	et	al.,	2007).	However,	in	this	study	we	did	not	
observe	 a	 decrease	 in	 arginase	 expression	 in	 animals	 administered	 grape	 seed	
flavanols	(Figure	1B),	demonstrating	that	the	increase	in	NO	availability	by	flavanols	
was	not	mediated	by	a	downregulation	of	arginase.	
3.2. Grape	seed	flavanol	regulation	of	the	vasoconstrictor	gene	expression	
profile	
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Cafeteria	 fed-rats	 are	 considered	 to	 be	 a	 robust	model	 for	 human	metabolic	
syndrome	 (MetS)	 due	 to	 its	 promotion	 of	 voluntary	 hyperphagia	 that	 results	 in	
rapid	weight	gain	(Sampey	et	al.,	2011).	The	excess	of	energy	intake	is	the	leading	
cause	of	MetS;	this	excess	is	stored	in	adipocytes	that	suffer	hyperplasia	and	start	
to	 release	 pro-inflammatory	 cytokines	 and	 adipocyte-related	 hormones	 (Campia,	
Tesauro,	 &	 Cardillo,	 2012).	 These	 compounds	 promote	 a	 pro-inflammatory	 state	
and	the	production	of	reactive	oxygen	species	in	the	vascular	endothelium,	which	is	
partially	responsible	for	endothelial	dysfunction	(Campia	et	al.,	2012).	In	this	study,	
the	expression	of	NOX4	(a	subunit	of	the	aortic	NADPH	oxidase,	the	main	producer	
of	 free	 radicals	 in	 the	 vasculature)	was	 decreased	 in	 animals	 administered	 grape	
seed	 flavanols	 (Figure	 2A).	 Although	 it	 has	 been	 described	 that	 NOX4	 exhibits	 a	
protective	role	in	the	vasculature;	the	increase	of	NOX4	under	stress	condition	has	
been	previously	described	as	detrimental	(Konior,	Schramm,	Czesnikiewicz-Guzik,	&	
Guzik,	2014).	In	fact,	overexpression	of	NOX4	has	been	described	in	atherosclerotic	
arteries	(Sorescu	et	al.,	2002).	Therefore,	a	decrease	in	endothelial	oxidative	stress	
could	 also	 explain	 the	 flavanol-mediated	 higher	 availability	 of	 NO	 that	 was	
responsible	 for	 the	 flavanol-induced	 antihypertensive	 effect.	 Agreeing	 to	 this,	we	
previously	 proposed	 that	 the	 antioxidant	 properties	 of	 flavanols	were	one	of	 the	
mechanisms	involved	in	the	antihypertensive	effect	of	LM-GSPE	(Pons	et	al.,	2015).	
Additionally,	 a	 previous	 study	 showed	 that	 grape	 seed	 polyphenols	were	 able	 to	
decrease	reactive	oxygen	species	(ROS)	production	in	endothelial	cells	(Shao	et	al.,	
2009).		
In	 addition,	 our	 results	 clearly	 showed	 that	 ET-1	 aortic	 gene	 expression	 was	
extremely	 inhibited	 only	 6	 hours	 after	 administration	 of	 LM-GPSE,	 resulting	 in	 5-
fold	 lower	 ET-1	 gene	 expression	 in	 rats	 administered	 375	 mg/kg	 LM-GSPE	
compared	 with	 control	 rats	 (Figure	 2B).	 This	 downregulation	 of	 aortic	 ET-1	
expression	was	accompanied	by	a	decrease	in	plasmatic	ET-1	levels	in	the	LM-GSPE	
animals	 comparing	 to	 the	 rats	 administered	 water	 (10%	 decrement,	 p<0.075)	
RESULTS	
	 123	
(Figure	 2C).	 This	 reduction	 is	 considered	 of	 special	 relevance	 taking	 into	 account	
that	 the	administration	of	 grape	 seed	 flavanols	normalized	plasma	ET-1	 values	 in	
CHR	respect	to	Wistar	control	rats	(p=NS,	data	not	shown).	This	finding	agrees	with	
other	in	vivo	and	in	vitro	studies	using	polyphenols	(Chao	et	al.,	2005;	Corder	et	al.,	
2001;	 Jiménez	 et	 al.,	 2007;	 Martínez-Fernández	 et	 al.,	 2014).	 Specifically,	 a	
decrease	 in	 ET-1	 levels	 after	 grape	 seed	 polyphenol	 extract	 administration	 to	
hypertensive	rats	has	been	reported	(X.	Liu	et	al.,	2012).	ET-1	overproduction	 is	a	
key	risk	factor	 in	the	development	of	vascular	disease	and	atherosclerosis	(Corder	
et	al.,	2001),	and	the	production	of	this	endothelial	factor	is	upregulated	in	obesity	
and	MetS	 (Tesauro	 &	 Cardillo,	 2011).	 The	 observed	 grape	 seed	 flavanol-induced	
downregulation	of	NOX4	and	ET-1	could	be	explained	by	the	fact	that	ET-1	is	known	
to	 increase	ROS	production	 in	the	vasculature	by	 increasing	NOX4	(Jiménez	et	al.,	
2007;	López-Sepúlveda	et	al.,	2008).	
3.3. Grape	seed	flavanol	regulation	of	KLF2	expression		
There	are	many	factors	that	regulate	eNOS	expression.	The	promoter	of	eNOS	
is	regulated	by	the	transcription	factor	Krüppel-like	factor	2	(KLF-2)	(Gracia-Sancho	
et	al.,	2010),	which	 is	a	key	endothelial	 transcription	factor	with	a	broad	range	of	
cardioprotective	actions	 including	 the	activation	of	eNOS	synthesis	 (Dekker	et	al.,	
2006;	Parmar	et	al.,	2006;	SenBanerjee	et	al.,	2004).	Likewise,	KLF-2	can	inhibit	the	
expression	of	other	important	genes	involved	in	the	regulation	of	vessel	tone,	such	
as	 the	 vasoconstrictor	 factor	 ET-1	 (Dekker	 et	 al.,	 2006;	 Parmar	 et	 al.,	 2006;	
SenBanerjee	 et	 al.,	 2004).	 Indeed,	 an	 increase	 in	 KLF-2	 expression	 in	 HUVECs	
induced	by	resveratrol	(Gracia-Sancho	et	al.,	2010)	and		a	grape	seed	extract	(Cui	et	
al.,	2012)	were	previously	reported.	Additionally,	an	increase	in	eNOS	expression	in	
HUVECs	via	KLF-2	 induction	has	been	 reported	 for	different	 flavonoids	 (Martínez-
Fernández	et	al.,	2014).	However,	in	this	study	no	changes	in	KLF-2	expression	were	
observed	 6	 h	 after	 LM-GSPE	 administration	 (Figure	 3A),	 although	 the	 potential	
participation	of	 this	 transcriptional	 factor	 in	 the	upregulation	of	eNOS	before	 this	
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time	point	could	not	be	ruled	out.	 Indeed,	an	 in	vitro	study	performed	in	HUVECs	
with	 (+)-catechin	 and	 (-)-epicatechin	 (the	 main	 monomers	 of	 LM-GSPE)	
demonstrated	 the	 upregulation	 of	 KLF-2	 2	 h	 post-treatment	 (Martínez-Fernández	
et	al.,	2014).		
3.4. The	effect	of	grape	seed	flavanols	on	sirtuin-1	signaling	
Sirt-1	 is	 an	 important	 NAD-dependent	 deacetylase	 that	 is	 involved	 in	 the	
regulation	of	aging,	cell	cycle	regulation,	apoptosis	and	inflammation	(Chung	et	al.,	
2010).	Moreover,	it	is	highly	expressed	in	endothelial	cells	and	is	able	to	influence	
endothelial	 function	 and	 oxidative	 stress	 (Mattagajasingh	 et	 al.,	 2007;	 Potente	&	
Dimmeler,	 2008).	 Previous	 studies	 have	 demonstrated	 that	 endothelial	
overexpression	 of	 Sirt-1	 improves	 the	 in	 vivo	 endothelial	 function	 (Zhang	 et	 al.,	
2008).	 Moreover,	 Sirt-1	 promotes	 endothelium-dependent	 vasodilation	 by	
targeting	 eNOS	 for	 deacetylation	 and	 consequently	 increasing	 NO	 availability	
(Arunachalam	 et	 al.,	 2010;	 Mattagajasingh	 et	 al.,	 2007;	 Ungvari	 et	 al.,	 2009).	 A	
recent	 study	 showed	 that	Sirt-1	activation	by	 resveratrol	was	necessary	 for	eNOS	
transcription	 (Xia	 et	 al.,	 2013).	 Although	 an	 increase	 in	 Sirt-1	 protein	 without	
changes	in	mRNA	expression	by	grape	seed	polyphenols	was	previously	reported	in	
HUVECs	 (Cui	 et	 al.,	 2012),	 the	 results	 presented	 herein	 clearly	 showed	 that	 LM-
GSPE	induced	Sirt-1	expression	in	vivo	(Figure	3B).	Moreover,	we	corroborated	that	
the	antihypertensive	effect	of	grape	seed	flavanols	was	directly	mediated	by	Sirt-1,	
because	 the	 selective	 Sirt-1	 inhibitor	 sirtinol	 completely	 abolished	 the	
antihypertensive	effect	of	LM-GSPE	in	SHR	(Figure	4A	and	4B).		
Therefore,	 in	 addition	 to	 the	 upregulation	 of	 eNOS	 expression	 grape	 seed	
polyphenols	may	 also	mediate	 the	 activation	 of	 eNOS	 through	 the	 promotion	 of	
Sirt-1	expression,	resulting	in	an	increase	in	NO	production.	The	production	of	NO	
induces	 the	 production	 of	 cAMP	 and	 consequently	 increases	 dilatation,	 thereby	
decreasing	 BP.	 Moreover,	 Sirt-1	 activation	 has	 been	 reported	 to	 inhibit	 NADPH	
oxidase	 activity	 (Zarzuelo	 et	 al.,	 2013),	 which	 is	 in	 agreement	 which	 the	
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downregulation	 of	 NADPH	 oxidase	 observed	 in	 this	 study.	 Finally,	 the	
donwregulation	of	ET-1	levels	and	expression	induced	by	grape	seed	flavanols	was	
in	agreement	with	various	studies	that	reported	that	the	Sirt-1	activator	resveratrol	
also	inhibited	ET-1	levels,	thereby	providing	better	regulation	of	vascular	tone	(J.-C.	
Liu,	Chen,	Chan,	Cheng,	&	Cheng,	2003;	Z.	Liu	et	al.,	2005;	Zou,	Wang,	Huang,	Cao,	
&	Wu,	2003),	although	the	 inhibitory	effects	of	resveratrol	on	ET-1	 levels	seemed	
be	 Sirt1-independent	 (Yang,	 Wang,	 Li,	 Zhang,	 &	 Feng,	 2010).	 Nevertheless,	 the	
potential	 participation	 of	 Sirt-1	 in	 the	 donwregulation	 of	 ET-1	 should	 be	 more	
deeply	studied	by	taking	into	account	that	in	this	study	KLF-2,	which	can	inhibit	the	
expression	 of	 ET-1,	 was	 not	 modified	 in	 grape	 seed	 flavanol-administered	 rats.	
Although	 KLF-2	 has	 been	 postulated	 to	 be	 a	mediator	 of	 the	 vascular	 protective	
effects	of	Sirt-1	based	on	the	finding	that	Sirt-1	activation	by	resveratrol	increased	
the	expression	of	KLF-2	in	HUVECs	(Gracia-Sancho	et	al.,	2010),	our	results	failed	to	
show	 any	 evidence	 of	 a	 relationship	 between	 Sirt-1	 and	 KLF-2	 6	 h	 after	 the	
administration	 of	 grape	 seed	 polyphenols	 to	 hypertensive	 rats.	 However,	 as	
mentioned	 above	 the	 potential	 participation	 of	 KLF-2	 before	 this	 time	 could	 be	
possible.	
In	conclusion,	Sirt-1	was	implicated	in	the	decrease	of	BP	by	LM-GSPE.	Sirt-
1	 is	 likely	 to	 play	 an	 important	 role	 in	 grape	 seed	 flavanol-mediated	 increases	 in	
bioavailable	 NO	 via	 decreased	 eNOS	 acetylation.	 Additionally,	 LM-GSPE	
downregulated	 ET-1,	 the	 major	 endothelial	 vasoconstrictor	 factor,	 and	 NADPH	
oxidase	 gene	 expression,	 the	 main	 producer	 of	 vascular	 ROS	 (Figure	 5).	 Taken	
together,	 these	 factors	could	 lead	to	an	 improvement	 in	endothelial	 function	and	
consequently	 a	 decrease	 in	BP	due	 to	 LM-GSPE.	 Further	 studies	 are	necessary	 to	
understand	the	role	of	KLF-2	in	the	enhancement	of	NO	availability.	
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Figure	legends	
Figure	1.	Aortic	gene	expression	of	endothelial	nitric	oxide	synthase	(eNOS)	
(A)	 or	 arginase-1	 (Arg-1)	 (B)	 in	 CHR	 6	 hours	 after	 administration	 of	water	 (white	
bar)	or	375	mg/kg	LM-GSPE	(black	bar).	Data	are	expressed	as	the	mean	±	standard	
error	 (SEM).	 Significant	differences	between	groups	were	assessed	by	Student’s	 t	
test.	 The	 asterisks	 indicate	 differences	 between	 groups	 at	 p<0.01	 (**).	 No	
significant	differences	were	found	for	Arg-1.	
Figure	 2.	 Aortic	 gene	 expression	 of	 NADPH	 oxidase	 subunit	 4	 (NOX4)	 (A),	
endothelin-1	(ET-1)	(B)	and	plasma	endothelin-1	(ET-1)	concentration	(C)	 in	CHR	6	
hours	after	administration	of	water	(white	bar)	or	375	mg/kg	LM-GSPE	(black	bar).	
Data	 are	 expressed	 as	 the	 mean	 ±	 standard	 error	 (SEM).	 Significant	 differences	
between	 groups	 were	 assessed	 by	 Student’s	 t	 test.	 The	 asterisks	 indicate	
differences	between	groups	at	p<0.05	(*)	or	p<0.01	(**).	
Figure	 3.	 Aortic	 gene	 expression	 of	 Krüppel-like	 factor	 2	 (KLF-2)	 (A)	 and	
Sirtuin	1	(Sirt-1)	(B)	in	CHR	6	hours	after	administration	of	water	(white	bar)	or	375	
mg/kg	 LM-GSPE	 (black	 bar).	 Data	 are	 expressed	 as	 the	 mean	 ±	 standard	 error	
(SEM).	 Significant	 differences	 between	 groups	were	 assessed	 by	 Student’s	 t	 test.	
The	 asterisks	 indicate	 differences	 between	 groups	 at	 p<0.01	 (**).	 No	 significant	
differences	were	found	for	KLF-2.	
	Figure	4.	Differences	in	systolic	blood	pressure	(SBP)	(A)	and	diastolic	blood	
pressure	(DBP)	(B)	in	SHR	6	hours	after	administration	of	water	or	375	mg/kg	LM-
GSPE	with	or	without	sirtinol	treatment	(1	mg/kg).	Data	are	expressed	as	the	mean	
±	standard	error	(SEM).	Letters	represent	significant	differences	(one-way	ANOVA;	
p	<	0.05).	
Figure	5.	Schematic	representation	of	the	molecular	mechanisms	involved	in	
the	lowering	effect	of	LM-GSPE	on	blood	pressure	in	the	aorta.	LM-GSPE	increased	
eNOS	mRNA	levels,	which	would	lead	to	major	production	of	NO.	Sirt-1,	which	was	
able	 to	 deacetylate	 and	 activate	 eNOS	 and	 inhibited	 NADPH	 oxidase,	 was	
upregulated	by	LM-GSPE.	NOX4	mRNA	was	decreased	by	the	extract,	which	would	
lead	 to	 a	 decrease	 in	 ROS	 production	 and	 consequently	 an	 increase	 in	 NO	
availability.	 LM-GSPE	 decreased	 the	 ET-1	 mRNA	 levels,	 which	 in	 turn	 increased	
NADPH	oxidase	activity.	All	of	 these	 factors	 led	 to	a	 restoration	of	 the	 imbalance	
caused	by	hypertension	due	to	an	improvement	in	endothelial	function.	The	green	
arrows	represent	activation	and	red	arrows	represent	inhibition.		
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Table 1. Total polyphenol content, individual phenolic compounds and 
antioxidant capacity of the grape seed extract studied.  
Compounds   Total amount (mg/g)* 
Total polyphenol content 1 554.16 ± 13.02 
Phenolic compound 2  
Gallic acid 19.0 ± 2.1 
Protocatechuic acid 1.1 ± 0.1 
Procyanidin dimera 154.5 ± 34.6 
Catechin 97.2 ± 8.2 
Epicatechin 59.0 ± 0.8 
Dimer-gallatea 42.6 ± 7.6 
Epigallocatechin gallate 0.4 ± 0.1 
Procyanidin trimera 30.5 ± 2.2 
Procyanidin tetramera 2.4 ± 0.2 
Epicatechin gallateb 59.3 ± 1.6 
Antioxidant capacity 3 18,161.22 ± 698.85 
*The values are expressed on a dry basis as mean ± SEM (n=3).  
1Measured by Folin-Ciocalteu´s method. 2HPLC-MS. 3ORAC 
assay, expressed as µmol of Trolox equivalents (TE) per gram of 
LM-GSPE. 
aQuantified using the calibration curve of procyanidin B2.  
bQuantified using the calibration curve of epigallocatechin gallate. 
Table adapted from (5). 
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Figure	1	
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Figure	2	
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Figure	3	
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Figure	4	
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Abstract	
Grape	seed	flavanols	are	known	to	exert	antihypertensive	effects.	In	this	study,	we	
aimed	 to	 examine	 the	 antihypertensive	 effects	 of	 grape	 seed	 flavanols	 on	 the	
renin-angiotensin-aldosterone	 system	 (RAAS)	 in	 an	experimental	model	of	obese-
hypertensive	 rats.	 Sixteen	 hypertensive	 cafeteria-hypertensive	 rats	 (CHRs)	 were	
intragastrically	administered	water	or	375	mg/kg	low	molecular	weight	grape	seed	
polyphenols	 extract	 (LM-GSPE)	 rich	 in	 flavanols	 and	 sacrificed	 6	 h	 post-
administration.	Blood	pressure	of	the	rats	was	recorded	before	administration	and	
before	 sacrificing.	 Angiotensin	 (Ang)	 I	 and	 II,	 aldosterone	 and	 bradykinin	 plasma	
levels	 were	 assessed	 using	 UHPLC-MS-MS.	 The	 plasma	 renin	 concentration	 was	
determined	by	ELISA.	Aorta	gene	expression	of	Ang	II	receptor	type	1	a	(ART1a)	and	
b	 (ART1b)	 and	 angiotensinogen	 in	 liver	 were	 analyzed	 by	 real-time	 PCR.	 The	
antihypertensive	 effects	 of	 LM-GSPE	 6	 h	 post-administration	 were	 confirmed.	
Moreover,	 plasma	 Ang	 I,	 Ang	 II	 and	 aldosterone	 levels	 were	 decreased	 in	 rats	
administered	LM-GSPE.	However,	no	changes	were	observed	 in	bradykinin	 levels.	
Plasma	renin	levels	were	also	not	altered	by	LM-GSPE.	No	changes	were	observed	
in	ATR1a	and	ART1b	expression	between	groups;	in	contrast,	liver	angiotensinogen	
mRNA	levels	were	increased	by	LM-GSPE.	Thus,	grape	seed	flavanols	inhibit	RAAS,	
highlighting	 a	 new	 mechanism	 by	 which	 flavanols	 exert	 their	 antihypertensive	
effects.		
	
	
Keywords:	 angiotensin;	 angiotensin	 converting	 enzyme;	 antihypertensive;	 aorta;	
cafeteria	diet-fed	rats;	polyphenols.		
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1. Introduction	
Cardiovascular	disease	(CVD)	is	the	leading	cause	of	death	worldwide,	and	two	
of	 the	major	 risk	 factors	 for	 CVD	 are	 hypertension	 (HTN)	 and	obesity.	 The	 renin-
angiotensin-aldosterone	 system	 (RAAS)	 plays	 a	 crucial	 role	 in	 the	 regulation	 of	
blood	pressure	(BP).	Moreover,	RAAS	hyperactivity	is	associated	with	obesity	1	and	
fat	 restriction,	 which	 reduces	 the	 RAAS	 activity.	 RAAS	 regulation	 of	 BP	 under	
normal	 conditions	 begins	 when	 renal	 blood	 flow	 is	 reduced	 and	 kidney	
juxtaglomerular	 cells	 secrete	 the	 enzyme	 renin	 into	 circulation.	 Renin	 converts	
angiotensinogen,	which	 is	 released	 by	 the	 liver,	 to	 angiotensin	 I	 (Ang	 I),	which	 is	
subsequently	converted	by	angiotensin	converting	enzyme	 (ACE)	 to	angiotensin	 II	
(Ang	 II),	 the	 major	 bioactive	 molecule	 of	 RAAS.	 Most	 Ang	 II	 pathophysiological	
effects	 are	 mediated	 by	 its	 union	 with	 type	 1	 receptor	 (ATR1),	 including	
vasoconstriction	 2	 through	 the	 release	of	 intracellular	 calcium	 3	and	 the	hormone	
aldosterone,	 which	 induces	 oxidative	 stress	 and	 increases	 BP	 4.	 Moreover,	 ACE	
catalyzes	 the	 inactivation	 of	 bradykinin,	 which	 has	 an	 important	 vasodilation	
activity.		
Flavan-3-ols,	 also	 named	 flavanols,	 are	 a	 type	 of	 polyphenol	 that	 is	 widely	
present	in	the	plant	kingdom	and	in	the	human	diet,	and	these	molecules	display	a	
broad	 range	 of	 biological	 effects,	 including	 antihypertensive	 activity.	 These	
compounds	range	from	the	monomer	(+)-catechin	and	its	isomer	(-)-epicatechin	to	
more	complex	structures	that	include	oligomeric	and	polymeric	proanthocyanidins.	
Grape	 seed	 is	 a	 by-product	 of	 the	 grape/wine	 industry	 and	 has	 been	 extensively	
investigated	 due	 to	 its	 flavanol	 abundance	 5,6.	 The	 health	 effects	 of	 grape	 seed	
flavanols	on	HTN	have	been	previously	reported	in	humans	7	and	in	rats	8–10.	Many	
different	 molecular	 targets	 and	 mechanisms	 have	 been	 proposed	 to	 explain	 the	
antihypertensive	 properties	 of	 grape	 seed	 flavanols.	 Experimental	 data	 indicate	
that	 this	 effect	 is	 endothelium-dependent	 11	 and	 mainly	 mediated	 through	 the	
nitric	 oxide	 (NO)	 pathway	 11,12.	 Nevertheless,	 other	 mechanisms	 for	 the	
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antihypertensive	 effect	 of	 flavanols	 have	 been	 described,	 such	 as	 a	 reduction	 of	
oxidative	 stress	 13,14.	 Regarding	 RAAS,	 ACE	 inhibition	 has	 been	 demonstrated	 by	
flavanols	15–20.	However,	this	inhibition	seems	to	depend	on	flavanol	structure	16,17.	
In	 particular,	 for	 grape	 seed	 flavanols	 in	 hypertensive	 rats,	 no	 changes	 in	 plasma	
ACE	 were	 found	 9,10.	 However,	 we	 hypothesize	 that	 RAAS	 components	 could	 be	
involved	 in	 the	 flavanol-induced	 reduction	 of	 BP	 in	 obese	 hypertensive	 rats.	
Therefore,	 the	 aim	of	 this	 study	was	 to	 evaluate	 the	 involvement	of	 RAAS	 in	 the	
antihypertensive	 effects	 of	 low-molecular-weight	 grape	 seed	 polyphenol	 extract	
(LM-GSPE)	in	an	experimental	model	of	obesity-induced	HTN.	
2. Material	and	Methods	
2.1. Low	molecular	weight	grape	seed	polyphenol	extract		
LM-GSPE	was	obtained	from	white	grape	seeds	and	was	kindly	provided	by	Les	
Dérives	 Résiniques	 et	 Terpéniques	 (Dax,	 France).	 According	 to	 the	 manufacturer,	
this	 flavanol-rich	 extract	 contained	monomeric	 (21.3%),	 dimeric	 (17.4%),	 trimeric	
(16.3%),	tetrameric	(13.3%)	and	oligomeric	(5–13	units;	31.7%)	procyanidins.	Table	
1	shows	the	total	polyphenol	and	flavan-3-ol	content	of	the	LM-GSPE	used	 in	this	
study	(taken	from	12).		
2.2. Experimental	procedure	in	rats	
Six-week-old	male	Wistar	 rats	 (Crl:WI)	were	purchased	 from	Charles	River	
Laboratories	(Barcelona,	Spain)	and	were	singly	housed	in	animal	quarters	at	22°C,	
with	a	 light/dark	period	of	12	h.	After	 two	weeks	of	quarantine,	 the	animals	had	
free	 access	 to	 a	 fresh	 cafeteria	 (CAF)	 diet	 consisting	 of	 bacon	 (10-12	 g),	 biscuits	
with	pâté	(12–15	g),	biscuits	with	cheese	(10–12	g),	muffins	(4-5	g),	carrots	(8-10	g),	
milk	with	sugar	(220	g/L;	50	mL),	water	(ad	libitum)	and	standard	chow	Panlab	A04	
(Panlab,	Barcelona,	Spain).	The	CAF	diet	had	a	calorie	breakdown	of	14%	proteins,	
35%	fat,	51%	carbohydrates	and	0.2%	sodium	12.	The	animals	were	fed	ad	libitum,	
and	the	food	was	renewed	daily.	The	CAF	administration	was	maintained	until	the	
end	of	the	experiment.		
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After	 18	 weeks,	 the	 animals	 were	 administered	 375	 mg/kg	 of	 LM-GSPE	
(n=8)	dissolved	in	tap	water	by	gastric	intubation	between	9	and	10	am.	Water	was	
used	as	a	negative	control	(n=8).	The	total	orally	administered	volume	was	always	1	
mL,	whether	it	was	water	or	LM-GSPE	in	a	water	solution.	BP	was	recorded	in	the	
rats	 by	 the	 tail-cuff	 method	 21,	 as	 described	 by	 Pons	 et	 al.	 10,	 before	 oral	
administration	 and	 6	 h	 post-administration,	 just	 prior	 to	 sacrifice	 (Figure	 1).	 The	
animals	 were	 sacrificed	 by	 decapitation	 after	 overnight	 fasting.	 Plasma	 samples	
were	obtained	by	centrifugation	 (2000	x	g,	15	min,	4°C)	and	stored	at	 -80°C	until	
the	analysis	was	performed.	Additionally,	the	 liver	and	aorta	thoracic	region	were	
removed	from	the	animals.	The	liver	was	directly	frozen	in	liquid	nitrogen,	and	the	
aorta	 was	 immediately	 submerged	 in	 cold	 PBS	 buffer	 treated	 with	
diethylpyrocarbonate	(DEPC)	at	0.1%	v/v	and	maintained	on	ice	during	the	cleaning	
process.	All	of	 the	perivascular	adipose	 tissue	and	 residual	blood	was	cleaned	off	
the	aorta,	 and	 the	aorta	was	 immediately	 frozen	 in	 liquid	nitrogen.	 The	 liver	 and	
aorta	were	stored	at	-80°C	until	posterior	analysis	was	performed.	
All	of	the	above-mentioned	experiments	were	performed	as	authorized	by	
the	 Animal	 Ethics	 Committee	 of	 the	University	 Rovira	 i	 Virgili	 (Tarragona,	 Spain).	
Permission	number	4249	of	the	Generalitat	de	Catalunya.	
2.3. Analysis	of	plasma	angiotensin	I	and	II,	aldosterone	and	bradykinin	by	
UHPLC-MS-MS	
2.3.1. Reagents	
Acetonitrile	and	formic	acid	were	of	HPLC	analytical	grade.	Ultrapure	water	was	
obtained	 from	 a	 Milli-Q	 advantage	 A10	 system	 (Madrid,	 Spain).	 Individual	 stock	
standard	solutions	of	human	Ang	II	(in	Milli-Q	water),	human	Ang	I	(in	0.1	M	acetic	
acid),	 bradykinin	 (in	 0.2	M	 acetic	 acid)	 and	 [Asn1,	 Val5]-Angiotensin	 II,	 as	 internal	
standard	(IS)	 (in	0.1	M	acetic	acid),	were	prepared	weekly	at	a	concentration	of	1	
mg/mL.	Aldosterone	was	prepared	at	a	concentration	of	0.1	mg/mL	in	acetonitrile.	
These	solutions	were	stored	 in	dark	glass	 flasks	at	 -80°C.	All	of	the	reagents	were	
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purchased	from	Sigma-Aldrich	(Madrid,	Spain).	
2.3.2. Plasma	preparation	
Prior	 to	 chromatographic	 analysis,	 undesirable	 compounds	 were	 eliminated	
from	the	rat	plasma	by	precipitation.	An	aliquot	of	IS	(2.5	µL)	was	added	to	100	µL	
of	 plasma,	 and	 then	 the	 mixture	 was	 diluted	 4	 times	 with	 a	 water:acetonitrile	
solution	(1:9,	v:v)	containing	0.1%	formic	acid.	The	solution	was	vortexed	and	kept	
at	4°C	for	10	min.	Then,	the	mixture	was	centrifuged	at	21382	x	g	for	15	min	at	4°C	
in	 a	Mikro	 200	 R	 centrifuge	 (Hettich	 GmbH	 &	 Co.KG,	 Tuttlingen,	 Germany).	 The	
supernatant	 aliquot	 (200	 µL)	 was	 evaporated	 to	 dryness	 using	 a	 nitrogen	
atmosphere.	Finally,	the	dried	residue	was	dissolved	in	50	µL	of	a	water:acetonitrile	
solution	(1.1:0.9,	v:v)	containing	0.1%	formic	acid	and	transferred	to	a	sample	vial	
at	an	IS	final	concentration	of	25	µg/L	for	LC-MS/MS	analysis.	
2.3.3. UHPLC-MS/MS	
The	 UHPLC	 system	 consisted	 of	 a	 1290	 LC	 Series	 (Agilent	 Technologies,	 Palo	
Alto,	CA).	The	different	compounds	were	separated	on	a	reverse-phase	C18	column	
(Acquity	BEH	300	Aº,	100	x	2.1	mm,	1.7μm	from	Waters	Corp.,	Milford,	MA,	USA)	
under	gradient	elution	using	0.1%	formic	acid	in	water	(solvent	A)	and	0.1%	formic	
acid	 in	 acetonitrile	 (solvent	B)	 at	 a	 flow	 rate	of	 0.4	mL/min.	 The	elution	 gradient	
consisted	in	5%	B	isocratic	(0−0.2	min),	5−40%	B	(0.2−2.5	min),	40%	B	isocratic	(2.5-
4.0	 min),	 40−98%	 B	 (4.0-4.5	 min),	 98%	 B	 isocratic	 (4.5−7.5	 min)	 and	 98−5%	 B	
(7.5−8.0	 min).	 The	 column	 was	 equilibrated	 at	 the	 initial	 conditions	 for	 2	 min	
before	each	run.	The	column	temperature	was	set	to	35°C	and	the	injection	volume	
was	2	μL.	
The	 UHPLC	 system	 was	 coupled	 to	 an	 Agilent	 6490	 Triple	 Quadrupole	 mass	
spectrometer	 (Agilent	 Technologies,	 Palo	 Alto,	 CA)	 equipped	 with	 an	 Agilent	 Jet	
Stream	(AJS)	ionization	source.	Ionization	was	conducted	in	a	positive	electrospray	
(ESI).	The	following	ESI	working	conditions	were	used:	(1)	capillary	voltage,	3	kV;	(2)	
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nozzle	voltage,	500	V;	 (3)	gas	temperature,	350°C;	 (4)	gas	 flow	rate,	12	L/min;	 (5)	
nebulizer	pressure,	20	psi;	(6)	sheath	gas	temperature,	350°C;	(7)	sheath	gas	flow,	
12	L/min;	(8)	high	pressure	RF	lens	voltage,	110	V;	(9)	low	pressure	RF	lens	voltage,	
60	V;	and	 (10)	electron	multiplier	voltage,	0	V.	Nitrogen	was	used	as	a	nebulizing	
and	collision	gas.	The	acquisition	was	performed	using	multiple	reaction	monitoring	
(MRM).	Optimized	MRM	conditions	and	all	 of	 the	quality	parameters	 required	 to	
perform	the	analysis	of	 these	compounds	are	shown	 in	Tables	2	and	3.	All	of	 the	
data	obtained	were	processed	with	 the	Agilent	MassHunter	Quantitative	Analysis	
software	(version	B.06.00).		
Individual	calibration	curves	for	Ang	I,	Ang	II,	bradykinin	and	aldosterone	were	
constructed	 from	 8	 different	 concentration	 levels	 in	 a	water:acetonitrile	 solution	
(1.1:0.9,	v:v)	containing	0.1%	of	formic	acid	and	obtained	by	plotting	the	analyte	vs.	
IS	peak	abundance	ratio.	Figure	2	shows	a	chromatogram	of	the	obtained	peaks.	
2.4. Plasma	renin	determination	
Plasma	 renin	 concentration	 was	 measured	 with	 an	 ELISA	 kit	 following	 the	
manufacturer’s	instructions	(Rat	Renin	ELISA	Kit,	MyBiosource,	Madrid	Spain).	
2.5. mRNA	extraction	from	liver	and	aorta	
The	frozen	hepatic	tissue	was	homogenized	with	lysis	buffer	(RNeasy	Mini	Kit,	
Qiagen	Barcelona,	Spain)	in	a	TissueLyser	LT	(Qiagen,	Barcelona,	Spain).	The	frozen	
aortic	 tissue	 was	 homogenized	 without	 buffer	 in	 a	 TissueLyser	 LT	 (Qiagen,	
Barcelona,	 Spain)	with	 7	mm	 stainless	 steel	 beads	 (Qiagen	Barcelona,	 Spain);	 the	
lysis	buffer	was	added	immediately	thereafter	(RNeasy	Mini	Kit,	Qiagen	Barcelona,	
Spain).	The	extracted	hepatic	and	aortic	mRNAs	were	quantified	using	a	Nanodrop	
1000	Spectrophotometer	(Thermo	Scientific,	Madrid,	Spain),	and	the	RNA	integrity	
was	checked	using	a	1%	agarose	gel	with	formaldehyde.		
2.6. Quantitative	polymerase	chain	reaction	
Retrotranscription	 of	 the	 extracted	 mRNA	 was	 performed	 using	 the	 High	
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Capacity	 cDNA	 Reverse	 Transcription	 Kit	 (Applied	 Biosystems,	 Madrid,	 Spain).	
Quantitative	 PCR	 amplification	 and	 detection	were	 carried	 out	 in	 a	 CFX96	 Touch	
Real	 Time	 PCR	 System	 (Bio-Rad,	 Barcelona,	 Spain)	 using	 96-well	 plates	 and	 SYBR	
PCR	 Premix	 reagent	 Ex	 TaqTM	 (Takara,	 Barcelona,	 Spain),	 according	 to	 the	
commercial	 protocol.	 Glyceraldehyde	 3-phosphate	 dehydrogenase	 (GADPH)	 was	
used	 as	 a	 housekeeping	 gene.	 Table	 4	 shows	 the	 characteristics	 of	 all	 of	 the	
primers,	which	were	synthetized	by	Biomers	(Söflinger,	Germany).	The	specificity	of	
each	 primer	 was	 verified	 by	 melt	 curve	 analysis	 and	 the	 amplification	 size	 was	
checked	by	3%	agarose	gel	electrophoresis.	The	qPCR	efficiency	was	calculated	by	
analyzing	a	2-fold	dilution	 series	of	 aorta	 cDNA.	The	 results	 are	presented	as	 the	
logarithm	of	cDNA	concentration	compared	 to	 the	obtained	Ct.	PCR	efficiency	 (E)	
was	calculated	with	the	following	formula:	E=10(1/slope).	Each	sample	was	evaluated	
in	 triplicate,	 and	 the	 relative	 expression	was	 calculated	 by	 dividing	 the	 ECt	 of	 the	
studied	gene	by	the	ECt	of	the	housekeeping	gene,	and	all	referenced	to	the	control	
situation.	
3. Results	and	discussion	
A	 meta-analysis	 study	 reported	 that	 participants	 supplemented	 with	 grape	
seed	 flavonoids	 had	 significantly	 reduce	 BP	 compared	 with	 control	 subjects	 7.	
Moreover,	 we	 have	 previously	 reported	 that	 LM-GSPE	 produces	 an	
antihypertensive	 effect,	 with	 the	 most	 effective	 dose	 being	 375	 mg/kg,	 and	 the	
maximum	 decrease	 occurring	 6	 h	 post-administration	 9,10.	 Furthermore,	 the	
endothelium-dependent	vascular	relaxing	effects	of	LM-GSPE	was	evidenced	 in	ex	
vivo	experiments	using	aorta	rings	 from	spontaneously	hypertensive	rats	 (SHR)	11.	
In	this	study,	CAF	diet-fed	rats	were	chosen	as	a	model	of	obesity	with	induced	HTN	
because	this	diet	promotes	voluntary	hyperphagia	that	results	in	rapid	weight	gain	
22.	In	addition,	animals	feeding	a	CAF	diet	for	10	weeks	were	evidenced	to	present	
HTN	12.	 In	the	present	study,	the	systolic	blood	pressure	(SBP)	and	diastolic	blood	
pressure	 (DBP)	 values	 after	 the	 feeding	period	with	CAF	diet	 and	before	 the	 LM-
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GSPE	administration	were	140	±	2	and	98	±	2	mmHg,	respectively.	As	expected,	LM-
GSPE	 (375	 mg/kg)	 decreased	 the	 SBP	 and	 DBP	 values	 in	 these	 animal	 6	 h	 post-
administration	 by	 -19	 ±	 2	 and	 -23	 ±	 4	 mm	 Hg,	 respectively,	 compared	 with	 the	
water-administered	rats,	whose	SBP	and	DBP	values	decreased	by	-2	±	1	and	-3	±	1	
mm	Hg,	respectively.	
The	 relationship	 between	 obesity	 and	 HTN	 is	 well	 established.	 However,	 the	
mechanism	 through	 which	 obesity	 directly	 causes	 HTN	 is	 still	 not	 clear.	 RAAS	
hyperactivity	 is	 associated	 with	 obesity	 1	 and	 fat	 restriction	 and	 successfully	
reduces	 the	amount	of	RAAS	components,	 indicating	 that	 the	degree	of	adiposity	
might	 have	 direct	 influence	 on	 this	 BP-regulating	 system.	 Additionally,	 blocking	
RAAS	has	been	related	to	a	decrease	 in	body	 fat	accumulation	 23–26.	Therefore,	 in	
this	study,	we	aimed	to	evaluate	the	involvement	of	RAAS	in	the	antihypertensive	
effect	of	grape	seed	flavanols	in	this	obesity-induced	HTN	experimental	model.	
The	results	show	that	although	aorta	Ang	II	type	1	receptor	expression	was	not	
modified	 by	 LM-GSPE	 (Figure	 3),	 Ang	 II	 plasma	 levels,	 the	most	 important	 RAAS	
bioactive	 peptide,	 were	 reduced	 by	 two-fold	 after	 6	 h	 of	 375	 mg/kg	 LM-GSPE	
administration	 (Figure	 4A).	 This	 result	 clearly	 implicates	 RAAS	 in	 the	
antihypertensive	 effect	 of	 grape	 seed	 flavanols	 in	 obese	 rats.	Moreover,	 the	 fact	
that	a	reduction	in	Ang	II	was	not	accompanied	by	changes	in	receptor	expression	
indicates	that	grape	seed	flavanols	inhibit	RAAS	upstream	of	the	pathway.		
Ang	II	is	able	to	disrupt	endothelial	nitric	oxide	synthase	(eNOS)	mRNA,	thereby	
inhibiting	 NO	 production	 27.	 It	 has	 also	 been	 shown	 to	 stimulate	 the	 activity	 of	
nicotinamide	 adenine	 dinucleotide	 phosphate	 (NADPH)	 oxidase	 28,29,	 the	 main	
endothelial	 producer	 of	 free	 radicals	 30.	 These	 free	 radicals	 can	 directly	 scavenge	
NO,	 inactivating	 its	 vasodilator	 action,	 and	 enhance	 ET-1	 synthesis	 31–33,	 which	
increases	NADPH	oxidase	activity	 34,35.	 Thus,	 the	 reduction	 in	plasma	Ang	 II	 levels	
mediated	 by	 grape	 seed	 flavanols	 could	 highlight	 the	 known	 NO-mediated	
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antihypertensive	effects	of	these	compounds	9,10.	In	fact,	the	upregulation	of	eNOS	
gene	 expression	 and	 the	 downregulation	 of	 ET-1	 and	 NADPH	 oxidase	 subunit	 4	
(NOX4)	gene	expression	has	been	 recently	 reported	by	our	group	 in	CAF	diet-fed	
rats	administered	grape	seed	flavanols	36.	
In	 addition	 to	 its	 potent	 effect	 as	 a	 vasoconstrictor,	 Ang	 II	 also	 promotes	 the	
production	 of	 aldosterone	 in	 the	 adrenal	 glands,	 which	 we	 found	 significantly	
reduced	 in	plasma	by	grape	seed	 flavanols	at	6	h	post-administration	 (Figure	4B).	
This	 hormone	 elevates	 water	 and	 salt	 reabsorption	 in	 the	 kidneys,	 resulting	 in	
cardiac	hypertrophy,	fibrosis,	HTN	and	diastolic	dysfunction	37.	Moreover,	elevated	
aldosterone	 concentrations	 are	 associated	 with	 high	 mortality	 in	 patients	 with	
severe	 congestive	 failure	 38.	 In	 this	 regard,	 the	 decreases	 in	 aldosterone	 plasma	
levels	 by	 LM-GSPE	 could	 be	directly	 related	 to	 an	 improvement	 in	 cardiovascular	
health.	
Remarkably,	the	decrease	 in	plasma	Ang	II	 is	accompanied	by	a	similar	drop	 in	
plasma	Ang	I	 (Figure	4C),	suggesting	that	ACE	was	not	 implicated	in	plasma	Ang	II	
reduction	at	6h	post-administration	of	LM-GSPE.	This	finding	is	 in	agreement	with	
our	 previous	 results	 showing	 that	 plasma	 ACE	 was	 not	 inhibited	 by	 these	
compounds	 in	 hypertensive	 rats	 9,10.	 39.	Moreover,	 plasma	bradykinin	 levels	were	
not	altered	by	LM-GSPE,	supporting	the	non-participation	of	ACE	in	RAAS	inhibition	
mediated	 by	 grape	 seed	 flavanols	 (Figure	 4D).	 However,	 these	 results	 did	 not	
eliminate	 the	 participation	 of	 this	 enzyme	 before	 6h	 post-administration	 of	 LM-
GSPE.	In	fact,	the	ACE	inhibitory	activity	of	flavanols	has	been	previously	reported	
both	in	vitro	15–17,40	and	in	vivo	20,41.		
Because	 renin	 is	 a	 specific	 RAAS	 enzyme,	 renin	 inhibition	 is	 considered	more	
selective	 than	 ACE	 inhibition,	 which	 also	 cleaves	 a	 number	 of	 other	 peptides	
causing	 side	 effects	 such	 as	 dry	 cough,	 allergic	 reaction	 or	 taste	 disturbance	 42.	
However,	 it	 has	 been	 described	 that	 RAAS	 inhibition	 frequently	 produces	 a	
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compensatory	action	that	returns	or	even	increases	the	release	of	Ang	II	and	renin:	
The	 so-called	Ang	 II/renin	escape	 43.	 	Nevertheless,	our	 results	did	not	 show	 that	
compensatory	 renin	 release	 because	 no	 changes	 were	 observed	 in	 plasma	 renin	
levels	 (Figure	 5).	 In	 contrast,	 hepatic	 angiotensinogen	 gene	 expression	 was	
upregulated	in	the	hypertensive	rats	administered	grape	seed	flavanols	(Figure	6),	
clearly	 indicating	 that	 a	 reduction	 in	 liver	 angiotensinogen	 expression	 was	 not	
implicated	in	the	plasma	reduction	of	Ang	I.	However,	it	is	likely	that	the	increase	in	
angiotensinogen	 mRNA	 represents	 a	 compensatory	 mechanism	 to	 increase	 low	
plasma	Ang	I	and	II	levels	produced	by	grape	seed	flavanols.	In	agreement	with	this	
result,	it	had	been	previously	reported	that	other	RAAS	inhibitors,	such	as	the	renin	
inhibitor	 CGP-29287,	 decreased	 plasma	 Ang	 II	 concentrations,	 which	 was	 also	
accompanied	by	an	increase	in	hepatic	angiotensinogen	mRNA	levels	44.		
Nevertheless,	although	ACE	could	be	involved	in	the	Ang	II	decrease,	our	results	
evidenced	 an	 important	 drop	 in	 Ang	 I	 levels	 that	 clearly	 would	 support	 an	
additional	 implication	of	grape	 seed	polyphenols	upstream	of	 the	pathway	and	 it	
points	to	a	direct	effect	of	these	compounds	on	the	reduction	of	Ang	I,	since	renin	
levels	were	not	modified	and	angiotensinogen	expression	was	upregulated	by	LM-
GSPE.	Therefore,	 in	 further	experiments	we	aim	 to	 investigate	 the	mechanism	by	
which	Ang	I	levels	are	reduced	by	LM-GSPE,	although	we	hypothesize	that	could	be	
by	a	direct	interaction	of	some	compound	present	in	LM-GSPE	with	Ang	I,	as	it	has	
been	 described	 for	 polyphenols	 to	 bind	with	 proteins	 and	miRNAs	 45,46	 However,	
this	assumption	need	to	be	carefully	investigated	since,	to	our	knowledge,	it	would	
involves	a	new	system	to	block	the	RAAS	not	described	at	this	moment.		
4. Concluding	remarks	
In	light	of	these	results,	grape	seed	flavanols	inhibit	RAAS	in	obese	hypertensive	
rats,	and	this	 inhibition	explains	the	 improvement	 in	endothelial	 function	and	the	
antihypertensive	and	cardioprotective	effects	exhibited	by	these	compounds.	This	
finding	 is	considered	of	special	relevance	because	currently,	the	first	drug	choices	
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for	obesity-induced	HTN	are	the	Ang	II	antagonist	and	ACE-inhibitors,	both	of	which	
block	 RAAS.	 It	 is	 also	 important	 to	 note	 that	 RAAS	 overactivity	 is	 not	 only	
associated	 with	 HTN	 but	 also	 with	 vascular	 inflammation,	 the	 development	 of	
atherosclerosis,	 left	 ventricular	 hypertrophy,	 nephrosclerosis	 and	 cardiovascular	
events,	 including	myocardial	 infarction,	stroke	and	heart	 failure.	We	are	currently	
conducting	 additional	 experiments	 to	 elucidate	 the	 specific	 compounds	 and	
mechanisms	that	could	be	implicated	in	the	cardioprotective	effects	of	grape	seed	
flavanols.		
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Figure	legends	
Figure	1.	A	graphical	representation	of	the	experimental	design	used	in	this	study.	
Figure	2.	Extracted	ion	chromatograms	for	plasma	(1)	angiotensin	I,	(2)	angiotensin	
II,	 (3)	 bradykinin	 and	 (4)	 aldosterone	 levels	 and	 their	 respective	 mass	 spectra	
fragmentation	from	CAF	diet-fed	rats	6	hours	after	the	administration	of	375	mg/kg	
LM-GSPE.	
Figure	3.	Aorta	gene	expression	of	angiotensin	II	receptors	Type	1	a	(ART1a)	and	b	
(ART1b)	in	cafeteria	diet-fed	rats	6	hours	after	the	administration	of	375	mg/kg	LM-
GSPE	 (black	 bar)	 or	 water	 (white	 bar).	 The	 results	 are	 expressed	 as	 the	mean	 ±	
standard	 error	 (SEM)	 for	 n=8	 animals	per	 group.	 	 No	 statistical	 differences	were	
demonstrated	assessed	by	the	Student-t	test.	
Figure	4.	Plasma	levels	of	(A)	angiotensin	II	(Ang	II),	(B)	aldosterone,	(C)	angiotensin	
I	 (Ang	 I)	 and	 (D)	 bradykinin	 in	 cafeteria	 diet-fed	 rats	 6	 hours	 after	 the	
administration	of	375	mg/kg	LM-GSPE	(black	bar)	or	water	(white	bar).	The	results	
are	expressed	as	the	mean	±	standard	error	(SEM)	for	n=8	animals	per	group.	The	*	
indicates	significant	differences	at	p	<	0.05	assessed	by	the	Student-t	test.	
Figure	 5.	 Plasma	 renin	 levels	 in	 cafeteria	 diet-fed	 rats	 6	 hours	 after	 the	
administration	of	375	mg/kg	LM-GSPE	(black	bar)	or	water	(white	bar).	The	results	
are	expressed	as	the	mean	±	standard	error	(SEM)	for	n=8	animals	per	group.		No	
statistical	differences	were	demonstrated	assessed	by	the	Student-t	test.	
Figure	6.	Liver	gene	expression	of	angiotensinogen	in	cafeteria	diet-fed	rats	6	hours	
after	 the	 administration	 of	 375	mg/kg	 LM-GSPE	 (black	 bar)	 or	water	 (white	 bar).	
The	results	are	expressed	as	the	mean	±	standard	error	(SEM)	for	n=8	animals	per	
group.	The	*	indicates	significant	differences	at	p	<	0.05	assessed	by	Student-t	test.	
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Table	1.	Total	polyphenol	content,	individual	phenolic	compounds	and	antioxidant	
capacity	of	the	grape	seed	extract	studied.		
	
Compounds			 Total	amount	(mg/g)*	
Total	polyphenol	content	1	 554.2	±	13.0	
Phenolic	compound	2	 	
Gallic	acid	 19.0	±	2.1	
Protocatechuic	acid	 1.1	±	0.1	
Procyanidin	dimera	 154.5	±	34.6	
Catechin	 97.2	±	8.2	
Epicatechin	 59.0	±	0.8	
Dimer-gallatea	 42.6	±	7.6	
Epigallocatechin	gallate	 0.4	±	0.1	
Procyanidin	trimera	 30.5	±	2.2	
Procyanidin	tetramera	 2.4	±	0.2	
Epicatechin	gallateb	 59.3	±	1.6	
Antioxidant	capacity	3	 18,161.2	±	698.85	
*The	values	are	expressed	on	a	dry	basis	as	mean	±	SEM	(n=3).		
1Measured	 by	 Folin-Ciocalteu´s	 method.	 2	 Quantified	 by	 HPLC-MS.	
3Determined	by	the	ORAC	assay,	expressed	as	μmol	of	Trolox	equivalents	(TE)	
per	gram	of	LM-GSPE.	
aQuantified	 using	 the	 calibration	 curve	 of	 procyanidin	 B2.	 	 bQuantified	 using	
the	calibration	curve	of	epigallocatechin	gallate.	
Table	adapted	from	[12].	
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Figure 2. Extracted ion chromatograms of Angiotensin I (1), Angiotensin II (2), 
Bradykinin (3) and Aldosterone (4) in plasma and their respective mass spectra 
fragmentation 6 h after ingestion of LM-GSPE (375 mg/kg). 
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Abstract
Physiological concentrations (1 μM)of 15 flavonoidswere evaluated inhumanumbilical vein endothelial cells in the presence of hydrogenperoxide (H2O2) for their
ability to affect endothelial nitric oxide synthase (eNOS) and endothelin-1 (ET-1) expression in order to establish the structural basis of their bioactivity. Flavonoid
effects on eNOS transcription factor Krüpple like factor-2 (KLF-2) expression were also evaluated. All studied flavonoids appeared to be effective compounds for
counteracting the oxidative stress-induced effects on vascular gene expression, indicating that flavonoids are an excellent source of functional endothelial regulator
products. Notably, the more effective flavonoids for KLF-2 up-regulation resulted in the highest values for eNOS expression, showing that the increment of eNOS
expressionwould take place throughKLF-2 induction. Structure–activity relationship studies showed that the combinations of substructures on flavonoid skeleton that
regulate eNOS expression are made up of the following elements: glycosylation and hydroxylation of C-ring, double bond C2_C3 at C-ring, methoxylation and
hydroxylation of B-ring, ketone group in C4 at C-ring and glycosylation in C7 of A-ring, while flavonoid features involved in the reduction of vasoconstrictor ET-1
expression are as follows: double bond C2_C3 at C-ring glycosylation in C7 of A-ring and ketone group in C4 of C-ring.
© 2015 Elsevier Inc. All rights reserved.
Keywords: Flavonoids; Endothelial function; Structure–activity relationship studies; eNOS; ET-1; KLF-2
1. Introduction
According to theWorld Health Organization, cardiovascular disease
(CVD) is the leading cause of deathworldwide,which represents 30% of
all global deaths. In fact, it is estimated that the number of people who
die of CVD will increase to 23.3 million by 2030 [1]. Endothelial tissue
regulates vascular tone and exerts finely tuned control over cardio-
vascular homeostasis, including nitric oxide (NO), one of the best
characterized vasodilator endothelial factors, and endothelin-1 (ET-1),
one of the strongest known vasoconstrictors [2–4]. NO synthases
(NOSs; EC 1.14.13.39) are a family of enzymes catalyzing theproduction
of NO from L-arginine. There are three isoforms of the NOS enzyme,
endothelial (eNOS), neuronal and inducible, with eNOS being the most
relevant NOS isoform in the vasculature. In addition, the promoter of
eNOS is regulated by the transcription factor Krüpple like factor 2
(KLF-2) [5–7]. Likewise, KLF-2 can also inhibit the expression of other
important genes involved in regulating vessel tone, such as ET-1 [8].
This important endothelial vasoconstrictor factor has been described to
be overexpressed in the vasculature in different hypertension (HTN)
models [9]. In fact, treatment with the ET receptor antagonists resulted
in ahigh vasorelaxation response, providing evidence that ET-1 contributes
to endothelial dysfunction in HTN [10].
Epidemiologic and intervention studies suggest that flavonoids
decrease the risk of CVD [11]. Flavonoids are low-molecular-weight
polyphenol molecules that are widely present in the plant kingdom,
and therefore in the human diet, and display a broad range of
biological effects, including anti-inflammatory and antioxidant
activities [12]. The basic structure is a 2-phenyl benzopyrone in
which the three-carbon bridge between the phenyl groups is usually
cyclized oxygen [13,14]. The flavonoids include several subfamilies
according to their degree of unsaturation and the degree of oxidation
of the oxygenated heterocycle: flavanones, flavones, flavonols,
isoflavones, flavanols and anthocyanidins [13–15]. The importance
of the flavonoid structure on its biological function is known; the
position and number of substituents in the flavonoid basic structure
significantly affect its antiproliferative, cytotoxic, antioxidant and
antienzymatic activities [16–19]. However, no studies have been
carried out to know the effect of different flavonoids on eNOS and ET-
1 expression and to establish the structural basis of this ability.
The protective effects of flavonoids on CVD could be attributed, in
part, to the beneficial effects of these compounds on endothelial
function [11]. It is known that consumption of certain flavonoids
potentiates NO endothelium-dependent relaxation [20]. Likewise,
previous studies reported that flavonoids, such as quercetin [21,22],
Available online at www.sciencedirect.com
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hesperidin [23] and red wine polyphenols, were shown to decrease
ET-1 production [24]. In addition, physiological concentrations
of epigallocatechin gallate blocked the stimulatory effect of H2O2 on
ET-1 mRNA expression in cultured vascular endothelial cells (human
umbilical vein endothelial cells, or HUVECs), while quercetin
increased the expression of eNOS and decreased ET-1 mRNA levels
[25]. All of these results indicate the potential of dietary flavonoids as
protective compounds on vascular health. However, the key molecular
flavonoid substructures that dictate their effectiveness in improving the
endothelium function through the modulation of mRNA expression of
key genes have yet to be characterized.
Therefore, the objective of this work was to define the key flavonoid
structural elements that are required for activating and inhibiting eNOS
and ET-1 mRNA expression, respectively, through the determination of
the ability of 15 flavonoids belonging to five structural subtypes (i.e., 4
flavanones, 2 flavanols, 1 isoflavone, 5 flavones and 3 flavonols) to affect
the mRNA expression of these endothelium factors under oxidative
stress conditions. In addition, the effects of these flavonoids on themRNA
expression of the potent inducer of eNOS expression, the transcription
factor KLF-2, were evaluated.
2. Materials and methods
2.1. Materials and chemicals
Endothelial growth medium (EGM-2 BulletKit), raw colorless medium and trypsin
neutralizing solution were purchased from Lonza (Barcelona, Spain), and flasks and plates
were obtained from Greiner Bio-One (Tarragona, Spain). Ultrapure water with 0.1% gelatin
was acquired from©EMDMillipore (Madrid, Spain), and 3-(4,5-dimethylthiazol-2-yl)-2,5-
diphenyltetrazolium bromide (MTT) formazan powder (1-(4,5-dimethylthiazol-2-yl)-3,5-
diphenylformazan) came from Sigma-Aldrich Química (Madrid, Spain). The RNeasy Mini
Kit was obtained from Qiagen (Barcelona, Spain), the High Capacity cDNA Reverse
Transcription Kit was obtained from Applied Biosystems (Madrid, Spain) and SYBR
PCRPremix reagentExTaq™wasobtained fromTakara (Barcelona, Spain). All primerswere
purchased from Biomers (Söflinger, Germany). Distilled water was obtained from a
Millipore Milli-Q® system.
Selection of flavonoids included representative food compounds differing in
presumed key chemical substituents of the flavonoid molecule, i.e. number of hydroxyl
groups, presence of double bond between carbons 2 and 3 (C2–C3), position of the B-
ring in C-ring, presence of a keto group on C4, methylation and glycosylation (Fig. 1).
All the studied flavonoids were kindly provided by Nutrafur S.A. (Murcia, Spain),
except for catechin and genistein, which were purchased from Sigma-Aldrich Química
(Barcelona, Spain), and hesperidin and luteolin, whichwere purchased from Santa Cruz
Biotechnology (Barcelona, Spain). Global HPLC profiles of the flavonoid compounds
used in this study have previously been reported by our group, and the purity for all
compounds was higher than 90% [16]. A 100-mM stock solution of individual
flavonoids was prepared daily in dimethyl sulfoxide (DMSO) and was further diluted
in culturemedia before being added to the cells. In all experiments, the final concentration
of DMSO was 0.01%.
2.2. Cells culture
HUVECs were obtained from Cascade Biologics™ (Mansfield, UK) as a frozen stock
(passage 4). The cells were defrosted and grown in endothelial growth medium (EGM-
2 BulletKit) supplemented with 2% fetal bovine serum), antibiotics (gentamicin sulfate/
amphotericin B), 0.4% human fibroblast growth factor-B, 0.04% hydrocortisone, 0.1%
human epidermal growth factor, ascorbic acid, heparin, vascular endothelial growth
factor and insulin-like growth factor (R3-IGF-1) in a humidified atmosphere at 37°C
under 5% CO2. The mediumwas changed 24 h after thawing and then every 48 h.When
the confluence was greater than 70%, cells were subcultured using 2 ml of trypsin–
EDTA andwashed with phosphate-buffered saline (PBS). Once cells were detached, the
trypsin effect was neutralized with 8 ml of trypsin-neutralizing solution and cells were
centrifuged (180×g, 7 min, rt). Lastly, cells were seeded at a minimum density of 103
cells·cm−2 in flasks and plates that were previously coated with 1% gelatin solution.
Gene expression trials were performed between passages 4 and 11 in six-well plates
when cells were at 80%–85% confluence.
Treatments were prepared in endothelial growth medium with a final concentra-
tion of each individual flavonoid and H2O2 at 1 and 50 μM, respectively. After a 24-h
incubation with treatments, the cells were harvested by aspirating and were carefully
washed with PBS. Cells were lysed using Lysis Reagent (Qiagen) and stored overnight
at −80°C.
HUVEC viability in the presence of individual flavonoids, DMSO and H2O2 at
concentrations of 1 μM, 0.01% and 50 μM, respectively, was previously verified using
the 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide quantitative
colorimetric assay as previously described [26].
2.3. RNA extraction and quantitative real-time polymerase chain reaction
Total RNA was extracted from the cells using RNeasy Mini Kit according to the
manufacturer's instructions. Total RNA was quantified using a Nanodrop 1000
Spectrophotometer (Thermo Scientific, Madrid, Spain), and the RNA integrity was
checked by 1% agarose gel with formaldehyde.
Retrotranscription of themRNAwas carried outwith theHigh Capacity cDNAReverse
Transcription Kit in MultiGene™ OptiMax Thermal Cycler (Labnet International Inc.,
Edison,NJ,USA), and the real-timequantitativepolymerase chain reaction (PCR) reactions
were performed on the CFX96 Touch Real Time PCR System (Bio-Rad, Barcelona, Spain)
using 96-well plates and SYBR PCR Premix reagent Ex Taq™ according to the
manufacturer's instructions. Glyceraldehyde 3-phosphate dehydrogenase (GADPH) was
selected as the housekeeping gene to allow quantification of the expression of eNOS, ET-1
and KLF-2. Primer-Blast software was used to design primers of GAPDH, KLF-2, eNOS and
ET-1 (Table 1), and the sequences were purchased from Biomers.
In order to examine primer efficiency, a twofold dilution series was prepared from
pooled cDNA samples of HUVECs. The results were represented as the logarithm
of cDNA concentration vs. obtained Ct. The efficiency (E) of each primer pair was
calculated by applying the formula: E=10(−1/slope). PCR reactions were performed in
duplicates, and the relative expression was calculated by dividing the ECt of the studied
gene and the ECt of the housekeeping gene in reference to the control (cells treated only
with medium). Specificity of each primer was verified by analysis of the melting curve,
and the amplicon size was confirmed by 3% agarose gel electrophoresis.
2.4. Statistical analysis
Relative mRNA expression data are expressed as the means±S.E.M.. Data were
analyzed by one-way analysis of variance (ANOVA) using SPSS software (Version 21.0
for Mac). Differences between groups were analyzed by Tukey post hoc text with Pb.05
and expressed with letters.
3. Results and discussion
The structures of all the flavonoids evaluated in HUVECs for their
capacity to modulate the expression of genes related to vascular tone
are represented in Fig. 1. In order to locate effective compounds that
counteract the oxidative stress-induced effects on vascular function,
flavonoids were studied under stress conditions, the origin of many
pathological conditions, using H2O2, which has been shown to alter
both eNOS and ET-1 production by endothelial cells [25,27]. Flavonoid
effects were studied at the physiological concentration of 1 μM [28].
Nevertheless, an important aspect of flavonoids is the changes that
occur to these molecules in vivo during first-pass metabolism. In
addition, the microflora extensively affects flavonoid hydrolysis and
hence further contributes to the variation in the molecular forms of
the flavonoids that are found in the blood and tissues [29]. In fact, the
limited description about bioactivity based on studies using flavo-
noids in nonphysiologically relevant forms or concentration has been
pointed out as the most important limitation in flavonoid research
[30]. However, in the in vitro studies the nonmetabolized forms are
normally used. This is due to the difficulty to obtain many commercial
flavonoid conjugates. Nevertheless, recently it was postulated that
orally administered quercetin, and probably other flavonoids, is
conjugated in the intestine and liver to be transported bloodstream
[31,32], and probably to be accumulated within diseased tissues [33],
being the free flavonoid, released from its metabolite, the responsible
for its activity.
3.1. Effects of H2O2 on HUVECs gene expression
Endothelial function is known to be affected by oxidative stress
[34]. Reactive oxygen species (ROS) have several effects on vascular
and endothelial function. Pathological conditions lead to an overpro-
duction of ROS and consequently oxidative stress, thus resulting in
endothelial dysfunction, increased contractibility and induction of
atherosclerotic events [35]. This condition also causes changes at the
transcriptional level, demonstrated through in vitro studies that
oxidative stress modulates the expression of certain genes involved in
endothelial dysfunction such as ET-1 [25,36]. Experimental conditions
used in this study (50 μM H2O2 for 24 h) resulted in an oxidative
278 L. Martínez-Fernández et al. / Journal of Nutritional Biochemistry 26 (2015) 277–284
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stress-induced vasoconstrictor gene expression profile in HUVECs,
including a clear down-regulation of eNOS expression and up-
regulation of ET-1. Fig. 2A shows the mRNA expression reduction
for eNOS. In contrast to our results, an up-regulation of eNOS
expression by H2O2 in cultured cells has been reported [25,37].
Nevertheless, other studies have shown that H2O2 can produce an
increase or, on the contrary, a decrease in eNOS transcription
depending on the studied cells, BAEC and pulmonary arterial
endothelial cells, respectively [38,39]. The apparent discrepancies
between the studies may be explained by differences in experimental
design (i.e., vehicle, time of treatment and dose of H2O2 used). On the
other hand, the administration of H2O2 to HUVECs did not affect KLF-2
mRNA expression (Fig. 2B), suggesting that the eNOS depletion in
H2O2 treated cells was not a result of this transcription factor but a
KLF-2 independent signaling pathway. In previous studies, it has been
reported that an oxidative stress stimuli of H2O2 could lead to an
increased KLF-2 expression in rat cardiac myocytes [40]. In contrast,
previous studies found that H2O2 down-regulated KLF-2 expression
Fig. 1. Structures of the different flavonoids used in this study.
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through the inhibition of the MEK5/ERK5/MEF2 signaling pathway
in endothelial cells [41], although the direct effect of oxidative stress
on endothelium-dependent KLF-2 production is not completely
described. However, it is important to point out that the KLF-2
expression does not provide information about its DNA binding
activity. Finally, mRNA expression of the vasoconstrictor ET-1 was
increased in response to the administration of H2O2 (Fig. 3). These
data are in agreement with previous studies, in which ET-1 levels are
augmented with 50 μM of H2O2 [25]. In fact, ET-1 and H2O2 are
intimately correlated. ET-1 has been shown to increase in response to
H2O2 levels, which in turn decreases eNOS expression [38]. In this
study, we have shown that H2O2may have an effect on ET-1 and eNOS
production in HUVECs.
3.2. Effects of flavonoids on HUVECs gene expression
According to our results, the studied flavonoids offset the effect of
H2O2 by increasing the expression of eNOS compared to control
values (P=NS in respect to control cells). The most effective
flavonoids to increase eNOS expression in vascular endothelial cells
under stress-induced conditions were genistein and luteolin (Fig. 1A).
These flavonoids increased mRNA expression more than threefold
in response to H2O2 compared to control cells. This result is in
agreement with recent studies in which both flavonoids have been
shown to increase eNOS mRNA expression [42,43]. In addition, cells
treated with rhoifolin, epicatechin, catechin and apigenin also
resulted in a significant increase in e-NOS expression in respect to
Table 1
Real-time PCR primers
Gene GenBank accession no. Amplicon length (bp) Sequences 5′-3′ Efficiency
eNOS NM_000603.4 182 Fw 5′-GGAGAATGGAGAGAGCTTTGCAG-3′ 1.82 (80%)
Rv: 5′-CCCCTGCACTGTCTGTGTT.3′
ET-1 NM_001955.4 217 Fw: 5′-CCGTTAAAAGGGCACTTGGG-3′ 1.96 (93.1%)
Rv: 5′-AGCGCCTAAGACTGCTGTTTC-3′
KLF-2 NM_016270.2 183 Fw: 5′-CACACAGGTGAGAAGCCCTACC-3′ 2.28 (112.9%)
Rv: 5′-CTACATGTGCCGTTTCATGTGCAG-3′
GAPDH NM_002046.4 91 Fw: 5-CCATGTTCGTCATGGGTGTG-3′ 1.92 (90%)
Rv: 5′-GGTGCTAAGCAGTTGGTGGTG-3′
KLF-2: Krüppel like factor-2; GAPDH: glyceraldehyde 3-phosphate dehydrogenase.
A
B
Fig. 2. Effect of different flavonoids on eNOS (A) and KLF-2 (B) mRNA expression. HUVECs were incubated for 24 h in the presence of 50 μMH2O2 and 1 μM flavonoids. The results are
expressed as relative mRNA expression of eNOS or KLF-2 in respect to the control cells. The plot represents the mean result±S.E.M. from three different passages. Different letters
express statistical significant differences assessed by one-way ANOVA with Tukey's post hoc test (Pb.05).
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the H2O2 control cells. According to these results, the highest
induction of KLF-2 mRNA expression resulted from luteolin, apigenin,
genistein, epicatechin, catechin and rhoifolin, indicating that for these
flavonoids, the increment of eNOS expression could be mediated by
KLF-2 induction. Moreover, luteolin and apigenin up-regulation of
KLF-2 gene expression was statistically significant. An increment of
KLF-2 expression in HUVECs by resveratrol [44] and also by a grape
seed extract [45] has been previously shown, but as far as we know,
this is the first time that an induction of KLF-2 expression by some
flavonoids is reported. However, additional studies would be neces-
saries to know flavonoid effect on DNA binding activity of KLF-2 or
whether it actually translocated to the nucleus.
The increasing tendencyof ET-1 expression in cells undergoingH2O2
induced-stress was not only counteracted by all the studied flavonoids
(P=NS in respect to control cells), but also reduced in respect to the
H2O2 control cells bymany of the studied flavonoids such as naringenin,
hesperetin, naringin, diosmin, diosmetin, quercetin, genistein,
luteolin and apigenin (Fig. 3). In fact, these flavonoids decreased mRNA
synthesis of the vasoconstrictor between 2.3 and 5.0 times compared to
the H2O2 control cells. These results correlate with previous studies in
which flavonoids as hesperetin [46] or quercetin decreased ET-1 mRNA
levels in HUVECs [25]. Although inhibition of ET-1 expression has been
associated with an increment of KLF-2 expression [47], our results fail
to show enough evidence to state a relationship between KLF-2 and ET-1.
In fact, the most active compounds that inhibit ET-1 expression did not
produce higher levels of KLF-2 mRNA.
In addition, all studied flavonoids showed a vasoprotective effect
on eNOS and ET-1 expression, reaching similar values to control cells
simultaneously for both genes. Accordingly, the eNOS mRNA up-
regulation and the simultaneous effect on ET-1 mRNA expression
down-regulation observed for the flavonoids could explain, at least in
part, the recognized health benefits of food rich in flavonoids on CVD
[48]. For instance, citrus, rich in flavanones [23], or cocoa, rich in
flavanols [49], as well as the wide use of the flavonoids diosmin or
quercetin as pharmaceutical agents (i.e., Daflon 500 and Venorutom)
[50], are all used for their vasoprotective properties. In addition, it is
important to underline that all the studied flavonoids have been
assayed under stress conditions at a potentially physiological
concentration of 1 μM [28], suggesting that these flavonoids could
be clear candidates to be used as functional endothelial regulator
products that which could be useful as nutritional supplements or in
pharmaceutical formulations. However, additional studies would be
necessaries to investigate the effect of flavonoids on eNOS protein or
activity to know the effects of these flavonoids on vascular health.
3.3. Structure–activity relationships
When correlating the chemical structures of the different
flavonoids with the effects on endothelial genes expression, a
structure–activity relationship emerged; these relationships varied
markedly between genes. Regarding eNOS expression modulation,
the principal features for their expression enhancing activity are as
follows: (a) the absence of 3-O-glycosylation and 3-hydroxylation of
the C-ring, (b) the double bond between C2 and C3 of the C-ring, (c)
the absence of 4′-O-methoxylation and the presence of 3′-hydroxylation
of the B-ring, (d) ketone group in C4 of the C-ring, and (e) the absence of
7-O-glycosylation of the A-ring. Moreover, the change of the B ring
position did not produce variation in the effect on eNOS expression;
however, flavone and isoflavone structures were the most effective in
enhancing eNOS mRNA expression (Fig. 4). In contrast, the flavanones
naringenin, hesperetin and naringin had the greatest effect on reducing
ET-1 mRNA expression. The structural characteristics related to the
down-regulation of this gene were as follows: (a) absence of the double
bond between C2 and C3 of the C-ring, (b) absence of 7-O-glycosylation
in A-ring, and (c) presence of ketone group at the C4 carbon of the C-
ring (Fig. 5).
3.3.1. The significance of the C2_C3 double bond in the C-ring on eNOS
and ET-1 mRNA expression: flavone vs. flavanone
As stated above, the significance of the C2_C3 double bond in the
C-ring on the eNOS and ET-1 mRNA expression is clear. The presence
of this double bound in a flavonoid results in the up-regulation of both
genes, indicating the importance of this moiety for the expression of
eNOS and ET-1. Therefore, the absence of this double bond produces
changes in the regulation of gene expression. These changes can be
observed more specifically by comparing the results between the
flavone apigenin and its corresponding structurally similar flavanone
naringenin. The presence of the C2_C3 double bond in apigenin
increases eNOS mRNA expression by 1.96 times compared with
naringenin (see Figs. 2A and 4). According to these results, the
absence of the C2_C3 double bond in naringenin leads to a 2.3-fold
reduction of ET-1 expression compared to apigenin (see Figs. 3 and 5).
Two main factors could explain the importance of this double bound
in the up-regulation of both genes. On the one hand, the molecular
electronic distribution would allow the maintenance of a definitive
structural conjugation, from the B-ring to the A and C rings, in
contrast to the flavanone structure, with which this definitive
structural conjugation is not possible. On the other hand, the
maintenance of a nearly planar structure would disappear whether
Fig. 3. Effect of different flavonoids on ET-1 mRNA expression. HUVECs were incubated for 24 h in the presence of 50 μMH2O2 and 1 μM flavonoids. The results are expressed as relative
mRNA expression of ET-1 with respect to the control cells. The plot represents the mean result±S.E.M. from three different passages. Different letters express statistical significant
differences assessed by one-way ANOVA with Tukey's post hoc test (Pb.05).
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this bond was saturated, producing a flavonoid skeleton with an
obtuse angle. This angle would be variable, determined by the rest of
the constituents of the molecule. Therefore, flavone luteolin is the
most effective flavonoid to stimulate eNOS expression, and the rest of
flavones included in this study (rhoifolin, diosmin and diosmetin) are
more effective than corresponding flavanones (naringin, naringenin,
hesperidin and hesperetin) in up-regulating eNOS expression.
Regarding ET-1, despite the fact that all the flavonoids resulted
in a decrease of ET-1 mRNA production under the stress-induced
condition, similar values compared to control cells, the absence of this
double bound in a flavonoid results in the reduction of ET-1
expression. In fact, the flavanone structures resulted in the greatest
impact on the vasoconstrictor synthesis reduction, suggesting that the
absence of C2_C3 double bound in the C ring is one of the most
important features for the effect of reducing ET-1 mRNA expression.
3.3.2. The significance of 3-hydroxylation and 3-glycosylation of
the C-ring: flavone vs. flavonol
According to all the structural aspects mentioned above, the
regulation of both genes by the flavonoids is related to a specific
electronic distribution. Therefore,minimal alteration of this electronic
distribution on the flavonoid structure, such as the addition of a sugar
moiety or a hydroxyl group in the C-3 position of the C ring (flavone
vs. flavonol) could produce changes in the regulation of gene
expression. The sugar moiety has been reported to play a crucial
role for specific modulatory actions, such as vasorelaxant or
antioxidant activities, of anthocyans and flavonoids as well as the
presence and number of hydroxyl groups [16,51–53]. In this study,
the 3-hydroxylation of the C-ring of quercetin as well as its 3-O-
glycosylation of rutin dramatically decreased eNOS mRNA expression
by 1.93 and 2.26 times, respectively, compared to luteolin (see
Figs. 2A and 4). In addition, a possible steric effect caused by a
substitution of the C ring cannot be ruled out, as indicated by the
lower observed effect on eNOS expression when a sugar moiety
instead of a hydroxyl group is in this position (rutin vs. quercetin).
However, these variations in the three positions of the C ring did not
seem to affect ET-1 mRNA expression (Figs. 3 and 5).
3.3.3. The presence of a catechol group in the B ring
The presence of a catechol group in the B ring also seems to be an
important structural motive in the activation of eNOS expression. On
one hand, the presence of hydroxylation at C-3 of the B ring increases
eNOS expression 1.38 times in response to the flavanol luteolin
compared to apigenin. On the other hand, the 4′-O-methoxylation of
the B ring led to a reduction in the up-regulation of eNOS, when
comparing the results between diosmetin and luteolin (1.87 times
lower). This suggests that the absence of a catechol group in the B ring
also modifies the global electronic distribution. However, these
variations did not seem to affect ET-1 mRNA synthesis.
3.3.4. The presence or absence of a carbonyl group in C4 (C-ring)
This functional group may also play a fairly important function. By
comparing luteolin vs. epicatechin or catechin, the presence of a
carbonyl group in the C ring results in a structure that is 1.35 and 1.39
more efficient for affecting eNOS mRNA expression, respectively. On
the contrary to this, its absence results in a 1.65 times increase of ET-1
mRNA expression when comparing the flavanols luteolin vs.
epicatechin. This result demonstrates that the effect of flavonoids is
gene dependent. However, it should be noted that the disappearance
of the carbonyl group is simultaneously accompanied by the disappear-
ance of the double bond C2_C3, whose structural significance has been
previously mentioned.
3.3.5. The significance of glycosylation at the 7-O (A-ring) position
7-O-glycosylation of the A-ring with the rutinose group presents
a clear negative effect on eNOS expression. The absence of rutinose
Fig. 4. Structural diagram which quantitatively assesses the effect of the addition or elimination of different structural elements from the flavonoid core on eNOS mRNA expression of
luteolin. According to these data, the significance order was: 3-O-glycosylation (absence: 2.26 times more expression when comparing luteolin vs. rutin)Ndouble bond C2_C3
(presence: 1.96 times more expression when comparing apigenin vs. naringenin)≈3-hydroxylation (absence: 1.93 times more expression when comparing luteolin vs. quercetin)N4′-
O-methoxylation (absences: 1.87 times more expression when comparing luteolin vs. diosmetin)N3′-hydroxylation (presence: 1.38 times more expression when comparing luteolin
vs. apigenin)≈4-carbonyl group (presence: 1.35/1.39 times more expression when comparing luteolin vs. epicatechin or luteolin vs. catechin, respectively)N7-rutinose glycosylation
(presence: 1.28 times more expression when comparing diosmin vs. diosmetin). Isoflavone B ring position produces no change when comparing luteolin vs. genistein.
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reduced the enhancer effect of the flavone structure on eNOS mRNA
production by 1.28 times when comparing diosmin vs. diosmetin (see
Figs. 2A and 4). According to this result, the 7-O-glycosylation with
rutinose increased ET-1 expression, reducing the flavanone structure
activity on the inhibition of ET-1 mRNA expression by 2.13 times
compared to the corresponding structurally similar flavanones
hesperidin vs. hesperetin. In agreement, the 7-O-glycosylation with
a neohesperidoside group (naringenin vs. naringin) also decreased
flavanone structure activity on the inhibition of ET-1 expression by
1.48 times (see Figs. 3 and 5).
3.3.6. The significance of the position of the B-ring in the C-ring: flavone
(2-B-ring) vs. isoflavone (3-B-ring)
The change of the B ring position in the C-ring did not produce any
variation in the expression of eNOS and ET-1.When comparing genistein
vs. luteolin, the flavone structure was as effective as the isoflavone
structure for promoting eNOS and decreasing ET-1 gene expression.
4. Conclusions
In this study, we have demonstrated that changes in the flavonoid
active core affect its capacity to modulate vascular key genes
expressed under stress conditions. All the studied flavonoids reduced
the stress-produced enhanced ET-1 expression and increased the
stress-produced down-regulation of eNOS expression. We also
provide examples of flavonoid structure–activity relationships and
establish the structural features needed for the regulation of eNOS
and ET-1 expression. We show that at the physiological flavonoid
concentration of 1 μM, the relative effect of the different substructures
on the up-regulation of eNOS mRNA expression is as follows: 3-O-
glycosylationNdouble bond C2_C3≈3-hydroxylationN4′-O-meth-
oxylationN3′-hydroxylation≈4-carbonyl groupN7-rutinose glycosyl-
ation. The features affecting the down-regulation of ET-1 mRNA
production include the following: double bond C2_C3≈7-rutinose
glycosylationN4-carbonyl groupN7-O-neohesperidoside glycosyla-
tion. In addition, through this study, we have also shed light on the
possible role of KLF-2 on eNOS mRNA up-regulation by most of the
studied flavonoids (luteolin, genistein, rhoifolin, epicatechin, catechin
and apigenin). Finally, we would like to remark that the application of
these flavonoids as modulators of key vascular genes could be useful
as nutritional supplements or in pharmaceutical formulations, although
additional studies would be necessaries to prove the flavonoid effects
not only in gene expression but also in vascular function.
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Abstract	
Gallic	 acid	 (GA)	 is	 a	 naturally	 occurring	 polyphenolic	 compound,	 and	
polyphenol-rich	extracts	have	been	reported	to	decrease	blood	pressure	(BP).	The	
aim	of	this	study	was	to	evaluate	the	antihypertensive	effects	of	low	doses	of	GA	in	
spontaneously	hypertensive	rats	(SHR)	and	to	establish	the	mechanism	involved	in	
its	 BP-lowering	 effect.	 We	 determined	 that	 low	 doses	 of	 GA	 (7	 and	 14	 mg/Kg)	
decrease	 systolic	 and	 diastolic	 BP	 in	 SHR,	 with	 maximal	 effect	 at	 6	 h	 post-
administration.	The	7	mg/Kg	dose	of	GA	was	the	most	effective,	behaving	similarly	
to	 the	 positive	 control,	 captopril-treated	 rats,	 whereas	 a	 hypotensive	 effect	 was	
not	 seen	 in	normotensive	 rats.	Moreover,	7	mg/Kg	of	GA	6	h	post-administration	
inhibited	the	renin-angiotensin-aldosterone	system	(RAAS)	by	reducing	the	plasma	
levels	 of	 angiotensin	 (Ang)	 I	 and	 II	 and	 improved	 endothelial	 function	 as	 GA	
decreased	 the	 endothelial	 vasoconstrictor	 factor	 endothelin-1.	 In	 addition,	 the	
endothelium	vasodilator	agents,	nitric	oxide	(NO)	and	prostacyclin,	contributed	to	
GA’s	 antihypertensive	 effects.	 GA	 also	 increased	 plasma	 bradykinin,	 which	 is	 a	
peptide	with	important	vasodilation	activity.	These	results	suggest	that	blockage	of	
the	RAAS	is	the	mechanism	underlying	the	antihypertensive	effects	of	GA,	reducing	
plasma	 levels	 of	Ang	 I,	 subsequently	 decreasing	 the	plasma	Ang	 II	 concentration,	
and	 as	 a	 result,	 improving	 endothelial	 function.	 In	 conclusion,	 GA	 has	 great	
potential	as	an	antihypertensive	agent.	Moreover,	blockage	of	 the	RAAS	by	GA	 is	
considered	 to	 be	 of	 special	 relevance	 because	 currently,	 RAAS	 overactivity	 is	
associated	 with	 not	 only	 hypertension	 but	 also	 other	 important	 cardiometabolic	
pathologies.		
Keywords:	 Bradykinin;	 endothelin-1;	 nitric	 oxide;	 prostacyclin;	 3,4,5-
trihydroxybenzoic	acid;	hypertension.	
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1. Introduction	
According	 to	 the	 World	 Health	 Organization,	 cardiovascular	 disease	 (CVD)	 is	 the	
leading	 cause	 of	 death	worldwide	 and	 represents	 30%	of	 all	 global	 deaths	 1.	 In	 fact,	 it	 is	
estimated	that	the	number	of	people	who	die	of	CVD	will	increase	to	23.3	million	by	2030	1.	
Hypertension	(HTN)	is	a	major	risk	factor	for	the	development	of	CVD	2.	High	blood	pressure	
(BP)	 treatment	 has	 been	 associated	 with	 an	 approximately	 40%	 reduction	 in	 the	 risk	 of	
stroke	 and	 a	 15%	 reduction	 in	 the	 risk	 of	myocardial	 infarction	 3.	 Epidemiological	 studies	
have	 shown	an	 inverse	 relationship	between	a	polyphenol-rich	diet	 consumption	and	 the	
risk	 of	 HTN	 and	 CVD	 4,5.	 The	 protective	 effects	 of	 polyphenols	 on	 CVD	 could	 be	 partly	
attributed	to	the	beneficial	effects	of	these	compounds	on	endothelial	function	6.	
Gallic	 acid	 (GA,	 3,4,5-trihydroxybenzoic	 acid)	 is	 a	 naturally	 occurring	 phenolic	
compound	 distributed	 widely	 throughout	 the	 plant	 kingdom,	 where	 it	 can	 be	 present	 in	
free-form	 or	 as	 a	 conjugate	 of	 polyphenol-type	 flavanols	 such	 as	 epigallocatechin,	
epigallocatechin	gallate	or	procyanidin	dimer	B2	gallate	7,8.		
Asparagus,	broccoli,	aubergine,	 strawberries,	bananas,	 tea	and	 red	and	white	wine	
are	 some	 of	 the	 foods	 and	 beverages	 naturally	 rich	 in	 GA	 9.	 Different	 studies	 have	
demonstrated	 the	 strong	 antioxidant	 10,	 anti-inflammatory	 11,	 anti-mutagenic	 12	 and	
anticancer	properties	13,14	of	GA,	and	daily	intake	may	reduce	the	risk	of	diseases	and	bring	
health	benefits	15.		More	recently,	GA	has	also	been	studied	for	its	beneficial	effects	on	CVD.	
It	 inhibits	 dyslipidemia,	 hepatosteatosis	 and	 oxidative	 stress	 in	 high-fat	 diet	 fed	 rats	 16,	
protects	 the	 myocardium	 against	 isoproterenol-induced	 oxidative	 stress	 in	 rats	 17,	
ameliorates	 the	 heart-function	 defects	 of	 myocardial	 dysfunction	 associated	 with	
streptozotocin-induced	 type-1	 diabetic	 rats	 18	 and	 exhibits	 anti-hyperglycemic	 and	 lipid-
lowering	properties	in	high-fat	diet	mice	19.	In	vitro	studies	have	also	demonstrated	that	GA	
attenuates	 platelet	 activation	 and	 platelet-leukocyte	 aggregation	 20.	 However,	 to	 our	
knowledge,	the	antihypertensive	effects	of	GA	have	not	been	widely	studied,	although	the	
antihypertensive	properties	of	extracts	 rich	 in	GA	21	or	condensed	tannins	 like	grape	seed	
extracts	have	been	shown	in	studies	8,22.		
Therefore,	the	purpose	of	this	study	was	to	investigate	the	antihypertensive	effects	
of	 low	 doses	 of	 GA	 in	 spontaneously	 hypertensive	 rats	 (SHR)	 and	 to	 establish	 the	
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mechanism	by	which	this	compound	reduces	BP.	
2. Material	and	methods	
2.1. Experimental	Procedure	in	Rats	
In	this	study,	we	used	17–22-week-old	male	SHRs	weighing	300.0	±	2	g	and	17–20-
week-old	male	normotensive	Wistar–Kyoto	(WKY)	rats	weighing	313.0	±	1	g.	All	the	animals	
were	purchased	from	Charles	River	Laboratories	(Barcelona,	Spain).	The	animals	were	singly	
housed	in	animal	quarters	at	22ºC	with	a	light/dark	period	of	12	h.	The	animals	were	fed	ad	
libitum	 with	 a	 standard	 chow	 diet	 of	 Panlab	 A04	 (Panlab,	 Barcelona,	 Spain).	 After	
quarantine,	 the	 animals	were	 subjected	 to	 a	 training	period	 to	habituate	 them	 to	 the	BP	
procedure.	
Systolic	 (SBP)	and	diastolic	blood	pressure	 (DBP)	were	 initially	 recorded	between	8	
and	10	am	in	the	rats	by	the	tail-cuff	method	23,	as	previously	described	24.	After	the	initial	
measurement	of	BP,	 tap	water	was	orally	 administered	 to	 the	SHRs,	 as	was	 captopril	 (50	
mg/Kg),	a	known	antihypertensive	drug,	as	a	positive	control,	or	different	doses	of	GA	(3.5,	
7	 and	 14	mg/Kg	 of	 body	 weight)	 (n=6	 per	 group).	 After	 oral	 administration,	 the	 BP	 was	
recorded	at	2,	4,	6,	8,	24	and	48	h.	A	single	dose	of	either	1	mL	of	water	or	the	appropriate	
solution	 of	 GA	 or	 captopril	was	 always	 orally	 administered	 to	 the	 animals.	 The	WKY	 rats	
were	treated	exclusively	with	water	or	7	mg/Kg	GA	under	the	same	conditions	as	the	SHR.		
Additionally,	 22-week-old	 SHRs	 were	 used	 to	 obtain	 fasting	 blood	 samples	 via	
saphenous	 vein	 extraction	 using	 heparin	 vials	 (Starsted,	 Barcelona,	 Spain).	 The	 GA-
administered	rats	were	given	7	mg/kg	GA	6	h	before	the	blood	was	extracted	(n=6).	The	GA	
was	orally	 administered	by	 gastric	 intubation	between	9	 and	10	 a.m.	 The	 control	 plasma	
was	also	obtained	via	the	saphenous	vein	but	from	animals	not	administered	GA	(n=6).	All	
the	blood	samples	were	centrifuged	at	2000	x	g	for	15	minutes	at	4°C	to	obtain	the	plasma,	
which	was	stored	at	-80°C	until	further	use.	
Additional	trials	were	conducted	in	which	a	single	dose	of	7	mg/kg	GA	or	water	was	
administered	 to	 the	 SHRs	 by	 gastric	 intubation	 between	 8	 and	 9	 am.	 In	 addition,	 both	
groups	 were	 intraperitoneally	 treated	 with	 1	 mL	 of	 saline/vehicle	 or	 30	 mg/kg	 L-NG-
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Nitroarginine	methyl	ester	 (L-NAME),	5	mg/kg	 indomethacin	or	1	mg/Kg	Sirtinol,	4	h	after	
the	 oral	 treatment	 (n=5	 per	 group).	 L-NAME	 and	 indomethacin	where	 dissolved	 in	 saline	
solution	but	Sirtinol	was	diluted	in	10%	DMSO	in	saline	solution.	The	controls	were	treated	
with	the	appropriate	vehicle	solution	depending	on	the	treatment	in	each	experiment.	SBP	
and	DBP	was	recorded	initially	and	6	h	post-administration.		
All	the	reagents	were	purchased	at	Sigma-Aldrich	(Barcelona,	Spain).	
The	 animal	 protocol	 followed	 in	 this	 study	 was	 approved	 by	 the	 Bioethical	
Committee	 of	 Universitat	 Rovira	 i	 Virgili	 (European	Commission	Directive	 86/609	 and	
Spanish	Royal	Decree	223/1988).	
2.2. Analysis	of	plasma	angiotensin	I	and	II	and	bradykinin	by	UHPLC-MS/MS	
2.2.1. Reagents	
Acetonitrile	 and	 formic	 acid	 were	 of	 HPLC	 analytical	 grade.	 Ultrapure	 water	 was	
obtained	 from	a	Milli-Q	 advantage	A10	 system	 (Madrid,	 Spain).	 Individual	 stock	 standard	
solutions	 of	 human	 angiotensin	 (Ang)	 II	 (in	Milli-Q	water),	 human	 Ang	 I	 (in	 0.1	M	 acetic	
acid),	bradykinin	(BK)	(in	0.2	M	acetic	acid)	and	[Asn1,	Val5]-Ang	II,	as	internal	standard	(IS)	
(in	0.1	M	acetic	acid),	were	prepared	weekly	at	a	concentration	of	1	mg/mL.	These	solutions	
were	 stored	 in	 dark	 glass	 flasks	 at	 -80°C.	 All	 the	 reagents	 were	 purchased	 from	 Sigma-
Aldrich	(Madrid,	Spain).	
2.2.2. Plasma	preparation	
Prior	to	chromatographic	analysis,	undesirable	compounds	were	eliminated	from	the	
rat	plasma	by	precipitation.	An	aliquot	of	IS	(2.5	µL)	was	added	to	100	µL	of	plasma,	and	the	
mixture	 was	 then	 diluted	 4	 times	 with	 a	 water:acetonitrile	 solution	 (1:9,	 v:v)	 containing	
0.1%	formic	acid.	The	solution	was	vortexed	and	maintained	at	4°C	for	10	min.	The	mixture	
was	 then	centrifuged	at	21382	x	g	 for	15	min	at	4°C	 in	a	Mikro	200	R	centrifuge	 (Hettich	
GmbH	&	Co.KG,	Tuttlingen,	Germany).	The	supernatant	aliquot	(200	µL)	was	evaporated	to	
dryness	using	a	nitrogen	atmosphere.	Finally,	the	dried	residue	was	dissolved	in	50	µL	of	a	
water:acetonitrile	 solution	 (1.1:0.9,	 v:v)	 containing	 0.1%	 formic	 acid	 and	 transferred	 to	 a	
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sample	vial	at	an	IS	final	concentration	of	25	µg/L	for	LC-MS/MS	analysis.	
2.2.3. UHPLC-MS/MS	
The	UHPLC	system	comprised	a	1290	LC	Series	(Agilent	Technologies,	Palo	Alto,	CA).	
The	different	compounds	were	separated	on	a	reverse-phase	C18	column	(Acquity	BEH	300	
Aº,	 100	 x	 2.1	mm,	 1.7	 μm	 from	Waters	 Corp.,	Milford,	MA,	 USA)	 under	 gradient	 elution	
using	0.1%	formic	acid	in	water	(solvent	A)	and	0.1%	formic	acid	in	acetonitrile	(solvent	B)	
at	a	flow	rate	of	0.4	mL/min.	The	elution	gradient	consisted	of	5%	B	isocratic	(0−0.2	min),	
5−40%	 B	 (0.2−2.5	 min),	 40%	 B	 isocratic	 (2.5-4.0	 min),	 40−98%	 B	 (4.0-4.5	 min),	 98%	 B	
isocratic	 (4.5−7.5	 min)	 and	 98−5%	 B	 (7.5−8.0	 min).	 The	 column	 was	 equilibrated	 at	 the	
initial	conditions	for	2	min	before	each	run.	The	column	temperature	was	set	to	35°C,	and	
the	injection	volume	was	2	μL.	
The	 UHPLC	 system	 was	 coupled	 to	 an	 Agilent	 6490	 Triple	 Quadrupole	 mass	
spectrometer	 (Agilent	 Technologies,	 Palo	 Alto,	 CA)	 equipped	 with	 an	 Agilent	 Jet	 Stream	
(AJS)	 ionization	 source.	 Ionization	 was	 conducted	 in	 a	 positive	 electrospray	 (ESI).	 The	
following	ESI	working	conditions	were	used:	 (1)	capillary	voltage,	3	kV;	 (2)	nozzle	voltage,	
500	V;	(3)	gas	temperature,	350°C;	(4)	gas	flow	rate,	12	L/min;	(5)	nebulizer	pressure,	20	psi;	
(6)	sheath	gas	temperature,	350°C;	(7)	sheath	gas	flow,	12	L/min;	(8)	high-pressure	RF	lens	
voltage,	110	V;	(9)	low-pressure	RF	lens	voltage,	60	V;	and	(10)	electron	multiplier	voltage,	0	
V.	Nitrogen	was	used	as	a	nebulizing	and	collision	gas.	The	acquisition	was	performed	using	
multiple	 reaction	 monitoring	 (MRM).	 Optimized	 MRM	 conditions	 and	 all	 the	 quality	
parameters	 required	 to	perform	the	analysis	of	 these	compounds	are	 shown	 in	Tables	1S	
and	 2S.	 All	 the	 data	 obtained	were	 processed	with	 the	 Agilent	MassHunter	 Quantitative	
Analysis	software	(version	B.06.00).		
Individual	 calibration	 curves	 for	 Ang	 I,	 Ang	 II	 and	 BK	 were	 constructed	 from	 8	
different	concentration	levels	in	a	water:acetonitrile	solution	(1.1:0.9,	v:v)	containing	0.1%	
formic	acid	and	were	obtained	by	plotting	the	analyte	vs.	IS	peak	abundance	ratio.	Figure	1S	
shows	a	representative	chromatogram	of	the	obtained	peaks	of	the	plasma	of	the	control	
and	the	GA-administered	(7	mg/Kg)	animals.	
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2.3. Biochemical	assays	
2.3.1. Plasma	angiotensin-converting	enzyme	activity.	
The	angiotensin-converting	enzyme	(ACE)	activity	in	the	plasma	was	measured	using	
a	fluorometric	method,	as	previously	reported	25.	Briefly,	plasma	aliquots	were	incubated	in	
triplicate	for	15	min	at	37ºC	with	40	μL	of	assay	buffer	containing	the	ACE	substrate	(5	mM	
Hip-His-Leu,	 0,1	 M	 sodium	 tetraborate	 decahydrate,	 300	 mM	 NaCl,	 pH	 8.3;	 Sigma,	
Barcelona,	 Spain).	 The	 reaction	 was	 stopped	 by	 the	 addition	 of	 0.35	 M	 NaOH.	 The	
concentration	 of	 the	 product,	 His-Leu,	 was	 measured	 fluorometrically	 after	 30	 min	 of	
incubation	with	2%	O-phthaldialdehyde	in	methanol.	The	fluorescence	measurements	were	
performed	at	37°C	 in	an	FLx800	Fluorescence	Microplate	Reader	(Bio-Tek-IZASA)	with	350	
nm	excitation	and	520	nm	emission	filters	and	Gen5TM	Data	Analysis	Software.	Black	96-well	
polystyrene	 microplates	 (Thermo	 Scientific,	 MERCK,	 Barcelona,	 Spain)	 were	 used.	 A	
calibration	 curve	 was	 constructed	 by	 adding	 different	 concentrations	 of	 rabbit	 lung	 ACE	
(Sigma,	Barcelona,	Spain)	to	each	plate.	The	ACE	activity	was	expressed	as	mU	ACE/mL	of	
plasma.	
2.3.2. Plasma	renin	determination	
The	plasma	renin	concentration	was	measured	with	an	ELISA	kit	(Rat	Renin	ELISA	Kit,	
MyBiosource,	Madrid	Spain),	following	the	manufacturer’s	instructions.	
2.3.3. Plasma	endothelin-1	determination	
Plasma	endothelin-1	(ET-1)	was	measured	with	the	ELISA	kit	(Endothelin-1	ELISA	kit,	
Enzo	Life	Sciences,	Barcelona,	Spain),	following	the	manufacturer’s	instructions.	
2.4. Statistical	analysis	
Data	were	 analyzed	by	 Student	 t-test	 or	 one-way	ANOVA	 (Tukey’s	 test)	 using	 IBM	
SPSS	 Statistics	 20.0.0	 for	Mac,	 as	 required.	 Kolmogorov-Smirnov	 and	 Levene’s	 tests	were	
used	 to	 check	 for	 the	 normality	 and	 equality	 of	 variances	 of	 the	 data,	 respectively,	 as	
required.		
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3. Results		
3.1. 	Short-term	effects	of	gallic	acid	on	blood	pressure		
An	antihypertensive	effect	of	GA	was	shown	in	SHRs	(Figures	1A	and	B).	The	lowest	
dose	of	3.5	mg/Kg	GA	did	not	significantly	reduce	BP,	but	higher	doses	of	GA	at	7	and	14	
mg/Kg	produced	a	decrease	in	SBP	and	DBP	similar	to	that	seen	in	the	captopril-treated	rats	
(i.e.,	 positive	 control),	 with	 the	 maximum	 decrease	 of	 BP	 achieved	 at	 6	 h	 post-
administration.	The	SBP	at	6	h	post-administration	was	decreased	-40	±	3	and	-40	±	8	mmHg	
for	the	7	and	14	mg/Kg	doses,	respectively.	The	DBP	followed	the	same	trend	as	the	SBP,	
with	 the	 7	 and	 14	 mg/kg	 GA	 doses	 decreasing	 BP	 at	 6	 h	 -32	 ±	 7	 and	 -21	 ±	 5	 mmHg,	
respectively.	Water	administration	produced	no	effect	on	the	SBP	or	DBP.	The	SBP	and	DBP	
recovered	their	normal	values	after	48	h	of	GA	administration.	
The	SBP	and	DBP	were	not	modified	when	water	or	7	mg/Kg	GA	(Figure	1C	and	1D)	
were	 administered	 to	 the	 normotensive	 animals;	 therefore,	 there	 was	 no	 hypotensive	
effect	in	the	normotensive	rats.			
1.1. 	Effect	 of	 gallic	 acid	 on	 the	 renin-angiotensin-aldosterone	 system	 in	
spontaneously	hypertensive	rats	
The	administration	of	7	mg/Kg	GA	to	SHRs	for	6	h	significantly	reduced	the	plasma	
concentration	 of	 Ang	 I	 and	 II.	 However,	 this	 compound	 increased	 the	 plasma	 rennin	
concentration	significantly	and	do	not	alter	the	ACE	activity	(Table	1).		
1.2. Effect	of	GA	on	Bradykinin	and	Endotelin-1	in	SHR	
The	 BK	 levels	 in	 plasma	were	 increased	 by	GA	 6	 h	 after	 the	 administration	 of	 a	 7	
mg/Kg	dose	of	 this	 compound	 (Table	1).	 The	plasma	 concentration	of	 the	ET-1	 (Figure	2)	
was	significantly	reduced.		
1.3. Effect	of	gallic	acid	on	blood	pressure	in	spontaneously	hypertensive	rats	
treated	with	NG-Nitro-L-arginine	methyl	ester	and	indomethacin	
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The	SBP	and	DBP	of	the	animals	that	received	water	and	saline	were	not	modified.	
On	the	contrary,	7	mg/Kg	GA	and	saline	caused	a	significant	decrease	in	SBP	and	DBP	that	
could	be	appreciated	6	h	post-administration.	Intraperitoneal	administration	of	30	mg/kg	of	
L-NAME	 did	 not	 have	 any	 effect	 on	 the	 SBP	 or	 DBP	 in	 the	 water	 group.	 However,	 the	
antihypertensive	effect	of	GA	was	completely	abolished	by	the	L-NAME	treatment	(figures	
3A	and	3B).		
In	an	additional	experiment,	the	antihypertensive	effect	of	7	mg/Kg	GA	was	slightly	
reduced	 in	 the	 indomethacin-treated	 rats,	 although	 indomethacin	 had	 no	 effect	 on	 the	
water-treated	rats	(Figures	3C	and	3D).	
1.4. Effect	of	gallic	acid	on	blood	pressure	in	spontaneously	hypertensive	rats	
treated	with	Sirtinol	
The	decrease	in	BP	produced	by	7	mg/Kg	GA	in	SHRs	6	h	post-administration	was	
not	changed	when	the	rats	were	treated	with	sirtinol	(Figures	4A	and	4B).	
4. Discussion	
GA	is	a	naturally	occurring	phenolic	compound	that	is	widely	distributed	throughout	
the	plant	kingdom	7.	Several	beneficial	health	effects	of	GA	have	been	reported	in	CVD	16–20.	
In	fact,	CVD	is	the	leading	cause	of	death	worldwide,	and	HTN	is	a	major	risk	factor	for	the	
development	 of	 these	 diseases	 2.	 Although	 several	 studies	 have	 demonstrated	 the	
antihypertensive	 effects	 of	 polyphenol-rich	 foods	 and	 extracts	 26,	 to	 our	 knowledge,	 the	
antihypertensive	 effects	 of	 GA	 have	 not	 been	 extensively	 studied.	 Furthermore,	 previous	
results	of	our	group	showed	that	after	an	acute	administration	of	a	grape	seed	extract	(375	
mg/Kg),	 rich	 in	 flavanols	 and	 GA,	 to	 cafeteria	 diet-fed	 rats	 a	 GA	 was	 found	 at	 high	
concentration	 in	 rat	 aortas	 but	 not	 in	 plasma	 (unpublished	 results).	 Therefore,	 we	
hypothesized	 that	 low	 doses	 of	 GA	 could	 reduce	 BP	 by	 blocking	 the	 RAAS	 with	 the	
involvement	 of	 endothelial-relaxing	 factors,	 as	 reported	 previously	 for	 polyphenol-rich	
extracts	containing	GA	and	their	conjugated	forms	8,22,24,27.		
To	 investigate	 this	 hypothesis,	 we	 initially	 administered	 different	 doses	 of	 GA	 to	
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SHRs	and	demonstrated	that	a	low	dose	of	this	compound	(7	mg/Kg)	reduced	the	SBP	and	
DBP	 similarly	 to	 the	 known	 antihypertensive	 drug	 captopril	 (50	 mg/kg).	 The	 maximum	
decrease	in	BP	was	reached	at	6	h	post-administration,	and	after	48	h,	the	BP	returned	to	
the	initial	value,	similar	 in	behavior	to	captopril.	 Importantly,	the	most	effective	dose	of	7	
mg/Kg	was	evaluated	in	normotensive	WKY	rats	demonstrating	that	GA	is	not	hypotensive	
at	this	dose.		
Captopril	 is	 a	 specific	 competitive	 ACE	 inhibitor	 that	 is	 a	 very	 effective	
antihypertensive	 agent	 in	 clinical	 practice.	 However,	 as	 GA	 is	 a	 naturally	 occurring	
antihypertensive	 agent	 present	 in	 many	 common	 foods	 and	 beverages,	 it	 would	 be	
expected	not	to	have	the	side-effects	associated	with	synthetically	produced	drugs	used	in	
the	control	of	HTN.	Therefore,	the	use	of	GA	at	such	a	low	dose	could	be	promising	as	an	
antihypertensive	agent.		
Our	 results	 showed	 that	 the	 plasma	 levels	 of	 Ang	 II,	 the	 most	 important	 RAAS	
bioactive	 peptide,	 were	 reduced	 after	 6	 h	 of	 GA	 administration.	 This	 result	 clearly	
implicates	 RAAS	 in	 the	 antihypertensive	 effects	 of	 GA	 in	 SHRs.	 Moreover,	 the	 results	
showed	that	GA	at	7	mg/Kg	did	not	affect	the	plasma	ACE	activity	6	h	post-administration,	
indicating	 that	 the	 measured	 drop	 in	 Ang	 II	 was	 independent	 of	 ACE	 activity	 inhibition.	
Although	 ACE	 inhibitory	 activity	 of	 different	 polyphenols	 has	 been	 demonstrated	 both	 in	
vitro	 28	and	 in	vivo	 29,30,	no	changes	 in	 the	plasma	ACE	activity	after	 the	administration	of	
grape	seed	extracts,	rich	in	free	GA	and	their	conjugated	forms,	have	been	found	6	h	post-
administration	 24,31.	 Remarkably,	 the	 decrease	 in	 plasma	 Ang	 II	 was	 accompanied	 by	 a	
similar	 drop	 in	 plasma	 Ang	 I,	 supporting	 a	 possible	 implication	 of	 GA	 upstream	 of	 the	
pathway	that	points	to	a	direct	effect	of	this	phenolic	acid	on	the	reduction	of	Ang	I.	
In	contrast,	renin	enzyme	converts	angiotensinogen	(which	 is	released	by	the	 liver)	
to	 Ang	 I	 in	 the	 circulation	 32.	 However,	 GA	 was	 found	 to	 increase	 the	 plasma	 renin	
concentration.	 Although,	 this	 may	 contradict	 the	 results,	 this	 is	 consistent	 with	 the	
increased	plasma	BK	by	GA,	a	peptide	that	has	important	vasodilation	capacity,	at	6	h	post-
administration.	 BK	 is	 formed	 from	 photolytic	 cleavage	 catalyzed	 by	 kallikrein	 from	 its	
kininogen	 precursor	 33.	 Although	 ACE	 is	 the	 obvious	 connection	 between	 the	 RAAS	 and	
kallikrein-kinin	 system	 (KKS)	 because	 ACE	 also	 catalyzes	 the	 breakage	 of	 BK,	 thereby	
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inactivating	it,	GA	did	not	affect	this	enzyme	6	h	post-administration.	Nevertheless,	several	
interactions	between	the	RAAS	and	KKS	have	been	discussed	33,	such	as	the	conversion	of	
inactive	prorenin	 into	active	renin	 in	a	process	that	 involves	the	activation	of	prekallikrein	
33.	Therefore,	we	believe	that	the	activation	of	kallikrein	as	a	negative	feedback	due	to	the	
low	levels	of	Ang	II	could	explain	the	increased	levels	of	renin	and	BK	due	to	the	effect	of	
GA	(Figure	5).	Therefore,	 in	further	experiments,	we	aim	to	 investigate	the	mechanism	by	
which	 Ang	 I	 levels	 are	 reduced	 by	 GA;	 we	 hypothesize	 that	 there	 could	 be	 a	 direct	
interaction	of	GA	with	Ang	 I	as	 the	binding	of	polyphenols	with	proteins	and	miRNAs	has	
been	described	34,35.	Nevertheless,	this	assumption	needs	to	be	carefully	investigated	since,	
to	our	knowledge,	it	would	involve	a	new	system	to	block	the	RAAS	that	has	not	yet	been	
described.		
Nitric	 oxide	 (NO)	 is	 one	 of	 the	 most	 potent	 vasodilator	 agents	 synthesized	 by	
endothelial	 cells,	 and	 it	 is	 produced	 by	 endothelial	 nitric	 oxide	 synthase	 (eNOS)	 36.	
Previously,	polyphenols	were	noted	to	enhance	NO	production	and	decrease	BP	37,38.	Ang	II	
can	 disrupt	 eNOS	 mRNA,	 thereby	 inhibiting	 NO	 production	 39	 and	 its	 dilatory	 effect.	 In	
contrast,	BK	increases	endothelial	NO	production	by	eNOS	40.	Therefore,	the	increase	of	BK	
and	decrease	of	Ang	 II	 levels	by	GA	point	 to	 the	 fact	 that	NO	could	be	decreased	by	GA,	
thereby	exerting	a	vasodilatation	effect.	The	 involvement	of	eNOS	in	the	antihypertensive	
effect	of	GA	was	confirmed	by	an	additional	experiment	in	which	we	showed	that	the	eNOS	
inhibitor	 L-NAME	 completely	 abolished	 the	 BP	 decrease	 produced	 by	 GA	 in	 SHRs	 and	
therefore	demonstrated	the	 involvement	of	NO	as	the	BP-regulating	mechanism	of	GA	by	
facilitating	NO	release.	
Ang	 II	 has	 a	 direct	 effect	 on	 the	 major	 enzyme	 producer	 of	 free	 radicals	 in	 the	
endothelium,	namely,	the	nicotinamide	adenine	dinucleotide	phosphate	(NADPH)	oxidases	
41,42.	Free	radicals	produced	directly	in	the	endothelium	can	not	only	eliminate	NO	but	also	
enhance	 the	 production	 of	 ET-1	 43,44.	 Furthermore,	 high	 ET-1	 levels	 also	 stimulate	 the	
activity	 of	 NADPH	 oxidases	 45,46.	 In	 fact,	 ET-1	 overproduction	 is	 a	 key	 risk	 factor	 in	 the	
development	of	vascular	disease	and	atherosclerosis	47.	Therefore,	another	mechanism	by	
which	polyphenols	can	decrease	BP	is	by	the	inhibition	of	the	endothelial	constrictor	factor,	
ET-1	47–49.	In	this	study,	we	also	demonstrated	that	GA	reduces	ET-1	levels	in	plasma	at	6	h	
post-administration,	which	could	contribute	to	the	BP-lowering	effect	of	this	compound	by	
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reducing	endothelial	vasoconstriction.		
Prostacyclin,	 also	 known	 as	 prostaglandin	 I2	 (PGI2),	 is	 another	 endothelial-derived	
vasodilator	 agent.	 The	 vasodilation	 properties	 of	 BK	 are	 related	 to	 the	 release	 of	
endothelium	factors	such	as	PGI2	
50.	PGI2	is	synthesized	by	the	action	of	the	cyclooxygenase	
(COX)	enzyme	and	PGI2	synthase	
51.	Therefore,	we	have	also	evaluated	the	effect	of	GA	in	
SHRs	intraperitoneally	injected	with	indomethacin,	which	is	an	inhibitor	of	the	COX	enzyme	
and	of	endothelial	prostanoid	biosynthesis.	Indomethacin	treatment	partially	abolished	the	
antihypertensive	effect	of	GA	in	SHRs,	indicating	that	endothelial	PGI2	could	also	contribute	
to	 the	effect	of	GA	on	arterial	BP.	Previous	results	of	our	group,	 in	which	the	effects	of	a	
grape	seed	extract	were	analyzed,	described	the	same	effect	on	BP	and	the	implication	of	
NO	 and	 PGI2	 in	 SHRs	
8,31	 and	 in	 cafeteria-hypertensive	 rats	 22.	 Because	 GA	 is	 also	 a	
component	of	grape	seed	extract	8	and	PGI2	is	not	implicated	in	the	antihypertensive	effects	
of	 other	 extracts	 rich	 in	 flavanols	 that	 do	not	 contain	GA	 (such	 as	 cocoa	 extracts	 52),	 the	
bioactive	compound	responsible	for	the	antihypertensive	activity	found	in	the	extract	could	
be	GA.		
More	 recently,	 sirtuins	 have	 been	 shown	 to	 have	 a	 significant	 impact	 on	 CVD	 and	
arteriosclerosis	through	inhibition	of	leukocyte	adhesion	and	regulation	of	eNOS	53.	Sirtuins	
can	 directly	 deacetylate	 eNOS,	 activate	 it	 and,	 consequently,	 enhance	 NO	 synthesis	 and	
improve	 endothelium-dependent	 vasodilation	 54.	 In	 this	 study,	 we	 inhibited	 the	 sirtuins	
pathway	using	sirtinol,	and	we	have	demonstrated	that	the	GA-dependent	decrease	of	BP	
was	not	mediated	by	sirtuins.	Therefore,	the	down	regulation	of	ET-1	levels	induced	by	GA	
appears	to	be	sirtuin-independent,	in	agreement	with	previous	results	seen	with	resveratrol	
55.		
Perspectives	
A	low	dose	of	GA	reduces	BP	in	a	similar	way	to	the	drug	captopril	in	SHRs,	without	
hypotensive	effects.	The	mechanism	implicated	in	the	BP-lowering	effect	can	be	explained	
by	 inhibition	 of	 the	 RAAS	 through	 a	 reduction	 in	 the	 plasma	 levels	 of	 Ang	 I	 and	 II,	
consequently	 improving	 endothelial	 function.	 In	 this	 sense,	 GA	 decreased	 plasma	 ET-1,	
changed	 the	 endothelium-derived	 NO	 availability;	 endothelial	 PGI2	 was	 also	 noted	 to	 be	
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involved	 in	the	GA’s	antihypertensive	effects.	GA	also	 increased	the	plasma	BK,	which	 is	a	
peptide	with	 important	vasodilation	activity	 (Figure	5).	Therefore,	we	believe	 that	GA	has	
great	potential	as	a	naturally	occurring	antihypertensive	agent,	even	though	the	effects	of	
this	 compound	 should	 be	 evaluated	 in	 further	 clinical	 trials.	 Finally,	 the	 inhibition	 of	 the	
RAAS	by	GA	is	considered	to	be	of	special	relevance	because	RAAS	overactivity	is	currently	
associated	 with	 not	 only	 HTN	 but	 also	 vascular	 inflammation,	 the	 development	 of	
atherosclerosis,	left	ventricular	hypertrophy,	nephrosclerosis	and	cardiovascular	events.	
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Figure	legends	
Figure	1.	Changes	in	(A)	systolic	blood	pressure	(SBP)	and	(B)	diastolic	blood	pressure	(DBP)	
in	spontaneously	hypertensive	rats	(SHR)	after	the	administration	of	different	doses	of	gallic	
acid	 (3.5,	 7	 and	 14	mg/Kg),	 water	 or	 captopril	 (50	mg/Kg).	 Changes	 in	 (C)	 systolic	 blood	
pressure	(SBP)	and	(D)	diastolic	blood	pressure	(DBP)	 in	Wistar-Kyoto	rats	after	treatment	
with	7	mg/Kg	gallic	acid	or	water.	Data	were	expressed	as	the	MEAN	±	SEM	for	6	animals	
per	group.	Letters	represent	significant	differences	assessed	by	two-way	ANOVA	with	Tukey	
Post-Hoc	test	(p<0.05).	
Figure	 2.	 Plasma	 endothelin-1	 (ET-1)	 concentration	 of	 spontaneously	 hypertensive	 rats	
(SHR)	 administered	 7	 mg/Kg	 gallic	 acid	 (black	 bar)	 or	 water	 (white	 bar)	 6	 h	 post-
administration.	 Data	 expressed	 as	 the	 MEAN	 ±	 SEM	 for	 6	 animals	 per	 group.	 Asterisk	
represents	significant	differences	assessed	by	independent	Student	t-test	(p<0.05).	
Figure	 3.	 Differences	 in	 (A)	 systolic	 blood	 pressure	 (SBP)	 and	 (B)	 diastolic	 blood	 pressure	
(DBP)	in	spontaneously	hypertensive	rats	(SHR)	6	h	post-administration	of	water	or	7	mg/Kg	
gallic	acid	and	30	mg/Kg	of	L-NAME	or	saline.	Differences	in	(C)	systolic	blood	pressure	(SBP)	
and	 (D)	diastolic	blood	pressure	 (DBP)	 in	 spontaneously	hypertensive	 rats	 (SHR)	6	h	post-
administration	of	water	or	7	mg/Kg	gallic	Acid	and	5	mg/Kg	of	indomethacin	or	saline.	Data	
expressed	 as	 the	 MEAN	 ±	 SEM	 for	 5	 animals	 per	 group.	 Letters	 represent	 significant	
differences	assessed	by	two-way	ANOVA	with	Tukey	Post-Hoc	test	(p<0.05).	
Figure	 4.	 Differences	 in	 (A)	 systolic	 blood	 pressure	 (SBP)	 and	 (B)	 diastolic	 blood	 pressure	
(DBP)	in	spontaneously	hypertensive	rats	(SHR)	6	h	post-administration	of	water	or	7	mg/Kg	
gallic	acid	and	1	mg/Kg	Sirtinol	or	vehicle	(10%	DMSO	in	saline	solution).	Data	expressed	as	
the	MEAN	±	SEM	for	5	animals	per	group.	Letters	represent	significant	differences	assessed	
by	two-way	ANOVA	with	Tukey	Post-Hoc	test	(p<0.05).	
Figure	 5.	 Schematic	 representation	 of	 the	 pathways	 involved	 in	 the	 decrease	 of	 blood	
pressure	 by	 gallic	 acid	 in	 spontaneously	 hypertensive	 rats	 (SHR),	 according	 to	 this	 study.	
Activated	pathways	 by	 gallic	 acid	 are	 represented	 in	 green	 and	blocked	pathways	 in	 red.	
ACE:	Angiotensin-Converting	Enzyme;	BP:	Blood	Pressure;	ET:	Endothelin;	Ang:	Angiotensin;	
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NADPH:	 nicotinamide	 adenine	 dinucleotide	 phosphate;	 ROS:	 Reactive	 Oxygen	 Species;	
eNOS:	 Endothelial	 nitric	 oxide	 synthase;	 NO:	 Nitric	 oxide;	 COX:	 Cyclooxigenase;	 PGI2Sin:	
Prostaglandin	I2	Synthase;	PGI2;	Prostaglandin	I2.		
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Table	 1.	 Plasma	 determinations	 of	 some	 of	 the	 renin	 angiotensin	 system	
components	 and	 bradykinin	 in	 spontaneously	 hypertensive	 rats	 administered	 7	
mg/Kg	Gallic	acid	or	water	(control	group)	for	6h.		
	
	 Control	 Gallic	acid	 p	
Ang	I	(nM)	 1.08	±	0.27	 0.32	±	0.01	 0.046	
Ang	II	(nM)	 0.27	±	0.07	 0.10	±	0.02	 0.038	
BK	(nM)	 0.37	±	0.06	 1.08	±	0.14	 0.003	
ACE	(mU/mL)	 25.47	±	1.48	 28.69	±	1.95	 0.076	
Renin	(pg/mL)	 11.96	±	0.76	 16.70	±	0.76	 0.003	
Data	 expressed	 as	MEAN	±	 SEM	 for	 6	 animals	 per	 group.	 Statistical	 differences	 were	 considered	 significant	 by	
independent	Student	t-test	at	p<0.05.	
ACE:	angiotensin	converting	enzyme;	Ang:	angiotensin;	BK:	Bradykinin.	
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Figure	2	
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Figure	3	
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Figure	4	
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CHAPTER	 3:	 PREVENTIVE	 LONG-TERM	 EFFECT	 OF	 GRAPE-SEED	
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Abstract	
The	 effects	 of	 grape	 seed	 polyphenols	 against	 the	 development	 of	
hypertension	 and	 other	 cardiometabolic	 conditions	 associated	 with	 metabolic	
syndrome	 (MetS)	 were	 studied	 in	 cafeteria	 (CAF)	 diet-fed	 rats.	 Two	 groups	 of	
Wistar	rats	were	fed	a	standard	(STD)	diet	or	the	CAF	diet	for	12	weeks.	Daily,	the	
CAF	 diet-fed	 rats	 were	 administered	 different	 doses	 of	 a	 low	 molecular-weight	
grape	 seed	 extract	 (LM-GSPE)	 (25,	 100,	 and	 200	mg/kg/day;	 n=10	 per	 group)	 or	
vehicle	 (n=10),	 and	 the	 STD	 diet-fed	 rats	 were	 administered	 LM-GSPE	 (100	
mg/kg/day;	n=10)	or	vehicle	(n=10).	The	body	weight	(BW),	waist	perimeter	(WP),	
and	systolic	and	diastolic	blood	pressure	 (BP)	were	 recorded	weekly.	The	animals	
were	 housed	 in	metabolic	 chambers	 every	 two	weeks	 to	 estimate	 the	 daily	 food	
and	 liquid	 intake	 and	 to	 collect	 feces	 and	urine	 samples.	 The	plasma	 lipid	profile	
was	 analyzed	 on	 the	 0th,	 4th,	 7th,	 10th	 and	 12th	 weeks	 of	 the	 experiment.	
Moreover,	plasma	leptin	was	measured	at	the	end	of	the	experimental	period.	The	
results	 demonstrated	 that	 LM-GSPE,	 when	 administered	 with	 the	 CAF	 diet,	
attenuated	 the	 increase	 in	 BP,	 BW,	WP	 and	 improved	 lipid	metabolism	 in	 these	
animals.	 However,	 although	 the	 25-	 and	 100-mg/kg/day	 doses	were	 sufficient	 to	
produce	beneficial	effects	on	BP	and	lipid	metabolism,	a	200-mg/kg/day	dose	was	
necessary	to	have	an	effect	on	BW	and	WP.	The	present	findings	suggest	that	LM-
GSPE	 is	 a	 good	 candidate	 for	 a	BP	 lowering	 agent	 that	 can	also	 ameliorate	other	
conditions	associated	with	MetS.	However,	its	dose	needs	to	be	optimized	for	use	
in	humans.	
	
Keywords:	 body	 weight;	 cholesterol;	 flavanols;	 lipid	 profile;	 triglycerides;	 waist	
perimeter		
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1. Introduction	
Metabolic	 syndrome	(MetS)	constitutes	an	extended	cluster	of	pathological	
conditions	that	include	insulin	resistance.	MetS	is	a	risk	factor	for	the	development	
of	 diabetes	 mellitus	 and	 cardiovascular	 (CV)	 events.	 This	 syndrome	 is	 clinically	
diagnosed	 by	 the	 presence	 of	 at	 least	 three	 of	 the	 following	 components:	 high	
waist	 perimeter	 (WP),	 hypertriglyceridemia,	 low	 high-density	 lipoprotein	 levels,	
high	 cholesterol,	 fasting	 hyperglycemia,	 and	 hypertension	 (HTN)	 (Ford,	 2005).	
Awareness	of	the	adverse	effects	of	MetS	is	steadily	increasing	due	to	its	expanding	
prevalence	worldwide,	 and	 efforts	 are	 underway	 to	 prevent	 the	 development	 of	
this	disease.		
Rats	fed	with	a	cafeteria	(CAF)	diet,	which	consists	of	free	access	to	standard	
(STD)	chow	and	water,	while	concurrently	receiving	highly	palatable,	energy	dense,	
unhealthy	 human	 food	ad	 libitum,	 are	 considered	 a	 robust	model	 of	 the	 human	
MetS	 (Sampey	 et	 al.,	 2011).	 This	 dietary	 model	 provides	 an	 exceptional	 tool	 to	
study	 obesity	 and	 MetS,	 both	 being	 pandemic	 diseases	 among	 the	 Western	
population.	 The	 CAF	 diet-fed	 rats	 display	 increased	 body	 weight	 (BW),	 more	
abdominal	fat,	and	develop	hyperinsulinemia,	hyperglycemia,	and	hepatic	steatosis	
(Higa,	 Spinola,	 Fonseca-Alaniz,	 &	 Evangelista,	 2014;	 Panchal	 &	 Brown,	 2010;	
Sampey	et	al.,	2011).	The	development	of	HTN	in	animals	fed	with	a	CAF	diet	for	10	
weeks	 has	 recently	 been	 reported	 by	 our	 group	 (Pons,	 Margalef,	 Bravo,	 Arola-
Arnal,	&	Muguerza,	2015).	Thus,	 this	animal	model	mimics	classical	human	MetS,	
particularly	 because	 HTN	 is	 one	 of	 the	 most	 prevalent	 complications	 associated	
with	MetS	 in	humans,	more	prevalent	 than	obesity	 (Cordero,	Moreno,	&	Alegría,	
2006).	
Grape	 seed,	 which	 is	 a	 by-product	 of	 the	 grape/wine	 industry,	 has	 been	
extensively	investigated	due	to	its	high	flavanol	content	(Quiñones	et	al.,	2013).	It	
has	been	reported	that	the	grape	seed	polyphenols	could	be	particularly	beneficial	
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in	 the	 control	 of	 most	 metabolic	 disturbances	 observed	 in	 MetS.	 Our	 research	
group	have	demonstrated	that	a	grape	seed	polyphenol-rich	extract,	which	 is	rich	
in	monomeric	flavanols	and	low	molecular-weight	proanthocyanidins	(Quiñones	et	
al.,	 2013),	 exhibits	 antioxidant	 properties	 (Puiggròs	 et	 al.,	 2005),	 improves	 lipid	
metabolism	(Del	Bas	et	al.,	2005),	 limits	adipogenesis	(Pinent	et	al.,	2005),	acts	as	
an	insulin-mimetic	agent	(Pinent	et	al.,	2004),	and	alleviates	inflammation	(Terra	et	
al.,	2011).	Additionally,	the	short-term	antihypertensive	properties	of	a	single	dose	
of	a	low	molecular-weight	grape	seed	polyphenol	extract	(LM-GSPE)	have	recently	
been	demonstrated	 in	spontaneously	hypertensive	rats	 (SHR)	and	 in	hypertensive	
CAF	 diet-fed	 rats	 (Pons	 et	 al.,	 2015;	 Quiñones	 et	 al.,	 2013).	 However,	 HTN	 and	
other	 cardiometabolic	 conditions	 are	 chronic	 pathologies	 that	 require	 chronic	
treatment.		
Therefore,	the	objective	of	this	study	was	to	evaluate	the	effect	of	the	long-
term	 intake	 of	 LM-GSPE	 on	 the	 development	 of	 HTN	 and	 other	 main	
cardiometabolic	risk	factors	associated	with	MetS	in	an	experimental	animal	model	
of	MetS,	namely,	CAF	diet-fed	rats.		
2. Materials	and	Methods	
2.1. Low	molecular-weight	polyphenol-rich	grape	seed	extract	
The	 grape-seed	 extract	 used	 in	 experiments	 is	 a	 low	 molecular-weight	
polyphenol-rich	extract	obtained	from	white	grape	seeds	and	was	kindly	provided	
by	Les	Dérives	Résiniques	et	Terpéniques	(Dax,	France).	Table	1S	shows	the	flavanol	
and	phenolic	acid	contents	of	the	grape	seed	extract	used	in	this	study	[taken	from	
(Margalef	et	al.,	2015).		
2.2. Animal	experimental	procedures	
Six-week-old	male	Wistar	 rats,	 Crl:WI,	 (n=60)	were	purchased	 from	Charles	
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River	Laboratories	(Barcelona,	Spain)	and	were	singly	housed	in	animal	quarters	at	
22ºC	under	a	 light/dark	period	of	12	h.	After	quarantine	and	a	 training	period	of	
two	weeks,	 the	animals	were	divided	 into	 two	dietary	groups	 (Figure	1).	The	STD	
diet-fed	 rats	 (n=20)	were	 fed	with	 the	STD	Panlab	A04	 (Panlab,	Barcelona,	 Spain)	
diet	and	tap	water	ad	libitum,	and	the	CAF	diet-fed	rats	(n=40)	had	free	access	to	a	
fresh	CAF	diet	 that	 consisted	of	 bacon	 (10-12	 g),	 sausages	 (8–12	g),	 biscuits	with	
pâté	(12–15	g),	biscuits	with	cheese	(10–12	g),	ensaïmadas	(pastries)	or	muffins	(4-
5	g),	carrots	(8-10	g),	milk	with	sugar	(220	g/L;	50	mL),	water,	and	the	STD	diet	ad	
libitum.	 The	 STD	 chow	 had	 a	 calorie	 breakdown	 of	 14%	 protein,	 8%	 fat,	 73%	
carbohydrates,	and	0.3%	of	sodium,	whereas	the	CAF	diet	had	a	calorie	breakdown	
of	14%	protein,	35%	fat,	51%	carbohydrates,	and	0.2%	of	sodium.	All	animals	were	
fed	fresh	food	daily	ad	libitum.	The	different	diets	were	maintained	for	12	weeks.	
During	the	training	period,	 the	animals	were	trained	to	 lick	water	containing	50%	
low-fat	condensed	milk	that	was	used	as	vehicle	(1	mL).	The	STD	diet-fed	animals	
were	administered	vehicle	or	vehicle	containing	100	mg/kg/day	LM-GSPE	(n=10	per	
group;	STD	and	STD100,	respectively)	daily	between	9	a.m.	and	10	a.m.	The	STD100	
group	was	studied	to	evaluate	the	effect	of	LM-GSPE	administration	on	the	blood	
pressure	 (BP)	 of	 normotensive	 rats.	 The	 CAF	 diet-fed	 animals	were	 administered	
vehicle	 or	 vehicle	 containing	 25,	 100,	 or	 200	 mg/kg/day	 of	 LM-GSPE	 (n=10	 per	
group;	CAF,	CAF25,	CAF100,	and	CAF200,	respectively)	daily	between	9	a.m.	and	10	
a.m.	
The	 BP,	 BW,	 and	 WP	 were	 recorded	 weekly	 in	 all	 groups	 (Figure	 1).	 The	
systolic	and	the	diastolic	BP	(SBP	and	DBP)	were	recorded	between	8	a.m.	and	11	
a.m.	 by	 the	 tail-cuff	method	 (Buñag,	 1973),	 as	 described	 elsewhere	 (Pons	 et	 al.,	
2014).	 To	 minimize	 the	 stress-induced	 variations	 in	 BP,	 all	 measurements	 were	
made	 by	 one	 person	 in	 the	 same	 stress-free	 environment.	 After	 the	 quarantine	
period,	BP	was	recorded	as	a	training	to	acclimatize	the	animals	to	the	procedure.	
The	 WP	 was	 assessed	 on	 the	 largest	 zone	 of	 the	 abdomen	 of	 the	 vertically	
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immobilized	rat	using	a	non-extensible	measuring	tape	with	an	accuracy	of	0.1	cm	
without	applying	pressure	to	the	body.		
Initially	and	every	two	weeks	thereafter,	the	animals	were	housed	for	24	h	in	
metabolic	 cages	 to	 estimate	 the	 daily	 food	 and	 liquid	 intake	 and	 to	 collect	 feces	
and	urine	samples.	The	complete	experimental	design	is	schematized	in	Figure	1.	At	
the	end	of	the	experimental	period,	all	rats	were	sacrificed	by	decapitation	after	a	
6-h	fasting.		
The	 animal	 protocol	 followed	 in	 this	 study	was	 approved	 by	 the	 Bioethical	
Committee	 of	 the	 Universitat	 Rovira	 i	 Virgili	 (European	 Commission	 Directive	
86/609	and	Spanish	Royal	Decree	223/1988).	
2.3. Biochemical	assays	
Plasma	 biochemical	 assays	 were	 performed	 using	 the	 blood	 samples	
collected	from	the	saphenous	vein	of	all	animals	after	6	h	of	starvation	on	the	0th,	
4th,	7th,	10th,	and	12th	week	of	the	experimental	feeding	period.	The	blood	samples	
were	 collected	 into	 tubes	 containing	 lithium	 heparin	 as	 anticoagulant	 and	 were	
centrifuged	 at	 2,500	 g	 for	 20	minutes	 at	 4ºC	 to	 obtain	 plasma,	 which	 was	 then	
divided	into	aliquots	and	stored	frozen	at	–80ºC	until	analysis.		
The	 total	plasma	cholesterol	 (TC)	and	 triglyceride	 (TG)	concentrations	were	
assayed	using	enzymatic	colorimetric	kits	(CHOD-POD	method	for	total	cholesterol	
and	GPO	method	for	triglycerides;	QCA,	Tarragona,	Spain).		
The	 plasma	 leptin	 concentrations	 were	 determined	 using	 the	 Rat	 Leptin	
ELISA	kit,	96-well	plate	(Millipore,	Madrid,	Spain).		
2.4. Statistical	analysis	
The	data	are	expressed	as	the	mean	±	SEM.	The	data	were	analyzed	by	one-
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way	ANOVA	or	two-way	ANOVA	(Tukey’s	test)	using	the	IBM	SPSS	Statistics	20.0.0	
for	Mac	 software.	 The	 Kolmogorov-Smirnov	 and	 the	 Levene's	 tests	were	 used	 to	
examine	 the	 normality	 and	 equality,	 respectively,	 of	 variances	 in	 the	 data.	 The	
differences	between	the	mean	values	were	considered	statistically	significant	when	
p<0.05.	
3. Results		
3.1. Blood	pressure	
Compared	 with	 the	 STD	 diet-fed	 rats,	 the	 animals	 fed	 with	 the	 CAF	 diet	
presented	 increased	 BP	 (figure	 2A	 and	 2B),	 with	 significant	 increases	 in	 SBP	 and	
DBP	beginning	during	 the	 second	week	of	 the	diet.	 The	 increase	 in	BP	 reached	a	
maximum	 from	 the	 sixth	 to	 the	 eighth	 week	 of	 the	 CAF	 diet	 intake.	 During	 this	
week,	 the	SBP	of	 the	STD	and	the	CAF	rats	differed	by	18.3%	(Figure	2A)	and	the	
DBP	of	these	two	groups	differed	by	14.2%	(Figure	2B).	Starting	from	the	9th	week	
of	the	diet,	a	mild	decline	in	the	BP	was	observed	in	CAF	diet-fed	animals,	but	the	
BP	values	were	higher	than	those	of	the	STD	diet-fed	rats.		
The	 long-term	 administration	 of	 LM-GSPE	 produced	 an	 antihypertensive	
effect	at	all	doses	assayed,	attenuating	the	rise	in	SBP	(Figure	2A)	and	DBP	(Figure	
2B)	 caused	 by	 the	 intake	 of	 the	 CAF	 diet.	 Although	 the	 100-	 and	 200-mg/kg/day	
doses	were	 the	most	 effective	 against	 the	 CAF	 diet-induced	 increase	 in	 SBP,	 the	
SBP	 of	 the	 CAF25	 group	 was	 also	 statistically	 lower	 than	 that	 of	 the	 CAF	 group	
(Figure	2A).	All	assayed	doses	of	the	LM-GSPE	were	effective	against	the	increase	in	
DBP	 at	 the	 end	of	 the	 study.	However,	 during	 the	 course	of	 the	 experiment,	 the	
100-	 and	 200-mg/kg/day	 doses	 were	 the	 most	 effective	 against	 the	 rise	 in	 DBP	
(Figure	2B).	
The	 STD100	 rats	 showed	 similar	 SBP	 and	 DBP	 measures	 as	 the	 STD	 rats	
(Figure	2C	and	2D).	
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3.2. Body	weight,	waist	perimeter,	and	plasma	leptin		
The	 BW	and	 the	WP	of	 all	 animals	 immediately	 before	 the	 experimental	 feeding	
were	 237	 ±	 2	 g	 and	 14	 ±	 0	 cm,	 respectively.	 The	 STD	 rats	 gained	 weight	
progressively	 during	 the	 course	 of	 the	 experiment.	 However,	 as	 expected,	 the	
weight	gain	in	the	group	fed	with	the	CAF	diet	was	significantly	higher	than	that	of	
the	rats	fed	with	the	STD	diet	(Figure	3A).	Compared	with	the	CAF	group,	during	the	
course	of	the	experiment,	there	was	a	statistically	insignificant	reduction	in	the	BW	
of	 the	 animals	 administered	 the	 highest	 doses	 of	 LM-GSPE	 (Figure	 3A).	 These	
differences	 between	 the	 BW	 of	 the	 CAF200	 and	 CAF	 groups	 became	 statistically	
significant	on	the	7th	and	the	8th	weeks	of	the	experiment	(Figure	3A).	In	addition,	
compared	with	 the	CAF	control	 rats,	 there	was	a	 reduction	 in	 the	BW	gain	at	 the	
end	of	the	experimental	period	in	animals	administered	200	mg/kg/day	of	LM-GSPE	
for	12	weeks	(Figure	3B).	
The	WP	of	the	CAF	group	was	also	found	to	be	higher	than	that	of	the	STD	
diet	group	(Figure	3C).	Additionally,	 the	WP	tended	to	decline	with	the	 long-term	
administration	 of	 the	 highest	 dose	 of	 LM-GSPE	 without	 statistically	 significant	
differences	 (Figure	 3C).	 On	 the	 7th	 week	 of	 the	 feeding	 period,	 the	 CAF100	 and	
CAF200	groups	showed	reduced	WP	when	compared	with	 the	CAF	group,	and	on	
the	8th	week,	 the	WP	of	 the	CAF200	group	was	 lower	 than	that	of	 the	CAF	group	
(Figure	3C).	
Compared	 with	 the	 STD	 diet,	 the	 CAF	 diet	 produced	 an	 increase	 in	 the	
plasma	leptin	concentration	at	the	end	of	the	experiment	(37.52	±	3.54	vs.	11.49	±	
0.55	 ng/mL,	 respectively).	 The	 LM-GSPE	 administration	 (25,	 100,	 and	 200	
mg/kg/day)	 failed	 to	 produce	 any	 significant	 changes	 in	 the	 plasma	 leptin	 levels	
versus	 the	 vehicle	 administration	 (40.28	 ±	 6.61,	 40.07	 ±	 4.38	 and	 42.62	 ±	 6.69	
ng/mL,	respectively).	
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3.3. Food	and	liquid	intake,	fecal	and	urine	excretion		
Throughout	 the	 course	of	 the	 study,	 the	 food	 intake	 in	 the	CAF	 group	was	
significantly	higher	than	that	in	the	STD	group	(Table	1).	Such	differences	were	not	
found	 between	 the	 CAF	 group	 and	 the	 CAF	 group	 administered	 the	 LM-GSPE.	
Additionally,	 irrespective	 of	 the	 treatment,	 the	 total	 protein,	 carbohydrate,	 lipid,	
and	salt	intake	during	the	course	of	the	experiment	were	significantly	higher	in	all	
groups	 fed	 with	 the	 CAF	 diet.	 Similarly,	 the	 total	 calories	 consumed	 during	 the	
course	of	the	experiment	was	also	found	to	be	higher	in	all	CAF	groups	versus	the	
STD	 group,	 and	 the	 LM-GSPE	 had	 no	 effect	 on	 this	 parameter.	 Additionally,	 the	
total	fluid	intake	was	significantly	higher	in	the	groups	fed	with	the	CAF	diet,	with	
or	without	the	LM-GSPE	administration,	than	in	the	STD	diet-fed	rats	(Table	1).		
Fecal	 excretion	 in	 the	 STD	 group	 was	 higher	 than	 that	 in	 the	 CAF	 group,	
without	differences	due	to	the	LM-GSPE	administration.	However,	urine	excretion	
was	higher	in	all	CAF	groups	compared	with	that	in	the	STD	group	(Table	1).	
3.4. Lipid	profile	
Initially,	the	plasma	TC	concentration	was	98.12	±	2.22	mg/dL.	As	expected,	
the	CAF	diet	caused	an	increase	in	TC	versus	the	STD	diet	(Figure	4A).	Specifically,	
on	the	7th	and	10th	weeks	of	the	experiment,	the	TC	in	the	CAF	group	was	found	to	
be	higher	than	that	 in	the	STD	group,	whereas	at	the	end	of	experimental	period,	
(12th	week)	there	were	no	significant	differences	between	the	TC	values	of	the	CAF	
and	STD	groups	(Figure	4B).	The	administration	of	100-	and	200-mg/kg/day	doses	
of	 the	 LM-GSPE	 to	 the	CAF	group	during	 the	experimental	period	normalized	 the	
plasma	TC	levels	in	these	animals	to	that	in	the	STD	group	(Figure	4A).	Additionally,	
on	the	7th	week	of	the	experimental	period,	the	plasma	TC	concentration	reached	a	
maximum	value	in	the	CAF	group,	whereas	a	significant	reduction	in	its	levels	was	
evident	in	the	respective	LM-GSPE	treatment	group	at	all	doses	studied	(Figure	4B).			
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The	 plasma	 TG	 levels	 were	 28.85	 ±	 1.09	 mg/dL	 at	 the	 beginning	 of	 the	
experiments.	 The	 CAF	 diet	 increased	 the	 plasma	 TG	 levels	 versus	 the	 STD	 diet	
(Figure	4A),	with	significant	differences	between	these	groups	observed	during	the	
7th	week	of	the	experiment	(Figure	4B).	Although	the	LM-GSPE	administration,	at	all	
doses	assayed,	produced	no	visible	differences	 in	the	plasma	TG	 levels	during	the	
course	 of	 the	 experiment	 (Figure	 4A),	 its	 administration	 at	 doses	 of	 25	 and	 100	
mg/kg/day	reduced	the	plasma	TG	levels	at	the	end	of	the	experiment	(12th	week	
of	the	diet)	(Figure	4D).		
4. Discussion	
Obesity	 is	associated	with	 the	 increased	 risk	of	CV	diseases,	which	 includes	
HTN,	 type	 2	 diabetes,	 and	 dyslipidemia,	 among	 others	 (Kaur,	 2014;	 Shin	 et	 al.,	
2013).	All	these	interconnected	risk	factors	are	clustered	together	in	the	term	MetS	
(Fontana	 et	 al.,	 2014).	 The	 relationship	 between	 obesity	 and	 HTN	 has	 been	well	
established.	 Modest	 reductions	 in	 the	 BW	 and	 BP	 reduce	 the	 incidence	 of	 CV	
events	 ((WHO),	 2011;	 Seimon	 et	 al.,	 2014).	 Obese	 individuals	 present	 higher	 BP,	
even	when	within	 the	 normotensive	 range	 (Landsberg	 et	 al.,	 2013).	 Studies	 have	
shown	 that	 high	 body	 mass	 index	 and	 visceral	 adipose	 tissue	 are	 significantly	
associated	with	HTN	(Chandra	et	al.,	2014).		
Rats	 fed	 with	 the	 CAF	 diet	 are	 considered	 a	 robust	 model	 of	 MetS	 and	
associated	comorbidities	(Sampey	et	al.,	2011).	This	dietary	model	has	been	widely	
used	 to	 study	obesity	 and	MetS.	 The	development	of	HTN	 in	 rats	 fed	with	a	CAF	
diet	for	10	weeks	has	been	reported	recently	by	our	group	(Pons	et	al.,	2015).	Here,	
we	 evaluated	 the	 time-course	 of	 the	 development	 of	 HTN	 and	 other	
cardiometabolic	 parameters	 in	 this	 animal	model.	 As	 the	 experiment	 progressed,	
the	 SBP	 and	 DBP	 of	 the	 CAF	 group	 increased	 compared	 with	 the	 STD	 group.	
Notably,	the	SBP	in	the	CAF	group	reached	a	maximum	of	145	mmHg	starting	from	
the	 6th	 to	 the	 8th	week	 of	 the	 diet	 and	 thereafter	 dropped	 to	 approximately	 140	
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mmHg	from	the	9th	to	the	12th	week,	indicating	that	the	duration	of	the	diet	can	be	
varied	to	modulate	the	severity	of	HTN	associated	with	MetS	 in	this	experimental	
model.	These	results	are	in	agreement	with	that	of	our	previous	study,	which	found	
that	the	SBP	was	140	mmHg	during	the	5th	and	10th	weeks	in	animals	under	the	CAF	
diet	(Pons	et	al.,	2015).	
Recently,	we	reported	that	a	single	oral	administration	of	375	mg/kg	of	the	
LM-GSPE	 concomitantly	 reduced	 more	 than	 one	 risk	 factor	 of	 CV	 disease	 by	
lowering	the	BP	and	ameliorating	hypertriglyceridemia	in	CAF	diet-fed	rats	(Pons	et	
al.,	 2014).	 The	 reduction	 in	 BP	 was	 similar	 to	 that	 caused	 by	 the	 short-term	
administration	 of	 50	 mg/kg	 of	 Captopril	 in	 these	 animals	 (Pons	 et	 al.,	 2015).	
However,	many	cardiometabolic	risk	factors,	such	as	HTN,	associated	with	MetS	are	
considered	 chronic	 pathologies	 that	 require	 chronic	 treatment.	 Additionally,	
because	a	universal	drug	 for	 the	 treatment	of	MetS	and	associated	comorbidities	
together	has	not	been	developed,	a	chronic	treatment	method	for	HTN	that	would	
also	 alleviate	 other	 components	 of	 MetS	 will	 be	 highly	 useful	 (WHO,	 2013).	
Therefore,	 in	 this	 study,	 we	 evaluated	 the	 effect	 of	 the	 long-term	 daily	
administration	of	 LM-GSPE	on	BP	and	other	 cardiometabolic	 risk	 factors	 in	a	CAF	
diet-fed	rat	model	of	MetS.	
The	 results	 of	 this	 study	 clearly	 showed	 that	 the	 long-term	 daily	
administration	 of	 LM-GSPE	 attenuated	 the	 development	 of	 HTN	 associated	 with	
MetS	 in	 the	 CAF	 diet-fed	 rats.	 However,	 the	 antihypertensive	 effect	 of	 LM-GSPE	
was	not	always	been	dose-responsive	(Pons	et	al.,	2015;	Quiñones	et	al.,	2013).	In	
particular,	in	the	present	study,	the	100-	and	200-mg/kg/day	doses	of	LM-GSPE	had	
similar	effects	on	both	SBP	and	DBP.	Thus,	 the	highest	doses	of	 LM-GSPE	had	no	
additional	 antihypertensive	 effect.	 Importantly,	 a	 potential	 hypotensive	 effect	 of	
LM-GSPE	was	rule	out	due	to	the	100-mg/kg/day	dose	of	LM-GSPE,	which	lowered	
both	SBP	and	DBP	during	 the	experimental	period,	 showed	no	BP	 lowering	effect	
when	administered	to	the	normotensive	STD	group.	
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Other	 studies	 on	 the	 antihypertensive	 effects	 of	 the	 long-term	
administration	 of	 phenolic	 compounds	 such	 as	 resveratrol	 (Rivera,	 Morón,	
Zarzuelo,	&	Galisteo,	2009)	and	other	flavanol-rich	extracts	(Quiñones	et	al.,	2010;	
Sánchez	 et	 al.,	 2010)	 have	 also	 found	 similar	 chronic	 antihypertensive	 effects	 as	
described	 here.	 However,	 the	 experimental	 models	 used	 in	 these	 studies	 were	
different.	In	the	present	study,	the	HTN	was	induced	by	an	unhealthy	diet,	and	the	
results	 confirmed	 the	 development	 of	 hyperphagia,	 obesity,	 and	 dyslipidemia	 in	
these	 animals.	 This	 was	 evidenced	 by	 the	 observed	 increase	 in	 food	 intake,	
increased	BW,	and	elevated	plasma	TC	and	TG	 in	 addition	 to	 the	HTN	developed	
after	the	12th	week	of	the	CAF	diet.	Therefore,	these	animals	mimicked	the	classical	
model	 of	 the	 human	 MetS.	 Additionally,	 elevated	 HOMA-IR	 and	 HOMA-β	 levels	
have	been	found	in	CAF	diet-fed	rats,	indicating	the	presence	of	peripheral	insulin	
resistance	and	increased	pancreatic	insulin	secretion	(Cedó	et	al.,	2013).		
It	 has	 been	 reported	 that	 modest	 changes	 in	 the	 BP	 and	 BW	 are	 more	
common	 in	 populations	 with	 CV	 diseases	 than	 marked	 changes	 (Seimon	 et	 al.,	
2014).	 In	 the	 present	 study,	 we	 found	mild	 increases	 in	 BW	 and	WP	 during	 the	
course	of	 the	experiment	 in	animals	 that	were	administered	LM-GSPE.	Moreover,	
we	 found	 significant	 differences	 in	 the	 total	 BW	 and	 WP	 during	 the	 7th	 and	 8th	
weeks	in	the	CAF200	group.	Additionally,	compared	with	the	CAF	group,	a	decline	
in	the	BW	gain	was	observed	in	the	CAF200	group	at	the	end	of	the	study.	Previous	
studies	have	found	a	reduction	in	obesity	in	rats	administered	polyphenol	extracts	
(Ikarashi	et	al.,	2011;	Kimura	et	al.,	2011;	Yamamoto	et	al.,	2000).	Similar	beneficial	
effects	 on	 the	 BW	 have	 also	 been	 observed	 in	 rats	 under	 a	 high-fat	 diet	
administered	with	cocoa,	which	is	rich	in	flavanols	(Dorenkott	et	al.,	2014;	Matsui	
et	al.,	2005),	and	 in	Zucker	rats	administered	a	cocoa	fiber	rich	 in	cocoa	flavanols	
(Sánchez	et	al.,	2010).	However,	some	studies	of	our	group	found	no	reduction	in	
the	adiposity	and	BW	after	grape-seed	flavanol	administration,	but	the	unfavorable	
alterations	 in	 lipid	 and	 glucose	 metabolism	 or	 energy	 metabolism	 were	
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ameliorated	 (Casanova	et	al.,	2014;	Pajuelo	et	al.,	2011;	Quesada	et	al.,	2012).	 In	
contrast,	a	 reduction	 in	 the	BW	gain	and	 inflammation	were	observed	 in	 the	CAF	
diet-fed	rats	administered	LM-GSPE	for	19	weeks	(Terra	et	al.,	2011).	Additionally,	
it	has	been	reported	that	in	high-fat	and	STD	diet-fed	hamsters,	the	administration	
of	 LM-GSPE	 for	 15	 days	 resulted	 in	 a	 significant	 reduction	 in	 the	 BW	 gain	 and	 a	
reduction	in	the	white	adipose	tissue	weight	(Caimari,	del	Bas,	Crescenti,	&	Arola,	
2013).	The	results	of	this	study	are	in	agreement	with	those	of	the	previous	studies	
on	 grape-seed	 flavanols,	 particularly	 in	 that	 the	 effect	 of	 these	 polyphenolic	
compounds	 on	 the	 BW	 appears	 to	 be	 a	 reduction	 in	 the	 BW	 gain	more	 than	 an	
increase	 in	 the	 BW	 itself	 (Salvadó,	 Casanova,	 Fernández-Iglesias,	 Arola,	 &	 Bladé,	
2015).	However,	we	also	observed	a	visible	effect	on	the	BW	and	WP	during	the	7th	
and	8th	weeks	in	the	CAF200	group.		
The	reduction	in	the	BW	gain	observed	in	the	CAF	diet-fed	animals	after	the	
administration	of	the	highest	dose	of	LM-GSPE	during	the	course	of	the	study	did	
not	appear	to	be	associated	with	a	satiety	effect.	Food	 intake	 in	all	 the	LM-GSPE-
administered	groups	was	comparable	and	was	similar	to	that	in	the	group	fed	with	
the	CAF	diet.	The	increased	total	fluid	consumption	observed	in	the	groups	fed	with	
the	CAF	diet	is	likely	a	consequence	of	the	hyperphagia	observed	in	these	animals.	
Consistent	with	this	result,	we	found	that	excretion	was	also	increased	in	the	CAF	
groups,	indicating	a	higher	fluid	intake.	
The	 association	 of	 leptin	 resistance	 to	 obesity	 and	 HTN	 has	 been	 well	
documented	 (Friedman,	2011;	 Jung	&	Kim,	2013;	 Simonds	et	 al.,	 2014).	 Together	
with	 the	 expansion	 of	 the	 adipose	 tissue,	 leptin	 concentration	 also	 increases	 in	
obesity,	 although	 its	 circulating	 levels	 are	 unable	 to	 promote	 its	 central	
anorexigenic	effects	 (Myers,	Leibel,	Seeley,	&	Schwartz,	2010).	 Increased	 levels	of	
leptin	 have	 been	 found	 to	 increase	 the	 appetite	 and	 obesity	 itself	 (Myers	 et	 al.,	
2010).	 In	 this	 study,	 we	 found	 increased	 levels	 of	 leptin	 in	 the	 CAF	 groups,	 a	
consequence	of	 the	diet-induced	 increase	 in	 the	BW.	However,	at	all	doses	used,	
RESULTS	
236	
the	long-term	administration	of	LM-GSPE	failed	to	modify	the	concentration	of	this	
hormone.	Previous	studies	on	the	effect	of	LM-GSPE	on	leptin	levels	in	obesity	have	
reported	 contradicting	 results	 (Caimari	 et	 al.,	 2013;	 Casanova	 et	 al.,	 2014),	 likely	
due	to	the	differences	in	the	animal	models,	different	experimental	conditions,	or	
the	different	doses	administered.	In	this	study,	we	found	no	effects	on	the	adipose	
tissue	 weight	 in	 the	 CAF	 group	 administered	 LM-GSPE	 (data	 not	 shown).	
Additionally,	there	was	no	effect	on	the	energy	intake.	Thus,	the	overall	results	of	
this	experiment	are	in	concordance.		
As	 the	 study	 progressed,	 the	 TC	 and	 TG	 levels	 in	 the	 CAF	 group	 increased	
compared	 to	 the	 STD	group.	However,	 similar	 to	 the	 changes	 in	BP,	 these	 values	
reached	 a	 maximum	 before	 the	 12th	 week	 of	 the	 CAF	 diet,	 indicating	 that	 the	
amount	 of	 time	 spent	 in	 the	 CAF	 diet	 can	 be	 varied	 to	modulate	 the	 severity	 of	
some	of	the	risk	factors,	such	as	HTN	and	lipid	levels,	associated	with	MetS	in	this	
experimental	model.		
The	 effect	 of	 LM-GSPE	 on	 lipid	 metabolism	 has	 been	 extensively	 studied	
(Bladé,	 Arola,	 &	 Salvadó,	 2010).	 The	 results	 of	 this	 study	 confirm	 the	 beneficial	
effect	 of	 this	 extract	 in	 ameliorating	 these	 CV	 risk	 factors.	 Thus,	 the	 long-term	
administration	of	LM-GSPE	(at	the	doses	of	100	and	200	mg/kg/day)	resulted	 in	a	
clear	 reduction	 in	 the	 CAF	 diet-induced	 hypercholesterolemia	 during	 the	
experimental	 feeding	 period.	 In	 fact,	 a	 reduction	 in	 the	 TC	 levels	 after	 the	
administration	of	 LM-GSPE	was	evident	on	 the	7th	 (for	 all	 the	 studied	doses)	 and	
the	10th	(for	the	doses	of	100	and	200	mg/kg/day)	weeks	of	the	CAF	diet.	Notably,	
the	 timing	of	 this	 reduction	 in	 the	TC	 levels	 coincided	with	 the	 timing	of	 the	CAF	
diet-induced	increase	in	TC	levels.	In	addition,	a	reduction	in	the	TG	levels	was	also	
observed	following	the	administration	of	LM-GSPE	to	the	CAF	group	at	the	end	of	
the	12th	week	of	the	experimental	 feeding	period.	However,	no	differences	 in	the	
TG	 levels	 were	 found	 during	 the	 experiment.	 In	 contrast	 to	 its	 effect	 on	 TC,	 the	
most	effective	doses	of	LM-GSPE	that	produced	beneficial	changes	in	the	TG	levels	
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were	 the	 25-	 and	 100-mg/kg/day	 doses,	 which	 did	 not	 include	 the	 highest	 dose	
administered.	 The	 lack	 of	 dose-dependent	 changes	 in	 the	 TG	 levels	 after	 the	
administration	of	LM-GSPE	has	been	previously	reported	by	our	group	(Margalef	et	
al.,	 2014).	 Thus,	 the	 lower	 doses	 of	 LM-GSPE	 appear	 to	 be	 more	 efficient	 in	
lowering	the	TG	levels	(Margalef	et	al.,	2014).	
In	 summary,	 the	 administration	 of	 LM-GSPE	 to	 the	 CAF	 diet-fed	 rats	
attenuated	the	increase	in	BP	and	improved	the	lipid	metabolism	in	these	animals.	
However,	 while	 the	 25-	 and	 100-mg/kg/day	 doses	 were	 sufficient	 to	 produce	
beneficial	 effects	 on	 the	 BP	 and	 lipid	 metabolism,	 the	 200-mg/kg/day	 dose	 was	
necessary	 to	have	an	effect	on	 the	BW	and	WP.	Therefore,	we	conclude	 that	 the	
LM-GSPE	 is	a	good	candidate	 for	 lowering	BP	 in	 the	 treatment	of	HTN	associated	
with	 MetS,	 particularly	 because	 it	 is	 able	 to	 simultaneously	 act	 on	 other	
cardiometabolic	risk	factors	associated	with	this	disorder.	However,	further	studies	
are	needed	to	establish	its	optimal	dose.		
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Figure	legends	
Figure	1.	Graphical	representation	of	the	experimental	design	used	in	this	study.	
Figure	 2.	 Changes	 in	 (A)	 systolic	 blood	 pressure	 (SBP)	 and	 (B)	 diastolic	 blood	
pressure	 in	 the	 standard	 (STD)	 diet-fed	 rats	 and	 the	 cafeteria	 (CAF)	 diet-fed	 rats	
administered	vehicle	or	different	doses	of	LM-GSPE	(25,	100,	and	200	mg/kg/day:	
CAF25,	CAF100,	and	CAF200,	respectively;	n=10	per	group)	for	12	weeks.	Changes	
in	 (C)	 SBP	 and	 (D)	 DBP	 of	 the	 standard	 diet-fed	 rats	 administered	 vehicle	 (STD;	
n=10)	or	100	mg/kg/day	of	LM-GSPE	 (STD100;	n=10)	daily	 for	12	weeks.	Data	are	
expressed	 as	 the	 mean	 ±	 SEM	 for	 10	 animals	 per	 group.	 Letters	 represent	
significant	differences	(two-way	ANOVA;	p<0.05).		
Figure	 3.	 (A)	Changes	 in	 the	body	weight	 (BW)	during	 the	experiment	 (significant	
differences:	two-way	ANOVA,	Tukey’s	post	hoc	test)	and	on	the	7th	and	8th	weeks	
of	the	experiment	(significant	differences:	one-way	ANOVA,	Tukey’s	post	hoc	test);	
(B)	 changes	 in	 the	 BW	gain	 at	 the	 end	 of	 the	 experiment	 (12th	week;	 significant	
differences:	 one-way	 ANOVA,	 Tukey’s	 post	 hoc	 test);	 (C)	 differences	 in	 the	waist	
perimeter	 (WP)	 during	 the	 experiment	 (significant	 differences:	 two-way	 ANOVA,	
Tukey’s	post	hoc	test)	and	on	the	7th	and	8th	weeks	of	the	experiment	(significant	
differences:	one-way	ANOVA,	Tukey’s	post	hoc	 test)	of	 the	 standard	diet-fed	 rats	
(STD;	 n=10)	 and	 the	 cafeteria	 diet-fed	 rats	 (CAF;	 n=10)	 administered	 daily	 with	
vehicle	 or	 different	 doses	 of	 LM-GSPE	 (25,	 100,	 and	 200	 mg/kg/day:	 CAF25,	
CAF100,	 and	 CAF200,	 respectively;	 n=10	 per	 group).	 Data	 are	 expressed	 as	 the	
mean	 ±	 SEM	 for	 10	 animals	 per	 group.	 Letters	 represent	 significant	 differences	
(p<0.05).		
Figure	4.	Changes	in	plasma	(A)	total	cholesterol	during	the	experiment	(significant	
differences:	 two-way	ANOVA,	Tukey’s	post	hoc	 test)	and	 (B)	at	 the	4th,	7th,	10th	
and	 12th	 weeks	 of	 the	 experiment	 (significant	 differences:	 one-way	 ANOVA,	
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Tukey’s	 post	 hoc	 test);	 changes	 in	 plasma	 (C)	 triglycerides	during	 the	 experiment	
(significant	differences:	two-way	ANOVA,	Tukey’s	post	hoc	test)	and	(D)	at	the	4th,	
7th,	 10th	 and	 12th	 weeks	 of	 the	 experiment;	 significant	 differences:	 one-way	
ANOVA,	Tukey’s	post	hoc	test)	of	standard	(STD;	n=10)	diet-fed	rats	and	cafeteria	
(CAF;	n=10)	diet-fed	rats	administered	daily	with	vehicle	or	different	doses	of	LM-
GSPE	(25,	100	and	200	mg/kg/day:	CAF25,	CAF100	and	CAF200,	respectively;	n=10	
per	 group).	 Data	 are	 expressed	 as	 the	 mean	 ±	 SEM	 for	 10	 animals	 per	 group.	
Letters	represent	significant	differences	(p<0.05).		
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Figure	1	
	
	 	
1
2
3
4
5
6
7
8
9
10
11
12
Ca
fe
te
ria
	d
ie
t-
fe
d	
ra
ts
	+
	2
00
	m
g/
Kg
	L
M
-G
SP
E	
(C
AF
20
0)
St
an
da
rd
	d
ie
t-
fe
d	
ra
ts
	(S
TD
)
St
an
da
rd
	d
ie
t-
fe
d	
ra
ts
	+
	1
00
	m
g/
Kg
	L
M
-G
SP
E	
(S
TD
10
0)
Ca
fe
te
ria
	d
ie
t-
fe
d	
ra
ts
	(C
AF
)
Ca
fe
te
ria
	d
ie
t-
fe
d	
ra
ts
	+
	2
5	
m
g/
Kg
	L
M
-G
SP
E	
(C
AF
25
)
Ca
fe
te
ria
	d
ie
t-
fe
d	
ra
ts
	+
	1
00
	m
g/
Kg
	L
M
-G
SP
E	
(C
AF
10
0)
Bl
oo
d	
pr
es
su
re
,	p
hy
si
ol
og
ic
al
	p
ar
am
et
er
s	d
et
er
m
in
at
io
n	
an
d	
pl
as
m
a	
ex
tr
ac
ct
io
n	
(in
	se
le
ct
ed
	w
ee
ks
			
			
),	
an
d	
m
et
ab
ol
ic
	c
ag
es
	(i
n	
se
le
ct
ed
	w
ee
ks
			
			
			
)	.
Q
ua
re
nt
in
e	
an
d	
			
	
tr
ai
ni
ng
	p
er
io
d	
			
			
			
			
			
			
			
			
			
			
		
Fe
ed
in
g	
pe
rio
d	
(1
2	
w
ee
ks
)
6	
w
ee
ks
	o
ld
8	
w
ee
ks
	o
ld
20
	w
ee
ks
	o
ld
RESULTS	
250	
Figure	2	
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Figure	3	
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Figure	4	
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Table	 1S.	 Main	 polyphenolic	 compounds	 (flavanols	 and	
phenolic	 acids)	 of	 the	 low-molecular	 grape	 seed	 polyphenol	
extract	(LM-GSPE)	used	in	this	study,	analysed	by	HPLC-MS/MS.	
Compound	 Concentration	(mg/g)	
Gallic	acid	 31.07	±	0.08	
Protocatechuic	acid	 1.34	±	0.02	
Vanillic	acid	 0.77	±	0.04	
PA	dimer	B2	 33.24	±	1.39	
PA	dimer	B11	 88.80	±	3.46	
PA	dimer	B31	 46.09	±	2.07	
Catechin	 121.32	±	3.41	
Epicatechin	 93.44	±	4.27	
Dimer	gallate1	 8.86	±	0.14	
Epicatechingallate	 21.24	±	1.08	
Epigallocatechingallate	 0.03	±	0.00	
Epigallocatechin2	 0.27	±	0.03	
PA	trimer1	 4.90	±	0.47	
PA	tetramer1	 0.05	±	0.01	
Abbreviations:	PA	(proanthocyanidin)	
The	results	are	expressed	on	a	wet	basis	as	the	mean	±	SD	(n=3).		
The	results	are	expressed	as	mg	of	phenolic	compound/g	of	GSPE	
1	Quantified	using	the	calibration	curve	of	proanthocyanidin	B2.	
2	Quantified	using	the	calibration	curve	of	epigallocatechingallte.	
Taken	from[13]	
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GENERAL	DISCUSION	
		For	more	than	a	decade	our	research	group	has	widely	studied	the	health	beneficial	
effects	 of	 grape-seed	polyphenols	 demonstrating	 how	 they	 exhibit	 antioxidant	 properties	
(Castrillejo	et	al.	2011),	improve	lipid	metabolism	(Bladé	et	al.	2010),	limit	adipogenesis,	act	
as	an	insulin-mimetic	agent	(Pinent	et	al.	2012)	and	reduce	inflammation	(Martinez-Micaelo	
et	 al.	 2012).	 The	 BP	 lowering	 properties	 of	 these	 compounds	 in	 SHR,	 a	model	 of	 genetic	
HTN,	 were	 also	 reported	 by	 our	 group	 (Quiñones	 et	 al.	 2013).	 Moreover,	 the	
antihypertensive	 effect	 of	 grape-seed	polyphenols	 in	 SHR	was	 shown	 to	be	 endothelium-
dependent	and	mediated	by	changes	in	NO	availability	and	partially	by	the	contribution	of	
PGI2	(Quiñones	et	al.	2014).	HTN	frequently	occurs	simultaneously	with	many	other	CV	risk	
factors	that	contribute	to	MetS	(Epstein	et	al.	1996;	Lakka	et	al.	2002;	 Isezuo	et	al.	2003).	
The	effect	of	grape-seed	polyphenols	on	different	components	of	MetS	has	been	studied	by	
our	 research	group,	using	cafeteria	diet-fed	 rats	as	a	model.	This	dietary	model	has	been	
described	to	develop	hyperphagia,	obesity,	glucose	 intolerance,	 inflammation	and	hepatic	
steatosis	 (Sampey	et	al.	2011;	Higa	et	al.	2014).	Recently	 it	was	 reported	 that	grape-seed	
polyphenols	exerted	a	punctual	and	simultaneous	effect	on	BP	and	 lipid	homeostasis	 in	a	
model	of	 cafeteria	diet-fed	 rats	 (Guerrero	Orjuela	2013).	 In	 the	 light	of	 these	 results,	 the	
objective	 of	 this	 Thesis	 was	 to	 evaluate	 the	 use	 of	 grape-seed	 polyphenols	 to	 improve	
endothelial	dysfunction	and	HTN	associated	with	MetS	in	cafeteria	diet-fed	rats.	
In	order	to	evaluate	the	antihypertensive	effectiveness	of	grape-seed	polyphenols	in	
MetS,	 firstly,	 the	use	of	cafeteria	diet-fed	 rats	as	a	model	of	diet-induced	HTN	associated	
with	MetS	needed	validation.	To	this	end,	the	evolution	of	the	BP	and	the	effect	on	BP	of	
grape-seed	 polyphenols	 in	 the	 cafeteria-fed	 animals	was	 determined	 [manuscript	 1]	 and	
[manuscript	 2].	 The	 results	 showed	 that	 from	 the	 fifth	 week	 of	 the	 feeding	 period,	 the	
cafeteria	diet-fed	rats	had	increased	values	of	BP	accompanied	by	hyperphagia	and	obesity,	
and	 thus,	 these	 animals	mimicked	 the	 classical	model	 of	 human	MetS.	 In	 addition	 to	 the	
progressive	increase	in	BW	and	BP	along	the	experiment,	high	plasma	insulin	levels	and	an	
increase	 in	plasma	TC	and	TG	at	 the	tenth	week	of	 the	experimental	 feeding	period	were	
observed	[manuscript	2].	Interestingly,	the	maximum	BP	values	and	the	highest	TC	and	TG	
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levels	were	observed	from	the	6th	to	8th	and	from	the	7th	to	10th	week	of	diet,	respectively,	
indicating	that	the	time	of	feeding	cafeteria	diet	modulates	the	severity	of	some	of	the	risk	
factors,	as	HTN	and	lipids,	associated	with	this	experimental	model	[manuscript	7].	At	the	
10th		week	of	the	feeding	period,	the	antihypertensive	effect	of	grape-seed	polyphenols	was	
confirmed	 and	 compared	 to	 the	 effect	 on	 BP	 of	 captopril,	 an	 ACE	 inhibitory	 drug.	 The	
results	 showed	 that	grape-seed	polyphenol	administration	decreased	BP	 to	normotensive	
values	 in	 these	obese-hypertensive	 rats.	 Importantly,	 these	compounds	did	not	affect	 the	
BP	in	normotensive	animals.	
	 Additionally,	the	most	effective	acute	dose	of	grape-seed	polyphenols	for	BP	reduction	
in	 this	 model	 of	 diet-induced	 HTN	 associated	 with	 MetS	 was	 determined	 and	 the	 time-
course	was	studied	[manuscript	2].	To	achieve	this	goal,	a	single	oral	administration	of	LM-
GSPE	was	tested	at	different	doses	(250,	375	and	500	mg/kg)	and	both	SBP	and	DPB	were	
recorded	 for	 48	hours.	 Interestingly,	 and	 in	 contrast	 to	Quiñones	 results	 (Quiñones	 et	 al.	
2013),	 the	 effects	 of	 grape-seed	 polyphenols	 on	 SBP	were	maintained	 48	 hours	 after	 its	
administration,	indicating	a	more	sustained	antihypertensive	effect	in	this	dietary	model	of	
HTN	and	MetS.	Furthermore,	 the	maximal	BP	decrease	was	evidenced	after	6	hours	after	
administration	of	LM-GSPE.	Paradoxically,	the	highest	dose	of	LM-GSPE	(500mg/Kg)	showed	
a	 lower	 antihypertensive	 effect	 than	 the	 medium	 dose	 (375mg/Kg),	 which	 was	 also	 the	
most	 effective	 in	 SHR	 (Quiñones	 et	 al.	 2013).	 This	 apparently	 surprising	 finding	with	 the	
highest	dose	has	also	been	described	in	SHR	administered	grape-seed	polyphenol	and	other	
flavanol-rich	compounds	such	as	cocoa	(Quiñones	et	al.	2013;	Cienfuegos-Jovellanos	et	al.	
2009).	 This	 fact	 could	 be	 explained	 by	 the	 pro-oxidant	 properties	 and	 the	 excessive	
production	of	ROS	caused	by	high	doses	of	flavanols	previously	described	(Procházková	et	
al.	 2011).	 Taken	 together,	 the	 results	 indicate	 that	 grape-seed	 polyphenols	 restore	 BP	
values	in	this	diet-induced	hypertensive	model.	
Once	 the	use	of	cafeteria	diet-fed	rats	had	been	validated	as	a	suitable	model	of	HTN	
associated	with	MetS	and,	the	effectiveness	of	grape-seed	polyphenols	in	reducing	BP	was	
demonstrated,	the	antihypertensive	mechanism	at	the	most	effective	dose	and	time-point	
(375	mg/Kg	6	hours	post-administration)	was	investigated.	First,	the	antioxidant	capacity	of	
LM-GSPE	and	the	plasma	ACE	activity	[manuscript	1],	together	with	the	implication	of	the	
NO	and	PGI2	[manuscript	2]	were	evaluated.	Results	showed	that	grape-seed	polyphenols	
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produced	a	decrease	in	oxidative	stress.	This	was	evidenced	by	a	decrement	in	the	hepatic	
lipid	 peroxidation	 products,	 although	 hepatic	 glutathione	 levels	 were	 not	 altered	 in	 this	
experiment.	 No	 changes	 in	 plasma	 ACE	 activity	 6	 hours	 after	 the	 administration	 of	 the	
extract	were	observed	either.	This	last	result,	however,	did	not	rule	out	the	participation	of	
this	enzyme	before	this	time	or	the	participation	of	other	compounds	of	the	RAAS	in	the	BP	
lowering	effect	of	grape-seed	polyphenols.	
Despite	 the	 lack	 of	 changes	 in	 ACE	 activity,	 the	 reduction	 of	 BP	 by	 grape-seed	
polyphenols	 in	 cafeteria	 model	 was	 demonstrated	 to	 be	 mainly	 produced	 via	 the	 NO	
pathway	 and	 partially	 by	 the	 PGI2	 pathway	 [manuscript	 2],	 in	 a	 similar	 way	 to	 the	
mechanism	operating	 in	BP	reduction	 in	SHR	administered	 the	same	extract	 (Quiñones	et	
al.	2014).	Afterwards,	and	 in	order	 to	delve	deeper	 into	 the	mechanisms	by	which	grape-
seed	polyphenols	reduce	BP	in	this	animal	model,	the	involvement	of	Sirt-1	in	this	effect	6	
hours	 post-administration	 of	 375	mg/kg	 of	 LM-GSPE	 was	 evaluated,	 and	 the	 endothelial	
vasoprotective	expression	pattern	was	studied	[manuscript	3].	The	results	showed	that	the	
eNOS	mRNA	level	 in	the	aorta	was	 increased,	which	would	 lead	to	a	higher	production	of	
NO.	Sirt-1	gene	expression,	which	is	able	to	deacetylate	and	activate	eNOS	(Mattagajasingh	
et	al.	2007)	and	inhibit	NADPH	oxidase	(Zarzuelo	et	al.	2013),	was	also	found	upregulated	in	
the	aorta	after	grape-seed	polyphenols	administration.	Moreover,	aortic	Nox4	mRNA	level	
was	decreased		and	that	would	lead	to	a	decrease	in	ROS	production	and	consequently	an	
increase	in	NO	availability	(Konior	et	al.	2014;	Gorlach	et	al.	2000).	Finally,	the	aortic	mRNA	
levels	of	ET-1,	which	is	known	to	increase	NADPH	oxidase	activity	(Lund	et	al.	2005),	were	
decreased.	 All	 of	 these	 findings	 suggest	 a	 restoration	 of	 the	 balance	 between	
vasoconstrictor	 and	 vasodilator	 endothelial	 factors	 altered	 by	 HTN	 and	 these	 data	 are	 in	
agreement	with	previous	ex	vivo	findings	from	our	group.	Those	experiments	demonstrated	
the	 endothelium-dependent	 relaxation	 of	 grape-seed	 polyphenols	 relaxed	 and	 the	
improvement	of	endothelial	function	(Quiñones	et	al.	2014).	Additionally,	375	mg/kg	of	LM-
GSPE	 was	 administered	 to	 SHR,	 as	 a	 better	 establish	 animal	 model	 of	 HTN.	 Then,	 these	
animals	were	 treated	with	1	mg/kg	 sirtinol	 (an	 inhibitor	 of	 Sirt-1)	 in	order	 to	 establish	 in	
vivo	 the	 role	 of	 Sirt-1	 in	 the	 BP	 lowering	 effect	 of	 LM-GSPE	 [manuscript	 3].	 The	
antihypertensive	 effect	 of	 these	 compounds	 was	 completely	 abolished	 by	 sirtinol,	
demonstrating	that	the	antihypertensive	effect	of	grape-seed	polyphenols	was	dependent	
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on	 Sirt-1.	 These	 results	 are	 relevant	 because	 they	 implicate	 Sirt-1	 in	 the	 decrease	 in	 BP	
induced	 by	 grape-seed	 polyphenols.	 Sirt-1	may	 play	 an	 important	 role	 in	 the	 grape-seed	
polyphenol-regulated	increase	of	NO	availability	by	deacetylating	eNOS	(Mattagajasingh	et	
al.	 2007).	 All	 these	 data	 highlight	 the	 important	 vasoprotective	 effect	 of	 LM-GSPE.	
Nevertheless,	no	changes	in	aortic	KLF-2	expression	in	vivo	were	observed	after	6	hours	of	
grape-seed	 polyphenol	 administration.	 However,	 the	 potential	 participation	 of	 this	
transcriptional	 factor	 in	 the	upregulation	of	eNOS	before	this	 time	point	can	not	be	ruled	
out,	since	in	vitro	results	carried	out	in	HUVECs	treated	with	(-)-epicatechin	and	(+)-catechin	
(the	main	monomeric	components	of	LM-GSPE)	showed	an	upregulation	of	KLF-2	at	2	hours	
post-treatment	[manuscript	5].		
The	relationship	between	obesity	and	HTN	is	well	established,	although	the	mechanisms	
through	 obesity	 directly	 causes	 HTN	 are	 still	 not	 clear	 (Kotsis	 et	 al.	 2010).	 One	 of	 the	
systems	that	HTN	and	MetS	have	 in	common	is	RAAS.	The	hyperactivity	of	RAAS,	which	 is	
one	 of	 the	most	 important	 systems	 in	 control	 of	 BP,	 is	 also	 associated	with	 obesity	 and	
MetS	(Fontana	et	al.	2014).	In	fact,	the	inhibition	of	this	system	results	in	a	decrease	in	BW	
(Weisinger	et	al.	2008),	indicating	that	the	degree	of	adiposity	might	have	a	direct	influence	
on	 this	 BP-regulating	 system.	 Therefore,	 the	 next	 question	 to	 address	 in	 this	 Thesis	 was	
whether	grape-seed	polyphenols	could	modulate	RAAS	to	decrease	BP	in	an	animal	model	
of	HTN	associated	with	obesity	and	MetS	[manuscript	4].	To	achieve	this	goal,	the	effect	of	
LM-GSPE	on	RAAS	at	the	dose	of	375	mg/kg	and	6	hours	post-administration	was	evaluated.	
The	results	showed	that	Ang	 II	plasma	levels,	 the	most	 important	RAAS	bioactive	peptide,	
and	plasma	Ang	I	levels	were	reduced	by	grape-seed	polyphenols.	Plasma	renin	levels	were	
not	altered	by	LM-GSPE	and	no	changes	were	observed	in	Ang	II	receptor	type	1	(AT1a	and	
AT1b)	 gene	 expression	 in	 the	 aorta,	 indicating	 that	 grape-seed	 polyphenols	 may	 inhibit	
RAAS	 at	 other	 levels	 of	 the	 pathway.	 On	 the	 contrary,	 liver	 angiotensinogen	mRNA	 level	
was	 increased,	which	may	represent	a	compensatory	mechanism	to	the	 low	plasma	Ang	 I	
and	II	levels	found	after	LM-GSPE	administration.		
Due	to	the	fact	that	the	drop	in	plasma	Ang	II	was	accompanied	by	a	similar	decrease	in	
Ang	 I,	 it	 demonstrated	 that	 ACE	 is	 not	 involved	 in	 Ang	 II	 reduction.	 This	 finding	 is	 in	
agreement	 with	 the	 measures	 of	 ACE	 activity	 that	 showed	 that	 this	 enzyme	 was	 not	
inhibited	 by	 these	 compounds	 in	 obese-hypertensive	 rats	 [manuscript	 1].	 In	 addition,	
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plasma	BK	levels	were	not	altered	by	LM-GSPE,	supporting	the	non-participation	of	ACE	in	
RAAS	 inhibition	mediated	by	 grape-seed	polyphenols.	However,	 as	previously	mentioned,	
these	results	did	not	rule	out	the	participation	of	this	enzyme	before	this	time.	Therefore,	
although	ACE	 could	 be	 involved	 in	 the	Ang	 II	 decrease,	 our	 results	 showed	 an	 important	
drop	 in	 Ang	 I	 levels	 that	 clearly	 would	 support	 an	 additional	 implication	 of	 grape-seed	
polyphenols	 upstream	 of	 the	 pathway	 and	 it	 points	 to	 a	 probable	 direct	 effect	 of	 these	
compounds	on	the	reduction	of	Ang	I.	
Nonetheless,	the	obtained	results	clearly	 implicate	RAAS	in	the	antihypertensive	effect	
of	 grape-seed	 polyphenols	 in	 HTN	 associated	 with	 MetS.	 Ang	 II	 is	 known	 to	 be	 able	 to	
disrupt	eNOS	mRNA,	thereby	inhibiting	NO	production	(Engeli	et	al.	2003).	It	has	also	been	
shown	 to	 stimulate	 the	 activity	 of	 NADPH	 oxidase	 (Seshiah	 et	 al.	 2002),	 the	 main	
endothelial	 producer	of	 free	 radicals.	 Free	 radicals	 can	directly	 scavenge	NO,	 stopping	 its	
vasodilator	action.	ROS	can	also	enhance	ET-1	synthesis	 (Hahn	et	al.	1990;	 Ito	et	al.	1993;	
Sung	 et	 al.	 1994),	 and	 therefore	 increase	 NADPH	 oxidase	 activity	 (Jiménez	 et	 al.	 2007).	
Thus,	 the	 reduction	 in	 plasma	 Ang	 II	 levels	 mediated	 by	 grape-seed	 polyphenols	 could	
explain	 the	 NO-mediated	 antihypertensive	 effect	 of	 these	 compounds	 that	 has	 been	
demonstrated	 in	 this	 Thesis	 [manuscript	 2].	 In	 addition	 to	 its	 potent	 effect	 as	 a	
vasoconstrictor,	 Ang	 II	 also	 promotes	 the	 production	 of	 aldosterone	 in	 the	 suprarenal	
glands,	 leading	 to	 sodium	and	water	 retention	 (Briet	&	 Schiffrin	 2013).	 Results	 showed	 a	
significantly	 reduced	 aldosterone	 levels	 in	 plasma	 after	 grape-seed	 polyphenol	
administration,	 which	 could	 be	 directly	 related	 to	 an	 improvement	 in	 CV	 health.	
Additionally,	 Ang	 II	 downregulates	 Sirt-1	 gene	 expression	 by	 activation	 of	 p38	 in	
endothelium,	 and	 inhibition	 of	 p38	 restores	 the	 detrimental	 actions	 of	 Ang	 II	 in	 EC	
(Marampon	et	al.	2013).	The	capacity	of	LM-GSPE	on	modulating	p38	at	6	hours	and	at	the	
dose	of	375	mg/Kg	was	studied.	Results	on	p38	mRNA	 levels	 in	aorta	showed	no	changes	
after	the	administration	of	LM-GSPE	(data	not	shown).	But,	this	result	cannot	rule	out	the	
participation	of	 this	protein	kinase	because	at	 this	 time-point	only	 the	mRNA	 levels	were	
determined.		
All	 these	 results	 demonstrated	 that	 grape-seed	 polyphenols	 inhibit	 RAAS	 in	 obese-
hypertensive	rats,	and	this	inhibition	may	explain	the	improvement	in	endothelial	function	
and	the	antihypertensive	and	cardioprotective	effect	exhibited	by	these	compounds.	These	
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results	are	considered	significant	because	currently,	the	first	family	of	drugs	recommended	
for	obesity-induced	HTN	are	 the	Ang	 II	 antagonists	 and	 the	ACE-inhibitors,	 both	of	which	
block	RAAS.	 It	 is	also	 important	 to	point	out	 that	RAAS	overactivity	 is	not	only	associated	
with	 HTN	 but	 also	 with	 vascular	 inflammation,	 the	 development	 of	 atherosclerosis,	 left	
ventricular	 hypertrophy,	 nephrosclerosis	 and	 CV	 events,	 including	 myocardial	 infarction,	
stroke	and	heart	failure	(Jayasooriya	et	al.	2008;	de	Kloet	et	al.	2009;	Weisinger	et	al.	2008;	
Santos,	Ferreira	&	Simões	E	Silva	2008).		
	
Figure	 10.	 Schematic	 representatoin	of	 the	pathways	 involved	 in	 the	decrease	of	blood	pressure	by	 LM-GSPE	 in	
cafeteria	diet-fed	rats.	Activated	patways	by	LM-GPSE	are	represented	in	green	and	blocked	pathways	in	red.	Ang:	
Angiotensin;	ACE:	angiotensin	converting	enzyme;	BP:	Blood	pressure;	COX:	cyclooxygenase;	ET:	Endothelin;	ETE:	
endothelin	converting	enzyme;	eNOS:	endothelial	nitric	oxide	synthase;	NADPH:	Nicotamide	adenine	dinucleotide	
phosphate;	 NO:	 Nitric	 oxide;	 PGI2:	 Prostaglandin	 I2	 or	 prostacyclin;	 PGI2Sin:	 Prostaglandin	 I2	 synthase;	 ROS:	
Reactive	oxigen	species;	Sirt:	Sirtuin.	
The	first	part	of	the	Thesis	confirmed	that	grape-seed	polyphenols	reduce	BP	in	a	dose-
depended	manner	in	an	animal	model	of	HTN	associated	with	MetS.	This	antihypertensive	
effect	can	be	explained	by	the	inhibition	of	RAAS	that	in	turn	improves	endothelial	function,	
which	may	be	mediated	by	Sirt-1.	The	second	part	of	the	Thesis,	aimed	to	investigate	which	
molecules	in	the	LM-GSPE	were	bioactive.	LM-GSPE	is	a	low	molecular-weight	polyphenol-
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rich	extract	which	characterisation	by	HPLC-MS/MS	(Quiñones	et	al.	2013)	showed	that	the	
most	 abundant	 compounds	 are	 the	 flavanol	 monomers,	 (-)-epicatechin,	 (+)-catechin	 and	
their	 gallated	 forms;	 dimers	 of	 these	 flavanols,	 known	 as	 procyanidins;	 and	 the	 phenolic	
acid,	 GA.	 Therefore,	 the	 vasoprotective	 and	 antihypertensive	 properties	 of	 these	
compounds	of	 the	extract	were	 investigated	as	potential	bioactive	 forms	 in	 LM-GSPE.	 (-)-
Epicatechin	and	(+)-catechin	flavanol	monomers	have	been	previously	reported	to	decrease	
BP	(Quiñones	et	al.	2015),	but	the	capability	to	modulate	endothelial	regulatory	genes	and	
endothelial	 dysfunction	 has	 not	 been	 explored.	 One	 of	 the	 aims	 of	 this	 Thesis	 was	 to	
evaluate	 (-)-epicatechin,	 (+)-catechin	 and	 other	 flavonoids’	 modulation	 of	 the	 two	 key	
endothelial	 factors	and	to	define	the	key	structural	 features	essential	 for	 that	modulation	
[manuscript	5].	For	this	study,	15	flavonoids	were	evaluated	in	HUVEC	in	presence	of	H2O2	
for	 their	 ability	 to	affect	 gene	expression	of	eNOS	and	ET-1.	Moreover,	 the	expression	of	
the	eNOS	transcription	factor	KLF-2	was	assessed.	All	assayed	flavanols	(i.e.	(-)-epicatechin	
and	 (+)-catechin)	 and	 affected	 endothelial	 gene	 expression	 by	 counteracting	 the	 stress	
effect	of	H2O2.	The	results	suggested	that	the	in	vitro	induction	of	eNOS	could	be	regulated	
by	KLF-2.	Examples	of	flavonoid	structure−activity	relationships	were	also	provided	and	the	
structural	features	needed	for	the	regulation	of	eNOS	and	ET-1	expression	at	a	physiological	
flavonoid	concentration	were	established.		
As	stated	before,	GA	is	the	most	abundant	non-flavonoid	phenolic	acid	in	LM-GSPE,	
and	is	absent	in	other	flavanol-rich	extracts	such	as	cocoa	extracts.	However,	GA	bioactivity	
in	the	reduction	of	BP	has	not	been	widely	evaluated	(Kang	et	al.	2015).	Therefore,	 it	was	
proposed	to	investigate	in	this	Thesis	the	antihypertensive	effectiveness	of	low	doses	of	GA	
and	to	determine	the	regulatory	mechanism	of	this	effect	[patent	1]	and	[manuscript	6].	To	
achieve	 this	 goal,	 the	 BP	 reduction	 capacity	 in	 SHR	 of	 three	 doses	 of	 GA	 (3.5,	 7	 and	 14	
mg/Kg)	was	evaluated	for	48	hours.	The	doses	of	GA	were	selected	based	in	the	GA	content	
found	 in	 the	 LM-GSPE.	 The	 quantity	 of	 GA	 in	 the	 most	 effective	 dose	 of	 LM-GSPE	 (375	
mg/Kg)	corresponded	to	7	mg/kg	of	GA	(Quiñones	et	al.	2013).	The	other	two	doses	were	
the	half	or	the	double.	Results	showed	that	GA	reduced	BP	at	this	low	dose	of	7	mg/Kg	and	
the	maximal	decrease	of	BP	was	found	6	hours	post-administration,	similar	to	the	effect	of	
captopril	 in	SHR.	Moreover,	a	hypotensive	effect	was	not	 found	 in	normotensive	animals.	
The	dose	of	7	mg/Kg	GA	6	hours	post-administration	 inhibited	 the	RAAS,	by	 reducing	 the	
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plasma	levels	of	Ang	I	and	II,	and	improved	endothelial	function	by	decreasing	plasma	ET-1.	
Additionally,	the	endothelium	vasodilator	agents	NO	and	PGI2	were	seen	to	be	involved	in	
the	 antihypertensive	 effect	 of	 GA.	 These	 results	 demonstrated	 similarities	 between	GA	 a	
LM-GSPE,	 in	 that	 PGI2	 implication	 has	 been	 demonstrated	 in	 both	 SHR	 (Quiñones	 et	 al.,	
2014)	 and	 in	 cafeteria-hypertensive	 rats	 [manuscript	 3].	 Interestingly,	 other	 flavanol-rich	
extracts	 without	 GA	 in	 their	 composition,	 such	 as	 cocoa	 extracts,	 demonstrated	 an	
antihypertensive	effect	without	the	 implication	of	PGI2	(Quiñones,	Muguerza,	et	al.	2011).	
Therefore,	 GA,	 as	 part	 of	 LM-GSPE,	 is	 responsible	 at	 least	 in	 part	 for	 PGI2-dependent	 BP	
lowering	effect.		
Thus,	these	results	showed	a	similar	behaviour	of	GA	to	LM-GSPE	and	also	suggested	
that	blockage	of	RAAS	is	the	main	mechanism	involved	in	the	antihypertensive	effect	of	GA	
because	 reduction	 of	 plasma	 levels	 of	 Ang	 I	 and	 II	 improve	 the	 endothelial	 function.	GA,	
unlike	 LM-GSPE,	 increased	 plasma	 renin	 and	 BK	 levels,	 most	 probably	 as	 a	 negative	
feedback	to	the	activation	of	kallikrein	due	to	the	low	levels	of	Ang	II	 in	plasma	(Su	2014),	
which	would	not	be	operating	 in	LM-GSPE	administered	rats.	Therefore,	since	LM-GSPE	 is	
an	 extract	 with	 multiple	 polyphenols,	 other	 compounds	 of	 LM-GSPE	 different	 from	 GA,	
could	exhibit	additional	effects	on	RAAS	that	might	explain	the	differences	observed	after	
LM-GSPE	 or	 GA	 administration.	 Nevertheless,	 another	 important	 consideration	 is	 the	
different	model	of	HTN	used	in	the	experiments	in	this	Thesis.	While	the	experiments	with	
LM-GSPE	 have	 been	 performed	 using	 a	 cafeteria-diet	 fed	 rats,	 the	 experiments	 with	 GA	
have	 been	 done	 with	 SHR.	 Furthermore,	 it	 has	 been	 demonstrated	 that	 the	
antihypertensive	effect	of	GA	was	not	mediated	by	Sirt-1,	unlike	LM-GSPE,	 indicating	 that	
GA	would	not	be	implicated	in	the	effect	of	LM-GSPE	on	Sirt-1.	Hence,	other	compounds	of	
LM-GSPE	different	from	GA,	such	as	(-)-epicatechin	or	(+)-catechin,	could	be	involved	in	the	
Sirt-1-mediated	 antihypertensive	 effect	 of	 grape-seed	 polyphenols,	 although	 this	 needs	
further	evaluation.	Consequently,	the	inhibition	of	RAAS	by	GA	and	LM-GSPE	is	considered	
of	special	relevance	because	currently,	as	it	was	previously	mentioned,	RAAS	overactivity	is	
not	 only	 associated	 with	 HTN	 but	 also	 with	 vascular	 inflammation,	 the	 development	 of	
atherosclerosis,	left	ventricular	hypertrophy,	nephrosclerosis	and	CV	events.	
Many	cardiometabolic	risk	factors	associated	with	MetS,	such	as	HTN,	are	chronic	
pathologies	and	thus,	chronic	 treatment	 is	needed.	 In	 this	context,	 it	was	 fundamental	 to	
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investigate	the	long-term	effect	of	grape-seed	polyphenols	on	the	development	of	HTN	and	
other	 cardiometabolic	 risk	 factors	 associated	 with	 MetS	 in	 cafeteria	 diet-fed	 rats	
[Manuscript	 7].	 In	 this	 study,	 cafeteria	diet-fed	 rats	were	administered	different	doses	of	
LM-GSPE	 (25,	 100	 and	 200	 mg/kg/day)	 for	 12	 weeks.	 The	 results	 showed	 that	 the	
development	of	HTN	due	to	the	unhealthy	diet	was	attenuated	in	the	rats	administered	LM-
GSPE.	While	doses	of	25	and	100	mg/kg	were	enough	to	obtain	beneficial	effects	on	BP	and	
lipid	 metabolism;	 doses	 of	 200	 mg/kg	 were	 necessary	 to	 obtain	 effects	 on	 BW	 or	 WP.		
Therefore,	LM-GSPE	is	proposed	as	a	good	candidate	to	be	used	as	a	BP-lowering	agent	in	
HTN	associated	with	MetS	 in	 chronic	 administration,	 to	 improve	 simultaneously	HTN	and	
comorbidities	of	MetS.	However	more	studies	are	needed	to	establish	the	most	convenient	
dose	to	be	used.		
Considering	 all	 the	 results	 of	 this	 Thesis,	 it	 was	 demonstrated	 that	 grape-seed	
polyphenols	 reduce	 BP	 acutely	 in	 a	 dose-dependent	manner	 in	 an	 animal	model	 of	 HTN	
associated	 with	 MetS	 and	 attenuate	 the	 increase	 in	 BP	 and	 other	 cardiometabolic	 risk	
factors	associated	with	MetS	due	to	an	unhealthy	diet.	The	maximum	effect	of	grape-seed	
polyphenols	was	 reached	6	hours	 after	 the	administration	of	 375	mg/Kg	of	 LM-GSPE	and	
the	BP	reduction	was	demonstrated	to	be	mediated	by	Sirt-1	and	blockage	of	RAAS.	Both	
effects	 could	 thus	 contribute	 to	 the	 improvement	 of	 endothelium	 function	 also	
demonstrated	 for	 these	 compounds.	 Additionally,	 some	 of	 the	 principal	 flavanols	 in	 LM-
GSPE,	 such	 as	 (-)-epicatechin,	 (+)-catechin	 were	 shown	 to	 be	 bioactive	 as	modulators	 of	
gene	expression	of	the	key	endothelial-derived	factors.	Moreover,	it	was	demonstrated	that	
a	single	low	dose	of	7	mg/kg	of	GA,	the	main	phenolic	acid	of	LM-GSPE,	decreased	BP	and	
that	GA	 is	 likely	 to	be	 the	compound	present	 in	LM-GSPE	 responsible	 for	PGI2-dependent	
antihypertensive	effect.	However,	 the	mechanisms	by	which	GA	and	 LM-GSPE	exert	 their	
antihypertensive	effect	differ	 slightly.	 Even	 though	GA	blocks	 the	RAAS	by	 reducing	Ang	 I	
and,	in	turn,	Ang	II,	the	antihypertensive	effect	of	GA	was	not	mediated	by	Sirt-1.	Therefore,	
at	 this	 point	 it	 is	 	 hypothesized	 that	 (-)-epicatechin,	 (+)-catechin,	 or	 other	 polyphenols	 in	
LM-GSPE	 are	 involved	 in	 the	 Sirt-1-mediated	 antihypertensive	 effect	 of	 grape-seed	
polyphenols.	This	needs	further	evaluation.	 	
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CONCLUSIONS	
1. Cafeteria	 diet-fed	 rats	 are	 a	 good	 model	 of	 diet-induced	 HTN	 associated	 with	
MetS,	in	which	animals	present	HTN	in	addition	to	obesity	and	dyslipidaemia.		
2. The	 feeding	 period	 modules	 the	 severity	 of	 HTN	 and	 dyslipidaemia	 associated	
with	MetS	in	cafeteria	diet-fed	rats.	
3. LM-GSPE	decreases	BP	 in	 the	 cafeteria-induced	hypertensive	 animals	 in	 a	 dose-
depended	manner.	
4. Administration	of	375	mg/Kg	of	 a	 LM-GSPE	 is	 the	most	effective	dose	 to	obtain	
the	BP	lowering	effect	and,	6	hours	post-administration	is	the	time	when	the	BP	
decrease	 is	maximal	 in	 the	cafeteria-diet	model.	The	administration	of	 this	dose	
produces	 an	 antihypertensive	 effect	 similar	 to	 the	 obtained	 with	 Captopril,	 a	
known	drug	used	in	clinical	practice.	
5. The	mechanism	operating	in	the	BP	lowering	effect	of	LM-GSPE	at	375	mg/Kg	and	
6	hours	post-administration	 in	 cafeteria-diet	 fed	 rats	 is	 demonstrated	 to	be	 the	
inhibition	 of	 RAAS	 and	 enhancement	 of	 Sirt-1	 pathway.	 Consequently,	 both	
pathways	improve	endothelial	dysfunction	via	the	implication	of	the	NO	pathway,	
the	partial	contribution	of	PGI2	and	the	increase	of	aortic	mRNA	ET-1.		
6. (-)-Epicatechin	 and	 (+)-catechin,	main	 flavanols	 present	 in	 LM-GSPE,	 affect	 gene	
expression	of	the	major	regulators	of	endothelial	function	under	oxidative	stress	
conditions	HUVEC,	acting	as	modulators	of	endothelial	dysfunction.	
7. GA,	the	main	phenolic	acid	present	in	LM-GSPE,	reduces	BP	in	SHR	at	a	low	dose	
of	7	mg/Kg	with	maximal	effect	6	hours	post-administration.	The	administration	
of	 this	 dose	 evidences	 an	 antihypertensive	 effect	 similar	 to	 the	 obtained	 with	
Captopril.	
8. The	mechanism	involved	in	the	antihypertensive	effect	of	GA	is	by	blockage	of	the	
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RAAS	 at	 reducing	 Ang	 I	 and	 II	 plasmatic	 levels	 and	 improvement	 of	 endothelial	
function	via	the	decrease	of	ET-1	and	the	increase	of	BK,	the	implication	of	the	NO	
pathway	and	the	contribution	of	PGI2.		
9. The	 antihypertensive	 effect	 of	 GA	 is	 mediated	 partially	 by	 PGI2.	 Therefore,	 GA	
may	be	the	compound	present	in	LM-GSPE	responsible	of	the	involvement	of	PGI2	
in	the	BP	lowering	properties	of	LM-GSPE.	
10. LM-GSPE	 and	GA	 exert	 antihypertensive	 effects	 only	when	BP	 values	 are	 above	
the	normotensive	values.	
11. Chronic	administration	of	grape-seed	polyphenols	attenuates	 the	 increase	of	BP	
and	 other	 cardiometabolic	 risk	 factors	 associated	 with	 MetS	 produced	 by	 an	
unhealthy	 cafeteria	 diet.	 The	 doses	 of	 25	 and	 100	mg/kg	 are	 enough	 to	 obtain	
beneficial	effect	in	BP	and	lipid	metabolism,	but	a	dose	of	200	mg/kg	is	necessary	
to	obtain	an	effect	on	obesity.			
	
Acute	(375	mg/Kg,	6h)	and	chronic	(200	mg/Kg/day)	administration	of	LM-GSPE	reduces	
BP	and	attenuates	the	development	of	HTN	associated	with	MetS,	respectively.	The	acute	
antihypertensive	 effect	 of	 grape-seed	 polyphenols	 produces	 an	 improvement	 of	
endothelial	 function	by	blockage	of	RAAS	and	 involvement	of	Sirt-1.	GA	and	monomeric	
flavanols,	 (-)-epicatechin	 and	 also	 (+)-catechin,	 are	 some	 of	 the	 bioactive	 compounds	
involved	in	this	health	effect.		
Therefore,	LM-GSPE	 is	proposed	as	a	good	candidate	 to	be	used	 in	HTN	associated	with	
MetS.		
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y	por	llenarme	de	regalos,	manualidades,	besos	y	abrazos,	te	llevo	en	el	corazón	mi	vida.	A	
Nicole,	 eres	 un	 cielito,	 solo	 con	mirarte	 la	 carita	 ya	 se	me	 arreglan	 todos	 los	 problemas	
Nico.	Estoy	 tan	orgullosa	de	 la	personita	que	eres,	 sigue	así	y	 llegarás	muy	 lejos	pequeño	
saltamontes	mío!!	Gracias	por	los	abrazos	que	me	das	cuando	llego	y	por	no	despegarte	de	
mi	 ni	 un	 minuto,	 de	 verdad	 que	 lo	 necesito	 un	 montón.	 Al	 meu	 petit	 drac,	 gràcies	 per	
regalar-nos	quan	vas	néixer	 la	que	potser	va	ser	 la	nit	més	emocionant	de	 la	nostra	vida.	
Gràcies	per	 la	teva	alegria	 i	per	sempre	voler	 jugar	a	en	 jan	Jordi	 i	el	drac	amb	mi,	a	timu	
molt	 Marc!	 Y	 a	 la	 pequeña	 de	 la	 casa,	 eres	 un	 bicho	 Nane!	 Me	 encanta	 tu	 energía	 y	
carácter,	me	recuerdas	a	alguien	de	casa	jaja.	Gracias	por	ser	tan	dulce	y	por	los	abrazos	tan	
bonitos	que	me	das	Daphne.	Que	sepas	que	volveré	para	hacerte	perrerías	y	hacerte	volar.	I	
a	n’es	terremoto	de	ca	nostra,	gràcies	pes	teu	somriure	i	sa	teva	alegria	incondicional	Sergi,	
mos	has	aportat	molt	a	casa	i	esper	aprendre	de	sa	teva	forma	d’esser.	Gràcies	també	per	
aprendre	es	meu	nom	just	después	de	mama,	papa,	yeya	i	agua	haha,	va	significar	molt	per	
jo,	t’estim	molt	pageset	meu.	Y	al	recién	llegado,	decirte	que	no	te	vas	a	aburrir	en	esta	casa	
Adrià,	 tienes	 unos	 cuantos	 abuelos,	 toooda	 una	 panda	 de	 tíos	 interminable	 deseosos	 de	
achucharte	y	un	montóooon	de	primos	que	ya	te	esperan	para	jugar,	chincharte	y	esas	que	
se	 hacen	 entre	 la	 familia.	 Pero	 créeme,	 somos	 buena	 gente,	 bienvenido	 a	 la	 familia!	 Als	
tiets,	 gràcies	per	 recordar-me	d’on	hem	 sortit	 tots,	 per	molt	 que	 voli	 per	 aquest	món	de	
Déu	 mai	 me	 n’oblidaré	 dels	 meus	 orígens.	 Espero	 que	 el	 padrí	 i	 la	 padrina	 estiguessin	
orgullosos	d’on	hem	arribat	tots	nosaltres,	va	per	vosaltres	també	aquesta	tesi.	Gràcies	tiet	
Sebastià	per	estimar-me	 i	per	 venir	 a	 veure’m	sempre	que	has	pogut.	Gràcies	per	 fer-me	
sentir	 en	 família	 quan	 he	 estat	 lluny	 de	Mallorca,	 de	 veritat	 no	 saps	 com	 t’ho	 agraeixo,	
t’estimo	molt.	Á	abuela,	gracias	por	reconocerme	cando	chego	a	casa	agora	que	xa	non	te	
acordas	de	ninguén,	e	perdona	por	mentirche	e	decirche	que	xa	non	vou	volver	marchar.	
Espero	que	aínda	estés	con	nos	cando	volva	de	verdade.	Ó	abuelo,	gracias	por	que	sei	que	
nos	 coidas	 desde	 o	 ceo	 e	 que	 estarías	moi	 orgulloso	 de	min	 e	 dos	meus	 irmaos.	 A	miña	
familia	galega,	perdón	por	haber	estado	tan	ausente	estos	anos	e	gracias	sobre	todo	ós	de	
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Barcelona	 polo	 apoio	 que	 tiven	 de	 vos,	 sobretodo	 ó	 principio	 da	 miña	 aventura	 en	
Catalunya.	A	Ferran	mil	 gràcies	per	 fer-me	 feliç	 i	per	estar	al	meu	costat	 i	 cuidar-me	 tots	
aquests	 anys,	 gràcies	 per	 haver	 lluitat	 per	 mi	 i	 per	 tot	 el	 que	 vam	 aconseguit	 junts.	 No	
hagués	arribat	de	la	mateixa	manera	sense	el	teu	recolzament.	
Vull	continuar	els	agraïments	per	 la	gent	amb	 la	què	he	passat	més	temps	aquests	
darrers	anys,	per	als	del	departament,	espero	no	oblidar-me	de	ningú.	M’agradaria	agrair	
en	 primer	 lloc	 a	 Lluís	 Arola	 per	 apostar	 per	 mi	 quan	 era	 una	 estudiant	 i	 per	 donar-me	
l’oportunitat	d’entrar	al	grup	quan	no	 tenia	 les	credencials	acadèmiques	suficients,	no	ho	
oblidaré	mai.	Gràcies	 també	per	buscar-me	 la	beca	de	doctorat,	quan	ens	vaig	oblidar	de	
tirar	els	papers	i	pels	“molt	bé	xiqueta”	que	m’has	regalat	després	de	cada	exposició	meva	i	
que	m’han	 donat	 tantes	 forces	 per	 continuar.	 A	 mis	 directoras	 de	 tesis	 Begoña	 y	 Anna,	
gracias	por	todos	estos	años	vividos,	por	las	comidas	en	el	japo	y	por	darme	la	oportunidad	
de	trabajar	con	vosotras,	he	aprendido	mucho	y	no	solo	de	ciencia	a	vuestro	lado.	Qué	vais	
a	 hacer	 ahora	 que	 Maria	 y	 yo	 hemos	 acabado?	 nos	 echareis	 de	 menos	 o	 por	 fin	
descansaréis	 un	poco?	 Jajaja.	Gracias	Begoña	por	 tu	 sinceridad	 conmigo,	 tu	 confianza,	 tu	
empatía,	 por	 hacerme	 crecer	 como	 científica	 y	 por	 enseñarme	 a	 ser	 una	 buena	 líder.	
Gracias	 también	por	toda	 la	 implicación	y	el	esfuerzo	tan	grande	que	has	hecho	para	que	
llegue	hasta	este	punto.	A	l’Anna,	gràcies	per	tot	el	que	he	après	treballant	amb	tu	i	gràcies	
per	la	implicació	i	la	feinada	que	has	fet	per	treure	a	flote	aquesta	tesi.	A	Mar,	gracias	por	
todo	lo	que	me	has	enseñado	y	por	los	momentos	de	confidencia.	A	Manuel,	gracias	por	tu	
amistad,	 por	 todos	 tus	 consejos,	 por	 escucharme	 y	 por	 ser	 más	 que	 un	 referente	 como	
persona	 y	 como	 científico.	 M’agradaria	 agrair	 també	 a	 la	 Cinta	 per	 les	 seves	 paraules	
positives	i	pels	seus	ànims	sempre.	Al	Gerard	Pujades	per	sempre	regalar-me	un	bon	dia	al	
matí	i	per	donar-me	ànims	durant	tot	aquest	camí.	Al	Miquel	Mulero	mil	gràcies	per	ajudar-
me	sempre	que	ho	he	necessitat,	he	après	molt	de	tu	i	sempre	et	tindré	com	a	referent.	A	la	
Montse	 Pinent	 per	 les	 seves	 bones	 paraules	 i	 el	 seu	 somriure,	 gràcies.	 A	 la	 Maite	 Blai,	
gràcies	 per	 donar-me	 l'oportunitat	 de	 fer	 divulgació	 als	 més	 petits	 i	 poder	 contagiar	 la	
passió	per	la	ciència,	gràcies	també	per	les	converses	de	fora	dels	despatxos.	A	Juan,	gracias	
por	haber	estado	dispuesto	a	ayudarme	siempre	que	lo	he	necesitado	y	por	ponerte	la	bata	
y	entrar	conmigo	en	el	laboratorio	aunque	no	te	tocaba,	espero	que	pronto	puedas	volver	a	
hacerlo.	A	l’Anna	Ardèvol,	més	que	gràcies,	perdó	per	molestar	tant	al	despatx	sempre	amb	
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tanta	reunió.	A	la	Pepa,	gràcies	per	introduir-me	al	grup	i	donar-me	l'oportunitat	quan	era	
becària	de	 secretaria	de	 fer	 el	 pas	 al	 laboratori.	Al	 Santi	García	 gràcies	pel	 bon	 l’esperit	 i	
pels	hola!	tan	entusiastes	que	ens	dius	pel	passadís.	A	Ximena,	gracias	por	tus	palabras	de	
ánimo	ya	al	final	de	la	tesis	y	por	esa	sonrisa	contagiosa,	el	grupo	ha	ganado	mucho	con	tu	
llegada	 igual	 que	 con	 la	 llegada	 de	 Gerard	 Aragonès.	 Gràcies	 Gerard	 també	 per	 la	 teva	
actitud	 positiva	 i	 per	 sempre	 estar	 disposat	 a	 ajudar.	 A	Monica	 Tous,	 mil	 gracias	 por	 el	
tiempo	invertido	en	mi	de	instrucción	en	el	laboratorio	y	por	dedicar	con	todas	tus	fuerzas	
tanto	 tiempo	 en	 el	 eterno	 experimento	 AO.	 Gracias	 por	 las	 conversaciones	 que	 hemos	
tenido	a	lo	largo	de	estos	años	y	por	haberme	dado	tu	apoyo	siempre.	Eres	un	ejemplo	para	
mí,	como	persona	y	como	científica,	muchas	gracias.	A	n’en	Toni,	moltes	gracis	per	ajudar-
me	 sempre	 que	 ho	 he	 necessitat,	 i	 per	 no	 haver	 perdut	mai	 s’accent	mallorquí,	 sempre	
m’ha	fet	traslladar-me	a	casa.	Al	Josep	de	Bas,	 l’Anna	Creixenti	 i	 la	resta	del	CTNS,	gràcies	
també	per	 la	vostra	ajuda	durant	aquesta	 tesi,	 sento	que	vam	perdre	molt	els	doctorants	
quan	vau	marxar	del	departament.	A	Niurka	gracias	por	ser	“tan	culo	 inquieto”	y	 tener	 la	
solución	para	cualquier	problema,	el	grupo	no	haría	nada	sin	ti.	A	Rosa,	gracias	por	el	buen	
rollo	y	 las	micro-conversaciones	matutinas	que	nos	echábamos	en	el	despacho	cuando	no	
había	 llegado	nadie	 aún.	A	 Yaiza	 y	Vanesa,	 gracias	 por	 vuestra	 ayuda	durante	mi	 tesis.	 A	
Braulio,	gracias	por	ayudar	me	cuando	realmente	no	te	tocaba	y	por	las	risas	y	el	buen	rollo	
que	es	tenerte	al	lado.	A	Santiago,	mil	gracias	por	todo	lo	que	haces	por	este	departamento,	
por	 los	 alumnos	 y	 por	 los	 docentes.	 Creo	 que	 no	 te	 valoramos	 lo	 suficiente,	 eres	 muy	
grande.	 I	 a	 la	 Pietat,	moltes	 gràcies	 per	 sempre	 estar	 de	 bon	 humor,	 pels	hola	 reina	 tan	
dolços	 que	 m’has	 regalat	 aquests	 anys	 i	 pel	 teu	 somriure	 incondicional,	 inclús	 quan	
físicament	 no	 has	 pogut.	 Ets	 un	 exemple	 de	 superació	 molt	 gran	 per	 a	 tots.	 A	 Montse	
Martínez	muchas	 gracias	 por	 tu	 simpatía	 y	 por	 tu	 cariño	 desde	 el	 primer	momento	 que	
entré	 a	 trabajar	 en	 el	 departamento.	 Gracias	 por	 apostar	 siempre	 por	 mi	 y	 por	 incluso	
dejarme	ropa	formal	para	ir	de	congreso	jaja,	no	sabes	lo	que	ha	significado	para	mi	tenerte	
cerca	 todos	estos	 años.	A	 la	 Esther	Palau,	 gràcies	per	 ajudar-me	a	 superar	 la	meva	por	 a	
contestar	el	telèfon	en	català	i	gràcies	per	implicar-te	tant	en	les	tesis	dels	teus	nens,	com	
tu	 ens	 deies.	 A	 Ingrid	 gracias	 por	 responder	 con	 una	 sonrisa	 siempre	 y	 por	 solucionar	
eficientemente	todos	nuestros	problemas.	A	la	Rosa	Abelló,	gràcies	pels	correus	informatius	
que	ens	 salven	el	 cul	més	d’una	 vegada	 i	 per	 ajudar-nos	quan	anem	 tan	perduts;	 gràcies	
també	per	haver-me	animat	al	final	de	la	tesi	a	dipositar	i	per	ajudar	a	Ferran	quan	vas	tenir	
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l'ocasió.	A	mi	Rafi,	gracias	por	tu	ayuda	en	esos	 largos	días	de	estabulario	y	por	acordarte	
siempre	 de	 mi	 incluso	 cuando	 estuve	 en	 Estados	 Unidos.	 Al	 resto	 de	 personal	 de	
mantenimiento	del	departamento,	gracias	por	facilitar	nuestras	vida	y	saludar	siempre	con	
una	sonrisa.	I	finalment	vull	agrair	als	meus	companys	de	batalla,	aquells	amb	els	que	hem	
viscut	 tants	moments.	 Gràcies	 en	 primer	 lloc	 a	 la	Maria	 per	 estar	 sempre	 al	meu	 costat	
treballant	 mano	 a	 mano	 en	 el	 desenvolupament	 de	 tots	 i	 cadascun	 dels	 experiments	
d’aquesta	 tesi.	HEM	ARRIBAT	AL	FINAL	MARIA	 i	no	mho	crec!!	Gràcies	pels	dies	 infinits	 a	
l'estabulari	i	pels	pitis	de	descans,	pels	caps	de	setmana	al	lab	i	per	aquell	dissabte	que	vam	
mesurar	les	rates	més	ràpid	que	mai	hahaha.	Al	meu	estimat	Aleix,	gràcies	per	sempre	tenir	
una	 paraula	 positiva,	 un	 somriure	 i	 una	 abraçada	 reservada	 per	mi.	He	 passat	molts	 bon	
moments	 amb	 tu	 aquests	 anys	 i	 he	 après	 de	 tu	 que	 la	 constància	 i	 l’esforç	 té	 la	 seva	
recompensa.	 Ets	 molt	 gran	 i	 t’admiro	 infinitament,	 costarà	 molt	 tornar	 a	 trobar	 una	
persona	 com	 tu,	m’has	 deixat	 una	marca	 al	 cor.	 A	 Husam,	 gracias	 por	 esos	 cafés	 y	 esas	
conversaciones,	 por	 las	 salidas	 al	 circo	 y	 por	 siempre	 apoyarme	 en	 todo,	 te	 echaré	 de	
menos	amigo.	A	Cristina	Rojas,	mil	gracias	por	haberme	ayudado	al	principio	de	la	tesis,	por	
haber	perdido	tu	tiempo	ayudando	a	los	recién	llegados	cuando	nadie	más	lo	hizo	y	gracias	
después	por	tu	amistad.	Eres	un	ejemplo	a	seguir	como	persona	y	como	científica.	A	David	
Pajuelo,	gracias	por	ayudarme	al	principio	de	 la	 tesis	 y	por	atender	mis	dudas	cuando	no	
tenías	tiempo	para	ello.	A	Lidia,	Victor,	Noe,	Laura	Baselga,	Ester	Casanova,	Anabel,	Neus,	
Ester	 Sala	 y	 Laura	Guasch	 gracias	 por	 los	momentos	 vividos	 en	 el	 departamento,	 por	 los	
cafés	tomados	y	por	lo	que	he	aprendido	de	vosotros.	A	l’Adrià	Cereto,	gràcies	per	aquests	
vuit	anys	al	teu	costat,	per	acceptar	l’amistat	d’aquesta	ignorant	que	sóc,	per	fer-me	riure	i	
per	les	teves	converses	quasi	surrealistes.	Ets	un	tio	molt	gran	i	no	només	literalment	haha,	
arribaràs	molt	lluny,	poques	vegades	te	trobes	a	la	vida	gent	tan	fora	de	sèrie	com	tu	i	jo	he	
tingut	la	sort	de	trobar-te,	gràcies.	A	Mª	José	gracias	por	tu	buen	rollismo,	por	tu	alegría	y	
por	siempre	tener	una	sonrisa	para	regalar	a	cualquiera	que	pase,	has	hecho	mis	días	aquí	
más	llevaderos.	A	Sarah	agradecer	lo	mismo,	sois	gente	que	da	gusto	tener	al	lado.	A	Joan,	
gràcies	 pels	 cafès	 de	 dues	 hores	 espontanis	 i	 per	 fer-me	 riure.	 Tant	 tu,	 com	 l’Adrià	 sou	
d’aquestes	 persones	 que	 vos	 sortiu	 de	 la	mitja,	 gràcies	 per	 haver	 compartit	 amb	mi	 part	
d’aquest	viatge	i	per	tot	el	que	he	après	de	tu.	A	mi	Paquita,	gracias	por	tu	ayuda	en	esta	
tesis	 y	por	 la	 Santa	Tecla	de	 la	que	no	nos	perdimos	ni	un	acto	hace	un	porrón	de	años.	
Espero	que	 tengas	mucha	 suerte	 y	 la	 vida	 te	devuelva	 todo	 lo	que	has	 invertido	 y	 sigues	
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invirtiendo	 aquí.	 A	 Andrea	 y	 Aleix	 Gimeno,	 por	 cercanía	 en	 el	 despacho	 al	 final	 de	 esta	
carrera,	 gracias	 por	 aguantar	mis	me	 abuurrrooo	 y	mis	 tengo	 hambreee	 y	 por	 animarme	
todo	el	rato,	sois	unas	bellísimas	personas	los	dos	y	da	gusto	tener	gente	así	al	lado,	mucha	
suerte	 guapos,	 os	 echaré	 de	 menos	 (y	 vosotros	 a	 mi	 también	 jeje).	 A	 la	 resta	 de	 nous	
companys,	perdó	per	no	haver	estat	més	a	prop,	però	heu	arribat	quan	jo	 ja	només	tenia	
ulls	per	l’escriptura.	Vos	desitjo	molta	sort	i	que	sobretot	tingueu	paciència,	que	tot	arriba,	
que	 això	 s’acaba	 també	 encara	 que	 sembli	 mentida!	 A	 “mis”	 becarios,	 gracias	 por	
enseñarme	lo	que	es	liderazgo	y	por	vuestra	dedicación	y	entusiasmo.	Especial	mención	por	
su	implicación	en	esta	tesis	a	Jessica	Reboucas,	Gemma	Ornosa,	Olaia	Baylo	y	Rebeca	Laza,	
sin	vosotras	no	hubiera	llegado	en	las	mismas	condiciones	al	final	del	trayecto,	espero	que	
hayáis	aprendido	algo	de	ciencia	conmigo.	I	no	vull	oblidar-me	dels	enòlegs	tampoc.	Gràcies	
Maria	Martí	per	la	teva	amistat	i	els	momentazos	juntes,	em	deus	encara	un	sopar	per	cert!	
A	 la	Mariona,	 la	Meri	Bordas,	 la	Marta	 i	el	Gus,	gràcies	per	 les	converses	 i	pels	 riures	 i	el	
pitis.	A	Judit	y	Isabel	Araque	gracias	por	vuestras	conversaciones	de	pasillo	y	comedor	y	por	
siempre	escucharme	y	ayudarme	en	lo	que	he	necesitado.	A	la	resta	d’enòlegs	gràcies	pels	
holas	de	passadís	i	pels	pitis	compartits.	
Als	de	Tarragona,	gràcies	per	tantes	Santa	Tecles	viscudes	i	per	acollir-me	com	a	una	
més.	Gràcies	per	tota	la	gent	que	ha	passat	per	la	meva	vida	i	ha	deixat	marca	i	ha	fet	que	
sigui	més	lleugera	la	distància.	A	David,	gracias	por	tu	amistad	y	por	siempre	estar	ahí	para	
mi,	por	todas	las	noches	de	estudio	junto	a	Javi,	por	fiesta	y	por	las	collejas.	Eres	y	has	sido	
como	 un	 hermano	 para	 mi,	 te	 quiero.	 Gracias	 a	 Chus	 y	 Manolo	 y	 al	 resto	 de	 la	 familia	
García-Fernández	por	ser	mi	familia	tarragonina	estos	años	y	por	siempre	estar	dispuestos	a	
ayudarme.	Gracias	por	acogerme	como	a	una	más,	os	estaré	eternamente	agradecida,	os	
quiero.	 Gracias	 Javi	 por	 estos	 años	 de	 amistad	 y	 por	 no	 dejar	 que	 ésta	 muera,	 eres	 mi	
ejemplo	de	constancia	y	fuerza,	te	lo	digo	siempre	pero	estoy	muy	orgullosa	de	ti	Perte.	A	
las	chicas	de	 la	carrera	gracias	por	 las	 risas	y	 los	buenos	momentos.	Al	Massons	y	el	Tiki,	
gracias	por	vuestra	amistad	y	por	las	conversaciones,	sois	muy	grandes	los	dos	también.	A	
l’Adrià	 Pagès,	 gràcies	 per	 tenir	 sempre	 una	 paraula	 positiva	 a	 dir-me,	 per	 la	 teva	 infinita	
amistat	 al	 llarg	d’aquests	 anys	 i	 per	 sempre	apostar	per	mi	 incondicionalment,	 estic	molt	
orgullosa	de	tenir-te	a	la	meva	vida,	ets	molt	gran.	A	la	Nat,	gracias	por	las	ralladas	que	has	
tenido	 que	 aguantar	 al	 final	 de	 la	 tesis,	 por	 las	 risas,	 las	 conversaciones,	 las	 fiestas	 y	 las	
ACKNOLEDGEMENTS	
308	
locuras,	 vales	mucho	 carinyet!	 Espero	 no	 echarte	 de	menos,	 porque	 esto	 significará	 que	
estaremos	 cerca	 la	 una	 de	 la	 otra.	 Infinitas	 gracias	 por	 haberte	 cruzado	 en	mi	 camino	 y	
haberme	 regalado	 estos	 meses	 de	 felicidad	 a	 tu	 lado.	 A	 Enric,	 gracias	 por	 esos	 viajes	
semanales	 que	 te	 pegaste	 para	 venir	 a	 cenar	 conmigo	 y	 escucharme.	 Gracias	 por	 tus	
consejos	 y	 porque	 después	 de	 ellos	 no	 he	 vuelto	 a	 ser	 la	 misma	 persona.	 A	MªCarmen	
gracias	por	acogerme	y	escucharme	todo	lo	que	he	necesitado	y	por	dejarme	hacer	un	poco	
de	niñera	cuando	más	echo	de	menos	a	mis	niños,	te	echaré	de	menos.	Matt,	thanks	for	all	
your	 dedication,	 I	 owe	 you	more	 than	 a	 dinner.	 I	 can’t	 be	more	 thankfull	 for	 correcting	
therefore	 and	 in	 addition	 my	 dyslexic	 horribly	 (horribilie?)	 wroten	 manuscripts	 and	
documents	every	time	I	need	 it	haha	and	thank	you	too	for	your	enormous	patience	with	
me	and	 for	 those	 classes	 that	were	more	 like	going	 to	 therapy,	 I’ll	miss	 you	my	 friend.	A	
Pere	gràcies	per	aparèixer	de	casualitat	per	fer	més	lleugers	aquests	darrers	moments	de	la	
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